{
  "data": [
    {
      "paragraphs": [
        {
          "qas": [
            {
              "id": "61f80d5d882a024a1000003c_001",
              "question": "Do only changes in coding regions of MEF2C cause developmental disorders?"
            }
          ],
          "context": ". these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\n. we identified four single - nucleotide variants and two copy - number variants upstream of mef2c in a total of ten individual probands\n\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\npossible mutations within highly conserved fetal brain - active elements cause neurodevelopmental disorders with a domi \" \" t mechanism.\n\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\n\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. here we show that de novo mutations in highly evolutionarily conserved fetal brain - active elements are significantly and specifically enriched in neurodevelopmental disorders\n"
        },
        {
          "qas": [
            {
              "id": "62211c853a8413c65300006d_001",
              "question": "Is CircRNA produced by back splicing of exon, intron or both, forming exon or intron circRNA?"
            }
          ],
          "context": "it has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\n\nexonic circrna, circular intronic rna, and exon - intron circular rna.\nexonic circular rnas ( circrnas ) are rna molecules that are covalently closed by back - splicing via canonical splicing machinery.\n\nas circular rnas ( circrnas ) are resistant to degradation by exonucleases, their abundance relative to linear rnas can be used as a surrogate marker for mrna stability in the absence of transcription.\nour objective was to characterize non - canonical circrnas, namely not originating from back splicing and circrna produced by non - coding genes.\n\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\n. circrnas are generally produced by a noncanonical splicing event called backsplicing that is dependent on the canonical splicing machinery, giving rise to circrnas classified into three main categories : exonic circrna, circular intronic rna, and\n\nadministration and protection from covid - 19 and influenza for those in need.\n. t\n\nhere, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\n"
        },
        {
          "qas": [
            {
              "id": "620c27e93a8413c653000006_001",
              "question": "Is METTL1 overexpression associated with better patient survival?"
            }
          ],
          "context": "here we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n. conversely, mettl1 overexpression induces oncogenic cell transformation and cancer.\n\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\nexpression ( met - high ) hepatocellular carcinoma previously treated wit\n"
        },
        {
          "qas": [
            {
              "id": "61f80c37882a024a1000003b_001",
              "question": "Do mutations in KCNT2 only cause phenotypes with epilepsy?"
            }
          ],
          "context": ". notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\nkcnt2 variants resulting in substitutions affecting the arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt\n\nkcnt2 variants resulting in substitutions affecting the arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt\nto investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\n\n. this is the first report of pathogenic variants in kcnt2 causing a developmental phenotype without epilepsy.\nkcnt2 variants resulting in substitutions affecting the arg190 residue have been shown to cause epileptic encephalopathy and a recognizable facial gestalt\n"
        },
        {
          "qas": [
            {
              "id": "61f593f8882a024a1000000f_001",
              "question": "Is there an association between pyostomatitis vegetans and Crohn's disease?"
            }
          ],
          "context": "pyostomatitis vegetans : a clue for diagnosis of silent crohn's disease.\nosis of crohn's disease\n\ndiffuse mucosal swelling, cobblestone mucosa, localised mucogingivitis, deep linear ulceration, fibrous tissue tags, polyps, nodules, pyostomatitis vegetans, and aphthous - like ulcers have been described in crohn's disease.\namong the main oral manifestations of ibd are cobblestoning of the oral mucosa, labial swellings with vertical fissures, pyostomatitis vegetans, angular cheilitis, perioral erythema, and glossitis.\n\npyostomatitis vegetans is frequently associated with chronic inflammatory bowel diseases and can, thus, give a diagnostic hint at an existing ulcerative colitis or crohns disease.\nsuccessful treatment with infliximab and methotrexate of pyostomatitis vegetans associated with crohn's disease.\n\n[ pyostomatitis vegetans and crohn's disease. a specific association of 2 diseases ].\noral crohn's disease and pyostomatitis vegetans. an unusual association.\n\npyostomatitis vegetans is frequently associated with chronic inflammatory bowel diseases and can, thus, give a diagnostic hint at an existing ulcerative colitis or crohns disease.\npyostomatitis vegetans ( pv ) is a rare condition characterized by pustules that affect the oral mucosa\n"
        },
        {
          "qas": [
            {
              "id": "6217e1ac3a8413c653000031_001",
              "question": "Is serotonin transported by platelets?"
            }
          ],
          "context": "platelet serotonin response was measured by serotonin augmented platelet aggregation and platelet serotonin receptor density.\nactivated platelets, which carry peripheral serotonin,\n\nplatelets transport and store virtually all plasma serotonin in dense granules\nactivated platelets, which carry peripheral serotonin,\n"
        },
        {
          "qas": [
            {
              "id": "61f59592882a024a10000010_001",
              "question": "Is Sotrovimab effective for COVID-19?"
            }
          ],
          "context": "the food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness.\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\n\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nthe food and drug administration has granted emergency use authorization to sotrovimab for the treatment of mild to moderate covid - 19 in patients at increased risk for progression to severe illness.\n"
        },
        {
          "qas": [
            {
              "id": "621b5bcc3a8413c65300003d_001",
              "question": "Is Otolin-1 a matrix protein?"
            }
          ],
          "context": "otolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\notoconia matrix protein, otolin - 1\n\nbinds to otolin - 1 and forming matrix protein architectures\notoconia matrix protein, otolin - 1\n"
        },
        {
          "qas": [
            {
              "id": "620aedee3a8413c653000001_001",
              "question": "Is AGO2 related to cytokinesis?"
            }
          ],
          "context": "notably, the expression of nanog, a key pluripotency regulator and repressor of extraembryonic endoderm specification in es cells, was significantly reduced in zic3 knockdown cells.\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\n\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\n\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\n\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\ntcf3, is recruited to a palindromic motif enriched in the promoter of cell cycle repressor genes, such as p15ink4b, p16ink4a and p19arf, which mediate the wnt - dependent anti - proliferative effect in mescs. consistently, abl\n\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\nphagosomal proteins are ubiquitylated, and ubiquitylation was found to be required for formation of acidic multivesicular structures.\n"
        },
        {
          "qas": [
            {
              "id": "621b61833a8413c65300003e_001",
              "question": "Is the protein HOXA11 associated with endometrial disease?"
            }
          ],
          "context": "both cd10 and hoxa11 have been implicated in regulation of endometrial homeostasis.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\n\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\n"
        },
        {
          "qas": [
            {
              "id": "621ed10f3a8413c653000062_001",
              "question": "Are Tregs CD4(+)CD25(+) regulatory T cells a positive regulator of the immune response?"
            }
          ],
          "context": "cd4 ( + ) cd25 ( + ) regulatory t cells ( treg ) play a central role in the prevention of autoimmunity and in the control of immune responses by down - regulating the function of effector cd4 ( + ) or cd8 ( + ) t cells.\nobjectives : cd4cd25 regulatory t cells ( tregs ) play a key role in the prevention of various inflammatory and autoimmune disorders by suppressing immune responses.\n\nit is well established that cd4cd25 regulatory t cells ( tregs ) downregulate inflammatory immune responses and help to maintain immune homeostasis.\ncd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are negative regulators of the immune system that induce and maintain immune tolerance.\n\nregulatory t cells ( tregs ) are cd4 ( + ) cd25 ( bright ) cd62l ( high ) cells that actively down - regulate immune responses.\ncd4 ( + ) cd25 ( + ) regulatory t cells ( tregs ) are potent modulators of immune responses.\n\ncd4 + cd25 + t regulatory cells ( tregs ) are classified as a subset of t cells whose role is the suppression and regulation of immune responses to self and non - self.\nt regulatory cells ( tregs ) have a role in immunosuppression and control of autoimmunity, and are currently an important topic in the study of immune response to tumor cells.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb4100a43ad31278000015_001",
              "question": "Is Mediator present at super enhancers?"
            }
          ],
          "context": "many genes determining cell identity are regulated by clusters of mediator - bound enhancer elements collectively referred to as super - enhancers.\nsuper - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\n\nfurthermore, the binding of sim2 marks a particular sub - category of enhancers known as super - enhancers. these regions are characterized by typical dna modifications and mediator co - occupancy ( med1 and med12 ).\nsuper - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\n\nbrd4 and mediator were found to co - occupy thousands of enhancers associated with active genes.\nsuper - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\n"
        },
        {
          "qas": [
            {
              "id": "62057b35c9dfcb9c0900002d_001",
              "question": "Does atemoya juice inhibit the CYP1A2 enzyme?"
            }
          ],
          "context": "the study analysed the prescribing and dispensing of cyp2d6 drugs ( metoprolol, donepezil, galantamine, codeine, tamoxifen ) together with cyp2d6 - blocking ssris ( paroxetine / fluoxetine ) or ssris without significant cyp2d6 inhibition\nantagonist fosphenytoin, magnesium, glycine site antagonist gv150526 and piracetam.\n\nthe results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\n\nthe results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "6217dc9d3a8413c65300002d_001",
              "question": "Is NfL (neurofilament light chain) a biomarker of neurodegeneration?"
            }
          ],
          "context": "neurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\n\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\n\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\n"
        },
        {
          "qas": [
            {
              "id": "621ebec63a8413c65300005d_001",
              "question": "Is Epistaxis associated with dental implant placement?"
            }
          ],
          "context": "the overall survival rate of the implants into the sinus cavity was 95. 6 %, without statistical differences according to the level of penetration. the clinical and radiological complications were 3. 4 % and 14. 8 % respectively\nimplant placement and protrusion of the implant up to 3mm beyond the sinus floor does not alter the stability and outcome of dental implants, one year post - restoration\n\n. this could be associated with minor complications ranging from epistaxis to sinusitis, which are manageable.\n. the most frequent clinical complication was the epistaxis,\n\n. this could be associated with minor complications ranging from epistaxis to sinusitis, which are manageable.\nthe overall survival rate of the implants into the sinus cavity was 95. 6 %, without statistical differences according to the level of penetration. the clinical and radiological complications were 3. 4 % and 14. 8 % respectively\n"
        },
        {
          "qas": [
            {
              "id": "61f58a1a882a024a10000009_001",
              "question": "Is Daprodustat effective for anemia?"
            }
          ],
          "context": "daprodustat for the treatment of anemia in patients not undergoing dialysis.\ndaprodustat for the treatment of anemia in patients undergoing dialysis.\n\nrates of gastrointestinal side effects, headache, and depression.\ndaprodustat is one of the orally administrated small - molecule hif - ph inhibitors, leading to an increase in erythropoietin production, which is regulated by hif. also, daprodustat is expected to improve iron metabolism\n\nand daprodustat may become an effective alternative for treatment of anemia with ckd.\ndaprodustat for the treatment of anemia in patients undergoing dialysis.\n"
        },
        {
          "qas": [
            {
              "id": "621218353a8413c653000013_001",
              "question": "Is REGN5458 a single-targeted antibody?"
            }
          ],
          "context": "in this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nis a monoclonal antibody that works directly against the spike protein of sars - cov - 2 to block its attachment and entry into a human cell.\n\nbased on positive results from a phase i / ii clinical trial\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nthus representing a notable drug target to explore.\n\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nefgartigimod is an fcrn inhibitor recently approved for mg treatment, and rozanolixizumab, nipocalimab and batoclimab are other agents in clinical trial development.\n\nefforts made to develop pharmacological treatments succeeded with the biotechnological agent lumasiran, a sirna product against glycolate oxidase, which has become the first effective therapy to treat ph1.\nfrom clinical effects of disease, supporting the conclusion that it is a promising smallpox antiviral therapeutic candidate.\n"
        },
        {
          "qas": [
            {
              "id": "6020a7391cb411341a00007e_001",
              "question": "Is Benralizumab effective for Chronic Spontaneous Urticaria?"
            }
          ],
          "context": "small molecules ( e. g. ligustrazine and sp600125 ) and large molecule antibodies ( e. g. lebrikizumab, benralizumab, dupilumab ) are being considered as novel agents for the pharmacotherapy of asthma.\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\nfinally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti - il - 5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce csu symptoms.\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\nsmall molecules ( e. g. ligustrazine and sp600125 ) and large molecule antibodies ( e. g. lebrikizumab, benralizumab, dupilumab ) are being considered as novel agents for the pharmacotherapy of asthma.\nbackground dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\n\nsmall molecules ( e. g. ligustrazine and sp600125 ) and large molecule antibodies ( e. g. lebrikizumab, benralizumab, dupilumab ) are being considered as novel agents for the pharmacotherapy of asthma.\nfinally, treatments aimed at reducing eosinophil accumulation and activation, such as the anti - il - 5 antibodies mepolizumab, reslizumab, and benralizumab, have been reported to reduce csu symptoms.\n\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\nthe appropriate use of these biologics, and of those in development ( e. g., benralizumab and dupilumab ), should be aided by further understanding of asthma phenotypes and endotypes, utilizing appropriate biomarkers.\n"
        },
        {
          "qas": [
            {
              "id": "6217dd013a8413c65300002f_001",
              "question": "Do the proteins Talin and Amot interact?"
            }
          ],
          "context": "we show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\nwe have further investigated this particular mutation by examining the interaction of the competitive antagonist d - tubocurarine ( curare ) with the receptor.\n\nwe show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\nbinds to otolin - 1 and forming matrix protein architectures\n\nwe show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\notolin - 1 is a collagen - like protein expressed in the inner ear of vertebrates.\n\nwe show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\ninhibition of the erk1 / 2 pathway relies largely on ampk activation\n\n. functional tests were performed to study their pathogenicity and understand the disease mechanism. results : the consistent clinical features of the affected individuals, from seven unrelated families, included choanal atresia, athelia or hypoplastic\nwe show that amot binds talin and is essential for relaying forces between fibronectin and the cytoskeleton\n"
        },
        {
          "qas": [
            {
              "id": "6220cbf83a8413c653000067_001",
              "question": "Do RNA binding Proteins  that bind to adenine uridine (AU)-rich elements (AREs) in the 5' untranslated region (UTR) of mRNAs (AU-RBPs) regulate the DNA Damage Response?"
            }
          ],
          "context": "factors ; 4 ) circrnas regulate biological and pathological processes by sponging mirnas, binding to rna - binding protein ( rbp ), regulators of splicing and transcription, modifiers of parental gene expression, and regulators of protein translation or\ny rna - binding proteins ( rbps ) have been shown to recognize and bind to mrnas that contains ares generally present in the 3'utr of mrnas. rbps\n\nsecondly, the degradation of some mrnas related to immune responses has been reported to be regulated by binding of rna - binding proteins to adenylate uridylate - rich elements ( au - rich elements, ares ) located in the 3'- untranslated region ( 3'- utr ).\npost - transcriptional mrna regulation by rna binding proteins ( rbps ) associated with au - rich elements ( ares ) present in the 3'untranslated region ( 3'utr ) of specific mrnas modulates transcript stability and translation in eukaryotic cells.\n\nhu proteins have been shown to bind to au - rich elements ( ares ) in the 3'- untranslated region of unstable mrnas.\nin the 3'- untranslated region, the destabilizing adenine - uridine ( au ) - rich elements ( ares ) control the expression of several transcripts through interactions with are - binding proteins ( aubps ) and rna degradation machinery.\n\ny rna - binding proteins ( rbps ) have been shown to recognize and bind to mrnas that contains ares generally present in the 3'utr of mrnas. rbps\nthe au / u - rich element - binding protein hur has been shown to bind to p53 mrna 3'utr and enhance translation in response to dna - damaging uvc radiation.\n\nsecondly, the degradation of some mrnas related to immune responses has been reported to be regulated by binding of rna - binding proteins to adenylate uridylate - rich elements ( au - rich elements, ares ) located in the 3'- untranslated region ( 3'- utr ).\nin the 3'- untranslated region, the destabilizing adenine - uridine ( au ) - rich elements ( ares ) control the expression of several transcripts through interactions with are - binding proteins ( aubps ) and rna degradation machinery.\n"
        },
        {
          "qas": [
            {
              "id": "6211566a3a8413c653000010_001",
              "question": "Has CPX-351 been approved by the FDA and the EMA?"
            }
          ],
          "context": "cpx - 351 ( united states : vyxeos\u00ae ; europe : vyxeos\u00ae liposomal ), a dual - drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1 : 5 molar ratio, is approved by the us fda and the ema for the treatment of adults with newly diagnosed\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\n\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\nbased on positive results from a phase i / ii clinical trial\n\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nand open - label extension studies are needed to determine the long - term safety and efficacy of this promising therapy.\n"
        },
        {
          "qas": [
            {
              "id": "6217dc173a8413c65300002b_001",
              "question": "Do we find bacteriophages in the gut?"
            }
          ],
          "context": "bacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\nalready without exogenous intervention, a multitude of phage - bacterial interactions occur within the human gut, some of which might play a direct role in disease progression\n"
        },
        {
          "qas": [
            {
              "id": "601d6fe11cb411341a000033_001",
              "question": "Is tirabrutinib effective for lymphoma?"
            }
          ],
          "context": ". this article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in japan.\nhistological verification of the treatment effect of tirabrutinib for relapsed / refractory primary central nervous system lymphoma.\n\ntirabrutinib was well tolerated and showed promising efficacy for b - cell nhl / cll.\nhistological verification of the treatment effect of tirabrutinib for relapsed / refractory primary central nervous system lymphoma.\n\nhere, we provide a comprehensive review of the preclinical and clinical activity of tirabrutinib, a drug approved in japan for relapsed or refractory primary central nervous system lymphoma and all lines of waldenstrom\nhistological verification of the treatment effect of tirabrutinib for relapsed / refractory primary central nervous system lymphoma.\n\ntirabrutinib was well tolerated and showed promising efficacy for b - cell nhl / cll.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "621ea5a53a8413c653000055_001",
              "question": "Are Epoxyeicosatrienoic acids (EETs) synthesized by cytochrome P450 epoxygenases from arachidonic acid?"
            }
          ],
          "context": "epoxyeicosatrienoic acids ( eets ), which are synthesized from arachidonic acid by cytochrome p450 epoxygenases, function primarily as autocrine and paracrine effectors in the cardiovascular system and kidney. t\nbiologically active epoxyeicosatrienoic acid ( eet ) regioisomers are synthesized from arachidonic acid by cytochrome p450 epoxygenases of endothelial, myocardial, and renal tubular cells.\n\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nbiologically active epoxyeicosatrienoic acid ( eet ) regioisomers are synthesized from arachidonic acid by cytochrome p450 epoxygenases of endothelial, myocardial, and renal tubular cells.\n\nepoxyeicosatrienoic acids ( eets ), synthesized by cytochrome p450 epoxygenases from arachidonic acid.\nepoxyeicosatrienoic acids ( eets ) are synthesized from arachidonic acid by cytochrome p450 epoxygenases in endothelial cells.\n\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\n"
        },
        {
          "qas": [
            {
              "id": "6027446d1cb411341a0000dd_001",
              "question": "Does trimetazidine protect from myocardial injury after percutaneous coronary intervention?"
            }
          ],
          "context": "interpretation : our results show that the routine use of oral trimetazidine 35 mg twice daily over several years in patients receiving optimal medical therapy, after successful pci, does not influence the recurrence of angina or the outcome ; these\nthe recurrence of angina or the outcome ; these findings should be taken into account when considering the place of trimetazidine in clinical practice.\n"
        },
        {
          "qas": [
            {
              "id": "62211d6f3a8413c65300006f_001",
              "question": "Are circRNAs susceptible to degradation by RNase R?"
            }
          ],
          "context": "y rna - binding proteins ( rbps ) have been shown to recognize and bind to mrnas that contains ares generally present in the 3'utr of mrnas. rbps\n. here, we demonstrate that standard protocols involving rnase r can fail to digest > 20 % of all highly expressed linear rnas, but these shortcomings can largely be overcome.\n\nis stable, difficult to cleave and resistant to rna exonuclease or rnase r degradation. circrn\nas circular rnas ( circrnas ) are resistant to degradation by exonucleases, their abundance relative to linear rnas can be used as a surrogate marker for mrna stability in the absence of transcription.\n\nn this review, we summarized the function of circrnas and indicated their roles in the pathogenesis of dr, which may provide new therapeutic targets for clinical treatment.\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\n\nas circular rnas ( circrnas ) are resistant to degradation by exonucleases, their abundance relative to linear rnas can be used as a surrogate marker for mrna stability in the absence of transcription.\neffect on the stability and translational rate of mrnas.\n\nbecause circrnas are not easily degraded by exonuclease rnase r, they can exist more stably in body fluids than linear rnas.\nas circular rnas ( circrnas ) are resistant to degradation by exonucleases, their abundance relative to linear rnas can be used as a surrogate marker for mrna stability in the absence of transcription.\n"
        },
        {
          "qas": [
            {
              "id": "62057f1ec9dfcb9c0900002e_001",
              "question": "Does atemoya juice inhibit tye CYP3A4 enzyme?"
            }
          ],
          "context": "the results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\n\nthe results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\nrates of gastrointestinal side effects, headache, and depression.\n\nthe study analysed the prescribing and dispensing of cyp2d6 drugs ( metoprolol, donepezil, galantamine, codeine, tamoxifen ) together with cyp2d6 - blocking ssris ( paroxetine / fluoxetine ) or ssris without significant cyp2d6 inhibition\n. here, we report the identification of 30 known drugs that inhibit viral replication\n"
        },
        {
          "qas": [
            {
              "id": "6217db763a8413c653000028_001",
              "question": "Is Mycobacterium abscessus a human pathogen?"
            }
          ],
          "context": "mycobacterium abscessus is unique in terms of its high morbidity and treatment failure rates\nmycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug resistance.\n\nmycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non - tuberculous mycobacteria ( ntm ) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost.\nmycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug resistance.\n\nmycobacterium abscessus is unique in terms of its high morbidity and treatment failure rates\nmycobacterium abscessus has been recognised as a dreadful respiratory pathogen among the non - tuberculous mycobacteria ( ntm ) because of misdiagnosis, prolonged therapy with poor treatment outcomes and a high cost.\n\nmycobacterium abscessus is unique in terms of its high morbidity and treatment failure rates\nmycobacterium abscessus lung disease is difficult to treat due to intrinsic drug resistance and the persistence of drug - tolerant bacteria.\n"
        },
        {
          "qas": [
            {
              "id": "62121c583a8413c653000016_001",
              "question": "Is MEDI2228 a bispecific antibody?"
            }
          ],
          "context": "we here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by bcma pyrrolobenzodiazepine ( pbd ) antibody drug conjugate ( adc ) medi2228 which can augment efficacy of these immunotherapies.\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer.\n\nrates of gastrointestinal side effects, headache, and depression.\nresults : six participants were enrolled. all had adverse events, mostly behavioral. two completed the trial and the other four withdrew due to adverse events. all participants reported resolution of these events after discontinuation of the drug\n\nwe randomly assigned patients with type 2 diabetes or obesity to intravenous tocilizumab ( an il - 6 receptor antagonist )\ndaily ) for 24 weeks, with an option to continue treatment if desired by the patient and treating physician.\n\nthese ctls recognize short peptides derived from tumour - associated antigens in conjunction with class i molecules expressed on tumour cells.\nsurface inhibitory molecules such as siglec - 8, anti - il - 1s such as canakinumab, bruton kinase ( btk ) inhibitors such as gdc - 0853 and anti - il - 5s such as benralizumab and mepolizumab. summary : the ongoing clinical trials on new targets of treatment hold\n\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n"
        },
        {
          "qas": [
            {
              "id": "601c4ff61cb411341a000022_001",
              "question": "Is proton beam therapy used for treatment of craniopharyngioma?"
            }
          ],
          "context": "initial experience with proton beam therapy in childhood - onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment.\npurpose : we compared proton beam therapy ( pbt ) with intensity modulated radiation therapy ( imrt ) for pediatric craniopharyngioma in terms of disease control, cyst dynamics, and toxic\n\nproton therapy for craniopharyngioma in adults : a protocol for systematic review and meta - analysis.\ninitial experience with proton beam therapy in childhood - onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment.\n\ninitial experience with proton beam therapy in childhood - onset craniopharyngioma patients shows promising results in terms of more protective radiological treatment.\nreports suggest a benefit to proton beam therapy for use in tumors of the skull base, including craniopharyngiomas, chordomas, skull - base sarcomas, and unresectable meningiomas. conclusions : use of proton beam th\n"
        },
        {
          "qas": [
            {
              "id": "601d73261cb411341a00003a_001",
              "question": "Is there a genetic cause of craniostenosis?"
            }
          ],
          "context": "[ genetic counseling in craniostenosis. results of a prospective study performed with a group of studies on craniofacial malformations ].\n. craniostenosis and developmental retardation were the primary presenting features in this patient.\n\nidentification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis.\n[ genetic counseling in craniostenosis. results of a prospective study performed with a group of studies on craniofacial malformations ].\n"
        },
        {
          "qas": [
            {
              "id": "620586a8c9dfcb9c09000032_001",
              "question": "Can bergapten cross the blood-brain barrier?"
            }
          ],
          "context": "several brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro bbb model.\nthe blood - brain barrier ( bbb ) consists of endothelial cells, astrocytes, and pericytes embedded in basal lamina ( bl ).\n\nthe blood - brain barrier ( bbb ) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\n\npotential neuroprotective effects of hesperidin on 3 - nitropropionic acid - induced neurotoxicity in rats.\nthese observations provide several possible mechanisms for central nervous system - related clinical deterioration that occurred when enlimomab was given in acute ischemic stroke.\n\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nseveral brain cell lines, as well as evaluate the permeability of those active molecules through an in vitro bbb model.\n\nneuroprotective agents are screened for use in patients with als.\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\n"
        },
        {
          "qas": [
            {
              "id": "620be4fd3a8413c653000002_001",
              "question": "Does TIMELESS-TIPIN participate in replisome disassembly?"
            }
          ],
          "context": "hsp90 co - chaperones pp5 and fkbps\ntimeless - tipin and ubxn - 3 promote replisome disassembly during dna replication termination in caenorhabditis elegans.\n\n. to investigate the molecular basis of tad formation, we performed hi - c experiments on cells depleted for the forkhead transcription factors, fkh1 and fkh2, previously associated with replication timing\ntimeless - tipin and ubxn - 3 promote replisome disassembly during dna replication termination in caenorhabditis elegans.\n\ninterplay between rnaseh2 and mov10 controls line - 1 retrotransposition.\ntimeless - tipin and ubxn - 3 promote replisome disassembly during dna replication termination in caenorhabditis elegans.\n\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\ntimeless - tipin and ubxn - 3 promote replisome disassembly during dna replication termination in caenorhabditis elegans.\n"
        },
        {
          "qas": [
            {
              "id": "60570fe494d57fd879000026_001",
              "question": "Is hemoglobin antimicrobial?"
            }
          ],
          "context": "the \u03b1137 - 141 peptide, a natural antimicrobial peptide, can be obtained after hydrolysis of hemoglobin, the main constituent of blood red part\nbeyond its physiological activity, hemoglobins are able to inhibit the growth of several microorganisms.\n\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\nbeyond its physiological activity, hemoglobins are able to inhibit the growth of several microorganisms.\n"
        },
        {
          "qas": [
            {
              "id": "620588f9c9dfcb9c09000033_001",
              "question": "Can bergapten cause phototoxicity?"
            }
          ],
          "context": "e in vivo determination of the spf. evidence of anti - inflammatory activity of the sunscreen antiphlogistics bisabolol and panthenol was also not apparent in the uv model over a time course of 48 h\nfurthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned.\n\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nfurthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned.\n\nfurthermore, the phototoxicity of bergapten combined with ultraviolet light has always been mentioned.\ncitrus fruits, and its aglycone hesperetin using cell - free bioassay system and primary cultured rat cortical cells.\n"
        },
        {
          "qas": [
            {
              "id": "6217d9bf3a8413c653000024_001",
              "question": "Can IFNg induce the expression of IDO?"
            }
          ],
          "context": "strong and positive correlation between ido1 and ifng mrna expression levels\nthe tryptophan - degrading activity of ido1 was not induced significantly by chlamydia infection alone, but the addition of ifng greatly increased its activity.\n\nimmune system and plays a role as a signaling and costimulatory molecule on t lymphocytes.\ncytolysis induction, and antigen - presenting cell functional modulation.\n\nstrong and positive correlation between ido1 and ifng mrna expression levels\nifng inducible ido / gtpch inflammation cascade\n\nstrong and positive correlation between ido1 and ifng mrna expression levels\nactivated pscs expressed il - 33 in the nucleus, and the expression was increased by il - 1\u03b2, tnf - \u03b1, pdgf - bb, and ifn - \u03b3, but not tgf - \u03b21.\n"
        },
        {
          "qas": [
            {
              "id": "602c2ade1cb411341a000124_001",
              "question": "Are TAMs good anticancer therapeutic targets?"
            }
          ],
          "context": "integrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\n\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n\ntherapeutics that have proven to be highly effective include the immunomodulatory drug thalidomide and its newer analogs, lenalidomide and pomalidomide, as well as the proteasome inhibitors bortezomib and carfilzomib\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n"
        },
        {
          "qas": [
            {
              "id": "6027434c1cb411341a0000dc_001",
              "question": "Is gabapentin effective for chronic pelvic pain?"
            }
          ],
          "context": "gabapentin not effective for chronic pelvic pain in women.\n. the mean average nrs pain score was 4 \u00b7 3 ( sd 2 \u00b7 3 ) in the gabapentin group and 4 \u00b7 5 ( sd 2 \u00b7 2 ) in the placebo group\n\nbackground : acupotomy has been widely used to treat nerve entrapment syndrome.\ngabapentin not effective for chronic pelvic pain in women.\n\nrates of gastrointestinal side effects, headache, and depression.\ngabapentin not effective for chronic pelvic pain in women.\n\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\ngabapentin not effective for chronic pelvic pain in women.\n"
        },
        {
          "qas": [
            {
              "id": "6056fbfc94d57fd87900001d_001",
              "question": "Does the royal jelly contain proteins?"
            }
          ],
          "context": "jellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\n\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\n\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\n\nnutrients such as 24 - methylenecholesterol, major royal jelly proteins, and 10 - hydroxy - 2 - decenoic acid.\nthe expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\n"
        },
        {
          "qas": [
            {
              "id": "6217c0b63a8413c65300001e_001",
              "question": "Does UBE4B promote renal cancer?"
            }
          ],
          "context": "ube4b might act as an oncogene in regulating rcc development. therefore it could be served as an effective indicator to predict os and a potential biomarker for targeted therapy of rcc patients.\nthis result indicates that they may be used as putative biomarkers for monitoring changes in bladder carcinogenesis in response to bcg immunotherapy.\n\nube4b might act as an oncogene in regulating rcc development. therefore it could be served as an effective indicator to predict os and a potential biomarker for targeted therapy of rcc patients.\nrecurrent superficial urothelial bladder cancer seem to be linked to immunological effector mechanisms.\n"
        },
        {
          "qas": [
            {
              "id": "6025d9e41cb411341a0000b7_001",
              "question": "Does addition of valproic acid improve survival of patients with diffuse intrinsic pontine glioma?"
            }
          ],
          "context": "diffuse intrinsic pontine gliomas ( dipg ) are the most aggressive brain tumors in children with 5 - year survival rates of only 2 %\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\n\nevent - free survival and overall survival of patients not treated with valproic acid were 6. 5 and 7. 8 months\nrates of gastrointestinal side effects, headache, and depression.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\npossesses potent anticonvulsant activity which might be mediated through modulation of gamma - amino butyric acid / benzodiazepine receptor action.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\n"
        },
        {
          "qas": [
            {
              "id": "621b950f3a8413c653000044_001",
              "question": "Is SMOC2 expressed during wound healing?"
            }
          ],
          "context": "the abnormal expression of tim - 3 on mdsc might be involved in the pathogenesis of pe, and could be a marker to evaluate the immune function in pe.\ndeficiency of the smoc2 matricellular protein impairs bone healing and produces age - dependent bone loss.\n\n. skin wounds treated with 5 % olipiphate ( 26 + 2 ) healed faster than those treated with 2 % solcoseryl ( 30 + 0. 8 ) or in control ( 33 + 0. 6 ). it was shown histologically that the proliferative and antiphlogistic effect of olipiphate involved no scars.\ndeficiency of the smoc2 matricellular protein impairs bone healing and produces age - dependent bone loss.\n\ndeficiency of the smoc2 matricellular protein impairs bone healing and produces age - dependent bone loss.\nthe regulation of immune responses, response to wounding, and organization of extracellular matrix, respectively.\n\ndeficiency of the smoc2 matricellular protein impairs bone healing and produces age - dependent bone loss.\n. quantitative real - time polymerase chain reaction analysis revealed that the expression of t - ucr uc. 63 + was increased in pc tissues. mtt assay and wound healing assay revealed that uc. 63 + was involved in cell growth and cell migration\n"
        },
        {
          "qas": [
            {
              "id": "620580afc9dfcb9c0900002f_001",
              "question": "Does daily atemoya juice intake change the pharmacokinetics of CYP1A2 substrates?"
            }
          ],
          "context": "the results indicate that a daily intake of atemoya would not change the pharmacokinetics of cyp1a2 substrates such as phenacetin as well as cyp2c9 - and cyp3a - substrate drugs.\n. in spite of this inhibition, preadministration of atemoya had no effect on the pharmacokinetics of phenacetin, a cyp1a2 substrate, in rats.\n"
        },
        {
          "qas": [
            {
              "id": "61f602a3882a024a1000001f_001",
              "question": "Is Cabotegravir effective for HIV prevention?"
            }
          ],
          "context": "an evaluation of cabotegravir for hiv treatment and prevention.\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\n\ncabotegravir long - acting for hiv - 1 prevention.\nan evaluation of cabotegravir for hiv treatment and prevention.\n"
        },
        {
          "qas": [
            {
              "id": "62211b973a8413c65300006c_001",
              "question": "Are G-quadruplexes(G4) possible drug targets for glioblastoma?"
            }
          ],
          "context": "the g - quadruplex ( g4 ) dna, which has been developed as a potential anticancer target in drug screening and design, plays a crucial role in the oncogene transcription and translation.\nthese observations indicate that 6otd targets gscs through g4 stabilization and promotion of dna damage responses. therefore, g4s are promising therapeutic targets for glioblastoma.\n\ntherefore, a novel g4 - directed therapeutic strategy could specifically target cancer stem cells in gbm.\nthese observations indicate that 6otd targets gscs through g4 stabilization and promotion of dna damage responses. therefore, g4s are promising therapeutic targets for glioblastoma.\n"
        },
        {
          "qas": [
            {
              "id": "622608ea3a8413c653000079_001",
              "question": "Is RUNX1T1 associate with obesity?"
            }
          ],
          "context": "mir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nrunx1t1 rs34269950 is associated with obesity and metabolic syndrome.\n\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\nrunx1t1 rs34269950 is associated with obesity and metabolic syndrome.\n\nbmi could be used as a candidate risk marker to identify people at higher risk of cognitive deficits, and as an intervention target for modifications of cognitive outcomes.\nrunx1t1 rs34269950 is associated with obesity and metabolic syndrome.\n"
        },
        {
          "qas": [
            {
              "id": "61f9cb19c9dfcb9c09000002_001",
              "question": "Is Adamts18 deficiency associated with cancer?"
            }
          ],
          "context": ". these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. however, the underlying mechanism is not clear. here we generated an adamts18 - deficient mouse strain as an in vivo model to investigate the role of adamts18 in the pathogenesis of colorectal cancer\n"
        },
        {
          "qas": [
            {
              "id": "61f5f89b882a024a10000019_001",
              "question": "Is Ozanimod effective for Ulcerative Colitis?"
            }
          ],
          "context": "ozanimod interferes with migrations of activated t cells to the site of inflammation and is a promising drug for the uc treatment. key words : crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.\nconclusions : there was a high rate of continued study participation and long - term benefit with ozanimod hcl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active uc in the touchstone ole\n\nsions : ozanimod was more effective than placebo as induction and mainte \" \" ce therapy in patients with moderately to severely active ulcerative colitis. ( fun\n. additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\n\nconclusions : there was a high rate of continued study participation and long - term benefit with ozanimod hcl 1 mg daily based on clinical, histological and biomarker measures in patients with moderately to severely active uc in the touchstone ole\nozanimod : a first - in - class sphingosine 1 - phosphate receptor modulator for the treatment of ulcerative colitis.\n\nsions : ozanimod was more effective than placebo as induction and mainte \" \" ce therapy in patients with moderately to severely active ulcerative colitis. ( fun\nozanimod interferes with migrations of activated t cells to the site of inflammation and is a promising drug for the uc treatment. key words : crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.\n\n. additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\nozanimod interferes with migrations of activated t cells to the site of inflammation and is a promising drug for the uc treatment. key words : crohns disease - mongersen - monoclonal antibodies - ozanimod - tofacitinib - ulcerative colitis.\n"
        },
        {
          "qas": [
            {
              "id": "621bd38d3a8413c653000046_001",
              "question": "Is esophageal adenocarcinoma associated with aberrant glycosylation?"
            }
          ],
          "context": "igg glycosylation profile was independently associated with esophageal precancerosis beyond inflammation, which could be an early biomarker for esophageal cancer.\ncomparative glycomic profiling of esophageal adenocarcinoma reveals a subset of glycans that can be selected as candidate biomarkers\n"
        },
        {
          "qas": [
            {
              "id": "622629d13a8413c65300007e_001",
              "question": "Can FTO promote pancreatic cancer development?"
            }
          ],
          "context": "foxa1 expression can independently predict chemosensitivity of er - positive breast cancer patients.\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\n\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\ninvasion, and metastasis of pancreatic cancer cells.\n\na new frontier to treat this therapeutically challenging subset of advanced egfr mutant patients.\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\n"
        },
        {
          "qas": [
            {
              "id": "621b8dee3a8413c653000042_001",
              "question": "Is Lysozyme abundant in human tears?"
            }
          ],
          "context": "lysozyme present in the natural tear\ntear lysozyme\n\nlysozyme in tears, saliva, sweat, and other body fluids,\nin this study we quantify lysozyme, the most prevalent protein in tear fluid,\n"
        },
        {
          "qas": [
            {
              "id": "6052715494d57fd87900000e_001",
              "question": "Is FTY720 FDA approved?"
            }
          ],
          "context": ". although the mechanism of fty720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials\n. in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment.\n"
        },
        {
          "qas": [
            {
              "id": "621d19cc3a8413c65300004a_001",
              "question": "Is cytokeratin a tumor marker?"
            }
          ],
          "context": "the immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\nthe most commonly used melanocytic markers include s100, melan - a, hmb45 and sox10\n\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\ncytokeratin fragment antigen 21 - 1 ( cyfra21 - 1 ) in patients with laryngeal squamous cell carcinoma ( lscc ) and its correlation with tumorigenesis and progression\n\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\ndifferent types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and merkel cell cancer as well as hematological tumors such as classic hodgkin's lymphoma.\n\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\nevels of inflammatory and tumor markers, including carbohydrate antigen ( ca ) 19 - 9, ca125, carcinoembryonic antigen ( cea ), ca153, and cytokeratin 19 fragments ( cyfra21 - 1 ),\n\ncytokeratin fragment 19 ( auc = 0. 6882, p < 0. 0001 ) proved best in detecting relapse.\nthe immunohistochemistry staining for cancer antigen 19 - 9, carcinoembryonic antigen, cytokeratin 20, and ki - 67 showed comparable intensities in both groups.\n"
        },
        {
          "qas": [
            {
              "id": "602596691cb411341a0000ad_001",
              "question": "Is tofacitinib a JAK inhibitor?"
            }
          ],
          "context": "the janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours m1 macrophage development.\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\n\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n\nrates of gastrointestinal side effects, headache, and depression.\n. deucravacitinib was well tolerated and safe.\n\ntwo different janus kinase ( jak ) inhibitors - baricitinib and tofacitinib - are effective and licensed in active rheumatoid arthritis ( ra ).\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\n\nand targeted synthetic ( ts ) dmards ( the janus kinase ( jak ) inhibitors tofacitinib, baricitinib, filgotinib, upadacitinib ).\nobjectives oral targeted synthetic disease - modifying anti - rheumatic drugs ( dmards ), including the janus kinase inhibitors tofacitinib and baricitinib, are the latest addition to the therapeutic options for rheumatoid arthritis ( ra ).\n"
        },
        {
          "qas": [
            {
              "id": "60292dc61cb411341a000110_001",
              "question": "\u0391re plants from the genus Strychnos the original source of curare?"
            }
          ],
          "context": ". the study reviews the historical and ethnographic aspects of the use of curares and timbos in the amazonian region. development : curare is prepared by boiling the roots, bark and stalks of different plants belonging to the loganiaceae ( strychnos )\nvelopment : curare is prepared by boiling the roots, bark and stalks of different plants belonging to the loganiaceae ( strychnos ) and menispermaceae families ( chondrodendron, curarea and abuta ).\n\nprinciples : loganiaceae ( strychnos species ) and menispermaceae ( abuta, chondrodendron, and curarea species ).\n. owing to their poisonous properties, some species of strychnos genus have been employed mainly in hunting and fishing, as an adjunct to weapons used not only in the search of food and clothes, but also for preventing depredation by wild animals\n\nthe ethnobotanical uses of south american species of strychnos l. ( loganiaceae ) are reviewed, with the exception of their major role in the preparation of curare, which will be dealt with in detail elsewhere.\nthe history to about 1850 of the muscle - relaxant poison curare is discussed, especially the developments leading to the botanical identification of the plants that yield the alkaloidal active principles : loganiaceae ( strychnos species ) and\n"
        },
        {
          "qas": [
            {
              "id": "61f9605f882a024a1000004f_001",
              "question": "Are variants in FHF2 (also known as FGF13) associated with encephalopathy?"
            }
          ],
          "context": ". our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\n. these gain - of - function effects are likely to increase neuronal excitability consistent with the epileptic potential of fhf2 variants\n\nmissense variants in the n - terminal domain of the a isoform of fhf2 / fgf13 cause an x - linked developmental and epileptic encephalopathy.\n. our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\n\n. our findings demonstrate that fhf2 variants are a cause of infantile - onset developmental and epileptic encephalopathy and underline the critical role of the fhf2a isoform in regulating nav channel function.\nthe treatment of fshd is currently supportive only.\n"
        },
        {
          "qas": [
            {
              "id": "602c26171cb411341a000122_001",
              "question": "Is AZD9668 a VEGF mRNA drug?"
            }
          ],
          "context": "azd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\n\nazd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\nefficacy, safety and tolerability of azd9668 ( 5, 20 and 60 mg bid ) were compared with placebo in a randomised, double - blind, placebo - controlled, 12 - week, phase iib trial ( nct00949975 : approved by an investigational review board ), in patients with\n"
        },
        {
          "qas": [
            {
              "id": "603400051cb411341a00014e_001",
              "question": "Is histone variant H3.3K27M associated with gliomas?"
            }
          ],
          "context": "well - known oncohistones, with mutations on both h3. 1 and h3. 3, include h3k36m in chondroblastoma, h3k27m in glioma\nreciprocal h3. 3 gene editing identifies k27m and g34r mechanisms in pediatric glioma including notch signaling.\n\nwell - known oncohistones, with mutations on both h3. 1 and h3. 3, include h3k36m in chondroblastoma, h3k27m in glioma\n. tp53 mutations are frequent in low - grade gliomas and secondary glioblastomas derived therefrom.\n"
        },
        {
          "qas": [
            {
              "id": "6081a83f4e6a4cf630000007_001",
              "question": "Is FKBP52 encoding a chaperone ?"
            }
          ],
          "context": "hsp90 co - chaperones pp5 and fkbps\nthe co - chaperone fk506 - binding protein 51 ( fkbp51 )\n\nco \u2011 chaperone fkbp52\nthe co - chaperone fk506 - binding protein 51 ( fkbp51 )\n\nhereditary polyneuropathy with optic atrophy due to pdxk variant leading to impaired vitamin b6 metabolism\nthe co - chaperone fk506 - binding protein 51 ( fkbp51 )\n"
        },
        {
          "qas": [
            {
              "id": "62004357c9dfcb9c09000015_001",
              "question": "Does \u03b1CGRP have amyloidogenic properties?"
            }
          ],
          "context": ". these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\n"
        },
        {
          "qas": [
            {
              "id": "60282c3f1cb411341a0000fe_001",
              "question": "Is istiratumab effective for pancreatic cancer?"
            }
          ],
          "context": "initiation of clinical trials testing these drugs in patients with stage iii nsclc\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\n\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\n. it is most frequently associated with cetuximab and erlotinib ; however, it has also been described in individuals treated with gefitinib or panitumumab.\n\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.\nshown to be effective for advanced biliary tract cancer.\n\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nthe insulin - like growth factor receptor ( igf - 1r ) monoclonal antibody figitumumab, while initially promising, appears to increase toxicity and death in combination with chemotherapy in the treatment of patients with nsclc of squamous histology ;\n\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n"
        },
        {
          "qas": [
            {
              "id": "601efda31cb411341a000069_001",
              "question": "Does bleomycin cause lung toxicity?"
            }
          ],
          "context": "pulmonary toxicity is a devastating complication of bleomycin chemotherapy.\nbleomycin lung toxicity is well established and can manifest as bleomycin - induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications.\n\nbleomycin sometimes causes fatal pulmonary toxicity, including bleomycin - induced pneumonitis.\nbleomycin lung toxicity is well established and can manifest as bleomycin - induced pneumonitis, but pneumomediastinum and pneumothorax are very rare complications.\n\nmechanisms of bleomycin - induced lung damage.\npulmonary toxicity is a devastating complication of bleomycin chemotherapy.\n\nthis report suggests that bleomycin lung toxicity may be reversible if treated aggressively.\npulmonary toxicity is a devastating complication of bleomycin chemotherapy.\n"
        },
        {
          "qas": [
            {
              "id": "6082f4374e6a4cf63000000f_001",
              "question": "Is Keutel syndrome a common genetic disorder?"
            }
          ],
          "context": "keutel syndrome is a rare autosomal - recessive condition characterized by abnormal cartilage calcification.\nkeutel syndrome ( omim 245150 ) is a very rare syndrome\n"
        },
        {
          "qas": [
            {
              "id": "601d724a1cb411341a000035_001",
              "question": "Is fusobacterium associated with Lemierre's syndrome?"
            }
          ],
          "context": "we report an unusual case of lemierre's syndrome due to a rare species of fusobacterium, that is, fusobacterium nucleatum preceded by mycoplasma pneumoniae pharyngitis and followed later by epstein - barr virus infectious mononucleosis.\nfusobacterium necrophorum, a well \u2010 known cause of lemierre's syndrome, was identified.\n\nwe report an unusual case of lemierre's syndrome due to a rare species of fusobacterium, that is, fusobacterium nucleatum preceded by mycoplasma pneumoniae pharyngitis and followed later by epstein - barr virus infectious mononucleosis.\nwe present a patient with an atypical presentation of fusobacterium infection, the genus responsible for lemierre's syndrome.\n\ninvasive infections with fusobacterium necrophorum including lemierre's syndrome : an 8 - year swedish nationwide retrospective study.\nincreased diagnosis of lemierre syndrome and other fusobacterium necrophorum infections at a children's hospital.\n\nlemierre's syndrome is a systemic complication commonly caused by oropharyngeal infection by fusobacterium species, which manifests itself as an internal jugular vein thrombosis formation.\nfusobacteria are most often associated with the classic presentation of lemierre's syndrome consisting of a sore throat, internal jugular vein thrombophlebitis, and septic emboli to the lungs.\n\nfusobacterium species have rarely been implicated in cases of gastrointestinal variant of lemierre's syndrome.\nwe present a patient with an atypical presentation of fusobacterium infection, the genus responsible for lemierre's syndrome.\n"
        },
        {
          "qas": [
            {
              "id": "621fd6083a8413c653000066_001",
              "question": "Unlike DNA, RNA is not methylated, yes or no?"
            }
          ],
          "context": "the methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation.\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna\n\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna\nthe detection and quantification of methylated rna can be beneficial to understand certain cellular regulation processes such as transcriptional modulation of gene expression, immune response, or epigenetic alterations.\n\na combined genetic and biochemical approach revealed that human dnmt2 did not methylate dna but instead methylated a small rna ; mass spectrometry showed that this rna is aspartic acid transfer rna ( trna ( asp ) ) and that dnmt2 specifically methylated\nhere, we propose that rna methylation began prior to dna methylation in the early forms of life evolving on earth.\n\nn6 - adenosine methylation ( m6a ) is one of the most common modifications on mrna.\n. among them, the most common rna modification, n6 - methyladenosine ( m6 a ), has been shown to dynamically and reversibly exert its functions in multiple ways, including splicing, export, decay and translation initiation efficiency to regulate mrna\n\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\n"
        },
        {
          "qas": [
            {
              "id": "620155b6c9dfcb9c09000024_001",
              "question": "Is covid-19 induced anosmia caused by disruption of nuclear architecture?"
            }
          ],
          "context": "in our retrospective cohort study comparing the clinical presentation of covid - 19 and other respiratory viral infections, we found that anosmia and dysgeusia were symptoms independently associated with covid - 19 and can be important differentiating\ndisruption of nuclear architecture as a cause of covid - 19 induced anosmia.\n"
        },
        {
          "qas": [
            {
              "id": "622dd1433a8413c6530000a5_001",
              "question": "Is taxilin a cancer marker?"
            }
          ],
          "context": "\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\nevels of inflammatory and tumor markers, including carbohydrate antigen ( ca ) 19 - 9, ca125, carcinoembryonic antigen ( cea ), ca153, and cytokeratin 19 fragments ( cyfra21 - 1 ),\n\n\u03b1 - taxilin, a binding partner of the syntaxin family, is a candidate tumor marker.\nexpression of \u03b1 - taxilin has been implicated in the development of human glioblastoma, hepatocellular carcinoma and renal cell carcinoma.\n"
        },
        {
          "qas": [
            {
              "id": "622668313a8413c653000087_001",
              "question": "Is PCAT6 a microRNA?"
            }
          ],
          "context": "in this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\n\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\n\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\nwe found that : i ) the circrna expression profile revealed 1, 285 significant differences in circrna expression, with circrna expression downregulated in 594 samples and upregulated in 691 samples via interactions with mirnas.\n\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n\nof cell and tissue types related to pathological states\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n"
        },
        {
          "qas": [
            {
              "id": "6201a4edc9dfcb9c09000028_001",
              "question": "Is HDAC1 required for GATA-1 transcriptional activity?"
            }
          ],
          "context": ". thus, gata - 1 deacetylation and its interaction with hdac1 modulates gata - 1 chromatin binding and transcriptional activity that control erythroid / megakaryocyte commitment and differentiation.\nhdac1 is required for gata - 1 transcription activity, global chromatin occupancy and hematopoiesis.\n"
        },
        {
          "qas": [
            {
              "id": "623a24d6f0baec9a1b000002_001",
              "question": "Is telomestatin, a novel statin drug used to treat high cholesterol?"
            }
          ],
          "context": "a novel telomerase inhibitor, telomestatin, isolated from streptomyces anulatus is the most potent telomerase inhibitor so far.\ntelomestatin is a natural product isolated from streptomyces anulatus 3533 - sv4 and has been shown to be a very potent telomerase inhibitor.\n\ntelomestatin, a strong telomerase inhibitor with g - quadruplex stabilizing activity, is a potential therapeutic agent for treating cancers.\ntelomerase inhibition with a novel g - quadruplex - interactive agent, telomestatin : in vitro and in vivo studies in acute leukemia.\n"
        },
        {
          "qas": [
            {
              "id": "61f7d4da882a024a10000033_001",
              "question": "Is there an association between Guillain\u2013Barr\u00e9 syndrome and covid vaccine?"
            }
          ],
          "context": "guillain - barre syndrome after covid - 19 vaccination.\ncase of guillain - barre syndrome following covid - 19 vaccine.\n\nto date, cases of guillain - barre syndrome ( gbs ) following a covid vaccine ( pfizer, johnson & johnson, janssen, astrazeneca ) have been reported.\nguillain - barre syndrome associated with covid - 19 vaccination.\n\ncase of guillain - barre syndrome following covid - 19 vaccine.\nguillain - barre syndrome associated with covid - 19 vaccination.\n\ncase of guillain - barre syndrome following covid - 19 vaccine.\nguillain - barre syndrome after covid - 19 vaccination.\n"
        },
        {
          "qas": [
            {
              "id": "61fa904fc9dfcb9c09000004_001",
              "question": "Is Erythropoietin effective for neuroprotection of Preterm Infants."
            }
          ],
          "context": "based on existing evidence, it is still too early to recommend epo as the standard treatment for preterm brain injury.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\n\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\nor death or in the frequency of serious adverse events. conclusions : high - dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe\n\nor death or in the frequency of serious adverse events. conclusions : high - dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\n"
        },
        {
          "qas": [
            {
              "id": "6226317a3a8413c653000080_001",
              "question": "Is Ameloblastoma (AB) a common benign tumor occurring in the brain?"
            }
          ],
          "context": "background ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\nameloblastoma ( ab ) is an aggressive and slow - growing tumor with high recurrence rate, which arises from odontogenic epithelium.\n\nameloblastoma ( ab ) is the most common benign epithelial odontogenic tumor occurring in the jawbone.\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\n\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\n. although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat.\n"
        },
        {
          "qas": [
            {
              "id": "622901d23a8413c65300008c_001",
              "question": "Is Ameloblastoma (AB) a benign tumor that never metastasizes?"
            }
          ],
          "context": "ameloblastoma is an odontogenic tumor, usually benign, which rarely metastasizes to distant organs.\nameloblastoma, a benign but locally aggressive odontogenic tumor, often demonstrates metastasis despite benign histological features and this variant is termed as metastasizing ameloblastoma ( metam ).\n\nalthough ameloblastomas rarely metastasise, recurrences together with radical surgery often result in facial deformity and significant morbidity.\n. although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat.\n\nameloblastoma ( ab ) is the most common benign epithelial odontogenic tumor occurring in the jawbone.\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\n\nbackground ameloblastoma ( ab ) is a common odontogenic epithelial tumor, with locally invasive behavior and high recurrence.\n. although some types of ameloblastoma can be treated predictably with aggressive surgical treatment, recurrent ameloblastoma and metastasising ameloblastoma are still difficult to treat.\n"
        },
        {
          "qas": [
            {
              "id": "620157bec9dfcb9c09000025_001",
              "question": "Is there any role of the 'Greek islands' in olfactory receptor choice?"
            }
          ],
          "context": ". the greek - island - bound transcription factor lhx2 and adaptor protein ldb1 regulate the assembly and maintece of olfactory receptor compartments, greek island hubs and olfactory receptor transcription, providing mechanistic insights into and\n. these contacts are orchestrated by intergenic olfactory receptor enhancers, the'greek islands ', which first contribute to the formation of olfactory receptor compartments and then form a multi - chromosomal super - enhancer that associates with the\n"
        },
        {
          "qas": [
            {
              "id": "622dc4b63a8413c6530000a4_001",
              "question": "Is paxillin affected by RANKL?"
            }
          ],
          "context": "paxillin levels induced by rankl in murine bone marrow cells.\nrankl promotes paxillin serine and tyrosine phosphorylation,\n"
        },
        {
          "qas": [
            {
              "id": "622b95dc3a8413c653000092_001",
              "question": "Is retinol binding protein 4 an adipokine?"
            }
          ],
          "context": "retinol - binding protein 4 ( rbp4 ) is a prominent adipokine i\nsystematic quantification of neurotrophic adipokines rbp4, pedf, and clusterin in human cerebrospinal fluid and serum.\n\nfetuin - a and retinol - binding protein 4 ( rbp4 ) are secreted as both hepatokine and adipokine.\nretinol - binding protein 4 ( rbp4 ) is a prominent adipokine i\n"
        },
        {
          "qas": [
            {
              "id": "622ce21d3a8413c65300009c_001",
              "question": "Is HYDIN (Hydrocephalus-inducing protein homolog) an axonemal protein?"
            }
          ],
          "context": "precise axonemal location of hydin, a protein that, when mutated, causes hydrocephalus, and defined a unique role for hydin in ciliary motility.\nhydin was recently identified as an axonemal protein ; however, its function is as yet unknown.\n"
        },
        {
          "qas": [
            {
              "id": "621e62c33a8413c653000050_001",
              "question": "Are there any R packages that help with visualizing data on spirals?"
            }
          ],
          "context": ". the flexibility and power of spiralize are demonstrated by five examples from real - world datasets.\n. here we present the r package spiralize that provides a general solution for visualizing data on spirals. spiralize implements numerous graphics functions so that self - defined high - level graphics can be easily implemented by users\n\nspiral layout has two major advantages for data visualization. first, it is able to visualize data with long axes, which greatly improves the resolution of visualization. second, it is efficient for time series data to reveal periodic patterns\n. here we present the r package spiralize that provides a general solution for visualizing data on spirals. spiralize implements numerous graphics functions so that self - defined high - level graphics can be easily implemented by users\n"
        },
        {
          "qas": [
            {
              "id": "61faa3bac9dfcb9c0900000b_001",
              "question": "Was ALVAC-HIV effective for HIV prevention in the HVTN 702 trial?"
            }
          ],
          "context": "improve overall survival or other efficacy end points.\n. the primary end point was e\n\na total sample of 10 adolescents and young adults diagnosed with as was obtained\nhowever, with the recent failure of the hvtn 702 clinical trial, comprehensive profiling of humoral immune responses may provide insight for these disappointing results.\n\nthe alvac - gp120 regimen did not prevent hiv - 1 infection among participants in south africa d\n. during the 24 - month follow - up, hiv - 1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group ( hazard ratio, 1. 02 ; 95 % confidence interval, 0. 81 to 1. 30 ; p = 0. 84 ). conclusions : the alvac - gp120 regimen did not\n\nthe advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\n. during the 24 - month follow - up, hiv - 1 infection was diagnosed in 138 participants in the vaccine group and in 133 in the placebo group ( hazard ratio, 1. 02 ; 95 % confidence interval, 0. 81 to 1. 30 ; p = 0. 84 ). conclusions : the alvac - gp120 regimen did not\n"
        },
        {
          "qas": [
            {
              "id": "622baf3f3a8413c653000099_001",
              "question": "Do Afamin bind Vitamin E?"
            }
          ],
          "context": "the human vitamin e - binding protein afamin\nafamin is a plasma vitamin e - binding glycoprotein\n\nafamin is a plasma vitamin e - binding glycoprotein\nafamin, a vitamin e - binding protein in human plasma\n\nthe human vitamin e - binding protein afamin\nafamin, a vitamin e - binding protein in human plasma\n"
        },
        {
          "qas": [
            {
              "id": "622632483a8413c653000081_001",
              "question": "Is disruption of immune regulation mechanisms associated with adverse pregnancy outcomes, including preeclampsia (PE)?"
            }
          ],
          "context": "preeclampsia can thus be considered a hyperinflammatory state associated with defective regulation of the immune system proposed as a key element in the pathological events of the placental subtype of this disorder.\nmaternal systemic and placental inflammatory responses participate in the pathogenesis of hypertensive disorders of preg \" \" cy including preeclampsia, a preg \" \" cy - specific syndrome, although the role of inflammation remains unclear.\n\ndisruption of complex immune regulation mechanisms is associated with adverse preg \" \" cy outcomes, including preeclampsia ( pe ).\nmaternal immune tolerance is important for maintaining preg \" \" cy, and researchers have increasingly focused on the critical roles of cytokines in the pathogenesis of pe in recent years.\n\ndisruption of complex immune regulation mechanisms is associated with adverse preg \" \" cy outcomes, including preeclampsia ( pe ).\nhowever, immune maladaptation and hemostatic imbalance have been suggested to be responsible for adverse preg \" \" t outcomes, such as preeclampsia ( pe ), miscarriage, recurrent spontaneous abortion ( rsa ) and intrauterine growth restriction ( iugr ).\n\ndisruption of complex immune regulation mechanisms is associated with adverse preg \" \" cy outcomes, including preeclampsia ( pe ).\ndisruption of well - controlled immune functions leads to infertility, placental inflammation, and numerous preg \" \" cy complications, including preeclampsia ( pe ).\n\npreeclampsia can thus be considered a hyperinflammatory state associated with defective regulation of the immune system proposed as a key element in the pathological events of the placental subtype of this disorder.\nour results indicate these proteins are new factors that play important roles in the immunological pathomechanism of preeclampsia.\n"
        },
        {
          "qas": [
            {
              "id": "62266c353a8413c65300008a_001",
              "question": "Can autophagy related lncRNAs be used for colorectal cancer prognosis?"
            }
          ],
          "context": ". in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n\nthe new arlncrna - based model predicts crc patient prognosis and provides new research ideas regarding potential mechanisms regulating the biological behavior of crc. arlncrnas may play important roles in personalized cancer treatment.\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nimmunofluorescence and immunoblotting investigations revealed the presence of cathepsin l in the nuclear compartment in addition to its expected endo - lysosomal localization in colorectal carcinoma cells.\nthe library of integrated cellular signatures ( lincs ) project provides comprehensive transcriptome profiling of human cell lines before and after chemical and genetic perturbations.\n"
        },
        {
          "qas": [
            {
              "id": "621e9aa13a8413c653000053_001",
              "question": "Are there roles for cohesin mutations in AML?"
            }
          ],
          "context": "several landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\n"
        },
        {
          "qas": [
            {
              "id": "622d0aa63a8413c6530000a0_001",
              "question": "Is ASF1 phopshorylated by  the Tousled-like kinases?"
            }
          ],
          "context": "asf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\ntlks interact specifically ( and phosphorylate ) with the chromatin assembly factor asf1, a histone h3 - h4 chaperone\n\nthe tousled - like kinases 1 and 2 ( tlk1 / 2 ) control histone deposition through the asf1 histone chaperone\nthe tousled - like kinases ( tlks ) are involved in chromatin assembly, dna repair, and transcription. two tlk genes exist in humans, and their expression is often dysregulated in cancer. tlks phosphorylate asf1\n\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nthe tousled - like kinases ( tlks ) are involved in chromatin assembly, dna repair, and transcription. two tlk genes exist in humans, and their expression is often dysregulated in cancer. tlks phosphorylate asf1\n\nasf1, a key histone h3 - h4 chaperone required for this process, is phosphorylated by tousled - like kinases ( tlks ).\nwe postulate that zrf1 operates in conjunction with cellular remodeling machines and suggest that on - site remodeling might be a hallmark of many chromatin - associated signaling pathways.\n"
        },
        {
          "qas": [
            {
              "id": "6237a6e93a8413c6530000b1_001",
              "question": "Does sphingosine-1 phosphoate suppress epiregulin?"
            }
          ],
          "context": "s1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\n\nthe pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\n\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\nhigh levels of col6a3 and its cleaved product, endotrophin ( etp )\n\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit.\neyelash trichomegaly is an uncommon drug - associated sequelae experienced during treatment with epidermal growth factor receptor ( egfr ) inhibitors\n\ngrhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\nthe pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\n"
        },
        {
          "qas": [
            {
              "id": "62068e67c9dfcb9c09000038_001",
              "question": "Can whole genome sequencing be used for diagnosis of mitochondrial disease?"
            }
          ],
          "context": "whole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31 % after exclusion of common causes\nbiparental inheritance of mitochondrial dna in humans.\n\nwhole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31 % after exclusion of common causes\nmapping, and segregation analysis for novel disease - causing gene discovery\n\nwhole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31 % after exclusion of common causes\nthe whole exome sequencing, further verified with sanger sequencing and parental background.\n\nwhole genome sequencing is a useful diagnostic test in patients with suspected mitochondrial disorders, yielding a diagnosis in a further 31 % after exclusion of common causes\n. therefore the methodology used in the analysis of greek patients must be able to detect both point and small frameshift mutations in addition to large genomic rearrangements across the entire coding region of the two genes.\n"
        },
        {
          "qas": [
            {
              "id": "622662e13a8413c653000085_001",
              "question": "Can METTL3 methylate long noncoding RNAs?"
            }
          ],
          "context": "this study aimed to explore the regulatory mechanism of methyltransferase3 ( mettl3 ) - mediated long non - coding rna ( lncrna ) n6 - methyladenosine ( m6a ) modification in the osteogenic differentiation of human adipose - derived stem cells ( hascs ) induced by\nthe methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation.\n\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\nthe methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation.\n\nthis study aimed to explore the regulatory mechanism of methyltransferase3 ( mettl3 ) - mediated long non - coding rna ( lncrna ) n6 - methyladenosine ( m6a ) modification in the osteogenic differentiation of human adipose - derived stem cells ( hascs ) induced by\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\n"
        },
        {
          "qas": [
            {
              "id": "622f6ad13a8413c6530000aa_001",
              "question": "Can parasite infections by Schistosoma japonicum prevent or improve asthma?"
            }
          ],
          "context": "therefore, we hypothesize that schistosoma japonicum egg antigens, a type of native antigen, can induce production of cd4 ( + ) cd25 ( + ) t cells with regulatory activity, modulating airway inflammation and inhibiting asthma development.\nschistosoma japonicum infection downregulates house dust mite - induced allergic airway inflammation in mice\n\nhas been shown that helminth infections including schistosoma mansoni may modulate atopic diseases including asthma. i\nschistosoma japonicum infection downregulates house dust mite - induced allergic airway inflammation in mice\n\n. japonicum infection ( allergen sensitization before infection ) on asthma were rarely investigated.\nhas been shown that helminth infections including schistosoma mansoni may modulate atopic diseases including asthma. i\n"
        },
        {
          "qas": [
            {
              "id": "6212c25c3a8413c653000019_001",
              "question": "Is there a role for CADM1 in Myelodysplastic syndrome (MDS)?"
            }
          ],
          "context": "the cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\ntogether with the frequent simultaneous deletions of kmt2a, atm and cbl and mutations of asxl1, sf3b1 and cbl, we show that cadm1 may be important in the physiopathology of the del ( 11q ) mds, extending its role as tumor - suppressor gene from solid\n\ntogether with the frequent simultaneous deletions of kmt2a, atm and cbl and mutations of asxl1, sf3b1 and cbl, we show that cadm1 may be important in the physiopathology of the del ( 11q ) mds, extending its role as tumor - suppressor gene from solid\n. the variant is associated with expression of cadm2 in the cingulate cortex ( p - value = 4 \u00d7 10 ( - 4 ) )\n\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\ntogether with the frequent simultaneous deletions of kmt2a, atm and cbl and mutations of asxl1, sf3b1 and cbl, we show that cadm1 may be important in the physiopathology of the del ( 11q ) mds, extending its role as tumor - suppressor gene from solid\n"
        },
        {
          "qas": [
            {
              "id": "625374a8e764a53204000027_001",
              "question": "Is periampullary carcinoma (PAC) a relatively rare genitourinary malignancy"
            }
          ],
          "context": "definition : periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors. methods : in the present study, we retrospectively reviewed the medical records of 16 patients\npatients with periampullary tumour has not been reported to date.\n\ndefinition : periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors. methods : in the present study, we retrospectively reviewed the medical records of 16 patients\nsome 20 - 40 % of the periampullary carcinoma is irresectable at the time of diagnosis. biliary stenting and surgical bypass are commonly used palliative procedure.\n\ndefinition : periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors. methods : in the present study, we retrospectively reviewed the medical records of 16 patients\nperiampullary adenocarcinomas are rare neoplasm that originates from the pancreatic head, the ampulla of vater, the distal bile duct or the duodenum.\n\nsome 20 - 40 % of the periampullary carcinoma is irresectable at the time of diagnosis. biliary stenting and surgical bypass are commonly used palliative procedure.\n. it is most commonly performed for periampullary malig \" \" cy but may also be indicated in select cases of chronic pancreatitis or benign periampullary tumors.\n\ndefinition : periampullary carcinomas are rare and constitute a special entity, as diagnosed earlier and having a better prognosis than other duodenal tumors. methods : in the present study, we retrospectively reviewed the medical records of 16 patients\npancreaticobiliary subtype of periampullary carcinoma ( pac ) has a poor prognosis in comparison to the intestinal subtype.\n"
        },
        {
          "qas": [
            {
              "id": "62015485c9dfcb9c09000023_001",
              "question": "Do SETD1A mutations predispose to schizophrenia?"
            }
          ],
          "context": ". our findings advance understanding of how setd1a mutations predispose to schizophrenia ( scz ) and point to novel therapeutic interventions.\nrecapitulation and reversal of schizophrenia - related phenotypes in setd1a - deficient mice.\n\n. notably, evolutionarily conserved setd1a targets are associated with neuropsychiatric genetic risk burden. reinstating setd1a expression in adulthood rescues cognitive deficits\n. our findings advance understanding of how setd1a mutations predispose to schizophrenia ( scz ) and point to novel therapeutic interventions.\n"
        },
        {
          "qas": [
            {
              "id": "61f7cca7882a024a1000002b_001",
              "question": "Is Sotatercept effective for Pulmonary Arterial Hypertension?"
            }
          ],
          "context": "sotatercept for the treatment of pulmonary arterial hypertension.\ndesign of a randomised, placebo - controlled clinical trial of nintedanib in patients with systemic sclerosis - associated interstitial lung disease ( senscis\u2122 ).\n\nsotatercept for the treatment of pulmonary arterial hypertension.\nrates of gastrointestinal side effects, headache, and depression.\n\nsotatercept for the treatment of pulmonary arterial hypertension.\nnewer agents with anti - fibrotic properties, such as pirfenidone or nintedanib, might hold promise also for the pulmonary fibrosis seen in sarcoidosis.\n"
        },
        {
          "qas": [
            {
              "id": "624f2355e764a5320400000b_001",
              "question": "Is the 22-item sino-nasal outcome test (SNOT-22) a widely used measure for Health-Related Quality-of-Life (HRQOL) associated with chronic rhinosinusitis (CRS)?"
            }
          ],
          "context": "the sino - nasal - outcome - test - 22 ( snot - 22 ) represents the reference questionnaire to assess symptoms, health - related quality - of - life ( hrqol ) and treatment - response in patients with chronic rhinosinusitis ( crs ).\nbackground : the 22 - item sino - nasal outcome test ( snot - 22 ) is a commonly utilized outcome measure for chronic rhinosinusitis ( crs\n\nthe sino - nasal - outcome - test - 22 ( snot - 22 ) represents the reference questionnaire to assess symptoms, health - related quality - of - life ( hrqol ) and treatment - response in patients with chronic rhinosinusitis ( crs ).\nbackground : prior study demonstrated that baseline 22 - item sino - nasal outcome test ( snot - 22 ) aggregate scores accurately predict selection of surgical intervention in patients with chronic rhinosinus\n\ntcomes included scores on the crs disease severity visual analog scale ( vas ), 22 - item sino - nasal outcome test ( snot - 22 ), 5 - dimension euroqol ( eq - 5d ) general health status vas, and 36 - item short - form health survey ( sf - 36 ) for hrqol and nasal\nthe sino - nasal - outcome - test - 22 ( snot - 22 ) represents the reference questionnaire to assess symptoms, health - related quality - of - life ( hrqol ) and treatment - response in patients with chronic rhinosinusitis ( crs ).\n\ntest ( snot - 22 ), a modification of a pre - existing instrument, the snot - 20. design, setting and participants : the national comparative audit of surgery for nasal polyposis and chronic rhinosinusitis was a prospective cohort study collecting data on\nbackground : prior study demonstrated that baseline 22 - item sino - nasal outcome test ( snot - 22 ) aggregate scores accurately predict selection of surgical intervention in patients with chronic rhinosinus\n"
        },
        {
          "qas": [
            {
              "id": "626aa563e764a53204000036_001",
              "question": "Is pRETRO-SUPER an adenoviral vector?"
            }
          ],
          "context": "the advanced - phase hiv prevention vaccine trials done in south africa ( hvtn 702 ) and in thailand ( rv144 ), which both investigated canarypox vectors and adjuvanted gp120 proteins, gave rise to different results\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\n\nat leu309 selectively and attenuated alzheimer's disease - like pathology and cognitive impairment in adeno - associated virus vector - 1 - i1pp2a rats.\nin this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\n\nrecapitulation and reversal of schizophrenia - related phenotypes in setd1a - deficient mice.\nin this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\n\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\nin this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\n\nthe use of antiretrovirals as pre - exposure prophylaxis ( prep ) is highly efficacious in hiv prevention.\nthe most commonly used prep medication ( truvada < br >\n"
        },
        {
          "qas": [
            {
              "id": "6201a85cc9dfcb9c0900002a_001",
              "question": "Is there a dependence between chromatin organization and dorsoventral gene expression in Drosophila?"
            }
          ],
          "context": ". in drosophila, the dna - binding protein zelda ( also known as vielfaltig ) is required for this transition and for transcriptional activation of the zygotic genome.\nindependence of chromatin conformation and gene regulation during drosophila dorsoventral patterning.\n\nindependence of chromatin conformation and gene regulation during drosophila dorsoventral patterning.\npcg proteins, dna methylation, and gene repression by chromatin looping.\n\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\nindependence of chromatin conformation and gene regulation during drosophila dorsoventral patterning.\n\nwhile analyzing chromatin immunoprecipitation data sets from 21 sequence - specific transcription factors active in the drosophila embryo, we found that binding of all factors exhibits a dose - dependent relationship with \" tagteam \" sequence motifs bound\nindependence of chromatin conformation and gene regulation during drosophila dorsoventral patterning.\n"
        },
        {
          "qas": [
            {
              "id": "61faa1fcc9dfcb9c0900000a_001",
              "question": "Is vocimagene amiretrorepvec effective for recurrent high-grade glioma?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\noverall survival for recurrent high - grade glioma was 13. 6 months ( 95 % confidence interval, 10. 8 to 20. 0 ) and was statistically improved relative to an external control ( hazard ratio, 0. 45 ; p = 0. 003 ).\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "61f93e68882a024a1000004d_001",
              "question": "Should perampanel be used for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "conclusions : perampanel was associated with a significant decline in alsfrs - r score and was linked to worsening of the bulbar subscore in the 8 mg group.\n. the trial was halted due to the large number of adverse events. discussion : the use of perampanel in this study of als was limited by its poor tolerability\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n"
        },
        {
          "qas": [
            {
              "id": "624c88a1e764a53204000002_001",
              "question": "Is Satb1 a transcription factor?"
            }
          ],
          "context": "pecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\nthe special at - rich sequence binding protein 1 ( satb1 ) and its role in solid tumors.\n\nsatb1 ( special at - rich binding protein 1 ) is a global chromatin organizer regulating the expression of a large number of genes\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nchromatin organizers satb2 and satb1\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\n\nthe transcription factor satb1 that regulates the t - cell maturation\nchromatin organizers satb2 and satb1\n"
        },
        {
          "qas": [
            {
              "id": "6228b3553a8413c65300008b_001",
              "question": "Are circular RNAs implicated in diseases of the eye?"
            }
          ],
          "context": "in this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\ncircrna is a rising star in researches of ocular diseases.\n"
        },
        {
          "qas": [
            {
              "id": "626aaaa8e764a5320400003a_001",
              "question": "Can epigenetic modifications be heritable?"
            }
          ],
          "context": "epigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\nepigenetic alterations are defined as heritable changes in gene expression mediated through mechanisms other than alterations in the dna sequence itself, including dna promoter methylation and various histone covalent modifications.\n\ntransient epigenetic changes across the entire genome can influence metabolic outcomes and might or might not be heritable.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n\nmore interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n\nsome of these epigenetic changes appear to be heritable.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n"
        },
        {
          "qas": [
            {
              "id": "61f7d2a5882a024a10000032_001",
              "question": "Is Belimumab used for lupus nephritis?"
            }
          ],
          "context": "a secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\na secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.\ncent findings : recently, the belimumab in subjects with systemic lupus erythematosus - lupus nephritis trial tested belimumab, an inhibitor of b - cell activating factor, as an add - on therapy to steroids and either mycophenolate mofetil ( mmf ) or\n"
        },
        {
          "qas": [
            {
              "id": "62507ca3e764a5320400000f_001",
              "question": "Is SOX10 expressed in melanoma cells?"
            }
          ],
          "context": "our study confirmed that sox10 is an oncogene and activate notch signaling pathway, which suggests the potential treatment for melanoma patients by target sox10 / notch axis.\nmelanocytic markers melan - a and sox10\n"
        },
        {
          "qas": [
            {
              "id": "61f939a5882a024a1000004a_001",
              "question": "Is tivantinib effective for MET-high hepatocellular carcinoma?"
            }
          ],
          "context": ". median overall survival was 10. 3 ( 95 % confidence interval : 8. 1 - 11. 6 ) and 8. 5 ( 6. 2 - 11. 4 ) mo in the tivantinib and placebo group, respectively ( hazard ratio = 0. 82, 95 % confidence interval : 0. 58 - 1. 15 ).\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\n\nin phase i and ii studies, tivantinib ( arq 197 ), an oral inhibitor of met, demonstrated promising antitumor activity in patients with hcc, both as monotherapy and in combination with sorafenib\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\n\n. a randomized phase ii trial in second - line hcc showed improved overall survival ( hazard ratio : 0. 38 ; p = 0. 01 ) in patients with met - high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.\ncabozantinib in the treatment of hepatocellular carcinoma.\n\n. a randomized phase ii trial in second - line hcc showed improved overall survival ( hazard ratio : 0. 38 ; p = 0. 01 ) in patients with met - high tumors, as demonstrated by immunohistochemistry, treated with tivantinib versus placebo.\nthis study did not confirm the significant efficacy of tivantinib as a second - line treatment for japanese patients with met - high hepatocellular carcinoma.\n"
        },
        {
          "qas": [
            {
              "id": "6250a545e764a53204000012_001",
              "question": "Is EuroQol 5-Dimension Health Assessment (EQ-5D) [a widely used, simple instrument that monitors the general health-related quality of life (HRQoL) in chronic disease] a 5 question assessment?"
            }
          ],
          "context": "to evaluate baseline disease severity and treatment response.\nobjective : the 6 - question euroqol 5 - dimension health assessment ( eq - 5d ) is a widely used, simple instrument that monitors general health - related quality of life ( hrqol ) in chronic disease.\n\ntcomes included scores on the crs disease severity visual analog scale ( vas ), 22 - item sino - nasal outcome test ( snot - 22 ), 5 - dimension euroqol ( eq - 5d ) general health status vas, and 36 - item short - form health survey ( sf - 36 ) for hrqol and nasal\nobjective : the 6 - question euroqol 5 - dimension health assessment ( eq - 5d ) is a widely used, simple instrument that monitors general health - related quality of life ( hrqol ) in chronic disease.\n"
        },
        {
          "qas": [
            {
              "id": "61f608d4882a024a10000023_001",
              "question": "Is sacituzumab govitecan effective for breast cancer?"
            }
          ],
          "context": "sacituzumab govitecan for metastatic triple - negative breast cancer : clinical overview and management of potential toxicities.\nsacituzumab govitecan in metastatic triple - negative breast cancer.\n\nsacituzumab govitecan in metastatic triple - negative breast cancer.\nefficacy and safety of anti - trop - 2 antibody drug conjugate sacituzumab govitecan ( immu - 132 ) in heavily pretreated patients with metastatic triple - negative breast cancer.\n\nsacituzumab govitecan in metastatic triple - negative breast cancer.\n. sacituzumab govitecan is an antibody - drug conjugate composed of an antibody targeting the human trophoblast cell - surface antigen 2 ( trop - 2 ), which is expressed in the majority of breast cancers, coupled to sn - 38 ( topoisomerase i inhibitor ) through\n\nsacituzumab govitecan was initially approved in april 2020 under accelerated approval for the treatment of patients with metastatic triple - negative breast cancer who received at least two prior therapies for metastatic disease\nsacituzumab govitecan in metastatic triple - negative breast cancer.\n"
        },
        {
          "qas": [
            {
              "id": "622905043a8413c65300008e_001",
              "question": "Is Acute Necrotizing Encephalopathy (ANE) which typically affects young, healthy children usually triggered by exposure to air pollution?"
            }
          ],
          "context": "acute necrotizing encephalopathy ( ane ) typically affects young, healthy children who develop rapid - onset severe encephalopathy triggered by viral infections.\nacute necrotizing encephalopathy ( ane ) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems.\n\nbackground : acute necrotizing encephalopathy ( ane ) is a rapidly progressive encephalopathy seen commonly in children triggered by various prodromal viral infections, most common being influenza virus and human herpes virus - 6. objective : we report two\nacute necrotizing encephalopathy ( ane ) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems.\n\nacute necrotizing encephalopathy of childhood ( anec ) is a disease, characterized by a respiratory or gastrointestinal infection, accompanied with fever, rapid alteration of consciousness, and seizures.\nacute necrotizing encephalopathy ( ane ) is a rapidly progressing neurologic disorder that occurs in children after common viral infections of the respiratory or gastrointestinal systems.\n"
        },
        {
          "qas": [
            {
              "id": "6251465ae764a53204000017_001",
              "question": "Is Phospholemman a membrane protein?"
            }
          ],
          "context": "phospholemman ( fxyd1 ) is a single - transmembrane protein regulator of na, k - atpase, expressed strongly in heart, skeletal muscle, and brain and phosphorylated by protein kinases a and c at ser - 68 and ser - 63, respectively.\nthe transmembrane lipoprotein phospholemman ( fxyd1 )\n"
        },
        {
          "qas": [
            {
              "id": "61f93c38882a024a1000004b_001",
              "question": "Can Isradipine slow progression of Early Parkinson Disease?"
            }
          ],
          "context": "these findings suggest that greater exposure to isradipine might slow disease progression.\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\n\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\nresults : isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy - adjusted unified parkinson's disease rating scale parts i - iii score over 36 months ( spearman rank correlation coefficient, rs :\n\nis the only fda - approved treatment for the hallucinations and delusions seen in patients with psychosis of parkinson's disease.\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\n"
        },
        {
          "qas": [
            {
              "id": "625144c9e764a53204000016_001",
              "question": "Is neurofilament light marker for disease?"
            }
          ],
          "context": "the neurodegeneration biomarker neurofilament light chain ( nfl )\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\n\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nneurofilament light chain protein ( nfl ) is a promising biomarker of neurodegeneration.\n\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nneurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with alzheimer's dementia, and psychiatric disorders.\n\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\nneurofilament light chain has a potential role in differentiating patients with frontotemporal dementia from healthy controls, patients with alzheimer's dementia, and psychiatric disorders.\n\nneurofilament light chain ( nfl ) is a relatively new biomarker for ms diagnosis and follow up.\nthe neurodegeneration biomarker neurofilament light chain ( nfl )\n"
        },
        {
          "qas": [
            {
              "id": "62532d42e764a53204000022_001",
              "question": "Is resistance training usually associated with increasing muscle hypertrophy?"
            }
          ],
          "context": "in resistance training, it has been empirically accepted that muscle hypertrophy is developed by low intensity and high volume training, while muscle strength and power are developed by high intensity and low volume training.\nit is universally accepted that resistance training promotes increases in muscle strength and hypertrophy in younger and older populations\n\nit has been proposed that protein supplementation during resistance exercise training enhances muscle hypertrophy.\nin resistance training, it has been empirically accepted that muscle hypertrophy is developed by low intensity and high volume training, while muscle strength and power are developed by high intensity and low volume training.\n\nit has been proposed that protein supplementation during resistance exercise training enhances muscle hypertrophy.\nit is universally accepted that resistance training promotes increases in muscle strength and hypertrophy in younger and older populations\n\nresistance training is one of the effective methods to overcome a decline in muscle mass,\nit is universally accepted that resistance training promotes increases in muscle strength and hypertrophy in younger and older populations\n"
        },
        {
          "qas": [
            {
              "id": "61f93cc7882a024a1000004c_001",
              "question": "Is nerinetide effective for ischaemic stroke?"
            }
          ],
          "context": ". serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nthese observations provide several possible mechanisms for central nervous system - related clinical deterioration that occurred when enlimomab was given in acute ischemic stroke.\n\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\n\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\n\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nthe short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor\n"
        },
        {
          "qas": [
            {
              "id": "61f938e7882a024a10000049_001",
              "question": "Is Algenpantucel-L effective for pancreatic cancer?"
            }
          ],
          "context": "conclusions : algenpantucel - l immunotherapy did not improve survival in patients with borderline resectable or locally advanced unresectable pdac receiving soc neoadjuvant chemotherapy and chemoradiatio\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\n\n. grade 3 or higher adverse events occurred in 105 of 140 patients ( 75 % ) in the standard group and in 115 of 142 patients ( 81 % ) in the experimental group ( p > 0. 05 ). conclusions : algenpantucel - l immunotherapy did not improve survival in patients with\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\n"
        },
        {
          "qas": [
            {
              "id": "62515021e764a53204000018_001",
              "question": "Is Mical an oxidoreductase?"
            }
          ],
          "context": "importance : to date, no study has characterized the mucocutaneous features seen in hospitalized children with multisystem inflammatory syndrome in children ( mis - c ) or the temporal association of these findings with the onset of systemic\nhowever, the newly described multisystem inflammatory syndrome in children ( mis - c ) associated with coronavirus disease 2019 ( covid - 19 ) has been associated with cardiac complications. m\n\nmical is an oxidoreductase\nthe oxidoreductase mical\n"
        },
        {
          "qas": [
            {
              "id": "61fa9a60c9dfcb9c09000007_001",
              "question": "Should istiratumab be used for Pancreatic Cancer?"
            }
          ],
          "context": "initiation of clinical trials testing these drugs in patients with stage iii nsclc\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\n\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\nand ovarian cancers, and demonstrated evidence of effectiveness against pancreatic and prostate cancers.\nshown to be effective for advanced biliary tract cancer.\n\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nconclusions : the addition of algenpantucel - l to standard adjuvant therapy for resected pancreatic cancer may improve survival. a multi - institutional, phase 3 study is ongoing\n\nthe insulin - like growth factor receptor ( igf - 1r ) monoclonal antibody figitumumab, while initially promising, appears to increase toxicity and death in combination with chemotherapy in the treatment of patients with nsclc of squamous histology ;\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "605b9c2a94d57fd879000035_001",
              "question": "Does Amblyopia affect the eye?"
            }
          ],
          "context": "objective : amblyopia or lazy eye is a common visual problem affecting children that cannot correct with lenses.\nthat, although amblyopia is a functional visual loss, rnfl thickness and optic nerve head topographic changes in strabismic and anisometropic amblyopic eyes may be affected by amblyopia.\n\nobjective : amblyopia or lazy eye is a common visual problem affecting children that cannot correct with lenses.\namblyopia is a developmental disorder resulting in poor vision in one eye.\n\namblyopia, commonly known as \" lazy eye, \" is a frequent but preventable cause of decreased vision\namblyopia is a developmental disorder resulting in poor vision in one eye.\n\natropine occlusion in the treatment of strabismic amblyopia and its effect upon the non - amblyopic eye.\ntogether with recent advances in our theoretical understanding of amblyopia and technological advances in amblyopia treatment, we anticipate improved visual outcomes for children affected by this very common eye condition.\n\nobjective : amblyopia or lazy eye is a common visual problem affecting children that cannot correct with lenses.\namblyopia is a developmental disorder of pattern vision.\n"
        },
        {
          "qas": [
            {
              "id": "603bc2b61cb411341a00015b_001",
              "question": "Is autism thought to be related to the  Arginine Vasopressin Peptide (AVP)?"
            }
          ],
          "context": "preclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\nthere has been intensified interest in the neuropeptides oxytocin ( ot ) and arginine vasopressin ( avp ) in autism spectrum disorders ( asd ) given their role in affiliative and social behavior in animals, positive results of treatment studies using ot,\n\ndysfunction of brain - derived arginine - vasopressin ( avp ) systems may be involved in the etiology of autism spectrum disorder ( asd ).\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\n\nwe therefore hypothesized that avp signaling deficits may contribute to social impairments in children with autism spectrum disorder ( asd ).\nthe behavioral effects of avp are mediated through the avp receptor 1a ( avpr1a ), making the avpr1a gene a reasonable candidate for autism susceptibility.\n\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\noxytocin ( oxt ) and arginine - vasopressin ( avp ), as these neuropeptides modulate various aspects of mammalian social behavior.\n"
        },
        {
          "qas": [
            {
              "id": "6278da4456bf9aee6f00000f_001",
              "question": "Is thalidomide used as an immunomodulatory drug nowadays?"
            }
          ],
          "context": "after nearly decades of extinction as a sedative and antiemetic, thalidomide reemerged as the parent compound of a novel and promising class of therapeutics termed the immunomodulatory drugs ( imids ).\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\n\nas immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases\npotential immunomodulatory, antiinflammatory, anti - angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma.\n\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\nin 1990s, however, thalidomide received attention due to the discovery of its anticancer potential derived from antiangiogenic and immunomodulatory activities, and its therapeutic effect on myeloma.\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\nthalidomide was developed in the 1950s as a sedative drug and withdrawn in 1961 because of its teratogenic effects, but has been rediscovered as an immuno - modulatory drug.\nas immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases\n"
        },
        {
          "qas": [
            {
              "id": "6278d0a756bf9aee6f00000e_001",
              "question": "Does p85\u03b1 homodimerize?"
            }
          ],
          "context": "hsp90 co - chaperones pp5 and fkbps\nhomodimerized p85\u03b1\n\nhomodimerized p85\u03b1\nlocalization, reconstitution of protein activity, and protein sequestration by oligomerization.\n\nhomodimerized p85\u03b1\nthe crispr - cas12a system can detect both l858r and t790m with a limit of detection of 0. 005 % in less than three hours.\n\nago2 localizes to cytokinetic protrusions in a p38 - dependent manner and is needed for accurate cell division.\nhomodimerized p85\u03b1\n\nhomodimerized p85\u03b1\n. these include the pikfyve kinase inhibitor apilimod, cysteine protease inhibitors mdl - 28170, z lvg chn2, vby - 825, and ono 5334, and the ccr1 antagonist mln - 3897\n"
        },
        {
          "qas": [
            {
              "id": "6276d2d956bf9aee6f000002_001",
              "question": "Do angiotensin-converting-enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) increase the likelihood of severe COVID-19?"
            }
          ],
          "context": "there are theoretical concerns that angiotensin - converting enzyme inhibitors ( aceis ) and angiotensin receptor blockers ( arbs ) could increase the risk of severe covid - 19.\nthere has been a lot of speculation that patients with coronavirus disease 2019 ( covid - 19 ) who are receiving angiotensin - converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) may be at increased risk for adverse outcomes.\n"
        },
        {
          "qas": [
            {
              "id": "6278ddfe56bf9aee6f000013_001",
              "question": "Are functional tests a good biomarker for Duchenne Muscular Dystrophy?"
            }
          ],
          "context": ". timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\n\nconclusion : the moderate correlation between functional tests, age and baseline mri measures supports mri as a biomarker in duchenne muscular dystrophy clinical trials.\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\n\nconclusion : the moderate correlation between functional tests, age and baseline mri measures supports mri as a biomarker in duchenne muscular dystrophy clinical trials.\n. timed functional testing may therefore be considered as an additional outcome measure in drug trials to evaluate the effects of therapy in ambulant patients with dmd and possibly in other neuromuscular disorders.\n"
        },
        {
          "qas": [
            {
              "id": "627926bc56bf9aee6f00001a_001",
              "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, particularly influenza?"
            }
          ],
          "context": "covid - 19 and can be important differentiating symptoms in patients presenting with acute respiratory illness\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n\ncovid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n\nalthough covid - 19 has been extensively characterized clinically, the factors distinguishing sars - cov - 2 from other respiratory viruses are unknown.\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n\nfindings indicate that clinical symptoms alone would be insufficient to distinguish between coronavirus disease 2019 and other respiratory infections ( eg, influenza ) and / or to evaluate the effects of preventive interventions ( eg, vaccinations ).\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n"
        },
        {
          "qas": [
            {
              "id": "627a6ef856bf9aee6f000020_001",
              "question": "Is lumbar puncture the first test that should be performed on a patient with increased intracranial pressure?"
            }
          ],
          "context": "although generally considered innocuous, there may be considerable danger when lumbar puncture is performed in the presence of increased intracranial pressure, especially when a mass lesion is present.\nthere are few abnormal ct scans presenting a contraindication for lumbar puncture and the majority of these patients usually have clinical signs to suggest raised intracranial pressure.\n\nalthough generally considered innocuous, there may be considerable danger when lumbar puncture is performed in the presence of increased intracranial pressure, especially when a mass lesion is present.\nlumbar puncture is performed routinely for diagnostic and therapeutic purposes in idiopathic intracranial hypertension, despite lumbar puncture being classically contraindicated in the setting of raised intracranial pressure.\n\nby evidence of significant intracranial hypertension.\n. the major contraindication is elevated intracranial pressure with evidence of a mass lesion.\n"
        },
        {
          "qas": [
            {
              "id": "6402c910201352f04a00000c_001",
              "question": "Can losartan reduce brain atrophy in Alzheimer's disease?"
            }
          ],
          "context": "recently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\ninterpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease.\n\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\n\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\ninterpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease.\n\nthe non - vascular, neural mechanism of action of lasmiditan may offer an alternative means to treat migraine especially in patients who have contra - indications for agents with vasoconstrictor activity.\ninterpretation : 12 months of treatment with losartan was well tolerated but was not effective in reducing the rate of brain atrophy in individuals with clinically diagnosed mild - to - moderate alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "63fa13da201352f04a000001_001",
              "question": "Is PRP-40 regulation of microexons a conserved phenomenon?"
            }
          ],
          "context": ". knockdown of the orthologous prpf40a in mouse neuroblastoma cells causes widespread dysregulation of microexons but not conventionally sized exons. prp - 40 regulation of neuronal microexons is therefore a widely conserved phenomenon.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n"
        },
        {
          "qas": [
            {
              "id": "64178e15690f196b51000020_001",
              "question": "Is casimersen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "he approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\n\nhe approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\n"
        },
        {
          "qas": [
            {
              "id": "640e2616201352f04a00002a_001",
              "question": "Is medical hydrology the same as Spa therapy?"
            }
          ],
          "context": "bath ) or ( balneo * ) or ( hydrotherap * ) or ( mineral water ) or ( thermal water ) or ( spring water ) or ( health resort medicine ) )\nhe worked to improve the status of spa medicine, recasting it as medical hydrology.\n\nacupotomy alleviates energy crisis at rat myofascial trigger points\nspa therapy is an integral part of the treatment of burn scars. the objective of this systematic review is to provide an overview of the spa therapy used in the treatment of burn scars and analyze its effects reported in clinical studies\n\nspa therapy is an integral part of the treatment of burn scars. the objective of this systematic review is to provide an overview of the spa therapy used in the treatment of burn scars and analyze its effects reported in clinical studies\nhydrotherapy, \" \" balneotherapy, \" \" spa therapy, \" \" spa treatment, \" \" creno - balneotherapy, \" \" water treatments, \" and \" aqua therapy, \" o\n"
        },
        {
          "qas": [
            {
              "id": "64178e73690f196b51000023_001",
              "question": "Is eteplirsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "allow assessment of high - functioning boys with duchenne muscular dystrophy.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n\neteplirsen - treated patients experienced a statistically significant longer median time to loa by 2. 09 years ( 5. 09 vs. 3. 00 years, p < 0. 01 ) and significantly attenuated rates of pulmonary decline vs. natural history patients ( fvc % p change : - 3. 3 vs\nat years 3 and 4, eteplirsen - treated patients demonstrated markedly greater mean 6mwt than controls ( difference in change from baseline of 132 m [ 95 % ci ( 29, 235 ), p = 0. 015 ] at year 3 and 159 m [ 95 % ci ( 66, 253 ), p = 0. 002 ] at year 4 )\n\nrates of gastrointestinal side effects, headache, and depression.\nat years 3 and 4, eteplirsen - treated patients demonstrated markedly greater mean 6mwt than controls ( difference in change from baseline of 132 m [ 95 % ci ( 29, 235 ), p = 0. 015 ] at year 3 and 159 m [ 95 % ci ( 66, 253 ), p = 0. 002 ] at year 4 )\n\nto date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n"
        },
        {
          "qas": [
            {
              "id": "63f02a82f36125a426000013_001",
              "question": "Does CIDEB mutation protect from liver disease?"
            }
          ],
          "context": "clinical genetic testing of protein - coding regions identifies a likely causative variant in only around half of developmental disorder ( dd ) cases\ngermline mutations in cideb and protection against liver disease.\n\ngermline mutations in cideb and protection against liver disease.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\n\ngermline mutations in cideb and protection against liver disease.\nwilsons disease and idiopathic toxicosis are examples of severe chronic liver diseases that are the results of genetic predisposition to the hepatic accumulation of copper.\n\ngermline mutations in cideb and protection against liver disease.\nprovides an endogenous mechanism to upregulate hepcidin, leading to sustained iron - restricted erythropoiesis and preventing systemic iron overload in \u03b2 - thalassemic mice.\n"
        },
        {
          "qas": [
            {
              "id": "64105502201352f04a00002d_001",
              "question": "Is North Star Ambulatory Assessment score a reliable clinical outcome for disease progression assessment in Duchenne Muscular Dystrophy?"
            }
          ],
          "context": "north star ambulatory assessment in brazilian portuguese is a reliable and valid instrument to measure functional capacity in boys with duchenne muscular dystrophy.\n. we hypothesised that boys with dmd could be clustered into groups sharing similar trajectories of ambulatory function over time, as measured by the north star ambulatory assessment ( nsaa ) total score.\n\nnorth star ambulatory assessment in brazilian portuguese is a reliable and valid instrument to measure functional capacity in boys with duchenne muscular dystrophy.\nthe north star ambulatory assessment is a functional scale specifically designed for ambulant boys affected by duchenne muscular dystrophy ( dmd ).\n"
        },
        {
          "qas": [
            {
              "id": "6415ca99690f196b51000019_001",
              "question": "Have chimeric antigen receptor (CAR)-T cell therapies been approved for the treatment of B cell malignancies?"
            }
          ],
          "context": "engineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nrelapsed or refractory b - cell all, with transient high - grade toxic effects.\n\nengineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nchimeric antigen receptor t cells demonstrate efficacy in b - cell malig \" \" cies, leading to us food and drug administration approval of axicabtagene ciloleucel ( october 2017 ) and tisagenlecleucel ( may 2018 ) for large b - cell lymphomas after 2 prior lines\n\nbackground : tisagenlecleucel is an anti - cd19 chimeric antigen receptor ( car19 ) t - cell therapy approved for the treatment of children and young adults with relapsed / refractory ( r / r ) b - cell acute lymphoblastic leukemia ( b - all ).\nengineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\n\nengineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nthe phase ii juliet trial suggests that the cd19 - targeting car t - cell therapy tisagenlecleucel produces durable responses in patients with relapsed and refractory diffuse large b - cell lymphoma.\n"
        },
        {
          "qas": [
            {
              "id": "64178e4b690f196b51000022_001",
              "question": "Is golodirsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "he approval, granted under the us fda accelerated approval program, was based on an observed increase in dystrophin production in skeletal muscle in patients treated with casimersen\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n\ngolodirsen is a provisionally approved pmo - based drug for approx. 8 % of all dmd patients amenable to exon 53 skipping.\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\n\ngolodirsen is a provisionally approved pmo - based drug for approx. 8 % of all dmd patients amenable to exon 53 skipping.\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\n\nthis study provides evidence for golodirsen biologic activity and long - term safety in a declining dmd population and suggests functional benefit versus external controls.\nn december 2019, intravenous golodirsen received its first global approval in the usa for the treatment of dmd in patients with a confirmed mutation of the dmd gene that is amenable to exon 53 skipping, based on positive results from a phase i / ii\n"
        },
        {
          "qas": [
            {
              "id": "63f043e4f36125a426000023_001",
              "question": "Is Baricitinib effective for Alopecia Areata?"
            }
          ],
          "context": "we reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata ( aa ) in recent 5 years including clinical trials and case reports.\nconclusions : the efficacy and safety profile of baricitinib was maintained during long - term treatment of japanese patients with ra and background methotrexate therapy.\n\nwe reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata ( aa ) in recent 5 years including clinical trials and case reports.\nconclusions : in two phase 3 trials involving patients with severe alopecia areata, oral baricitinib was superior to placebo with respect to hair regrowth at 36 weeks.\n"
        },
        {
          "qas": [
            {
              "id": "64137616201352f04a000041_001",
              "question": "Anemia is not associated with chronic kidney failure"
            }
          ],
          "context": "anemia is a common complication of chronic kidney disease.\nanaemia is a common manifestation ofa chronic kidney failure.\n\nanemia is a common complication of chronic kidney disease.\nanemia in children with chronic kidney disease\n\ntreatment of anemia in patients with chronic kidney disease\ne treatment of anemia in chronic kidney disease.\n\nanemia is an adverse outcome and common complication in chronic kidney disease patient\nanaemia is a common manifestation ofa chronic kidney failure.\n\nanemia is as a frequent complication in patients with chronic kidney disease, which gains in importance in the treatment of patients with renal disease.\nanemia is a common complication of chronic kidney disease.\n"
        },
        {
          "qas": [
            {
              "id": "64163660690f196b5100001d_001",
              "question": "Is deflazacort more efficient than prednisone/prednisolone for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "though deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\nfunctional decline compared with those receiving prednisone / prednisolone.\n\nallow assessment of high - functioning boys with duchenne muscular dystrophy.\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\n\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\nthough deflazacort and prednisone improve clinical endpoints in duchenne muscular dystrophy ( dmd ) patients, deflazacort produces fewer side effects.\n"
        },
        {
          "qas": [
            {
              "id": "64144200201352f04a000043_001",
              "question": "Is anaphylaxis a results of mast cell activation?"
            }
          ],
          "context": "anaphylaxis is a life - threatening syndrome resulting from the sudden release of mast cell - and basophil - derived mediators into the circulation.\nacute anaphylaxis to small molecule drugs is largely considered to be antibody - mediated with immunogloblin e ( ige ) and mast cell activation being key.\n\nmediators involved in allergic inflammation and anaphylactic reactions\nhuman mast cells, by elaborating vasoactive mediators and cytokines, are the primary effector cells of anaphylaxis.\n\nanaphylaxis results from severe systemic mast cell activation. in addition to ige - mediated and physical triggers, it may occur with a clonal mast cell\nanaphylaxis results from the massive activation of the mast cells ( mcs ).\n\nanaphylaxis is a life - threatening syndrome resulting from the sudden release of mast cell - and basophil - derived mediators into the circulation.\nwhich occurs rapidly upon allergen challenge in humans undergoing anaphylaxis.\n\nanaphylaxis is a rapidly evolving, acute, life - threatening reaction that occurs rapidly on contact with a trigger\n. anaphylaxis may be triggered by a variety of antigens including insect and reptile venom, a variety of drugs, vaccines, and food\n"
        },
        {
          "qas": [
            {
              "id": "64178e34690f196b51000021_001",
              "question": "Is viltolarsen effective for the treatment of Duchenne muscular dystrophy?"
            }
          ],
          "context": "to date, four pmos, including eteplirsen, casimersen, viltolarsen, and golodirsen, have been conditionally approved by the fda for the treatment of dmd.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n\nviltolarsen restores the reading frame of the dmd gene by skipping exon 53 and produces a truncated but functional form of dystrophin.\nucleotide viltolarsen targets exon 53 of the dystrophin gene, and could be an effective treatment for patients with duchenne muscular dystrophy ( dmd ).\n"
        },
        {
          "qas": [
            {
              "id": "6410f839201352f04a000032_001",
              "question": "Can the concept of digital twins be applied in Precision Nutrition?"
            }
          ],
          "context": "a \" virtual digital twin, \" which could serve to guide nutrition in a personalized manner.\nwe herein discuss how genetic information combined with longitudinal metabolomic, immune, behavioral, and gut microbial parameters, and bioclinical variables could define a digital replica of oneself, a \" virtual digital twin, \" which could serve to\n"
        },
        {
          "qas": [
            {
              "id": "64040edf201352f04a000011_001",
              "question": "Based on clinical trial data, can pioglitazone delay cognitive impairment for people at risk for Alzheimer's disease?"
            }
          ],
          "context": "interpretation : pioglitazone did not delay the onset of mild cognitive impairment.\nfive weeks of treatment with the glp - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.\n\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\ninterpretation : pioglitazone did not delay the onset of mild cognitive impairment.\n\nimpairments in cognitive function have been associated with obesity in both people and rodents.\ninterpretation : pioglitazone did not delay the onset of mild cognitive impairment.\n\nrates of gastrointestinal side effects, headache, and depression.\ninterpretation : pioglitazone did not delay the onset of mild cognitive impairment.\n\ninterpretation : pioglitazone did not delay the onset of mild cognitive impairment.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n"
        },
        {
          "qas": [
            {
              "id": "63f9cdb033942b094c000012_001",
              "question": "Does silencing of SRRM4 promote microexon inclusion?"
            }
          ],
          "context": "srrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\n\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n\nwe show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n. microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n"
        },
        {
          "qas": [
            {
              "id": "64040af9201352f04a00000d_001",
              "question": "Is levosimendan effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "interpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nconclusions : levosimendan did not achieve the primary endpoint of improving sitting svc in als. headache and increased heart rate were increased on levosimendan, although it was otherwise well tolerated.\n. although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo.\n\ninterpretation : levosimendan was not superior to placebo in maintaining respiratory function in a broad population with amyotrophic lateral sclerosis\nconclusions : levosimendan did not achieve the primary endpoint of improving sitting svc in als. headache and increased heart rate were increased on levosimendan, although it was otherwise well tolerated.\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n"
        },
        {
          "qas": [
            {
              "id": "641365f6201352f04a00003a_001",
              "question": "Is Iron deficiency anemia a common complication of chronic kidney disease?"
            }
          ],
          "context": "options for the anemia of chronic kidney disease.\ntreatment of anemia in patients with chronic kidney disease\n\ntreatment of anemia in patients with chronic kidney disease\nthe diagnosis of iron deficiency anemia in patients with ckd is complicated due to the relatively low predictive ability of routine serum iron markers ( e. g., ferritin and transferrin saturation ) and more invasive measurements such as bone marrow iron\n\nanemia is a common complication of chronic kidney disease.\niron deficiency anemia ( ida ) is a frequent complication of chronic kidney disease ( ckd ) and is associated with adverse outcomes in these patients.\n\nanemia is a common complication of chronic kidney disease.\nanemia is a frequent complication of kidney disease.\n\nanemia is a common complication of chronic kidney disease.\niron deficiency is common in individuals with chronic kidney disease and plays a major role in the development of anemia.\n"
        },
        {
          "qas": [
            {
              "id": "6410ef9b201352f04a000031_001",
              "question": "Can modulation of KCNQ1 splicing prevent arrhythmias?"
            }
          ],
          "context": "amiloride regulates iks and aps with transmural differences and reduces arrhythmogenicity through the modulation of kcnq1 splicing. we suggested that the modulation of kcnq1 splicing may help prevent arrhythmia.\nalthough ongoing phase iii clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk.\n\namiloride regulates iks and aps with transmural differences and reduces arrhythmogenicity through the modulation of kcnq1 splicing. we suggested that the modulation of kcnq1 splicing may help prevent arrhythmia.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\namiloride regulates iks and aps with transmural differences and reduces arrhythmogenicity through the modulation of kcnq1 splicing. we suggested that the modulation of kcnq1 splicing may help prevent arrhythmia.\n. notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\n"
        },
        {
          "qas": [
            {
              "id": "6414c124690f196b51000002_001",
              "question": "Is trichotillomania encountered with equali frequency in males and females?"
            }
          ],
          "context": "other body - focused repetitive behaviors, such as trichotillomania.\nfuture studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.\n"
        },
        {
          "qas": [
            {
              "id": "63f9cd2f33942b094c000011_001",
              "question": "Does microexon alternative splicing of small GTPase regulators have implication in central nervous system diseases?"
            }
          ],
          "context": "in this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n. we show that two of these lncrnas regulate the extent of neuronal outgrowth\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n"
        },
        {
          "qas": [
            {
              "id": "6411b4a8201352f04a000035_001",
              "question": "Is prosopagnosia also known as lack of auditory recognition?"
            }
          ],
          "context": "anecdotally, it has been reported that individuals with acquired prosopagnosia compensate for their inability to recognize faces by using other person identity cues such as hair, gait or the voice.\nprosopagnosia is a selective visual agnosia characterized by the inability to recognize the identity of faces.\n\nby \" prosopagnosia \" - namely, by a form of visual agnosia, specifically affecting face recognition.\nanecdotally, it has been reported that individuals with acquired prosopagnosia compensate for their inability to recognize faces by using other person identity cues such as hair, gait or the voice.\n\nprosopagnosia is a rare neurological sign, characterized by disturbance of recognition of faces.\nprosopagnosia is a selective visual agnosia characterized by the inability to recognize the identity of faces.\n\nprosopagnosia is a type of visual agnosia with inability to identify faces, usually secondary to brain lesion in associative cortex areas, but there is also a congenital form known as developmental prosopagnosia.\nanecdotally, it has been reported that individuals with acquired prosopagnosia compensate for their inability to recognize faces by using other person identity cues such as hair, gait or the voice.\n\nby \" prosopagnosia \" - namely, by a form of visual agnosia, specifically affecting face recognition.\nprosopagnosia is a rare neurological sign, characterized by disturbance of recognition of faces.\n"
        },
        {
          "qas": [
            {
              "id": "641357bc201352f04a000039_001",
              "question": "Do cells undergoing necroptosis show disruption of their cell membranes?"
            }
          ],
          "context": "necroptosis is a programmed cell death pathway triggered by activation of receptor interacting protein kinase 3 ( ripk3 ), which phosphorylates and activates the mixed lineage kinase - like domain pseudokinase, mlkl, to rupture or permeabilize the plasma\nnecroptosis is a form of caspase - independent programmed cell death that arises from disruption of cell membranes by the mixed lineage kinase domain - like ( mlkl ) pseudokinase after its activation by the upstream kinases, receptor interacting protein\n\nboth necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.\nthus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\n\nnecroptosis, a form of programmed cell death, is characterized by the loss of membrane integrity and release of intracellular contents, the execution of which depends on the membrane - disrupting activity of the mixed lineage kinase domain - like protein\nboth necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.\n\nnecroptosis is a highly inflammatory form of programmed cell death that results from mlkl - mediated disruption of the cell membrane.\nboth necrosis and necroptosis show similar morphological features and are characterized by an increase in cell volume, cell membrane permeabilization, and rupture that lead to cellular demise.\n\nnecroptosis is a programmed cell death pathway triggered by activation of receptor interacting protein kinase 3 ( ripk3 ), which phosphorylates and activates the mixed lineage kinase - like domain pseudokinase, mlkl, to rupture or permeabilize the plasma\nthus, cells undergoing necroptosis need to overcome these independent suppressive mechanisms before plasma membrane disruption can occur.\n"
        },
        {
          "qas": [
            {
              "id": "641ad941690f196b5100003d_001",
              "question": "Are LOQ and LOD the same?"
            }
          ],
          "context": "the limit of detection ( lod ) and limit of quantitation ( loq )\n* limit of blank ( lob ), limit of detection ( lod ), and limit of quantitation ( loq ) are terms used to describe the smallest concentration of a measurand that can be reliably measured by an analytical procedure.\n"
        },
        {
          "qas": [
            {
              "id": "64179337690f196b51000034_001",
              "question": "Do machine learning-based methods outperform statistical methods for survival analysis?"
            }
          ],
          "context": "we review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high - dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.\nour results reveal that machine - learning - based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i. e., cox proportional hazard model.\n\nwe review traditional survival methods and regularization methods, with various penalty functions, for the analysis of high - dimensional genomics, and describe machine learning techniques that have been adapted to survival analysis.\nthis analysis revealed that survival analysis models outperformed binary classification models for risk assessment, and the performance of the survival analysis methods - cox model regularized with ridge penalty ( cox - ridge ) and partial least squares\n\nbackground : over the recent years, machine learning methods have been increasingly explored in cancer prognosis because of the appearance of improved machine learning algorithms\nour results reveal that machine - learning - based models such as random survival forests, gradient boosted survival model, and survival support vector machine can outperform the traditional statistical methods, i. e., cox proportional hazard model.\n"
        },
        {
          "qas": [
            {
              "id": "6402c868201352f04a00000b_001",
              "question": "Was erythropoietin effective for optic neuritis in the TONE trial?"
            }
          ],
          "context": "interpretation : erythropoietin as an adjunct to corticosteroids conveyed neither functional nor structural neuroprotection in the visual pathways after optic neuritis.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\n\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\nerythropoietin rct that failed to demonstrate differences between groups for both primary and secondary outcomes.\n\nor second - line chemotherapy compared with placebo in the determine study.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n"
        },
        {
          "qas": [
            {
              "id": "64299b6a57b1c7a315000001_001",
              "question": "Is COVID-19 caused by the Omicron variant less severe than infection caused by other variants?"
            }
          ],
          "context": "it is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\ntherefore, many - but not all - of the antibody products with emergency use authorization should retain substantial efficacy against the prevailing variant strains of sars - cov - 2.\n\none of the newest variants is omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated.\nthese early national data suggest that omicron is associated with a two - thirds reduction in the risk of covid - 19 hospitalisation compared with delta.\n\none of the newest variants is omicron, which shows an increase in its transmissibility, but also reportedly reduces hospitalization rates and shows milder symptoms, such as in those who have been vaccinated.\nthe omicron is highly transmissible and is spreading faster than any previous variant, but may cause less severe symptoms than previous variants.\n\nearly work suggests that infections caused by the omicron variant may be less severe than those caused by the delta variant.\nhowever, we found that infections by omicron were significantly less severe than those caused by delta and other previous variants.\n"
        },
        {
          "qas": [
            {
              "id": "64040bd8201352f04a00000e_001",
              "question": "Should be used bexarotene for relapsing-remitting multiple sclerosis?"
            }
          ],
          "context": "specifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\ninterpretation : we do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.\n\nspecifically, the current evidence regarding treatment of progressive ms with ocrelizumab, simvastatin, ibudilast, alpha - lipoic acid, high - dose biotin, siponimod, and cell - based therapies are discussed.\n. it was approved by the food and drug administration ( fda ) in march 2017 for using in adults with relapsing - remitting multiple sclerosis ( rrms ) and primary progressive multiple sclerosis ( ppms ).\n\nibudilast for the treatment of multiple sclerosis.\ninterpretation : we do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.\n\nrates of gastrointestinal side effects, headache, and depression.\ninterpretation : we do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.\n\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\ninterpretation : we do not recommend the use of bexarotene to treat patients with multiple sclerosis because of its poor tolerability and negative primary efficacy outcome.\n"
        },
        {
          "qas": [
            {
              "id": "6429ee7457b1c7a31500000b_001",
              "question": "Can analgesics or antipyretics be taken for side effects following COVID-19 vaccination?"
            }
          ],
          "context": ". some studies revealed changes in certain immune response parameters post - vaccination when analgesics / antipyretics were used either prophylactically or therapeutically. still, there is no evidence that these changes impact vaccine efficacy\nanalgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\n\nwhile antipyretic analgesics are widely used to ameliorate vaccine adverse reactions, their use has been associated with blunted vaccine immune responses.\nanalgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\n"
        },
        {
          "qas": [
            {
              "id": "64281a47690f196b5100004f_001",
              "question": "Is OXLUMO (lumasiran) used for the treatment of primary hyperoxaluria?"
            }
          ],
          "context": "oxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\nrates of gastrointestinal side effects, headache, and depression.\n\noxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\nlumasiran in the management of patients with primary hyperoxaluria type 1 : from bench to bedside.\n\nlumasiran was recently approved in the treatment of primary hyperoxaluria type 1 and nedosiran is in the approval process.\noxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\n\npharmaceuticals for the treatment of primary hyperoxaluria type 1 ( ph1 ).\noxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\n"
        },
        {
          "qas": [
            {
              "id": "6429cfb557b1c7a315000005_001",
              "question": "Should patients using inhaled glucocorticoids for asthma or COPD be advised to stop these medications to prevent COVID-19?"
            }
          ],
          "context": "evidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\nour study supports the recommendation that patients with chronic pulmonary diseases, including asthma and copd who require treatment with either inhaled or systemic corticosteroids, should continue their use during the covid - 19 pandemic.\n\nour study supports the recommendation that patients with chronic pulmonary diseases, including asthma and copd who require treatment with either inhaled or systemic corticosteroids, should continue their use during the covid - 19 pandemic.\nadditionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe covid - 19, but there is no evidence guiding the use of biologic therapy.\n\nevidence from clinical studies indicates that the inhaled corticosteroids ( ics ) routinely taken for asthma and copd could have had a protective role in preventing severe covid - 19 and, therefore, may be a promising treatment for covid - 19.\nadditionally, the use of systemic or inhaled glucocorticoids does not appear to increase the risk of severe covid - 19, but there is no evidence guiding the use of biologic therapy.\n\nthe benefit - risk ratio is however clearly in favor of continuing inhaled corticosteroids in patients with asthma or copd.\nwith fewer asthma exacerbations when labas and inhaled glucocorticoids were withdrawn, with improved lung function and reduced levels of th2 - associated inflammatory markers.\n"
        },
        {
          "qas": [
            {
              "id": "6432f75757b1c7a31500001d_001",
              "question": "Is Zanubrutinib a first-generation BTK inhibitor approved by US Food and Drug Administration (FDA)?"
            }
          ],
          "context": "cabozantinib in the treatment of hepatocellular carcinoma.\nin the united states, zanubrutinib, a next - generation btk inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with waldenstrom macroglobulinemia, and for adults with\n\nin the united states, zanubrutinib, a next - generation btk inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with waldenstrom macroglobulinemia, and for adults with\nconclusion : baricitinib demonstrated a consistent, beneficial treatment effect in bdmard - refractory patients across subgroups based on baseline characteristics and prior bdmard use.\n\nin the united states, zanubrutinib, a next - generation btk inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with waldenstrom macroglobulinemia, and for adults with\n. this article summarizes the milestones in the development of tirabrutinib leading to the first approval of tirabrutinib for the treatment of recurrent or refractory primary central nervous system lymphoma in japan.\n\nin the united states, zanubrutinib, a next - generation btk inhibitor, has been approved for treating adults with mantle cell lymphoma who have received at least one prior therapy, for adults with waldenstrom macroglobulinemia, and for adults with\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "63eef94ff36125a426000010_001",
              "question": "Is Cinpanemab effective for Parkinson\u2019s Disease?"
            }
          ],
          "context": "[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\n\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\n\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\n\nis the only fda - approved treatment for the hallucinations and delusions seen in patients with psychosis of parkinson's disease.\nconclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\n"
        },
        {
          "qas": [
            {
              "id": "643306cc57b1c7a315000027_001",
              "question": "Can CRISPR/Cas12a be used for the detection of EGFR mutations in circulating DNA?"
            }
          ],
          "context": ". sensitive and accurate detection of brca1 and brca2 mutations is crucial for personalized clinical management of individuals affected by breast or ovarian cancer, and for the identification of at - risk healthy relatives\nthe crispr - cas12a system can detect both l858r and t790m with a limit of detection of 0. 005 % in less than three hours.\n\n. to identify additional therapeutic targets in aml, we optimize a genome - wide clustered regularly interspaced short palindromic repeats ( crispr ) screening platform and use it to identify genetic vulnerabilities in aml cells\nthe crispr - cas12a system can detect both l858r and t790m with a limit of detection of 0. 005 % in less than three hours.\n"
        },
        {
          "qas": [
            {
              "id": "63f9ccdc33942b094c00000f_001",
              "question": "Is PRP-40 involved in microexon splicing?"
            }
          ],
          "context": ". microexons can be relieved from prp - 40 dependence by artificially increasing exon size or reducing flanking intron size, indicating that prp - 40 is specifically required for microexons surrounded by conventionally sized introns\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n"
        },
        {
          "qas": [
            {
              "id": "6404199d201352f04a000019_001",
              "question": "Is ocrelizumab effective for primary progressive multiple sclerosis?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nocrelizumab ( ocrevus\u00ae ) is an intravenously administered, humanized anti - cd20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis ( rms ) or primary progressive multiple sclerosis ( ppms ).\n\nocrelizumab ( ocrevus\u00ae ) is an intravenously administered, humanized anti - cd20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis ( rms ) or primary progressive multiple sclerosis ( ppms ).\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\n\nbackground : ocrelizumab is a humanised anti - cd20 monoclonal antibody developed for the treatment of multiple sclerosis ( ms )\nocrelizumab ( ocrevus\u00ae ) is an intravenously administered, humanized anti - cd20 monoclonal antibody approved for the treatment of adults with relapsing forms of multiple sclerosis ( rms ) or primary progressive multiple sclerosis ( ppms ).\n"
        },
        {
          "qas": [
            {
              "id": "63f9cdcc33942b094c000013_001",
              "question": "Does silencing of SRRM4 inhibit tumor growth across cancers?"
            }
          ],
          "context": ". we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n\nwe show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n\nwe show that this silencing is favorable for tumor growth, as decreased srrm4 expression in tumors is correlated with an increase in mitotic gene expression, and up - regulation of srrm4 in cancer cell lines dose - dependently inhibits proliferation in\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n"
        },
        {
          "qas": [
            {
              "id": "64041e97201352f04a00001e_001",
              "question": "Is daridorexant effective for insomnia?"
            }
          ],
          "context": ". treatment with daridorexant has resulted in a slightly higher incidence of adverse events [ risk ratio ( rr ) = 1. 19 ; 95 % ci, 1. 05 - 1. 35 ;, p = 0. 005 ], specifically somnolence ( rr = 1. 19 ; 95 % ci, 1. 13 - 3. 23 ; p = 0. 005 ) and fatigue ( rr = 2. 01 ; 95 % ci,\n. daridorexant is superior to placebo in improving sleep quality.\n\n. treatment with daridorexant has resulted in a slightly higher incidence of adverse events [ risk ratio ( rr ) = 1. 19 ; 95 % ci, 1. 05 - 1. 35 ;, p = 0. 005 ], specifically somnolence ( rr = 1. 19 ; 95 % ci, 1. 13 - 3. 23 ; p = 0. 005 ) and fatigue ( rr = 2. 01 ; 95 % ci,\ndaridorexant ( quviviq\u2122 ; idorsia pharmaceuticals ltd. ) is an orally administered dual orexin type 1 and type 2 ( ox1 and ox2 ) receptor antagonist ( dora ) being developed for the treatment of insomnia.\n\n. treatment with daridorexant has resulted in a slightly higher incidence of adverse events [ risk ratio ( rr ) = 1. 19 ; 95 % ci, 1. 05 - 1. 35 ;, p = 0. 005 ], specifically somnolence ( rr = 1. 19 ; 95 % ci, 1. 13 - 3. 23 ; p = 0. 005 ) and fatigue ( rr = 2. 01 ; 95 % ci,\nrates of gastrointestinal side effects, headache, and depression.\n\n. daridorexant is superior to placebo in improving sleep quality.\ndaridorexant was superior to placebo in reducing wake time after sleep onset ( md = - 13. 26 ; 95 % ci, - 15. 48 to - 11. 03 ; p < 0. 00001 ), latency to persistent sleep ( md = - 7. 23 ; 95 % ci, - 9. 60 to - 4. 85 ; p < 0. 00001 ), with increasing the total sleep time\n"
        },
        {
          "qas": [
            {
              "id": "64041dae201352f04a00001d_001",
              "question": "Is deucravacitinib effective for psoriasis?"
            }
          ],
          "context": "introduction : deucravacitinib is an oral, selective tyrosine kinase 2 inhibitor that demonstrated therapeutic benefit in a phase 2 clinical trial of adults with moderate to severe plaque psoriasis.\nconclusion : deucravacitinib was superior to placebo and apremilast across multiple efficacy endpoints and was well tolerated in moderate to severe psoriasis.\n"
        },
        {
          "qas": [
            {
              "id": "6428da47690f196b51000051_001",
              "question": "Can the epigenetic status of introns affect gene expression?"
            }
          ],
          "context": "some of these epigenetic changes appear to be heritable.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\n\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\n\nthe untranslated regions of mrnas can determine gene expression by influencing mrna stability and translational efficiency.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\n\nmore interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nepigenetic inheritance systems enable the environmentally induced phenotypes to be transmitted between generations.\n\nconsistent with previous work we found that intragenic methylation is positively correlated with gene expression and that exons are more highly methylated than their neighboring intronic environment.\ninterestingly, hypomethylation of introns is correlated with higher levels of intron expression in mrna and the methylation level of an intron is inversely correlated with its retention in mrna from the gene in which it is located.\n"
        },
        {
          "qas": [
            {
              "id": "642d4c9b57b1c7a315000013_001",
              "question": "Are Luminopsins a fusion proteins of luminol and Rhodopsin ?"
            }
          ],
          "context": "bioluminescence - optogenetics is mediated by luminopsin fusion proteins - light - sensing opsins fused to light - emitting luciferases.\nluminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.\n\nouse ips - npcs were transduced with a novel optochemogenetics fusion protein, luminopsin 3 ( lmo3 ), which consisted of a bioluminescent luciferase, gaussia luciferase, and an opsin, volvox channelrhodopsin 1.\nluminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.\n\nluminopsins are fusion proteins of luciferase and opsin that allow interrogation of neuronal circuits at different temporal and spatial resolutions by choosing either extrinsic physical or intrinsic biological light for its activation.\nluminopsins by fusing light - sensing opsins with light - emitting luciferases.\n"
        },
        {
          "qas": [
            {
              "id": "6428da98690f196b51000053_001",
              "question": "Is there a way to distinguish COVID-19 clinically from other respiratory illnesses, such as influenza?"
            }
          ],
          "context": "covid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n\nfindings indicate that clinical symptoms alone would be insufficient to distinguish between coronavirus disease 2019 and other respiratory infections ( eg, influenza ) and / or to evaluate the effects of preventive interventions ( eg, vaccinations ).\nit is difficult to distinguish coronavirus disease - 2019 ( covid - 19 ) from other viral respiratory tract infections owing to the similarities in clinical and radiological findings.\n\ncovid - 19 and can be important differentiating symptoms in patients presenting with acute respiratory illness\ncovid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\n\nalthough covid - 19 has been extensively characterized clinically, the factors distinguishing sars - cov - 2 from other respiratory viruses are unknown.\nduring influenza season, differentiating other causes of respiratory illness from covid - 19 is difficult, because common clinical manifestations of covid - 19 mimic those of influenza.\n\nwe show that although covid - 19 and influenza are different in many ways, there are numerous similarities ; thus, in addition to using nucleic acid - based polymerase chain reaction ( pcr ) and antibody - based approaches, clinicians and epidemiologists\ncovid - 19 and flu are two respiratory illnesses which share similar clinical symptoms.\n"
        },
        {
          "qas": [
            {
              "id": "6428d7da690f196b51000050_001",
              "question": "Can untranslated regions (UTRs) regulate gene expression?"
            }
          ],
          "context": "untranslated gene regions ( utrs ) play an important role in controlling gene expression.\n3'untranslated regions ( utrs ) are known to play an important role in posttranscriptional regulation of gene expression.\n\n. our analyses show that non - coding variants upstream of genes within which coding variants are known to cause dd are an important cause of severe disease and demonstrate that analyzing 5'utrs can increase diagnostic yield\n. we screened 9, 858 probands from the deciphering developmental disorders ( ddd ) study for de novo mutations in the 5'untranslated regions ( 5'utrs ) of genes within which variants have previously been shown to cause dd through a domit\n\nthe 3'untranslated region ( 3'utr ) can control gene expression by affecting the localization, stability and translation of mrnas.\nuntranslated gene regions ( utrs ) play an important role in controlling gene expression.\n\nthe 5'and 3'untranslated regions ( utrs ) regulate crucial aspects of post - transcriptional gene regulation that are necessary for the maintece of cellular homeostasis\n3'untranslated regions ( utrs ) are known to play an important role in posttranscriptional regulation of gene expression.\n\neukaryotic gene expression is precisely regulated at all points between transcription and translation. in this review, we focus on translational control mediated by the 3'- untranslated regions ( utrs ) of mrnas\nmany studies using reporter assays have demonstrated that 3'untranslated regions ( 3'- utrs ) regulate gene expression by controlling mrna stability and translation.\n"
        },
        {
          "qas": [
            {
              "id": "63f9cbb433942b094c00000c_001",
              "question": "Is alternative splicing associated with heart disease?"
            }
          ],
          "context": "here, we review the emerging understanding that both, circrnas produced by co - and posttranscriptional head - to - tail \" backsplicing \" of a downstream splice donor to a more upstream splice acceptor, as well as circrnas generated from intronic lariats\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nwe identified > 200 significant alternative splicing ( as ) events and distinct as profiles were observed in the right ( rv ) and left ( lv ) ventricles in pln - r14del compared to wt mouse hearts.\n\nepigenetic processes, defined as heritable changes in gene expression that occur without changes to the dna sequence, have emerged as a promising area of cardiovascular disease research.\nwe identified > 200 significant alternative splicing ( as ) events and distinct as profiles were observed in the right ( rv ) and left ( lv ) ventricles in pln - r14del compared to wt mouse hearts.\n"
        },
        {
          "qas": [
            {
              "id": "61fa941ec9dfcb9c09000005_001",
              "question": "Should Intepirdine be used for Alzheimer's disease?"
            }
          ],
          "context": "discussion : intepirdine as adjunctive therapy to donepezil did not produce statistical improvement over placebo on cognition or activities of daily living in mild - to - moderate ad dementia patients.\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\n"
        },
        {
          "qas": [
            {
              "id": "61f7cb37882a024a10000029_001",
              "question": "Is rilonacept effective for pericarditis?"
            }
          ],
          "context": "tocilizumab, a monoclonal antibody against the il - 6 receptor, was initiated at a dose of 8 mg / kg every 4 weeks.\nobjective : to review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis ( rp ).\n\ncurrently, anakinra and rilonacept, have demonstrated beneficial impact in clinical outcomes with a reasonable safety profile in randomized clinical trials\nobjective : to review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis ( rp ).\n\nrates of gastrointestinal side effects, headache, and depression.\ncharacterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients.\n\ncharacterized by an evident inflammatory recurrent phenotype, and recent data have shown the striking efficacy of anakinra and rilonacept in these patients.\nobjective : to review the pharmacology, efficacy, and safety of rilonacept for the prevention and treatment of recurrent pericarditis ( rp ).\n"
        },
        {
          "qas": [
            {
              "id": "64041f38201352f04a00001f_001",
              "question": "Is tebentafusp effective for uveal melanoma?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nthis article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.\n\ntebentafusp was granted full approval on january 25th 2022 in the setting of hla - a * 02 : 01 - positive adult patients with unresectable or metastatic uveal melanoma.\nthis article summarizes the milestones in the development of tebentafusp leading to this first approval for unresectable or metastatic uveal melanoma.\n"
        },
        {
          "qas": [
            {
              "id": "63f73f1b33942b094c000008_001",
              "question": "Is erenumab effective for trigeminal neuralgia?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nreceptor ( erenumab ) effectively prevent migraine attacks.\n\ninterpretation : erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and cgrp probably does not have an important role in paroxysmal pain.\nreceptor ( erenumab ) effectively prevent migraine attacks.\n\nmultiple sclerosis, neuropathic pain, medication overuse headache, stroke, opioid, alcohol and methamphetamine abuse.\nbackground : acupotomy has been widely used to treat nerve entrapment syndrome.\n\nfour monoclonal antibodies ( mabs ) targeting the cgrp pathway are currently under evaluation for the prevention of episodic and chronic migraine : eptinezumab ( ald403 ), fremanezumab ( tev - 48125 ), galcanezumab ( ly2951742 ), and erenumab ( amg334 ).\nreceptor ( erenumab ) effectively prevent migraine attacks.\n\ninterpretation : erenumab did not reduce pain intensity compared with placebo in patients with trigeminal neuralgia and cgrp probably does not have an important role in paroxysmal pain.\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\n"
        },
        {
          "qas": [
            {
              "id": "643c88a257b1c7a315000030_001",
              "question": "Can other vaccines be given with COVID-19 vaccine?"
            }
          ],
          "context": "it is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\n. the centers for disease control and prevention ( cdc ) has shifted their recommendations recently, allowing for the co - administration of the currently available covid - 19 vaccines with other vaccines\n\n. the centers for disease control and prevention ( cdc ) has shifted their recommendations recently, allowing for the co - administration of the currently available covid - 19 vaccines with other vaccines\nconcomitant administration of covid - 19 and influenza vaccines could reduce burden on health - care systems. we aimed to assess the safety of concomitant administration of chadox1 or bnt162b2 plus an age - appropriate influenza vaccine.\n\n. this is based on the experience with non - covid - 19 vaccines, where the immunogenicity and adverse event profiles were generally similar when vaccines are administered simultaneously or alone.\nhealth benefits versus risks to assess whether to continue vaccination\n\nit is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\n. specific data on the impact of analgesic / antipyretic medications on immunogenicity of covid - 19 vaccines are limited\n"
        },
        {
          "qas": [
            {
              "id": "6441302d57b1c7a315000056_001",
              "question": "Is music therapy effective for pain management in neonates?"
            }
          ],
          "context": "this review supports the beneficial effects of music - based interventions on the health of preterm infants in a neonatal intensive care unit ; however, it also offers suggestions for future studies in order to increase the number of interventions with\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\n\nthis review supports the beneficial effects of music - based interventions on the health of preterm infants in a neonatal intensive care unit ; however, it also offers suggestions for future studies in order to increase the number of interventions with\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\n\nthis review supports the beneficial effects of music - based interventions on the health of preterm infants in a neonatal intensive care unit ; however, it also offers suggestions for future studies in order to increase the number of interventions with\nto increase the number of interventions with music therapists, since the results of music therapy approaches were more consistent for physiological and behavioural outcomes.\n\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\n"
        },
        {
          "qas": [
            {
              "id": "63f02b50f36125a426000014_001",
              "question": "Is there any association between Tripe palms and cancer?"
            }
          ],
          "context": "background : tripe palms ( tp ) is one of the rare cutaneous paraneoplastic manifestations of various intra - abdominal malig \" \" cies.\n. special forms are florid cutaneous papillomatosis and tripe palms.\n\nbackground : tripe palms ( tp ) is one of the rare cutaneous paraneoplastic manifestations of various intra - abdominal malig \" \" cies.\nbladder cancer with an concomitant with tripe palms ( tp ) and / or mucosal involvement is relatively rare and, to our knowledge, only seven cases of an with bladder cancer have been reported in the english literature.\n"
        },
        {
          "qas": [
            {
              "id": "641c516d690f196b5100003f_001",
              "question": "Can Amyotrophic Lateral Sclerosis (ALS) be associated with a mutation of the Super Oxide Dismutase 1 (SOD) gene?"
            }
          ],
          "context": "it has been reported that mutations in the superoxide dismutase ( sod ) 1 gene can lead to als.\ngenetic mutations in cu / zn superoxide dismutase ( sod1 ) have been associated with one kind of familial amyotrophic lateral sclerosis ( als1 ).\n\nthe sod1 gene encoding the superoxide dismutase 1 ( sod1 ) protein is mutated in approximately 15 % of familial amyotrophic lateral sclerosis ( als ) and 3 % of sporadic als.\nthe superoxide dismutase - 1 ( sod1 ) gene is the first gene for familial amyotrophic lateral sclerosis ( als ) with autosomal domi \" \" t inheritance.\n\na predilection for disease onset in the lower limbs appears to be a distinguishing feature of familial als with sod - 1 mutations, and accords with findings in transgenic mouse models.\neight of 38 patients ( 21 % ) with familial and 5 of 175 patients ( 3 % ) with sporadic amyotrophic lateral sclerosis ( als ) had missense mutations in the sod - 1 gene.\n"
        },
        {
          "qas": [
            {
              "id": "643c396457b1c7a31500002d_001",
              "question": "Are any medications available to prevent COVID-19 following exposure?"
            }
          ],
          "context": "to test hydroxychloroquine as postexposure prophylaxis for sars - cov - 2 infection.\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\n\nguillain - barre syndrome after covid - 19 vaccination.\ncase of guillain - barre syndrome following covid - 19 vaccine.\n\nit is unknown if the efficacy of the coronavirus disease - 19 ( covid - 19 ) vaccine is affected by the co - administration of other vaccines\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\n\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nto be an effective treatment and post - exposure prophylaxis measure for coronavirus disease 2019 ( covid - 19 ).\n\ncovid - 19 vaccine causing guillain - barre syndrome, a rare potential side effect.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "6440092d57b1c7a315000040_001",
              "question": "Has RTA 408 received FDA approval?"
            }
          ],
          "context": "in august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\nin 2009 the us food and drug administration accepted a complete - response submission for the use of actemra ( tocilizumab ), the first humanized il - 6 receptor - inhibiting monoclonal antibody, for the treatment of ra.\n\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\nconclusions : these results support an immune - related mechanism of action for toca 511 and toca fc, and suggest that molecular and immunologic signatures are related to clinical benefit from treatment.\n\nclinical and immunological studies of rotavirus vaccines.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nbackground : the risk assessment and prediction tool ( rapt ) is used to predict patient discharge disposition after total joint arthroplasty.\nthe rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.\n\nrates of gastrointestinal side effects, headache, and depression.\nthe safety and efficacy of the use of methotrexate in long - term therapy for rheumatoid arthritis.\n"
        },
        {
          "qas": [
            {
              "id": "643c446357b1c7a31500002f_001",
              "question": "Can reinfection occur after SARS-CoV-2 infection?"
            }
          ],
          "context": "it is currently unclear whether severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently\nbetter understanding of the protective duration of prior sars - cov - 2 infection against reinfection is needed.\n\ncomparative genomic analysis demonstrates that true reinfection following sars - cov - 2 infection is possible.\nsars - cov - 2 reinfection can occur but is a rare phenomenon suggestive of protective immunity against reinfection that lasts for at least a few months post primary infection.\n\nreinfection by sars - cov - 2 under endemic conditions would likely occur between 3 months and 5 \u00b7 1 years after peak antibody response, with a median of 16 months.\nbetter understanding of the protective duration of prior sars - cov - 2 infection against reinfection is needed.\n\nreinfection with sars - cov - 2 is a strong possibility. this case raises concerns that asymptomatic infections may not provide long - term protective immunity to all patients, which could make them susceptible to reinfection.\nbetter understanding of the protective duration of prior sars - cov - 2 infection against reinfection is needed.\n\nit is currently unclear whether severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) reinfection will remain a rare event, only occurring in individuals who fail to mount an effective immune response, or whether it will occur more frequently\nreinfection with sars - cov - 2 is a strong possibility. this case raises concerns that asymptomatic infections may not provide long - term protective immunity to all patients, which could make them susceptible to reinfection.\n"
        },
        {
          "qas": [
            {
              "id": "63ee5eeaf36125a426000002_001",
              "question": "Does mutation of ARTEMIS gene causes severe combined immunodeficiency?"
            }
          ],
          "context": "artemis deficiency disrupts development of adaptive immunity and leads to radiosensitive t - b - severe combined immunodeficiency ( rs - scid ).\npathogenic variants in dclre1c encoding artemis cause t - b - nk + severe combined immunodeficiency ( scid ), and patients with artemis - deficient scid ( art - scid ) require definitive therapy with allogeneic hematopoietic cell transplantation ( hct ).\n\ntreatment for patients with ada - severe combined immunodeficiency ( ada - scid ) who lack a suitable matched related bone marrow donor.\npathogenic variants in dclre1c encoding artemis cause t - b - nk + severe combined immunodeficiency ( scid ), and patients with artemis - deficient scid ( art - scid ) require definitive therapy with allogeneic hematopoietic cell transplantation ( hct ).\n"
        },
        {
          "qas": [
            {
              "id": "640c821c201352f04a000023_001",
              "question": "Is Wilson's disease described as an iron storage disease?"
            }
          ],
          "context": "objectives : wilson's disease ( wd ) is a metabolic disorder leading to hepatic and extrahepatic copper\nobjective : wilson's disease ( wd ) is a hereditary disorder of copper metabolism\n\nwilson's disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.\nwilson's disease is a genetic disorder of copper metabolism with a hepatic or neurologic presentation.\n\nwilson's disease is one such hereditary disease that creates chaos in tissues, usually the brain and liver, via deposition of abnormal amounts of copper in them.\nwilson's disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.\n\nwilson's disease represents a copper storage disease.\nhemochromatosis and wilson's disease are known as iron and copper accumulation disorders, respectively.\n\nproject : wilson's disease ( wd ) is an inherited disorder of copper metabolism characterised by juvenile liver cirrhosis and by neurological symptoms\nwilson's disease is an inherited disorder associated with copper accumulation in the liver, brain and other vital organs.\n"
        },
        {
          "qas": [
            {
              "id": "6440084357b1c7a31500003e_001",
              "question": "Is omaveloxolone an activator of NFkB?"
            }
          ],
          "context": "the effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\n\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\n\noxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\nseveral new drugs have been approved to treat rare genetic disorders : setmelanotide for certain conditions causing obesity ; lumasiran for primary hyperoxaluria type 1, a kidney disorder ; and lonafarnib for two diseases that cause premature aging.\n\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\n. these include the pikfyve kinase inhibitor apilimod, cysteine protease inhibitors mdl - 28170, z lvg chn2, vby - 825, and ono 5334, and the ccr1 antagonist mln - 3897\n\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\n"
        },
        {
          "qas": [
            {
              "id": "64040d73201352f04a000010_001",
              "question": "Can Efgartigimod be used for myasthenia gravis?"
            }
          ],
          "context": "this article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\n\ninterpretation : efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\n\ninterpretation : efgartigimod was well tolerated and efficacious in patients with generalised myasthenia gravis.\n. in december 2021, intravenous efgartigimod received its first approval in the usa for the treatment of generalized myasthenia gravis in adults who are anti - acetylcholine receptor ( achr ) antibody positive.\n"
        },
        {
          "qas": [
            {
              "id": "6422e7ba690f196b51000044_001",
              "question": "Have Quercetin-biapigenin nanoparticles been shown to be effective in penetrating the blood-brain barrier"
            }
          ],
          "context": "the present study aimed to investigate the potential protective effect of quercetin - biapigenin encapsulated into poly ( \u025b - polycaprolactone ) ( pcl ) \" \" oparticles against t - booh - induced oxidative stress in several brain cell lines, as well as evaluate the\nmicrobubbles in combination with focused ultrasound for the delivery of quercetin - modified sulfur oparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat alzheimer's disease.\n\nthe present study aimed to investigate the potential protective effect of quercetin - biapigenin encapsulated into poly ( \u025b - polycaprolactone ) ( pcl ) \" \" oparticles against t - booh - induced oxidative stress in several brain cell lines, as well as evaluate the\nit is also reported that safety was tolerable within the limited study period. < br > < b > areas covered < / b > : we here review the recent progress in the development of baricitinib and its potential for the treatment of ra.\n"
        },
        {
          "qas": [
            {
              "id": "6429eb8457b1c7a31500000a_001",
              "question": "Is adenosine methylation an epigenetic modification?"
            }
          ],
          "context": "methylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\n\nn6 - methyladenosine ( m6a ) is a dynamic reversible methylation modification of the adenosine n6 position and is the most common chemical epigenetic modification among mrna post - transcriptional modifications, including methylation, demethylation, and\nmethylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\n\nthe methyltransferase - like 3 ( mettl3 ) is a key component of the large n6 - adenosine - methyltransferase complex in mammalian responsible for rna n6 - methyladenosine ( m6a ) modification, which plays an important role in gene post - transcription modulation.\nmethylation of the n6 position of adenosine ( m6a ) is a post - transcriptional epigenetic modification of rna.\n\nn6 - adenosine methylation ( m6a ) is one of the most common modifications on mrna.\nfirst, stress - induced methylation changes are common and are mostly heritable.\n"
        },
        {
          "qas": [
            {
              "id": "64412c2757b1c7a315000055_001",
              "question": "Can breastfeeding be used to alleviate the procedural pain in neonates?"
            }
          ],
          "context": "breastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain.\n\nbf could significantly reduce pain response in healthy - term neonates during heel lance. mt did not enhance the effect of pain relief of bf.\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\n"
        },
        {
          "qas": [
            {
              "id": "64042000201352f04a000020_001",
              "question": "Can lenacapavir be used for HIV?"
            }
          ],
          "context": "in august 2022, lenacapavir received its first approval in the eu for use in combination with other antiretroviral ( s ) in adults with multi - drug resistant hiv infection, for whom it is otherwise not possible to construct a suppressive anti - viral\nour findings suggest that cabotegravir should be evaluated in clinical trials as a potential option for antiretroviral therapy and preexposure prophylaxis in hiv - 2 - prevalent settings.\n\ncabotegravir : its potential for antiretroviral therapy and preexposure prophylaxis.\nin august 2022, lenacapavir received its first approval in the eu for use in combination with other antiretroviral ( s ) in adults with multi - drug resistant hiv infection, for whom it is otherwise not possible to construct a suppressive anti - viral\n\nin august 2022, lenacapavir received its first approval in the eu for use in combination with other antiretroviral ( s ) in adults with multi - drug resistant hiv infection, for whom it is otherwise not possible to construct a suppressive anti - viral\npurpose of review : this review summarizes available data for lenacapavir, an investigational first - in - class agent that disrupts functioning of hiv capsid protein across multiple steps in the viral life cycle.\n"
        },
        {
          "qas": [
            {
              "id": "6402c3fd201352f04a000009_001",
              "question": "Was prehospital transdermal glyceryl trinitrate effective for stroke in the RIGHT-2 trial?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nresults : six participants were enrolled. all had adverse events, mostly behavioral. two completed the trial and the other four withdrew due to adverse events. all participants reported resolution of these events after discontinuation of the drug\n\n. secondary functional outcome measures for favorable six - month recovery i. e. a mrs of 0 to 3 ( or : 3. 45 ; 95 % ci 0. 79 - 15. 01 ) were comparable for both groups\n. the primary end point was e\n\nmetastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study.\npatients meeting diagnostic criteria for crs were prospectively enrolled in a cross - sectional study\n\nmethods : we studied all patients of the glycine antagonist ( gavestinel ) in neuroprotection ( gain ) international trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke - related causes\n. the gain international trial was a randomized, double - blind, placebo - controlled, and parallel - group trial ; because the study drug had no effect on stroke outcome, treatment groups were combined for this analysis.\n\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\ninterpretation : prehospital treatment with transdermal gtn does not seem to improve functional outcome in patients with presumed stroke.\n"
        },
        {
          "qas": [
            {
              "id": "643ff48a57b1c7a31500003d_001",
              "question": "Is omaveloxolone a suppressor of Nrf2?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\n\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\n\nforced overexpression of ho - 1, pharmacological activation of ho - 1 with the agonists rta - 408 ( omaveloxolone, an fda - approved drug ) and rta - 402 repressed cell death, and treatment with ho - 1 antagonist snpp exacerbated the cell death.\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\n\noxlumo ( lumasiran ) for the treatment of primary hyperoxaluria,\nseveral new drugs have been approved to treat rare genetic disorders : setmelanotide for certain conditions causing obesity ; lumasiran for primary hyperoxaluria type 1, a kidney disorder ; and lonafarnib for two diseases that cause premature aging.\n"
        },
        {
          "qas": [
            {
              "id": "64410f8057b1c7a315000054_001",
              "question": "Can salivary cortisol be used to evaluate pain in neonates?"
            }
          ],
          "context": "we observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\n\nour findings did not support the additional benefit of music intervention on neonatal stress response to venepuncture in preterm infants.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\n\nto evaluate baseline disease severity and treatment response.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\n\nthe best non - pharmacological methods are breastfeeding followed by non - nutritive sucking coupled with sucrose sucking.\nclinical equipoise : protons and the child with craniopharyngioma.\n"
        },
        {
          "qas": [
            {
              "id": "6402c0d5201352f04a000008_001",
              "question": "Does nintedanib improve response rate in patients with bladder cancer?"
            }
          ],
          "context": ". these data might have direct implications for the ongoing phase iii clinical trial with nintedanib in ssc - associated interstitial lung disease.\ninterpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\n\npotential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.\ninterpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\n\natezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising pd - 1 / pd - l1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.\ninterpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\n\ninterpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\ninterpretation : the addition of nintedanib to chemotherapy was safe but did not improve the rate of pathological complete response in muscle - invasive bladder cancer. funding : boehringer ingelheim.\n. nintedanib is a tyrosine - kinase inhibitor that blocks several profibrotic pathways, inhibiting proliferation and migration of fibroblasts and decreasing the synthesis of extracellular matrix proteins\n"
        },
        {
          "qas": [
            {
              "id": "63f9ee5c33942b094c000014_001",
              "question": "Does SRRM4 regulate neuronal-specific microexon splicing of TAF1 mRNA?"
            }
          ],
          "context": "neuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n. further, this proliferation inhibition is accompanied by induction of neural - like expression and splicing patterns in cancer cells, suggesting that srrm4 expression shifts the cell state away from proliferation and toward differentiation\n\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\nneuronal - specific microexon splicing of taf1 mrna is directly regulated by srrm4 / nsr100.\nsrrm4 expands the repertoire of circular rnas by regulating microexon inclusion.\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\nprp - 40 is particularly required for inclusion of neuronal microexons, and our data indicate that prp - 40 is a central regulator of microexon splicing\n"
        },
        {
          "qas": [
            {
              "id": "6431f71057b1c7a315000019_001",
              "question": "In twin-twin transfusion syndrome, are the twins identical?"
            }
          ],
          "context": "twin - twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.\nmonochorionic twins are at increased risk for unique complications including twin - twin transfusion syndrome ( ttts ), selective intrauterine growth restriction ( siugr ), and twin - reversed arterial perfusion ( trap ) sequence.\n\ntwin - twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.\nthe twin - twin transfusion syndrome is a rare but severe complication in monozygotic twins.\n\ntwin - twin transfusion syndrome ( ttts ) is an unusual and serious condition that occurs in twin preg \" \" cies when identical twins share a placenta but develop discordant amniotic fluid volumes.\ntwin - twin transfusion syndrome is a serious complication of monozygotic, monochorionic, diamniotic twins resulting from transplacental vascular communications.\n"
        },
        {
          "qas": [
            {
              "id": "6415b7b8690f196b5100000c_001",
              "question": "Optogenetics refers to the study of gene expression optimization"
            }
          ],
          "context": "optogenetics refers to the genetic modification of cells to express light - sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.\noptogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits.\n\noptogenetics is an innovative technique for optical control of cells.\noptogenetics refers to techniques that use light to control the cellular activity of targeted cells.\n\noptogenetics refers to the genetic modification of cells to express light - sensitive proteins, which mediate ion flow or secondary signalling cascades upon light exposure.\nthe recently introduced term'optogenetics'describes a variety of techniques for expressing genes in nerve cells that render them responsive to light.\n\noptogenetics involves the use of genetically encoded and optically active proteins, namely opsins, to control neuronal circuits.\noptogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light.\n\noptogenetics is an innovative technique for optical control of cells.\noptogenetics controls neural activity and behavior in living organisms through genetically targetable actuators and light.\n"
        },
        {
          "qas": [
            {
              "id": "63f03155f36125a426000019_001",
              "question": "Was DNX-2401 tested for treatment of Diffuse Intrinsic Pontine Glioma?"
            }
          ],
          "context": "phase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\nmethods : we conducted a single - center, dose - escalation study of dnx - 2401, an oncolytic adenovirus that selectively replicates in tumor cells, in patients with newly diagnosed dipg.\n\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\ndnx - 2401, an oncolytic virus, for the treatment of newly diagnosed diffuse intrinsic pontine gliomas : a case report.\n"
        },
        {
          "qas": [
            {
              "id": "6436953757b1c7a315000028_001",
              "question": "Is Functional Neurological Disorder (FND) classified as a psychosomatic disorder?"
            }
          ],
          "context": "historically, functional neurological disorder ( fnd ) has been described in psychodynamic terms as the physical manifestation of psychological distress.\nfunctional neurological disorders ( fnds ), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options.\n\nfunctional neurological disorder ( fnd ), otherwise known as conversion disorder, is characterized by abnormal sensory or motor symptoms that are determined to be \" incompatible \" with neurological disease.\nconversion disorder or functional neurological disorder is a neurological symptom complex originating from psychological factors, which manifests in voluntary motor and sensory functions or as unexplained epilepsy - like seizures.\n\nfunctional neurological disorder reflects impairments in brain networks leading to distressing motor, sensory and / or cognitive symptoms that demonstrate positive clinical signs on examination incongruent with other conditions.\nfunctional neurological disorder ( fnd ) is a complex neuropsychiatric condition characterized by the presence of neurological symptoms and signs ( either motor or sensory ) that cannot be explained by any known medical or mental disease.\n\nfunctional neurological disorder ( fnd ), previously regarded as a diagnosis of exclusion, is now a rule - in diagnosis with available treatments.\nhe diagnosis of functional neurological disorder ( fnd ) requires differentiation from other neurologic diseases / syndromes, and from the comparatively rare diagnosis of feigning ( malingering and factitious disorder )\n\nfunctional neurological disorder ( fnd ), previously regarded as a diagnosis of exclusion, is now a rule - in diagnosis with available treatments.\nfunctional neurological disorders ( fnds ), which are sometimes also referred to as psychogenic neurological disorders or conversion disorder, are common disabling neuropsychiatric disorders with limited treatment options.\n"
        },
        {
          "qas": [
            {
              "id": "645004fa57b1c7a31500008b_001",
              "question": "Are accessible enhancers necessarily active?"
            }
          ],
          "context": ". while the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.\nrepressed or display condition - specific enhancer activity.\n\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\n. while the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.\n\nin this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers.\n. while the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.\n\n. instead, recent studies focusing on the quantitative nature of accessibility signal reveal subtle differences between active enhancers and their different inactive counterparts : the closed silenced state and the accessible primed and repressed\n. while the open structure as such is not a specific indicator of enhancer activity, active enhancers display a higher degree of accessibility than the primed and repressed states.\n"
        },
        {
          "qas": [
            {
              "id": "63eef9b6f36125a426000011_001",
              "question": "Is Prasinezumab effective for Parkinson\u2019s Disease?"
            }
          ],
          "context": "conclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\n"
        },
        {
          "qas": [
            {
              "id": "63f02e1bf36125a426000016_001",
              "question": "Was AAVS3 developed for hemophilia A?"
            }
          ],
          "context": "phase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\n\nphase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\n\nphase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\n\nphase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\n. three observational studies ( n = 281 ) suggested less haematoma growth with rapid tranexamic acid infusion.\n\nphase 1 - 2 trial of aavs3 gene therapy in patients with hemophilia b.\nphase 3 trial of lumasiran for primary hyperoxaluria type 1 : a new rnai therapeutic in infants and young children.\n"
        },
        {
          "qas": [
            {
              "id": "6419d79c690f196b5100003b_001",
              "question": "Does iron regulate oligodendrocyte maturation?"
            }
          ],
          "context": "the essential role of iron in the development of oligodendrocytes.\nwhen disrupted, iron homeostasis negatively impacts oligodendrocyte ( olg ) differentiation and impairs myelination.\n\nthe essential role of iron in the development of oligodendrocytes.\niron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes.\n\nthe essential role of iron in the development of oligodendrocytes.\nthese data indicate that iron delivered via transferrin and its receptor is intrinsically involved in oligodendrocyte maturation and thus plays a critical role in the onset of myelination.\n\niron modulates the differentiation of a distinct population of glial precursor cells into oligodendrocytes.\nthese data indicate that iron delivered via transferrin and its receptor is intrinsically involved in oligodendrocyte maturation and thus plays a critical role in the onset of myelination.\n"
        },
        {
          "qas": [
            {
              "id": "644efd5157b1c7a315000086_001",
              "question": "Are epigenetic changes heritable?"
            }
          ],
          "context": "transient epigenetic changes across the entire genome can influence metabolic outcomes and might or might not be heritable.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n\nmore interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nsome of these epigenetic changes appear to be heritable.\n\nsome of these epigenetic changes appear to be heritable.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\nepigenetic mechanisms, which include dna methylation, histone modification, and microrna ( mirna ), can produce heritable phenotypic changes without a change in dna sequence.\n"
        },
        {
          "qas": [
            {
              "id": "644efd2c57b1c7a315000085_001",
              "question": "Do epigenetic changes change the DNA sequence?"
            }
          ],
          "context": "more interestingly, epigenetic changes are reversible heritable changes which pass through generations.\nsome of these epigenetic changes appear to be heritable.\n\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic modifications are classified as heritable and reversible chemical modifications of chromatin that do not cause changes in dna sequence.\n\nepigenetic changes to the genome are biochemical alterations to the dna that do not change an individual's genome but do change and influence gene expression.\nepigenetic changes are reversible and do not affect the dna sequence itself but rather control levels of gene expression.\n\nepigenetic changes are inheritable modifications that can modify the gene expression without changing the dna sequence. the most common epigenetic alternations consist of dna methylation and histone modifications.\nepigenetic changes are reversible and do not affect the dna sequence itself but rather control levels of gene expression.\n\nenvironmentally caused changes in chromosomes that do not alter the dna sequence but cause phenotypic changes by altering gene transcription are summarized as epigenetics.\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\n"
        },
        {
          "qas": [
            {
              "id": "6414c5ba690f196b51000007_001",
              "question": "Can skin picking phenotype present following methylphenidate treatment?"
            }
          ],
          "context": "future studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\n\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\nconclusions \u2022 the review indicates that yoga, aerobic exercise, acupuncture, biofeedback, hypnosis, and inositol and n - acetylcysteine all show promise in the treatment of excoriation disorder and other body - focused repetitive behaviors, such as\n\n. the frequency of clinical features, objective software - based facial analysis metrics, and genome - wide peripheral blood dna methylation patterns in these patients were significantly different from that of ks1\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\n\nrates of gastrointestinal side effects, headache, and depression.\nnewly developed skin picking after methylphenidate treatment in attention deficit hyperactivity disorder : possible mechanisms.\n"
        },
        {
          "qas": [
            {
              "id": "644f0fd257b1c7a31500008a_001",
              "question": "Do enhancers have to be close to their gene targets?"
            }
          ],
          "context": "computational identification of enhancers is difficult because they do not exhibit clear location preference relative to their target gene and also because they lack clearly distinguishing genomic features.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n\ndissecting super - enhancer hierarchy based on chromatin interactions\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\n\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancers are often located many tens of kilobases away from the promoter they regulate, sometimes residing closer to the promoter of a neighboring gene.\n\nenhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\n"
        },
        {
          "qas": [
            {
              "id": "64463f9357b1c7a31500006a_001",
              "question": "Are there any other types of Spinal Muscular Atrophy except for types 1-4?"
            }
          ],
          "context": "spinal muscular atrophy ( sma ) with respiratory distress type 1 ( smard1 ) is an exceptionally rare type of sma.\ncurrently, new therapies are emerging that promise more convenience and an improved safety profile ( ofatumumab ) or remyelinating potential with clinical improvement ( opicinumab ).\n\neight of 38 patients ( 21 % ) with familial and 5 of 175 patients ( 3 % ) with sporadic amyotrophic lateral sclerosis ( als ) had missense mutations in the sod - 1 gene.\nspinal muscular atrophy ( sma ) with respiratory distress type 1 ( smard1 ) is an exceptionally rare type of sma.\n\nthe total ache activity was either normal or decreased in the childhood sma ( type 1 ), the other sma groups and disease controls ( als, x - linked sma ).\nspinal muscular atrophy ( sma ) with respiratory distress type 1 ( smard1 ) is an exceptionally rare type of sma.\n\nwe have developed a new scale and the associated classification system, to assess the functional ability of children diagnosed with dmd\nspinal muscular atrophy ( sma ) with respiratory distress type 1 ( smard1 ) is an exceptionally rare type of sma.\n"
        },
        {
          "qas": [
            {
              "id": "640418af201352f04a000018_001",
              "question": "Is Tilavonemab effective for progressive supranuclear palsy?"
            }
          ],
          "context": "conclusions : in participants with early parkinson's disease, the effects of cinpanemab on clinical measures of disease progression and changes in dat - spect imaging did not differ from those of placebo over a 52 - week period.\nusing tau antibodies for progressive supranuclear palsy.\n\nusing tau antibodies for progressive supranuclear palsy.\n. although this study did not provide evidence of efficacy in progressive supranuclear palsy, the findings provide potentially useful information for future investigations of passive immunisation using tau antibodies for progressive supranuclear\n\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\nhistological verification of the treatment effect of tirabrutinib for relapsed / refractory primary central nervous system lymphoma.\n\nusing tau antibodies for progressive supranuclear palsy.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n"
        },
        {
          "qas": [
            {
              "id": "641791ed690f196b51000032_001",
              "question": "Is SARS-CoV-2 transmitted through breast milk?"
            }
          ],
          "context": "however, there is limited published literature related to vertical transmission of any human coronavirus ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nhowever, there is limited published literature related to vertical transmission of any human coronaviruses ( including sars - cov - 2 ) via human milk and / or breastfeeding.\n\nwhether sars - cov - 2 was transmitted through breast milk is unknown.\ncurrently, there is no evidence of sars - cov - 2 transmission through breast milk.\n\nof sars - cov - 2 positive lactating mothers giving birth at our institution, most of their breast milk samples ( 95 % ) contained no detectable virus, and there was no evidence of covid - 19 infection in their breast milk - fed neonates. key points : \u00b7 breast\nextracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\n\nwhether sars - cov - 2 was transmitted through breast milk is unknown.\nno breast milk samples were positive for sars - cov - 2 and, to date, there is no evidence on the presence of sars - cov - 2 in breast milk of preg \" \" t women with covid - 19.\n\nno breast milk samples were positive for sars - cov - 2 and, to date, there is no evidence on the presence of sars - cov - 2 in breast milk of preg \" \" t women with covid - 19.\nbreast milk - fed neonates. key points : \u00b7 breast milk may rarely contain detectable sars - cov - 2 rna and was not detected in asymptomatic mothers.\n"
        },
        {
          "qas": [
            {
              "id": "644284a957b1c7a31500005c_001",
              "question": "Is there any treatment for the Facioscapulohumeral Muscular Dystrophy?"
            }
          ],
          "context": "allow assessment of high - functioning boys with duchenne muscular dystrophy.\nfacioscapulohumeral muscular dystrophy ( fshd ) is a slowly progressive muscular dystrophy without approved therapies.\n\nquantitative muscle strength assessment in duchenne muscular dystrophy : longitudinal study and correlation with functional measures.\nfacioscapulohumeral muscular dystrophy ( fshd ) is a slowly progressive muscular dystrophy without approved therapies.\n\nthe treatment of fshd is currently supportive only.\nfacioscapulohumeral muscular dystrophy ( fshd ) is a slowly progressive muscular dystrophy without approved therapies.\n"
        },
        {
          "qas": [
            {
              "id": "644e642a57b1c7a315000075_001",
              "question": "Do all proteins start with methionine?"
            }
          ],
          "context": "protein synthesis generally starts with a methionine that is removed during translation.\nprotein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. n - terminal methionine can be co - translationally cleaved by the enzyme methionine aminopeptidase ( map ).\n\nmethionine is the universal translation start but the first methionine is removed from most mature proteins.\nprotein synthesis generally starts with a methionine that is removed during translation.\n\nprotein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. n - terminal methionine can be co - translationally cleaved by the enzyme methionine aminopeptidase ( map ).\nprotein synthesis generally starts with a methionine that is removed during translation.\n\nprotein synthesis is initiated universally with the amino acid methionine. in escherichia coli, studies with anticodon sequence mutants of the initiator methionine trna have shown that protein synthesis can be initiated with several other amino acids\nprotein synthesis is initiated by methionine in eukaryotes and by formylmethionine in prokaryotes. n - terminal methionine can be co - translationally cleaved by the enzyme methionine aminopeptidase ( map ).\n"
        },
        {
          "qas": [
            {
              "id": "5c58a74e86df2b917400000d_001",
              "question": "Is Baloxavir effective for influenza?"
            }
          ],
          "context": ". in february 2018, baloxavir received its first global approval in japan for the treatment of influenza a or b virus infections.\nbackground : baloxavir marboxil is a selective inhibitor of influenza cap - dependent endonuclease. it has shown therapeutic activity in preclinical models of influenza a and b virus infections, including strains resistant to current antiviral agents.\n"
        },
        {
          "qas": [
            {
              "id": "5be44bef133db5eb78000014_001",
              "question": "Are there microbes in human breast milk?"
            }
          ],
          "context": "as a common effect in all birth scenarios, pre - and postnatal pet exposure enriched the abundance of oscillospira and / or ruminococcus ( p < 0. 05 ) with more than a twofold greater likelihood of high abundance\nthe origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\n\nhowever, there is limited published literature related to vertical transmission of any human coronavirus ( including sars - cov - 2 ) via human milk and / or breastfeeding.\nthe origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\n\nextracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\nthe origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\n\nbreast milk - fed neonates. key points : \u00b7 breast milk may rarely contain detectable sars - cov - 2 rna and was not detected in asymptomatic mothers.\nthe origins of the bacteria in milk are thought to include the maternal gastrointestinal tract ( via an entero - mammary pathway ) and through bacterial exposure of the breast during nursing.\n"
        },
        {
          "qas": [
            {
              "id": "5c61bacae842deac67000001_001",
              "question": "Is cariprazine effective for treatment of bipolar disorder?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nbackground : we evaluated the safety / tolerability of longer - term open - label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania.\n\nclinically relevant response and remission outcomes in cariprazine - treated patients with bipolar i disorder.\nbackground : we evaluated the safety / tolerability of longer - term open - label treatment with cariprazine in patients who had responded to cariprazine for acute bipolar mania.\n"
        },
        {
          "qas": [
            {
              "id": "5c55d75807647bbc4b000008_001",
              "question": "Is Bobble head doll syndrome associated with hydrocephalus?"
            }
          ],
          "context": "suprasellar arachnoid cysts can have varied presentations with signs and symptoms of obstructive hydrocephalus, visual impairment, endocrinal dysfunction, gait ataxia and rarely bobble - head doll movement.\nall the patients presented a psychomotor retardation due to an obstructive hydrocephalus.\n\nbrain magnetic reso \" \" ce imaging showed a large suprasellar arachnoid cyst extending into the third ventricle, with obstructive hydrocephalus, characteristic of bobble - head doll syndrome.\nbobble - head doll syndrome is usually associated with dilation of the third ventricle, but is rarely associated with posterior fossa disease. patient : we describe an infant with fetal hydrocephalus and an arachnoid cyst of the posterior fossa.\n"
        },
        {
          "qas": [
            {
              "id": "5be44f50133db5eb78000017_001",
              "question": "Can breastfeeding confer protection from type I diabetes?"
            }
          ],
          "context": "in the neonate and infant, among other benefits, lactation confers protection from future both type 1 and type 2 diabetes.\nthe results from the tn - 10 teplizumab prevention trial show that the diagnosis of type 1 diabetes can be delayed by treatment with a fcr non - binding monoclonal antibody to cd3 in people at high risk for disease.\n\nclinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\nin the neonate and infant, among other benefits, lactation confers protection from future both type 1 and type 2 diabetes.\n\nin the neonate and infant, among other benefits, lactation confers protection from future both type 1 and type 2 diabetes.\ntreatment of type 1 diabetes with teplizumab : clinical and immunological follow - up after 7 years from diagnosis.\n"
        },
        {
          "qas": [
            {
              "id": "5be47bff133db5eb78000018_001",
              "question": "Can pets affect infant microbiomed?"
            }
          ],
          "context": "hese results reveal a novel form of immune protective mechanism, which may play an important role in the modulating effect of helminth infection on allergic asthmatic reactions.\n. among vaginally born infants with maternal intrapartum antibiotic prophylaxis exposure, streptococcaceae were substantially and significantly reduced by pet exposure ( p < 0. 001, fdrp = 0. 03 ), reflecting an 80 % decreased likelihood of high abundance\n\n. among vaginally born infants with maternal intrapartum antibiotic prophylaxis exposure, streptococcaceae were substantially and significantly reduced by pet exposure ( p < 0. 001, fdrp = 0. 03 ), reflecting an 80 % decreased likelihood of high abundance\nan 80 % decreased likelihood of high abundance ( or 0. 20, 95 % ci, 0. 06 - 0. 70 ) for pet exposure during preg \" \" cy alone and a 69 % reduced likelihood ( or 0. 31, 95 % ci, 0. 16 - 0. 58 ) for exposure in the pre - and postnatal time periods.\n\nas a common effect in all birth scenarios, pre - and postnatal pet exposure enriched the abundance of oscillospira and / or ruminococcus ( p < 0. 05 ) with more than a twofold greater likelihood of high abundance\nirradiation profoundly impacted gut microbiota profiles in both animals.\n\nas a common effect in all birth scenarios, pre - and postnatal pet exposure enriched the abundance of oscillospira and / or ruminococcus ( p < 0. 05 ) with more than a twofold greater likelihood of high abundance\n. among vaginally born infants with maternal intrapartum antibiotic prophylaxis exposure, streptococcaceae were substantially and significantly reduced by pet exposure ( p < 0. 001, fdrp = 0. 03 ), reflecting an 80 % decreased likelihood of high abundance\n"
        },
        {
          "qas": [
            {
              "id": "5be48282133db5eb7800001b_001",
              "question": "Is there any association between the human gut microbiome and depression?"
            }
          ],
          "context": "specific members of the gut microbiota are reliable biomarkers of irradiation intensity and lethality in large animal models of human health.\nbacterial viruses ( bacteriophages, phages ) of the gut have increasingly become a focus in microbiome studies, with an understanding that they are likely key players in health and disease.\n\nmay be involved in the pathophysiology of stress - related psychiatric disorders, particularly depression.\nobesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition - related brain areas in patients with mdd.\n\nmoreover, recent findings are suggestive of the possibility that dysregulation of the enteric microbiota ( i. e., dysbiosis ) and associated bacterial translocation across the intestinal epithelium may be involved in the pathophysiology of\nmay be involved in the pathophysiology of stress - related psychiatric disorders, particularly depression.\n\nhere, we conduct a meta - review to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response.\nour findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\n\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5c2f8127133db5eb78000032_001",
              "question": "Are whole-genome duplications more divergent than small-scale duplications in yeast?"
            }
          ],
          "context": "also, we observe that transporter and glycolytic genes have a higher probability to be retained in duplicate after wgd and subsequent gene loss, both in the model as in s. cerevisiae, which leads to an increase in glycolytic flux after wgd\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\n\nwhole - genome duplicates tend to exhibit less profound phenotypic effects when deleted, are functionally less divergent, and are associated with a different set of functions than their small - scale duplicate counterparts.\nempirical data shows that whole - genome duplications ( wgds ) are more likely to be retained than small - scale duplications ( ssds ), though their relative contribution to the functional fate of duplicates remains unexplored.\n\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\nempirical data shows that whole - genome duplications ( wgds ) are more likely to be retained than small - scale duplications ( ssds ), though their relative contribution to the functional fate of duplicates remains unexplored.\n"
        },
        {
          "qas": [
            {
              "id": "5c34794fda8336e21a000001_001",
              "question": "Do yeast LTR give rise to circular DNA?"
            }
          ],
          "context": ". around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\na recent study on circular dnas in yeast found that transposable element sequence residing in circular structures mostly corresponded to full - length transposable elements.\n\nto explore the potential for using this methodology to express circular rna in vivo, circular forms of the hdv ribozyme and rnasep rna were produced in e. coli.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\n\nty eccdna can arise from the circularization of extrachromosomal linear dna during the transpositional life cycle of retrotransposons, or from circularization of genomic ty dna\na recent study on circular dnas in yeast found that transposable element sequence residing in circular structures mostly corresponded to full - length transposable elements.\n\nty eccdna can arise from the circularization of extrachromosomal linear dna during the transpositional life cycle of retrotransposons, or from circularization of genomic ty dna\nsimilarly, circular dnas can be generated by recombination between ltrs residing at different genomic loci, in which case the circular dna will contain the intervening sequence.\n"
        },
        {
          "qas": [
            {
              "id": "5c644c3de842deac67000018_001",
              "question": "Is cohesin linked to myeloid differentiation?"
            }
          ],
          "context": "several landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\n"
        },
        {
          "qas": [
            {
              "id": "5be49287133db5eb7800001e_001",
              "question": "Is pembrolizumab effective against Ewing's sarcoma?"
            }
          ],
          "context": "the potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nand pembrolizumab ) and pd - l1 inhibitors ( atezolizumab, durvalumab, and avelumab ) in patients with nsclc.\n\nthe first interim analysis of a randomized phase iii trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab ; these treatments currently apply to selected patients.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nrhabdomyosarcoma and other soft tissue sarcomas, ewing's sarcoma and other bone sarcomas.\nlow - grade extraskeletal osteosarcoma is a rare tumor that may arise de novo or following radiation therapy.\n\nnone of the 13 patients with ewing's sarcoma had an objective response.\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\n\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nthe first interim analysis of a randomized phase iii trial likewise provided a 6 months longer median overall survival compared to investigator's choice, mostly pembrolizumab ; these treatments currently apply to selected patients.\n"
        },
        {
          "qas": [
            {
              "id": "5be94b87133db5eb78000020_001",
              "question": "Can gene therapy restore auditory function?"
            }
          ],
          "context": ". the data represent unprecedented recovery of inner ear function and suggest that biological therapies to treat deafness may be suitable for translation to humans with genetic inner ear disorders.\nwe demonstrate recovery of gene and protein expression, restoration of sensory cell function, rescue of complex auditory function and recovery of hearing and balance behavior to near wild - type levels\n\nadministration and protection from covid - 19 and influenza for those in need.\n. t\n"
        },
        {
          "qas": [
            {
              "id": "5c58447f07647bbc4b000021_001",
              "question": "Is the PINES framework being used for the prediction of coding variants?"
            }
          ],
          "context": ". pines enables analyses to be customized towards genomic annotations from cell types of the highest relevance given the phenotype of interest\nhere, we introduce the computational framework pines ( phenotype - informed noncoding element scoring ), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype - dependent manner\n\n. we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\nhere, we introduce the computational framework pines ( phenotype - informed noncoding element scoring ), which predicts the functional impact of noncoding variants by integrating epigenetic annotations in a phenotype - dependent manner\n"
        },
        {
          "qas": [
            {
              "id": "5c647c52e842deac6700001c_001",
              "question": "Is erythropoietin effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\n\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nor death or in the frequency of serious adverse events. conclusions : high - dose erythropoietin treatment administered to extremely preterm infants from 24 hours after birth through 32 weeks of postmenstrual age did not result in a lower risk of severe\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n"
        },
        {
          "qas": [
            {
              "id": "5c6638717c78d69471000012_001",
              "question": "Is celecoxib effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "results celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\nrates of gastrointestinal side effects, headache, and depression.\n\nneuroprotective agents are screened for use in patients with als.\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\n\nneuroprotective agents are screened for use in patients with als.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n"
        },
        {
          "qas": [
            {
              "id": "5c531e887e3cb0e231000018_001",
              "question": "Are ultraconserved enhancers important for normal development?"
            }
          ],
          "context": "ultraconserved enhancers are required for normal development.\nenhancer elements are essential for tissue - specific gene regulation during mammalian development\n\nultraconserved enhancers are required for normal development.\n. we identified de novo mutations in three classes of putative regulatory elements in almost 8, 000 patients with developmental disorders\n\nultraconserved enhancers are required for normal development.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n"
        },
        {
          "qas": [
            {
              "id": "5c5f12d91a4c55d80b000016_001",
              "question": "Is chlorotoxin a peptide?"
            }
          ],
          "context": "chlorotoxin peptide\nchlorotoxin ( ctx ) is a 36 - amino - acid disulfide - containing peptide derived from the venom of the scorpion leiurus quinquestriatus.\n"
        },
        {
          "qas": [
            {
              "id": "5c00f38e133db5eb78000023_001",
              "question": "Does vesatolimod inhibit TLR7?"
            }
          ],
          "context": "vesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n\nvesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\nthe sphingosine - 1 - phosphate receptor - 1 ( s1p1 ) agonist ozanimod ameliorates ulcerative colitis, yet its mechanism of action is unknown.\n\nvesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\na new frontier to treat this therapeutically challenging subset of advanced egfr mutant patients.\nvesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\n\nvesatolimod ( gs - 9620 ) is an oral agonist of toll - like receptor 7, an activator of innate and adaptive immune responses.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n"
        },
        {
          "qas": [
            {
              "id": "5c5f21a81a4c55d80b00001c_001",
              "question": "Is selenocysteine an aminoacid?"
            }
          ],
          "context": "selenocysteine ( sec ), a rare genetically encoded amino acid with unusual chemical properties, is of great interest for protein engineering.\nselenocysteine ( sec ) is a naturally available se - containing amino acid that displays splendid anticancer activities against several human tumors.\n\nselenocysteine ( sec ) is a naturally available se - containing amino acid that displays splendid anticancer activities against several human tumors.\nselenocysteine ( sec ), a rare genetically encoded amino acid with unusual chemical properties, is of great interest for protein engineering.\n"
        },
        {
          "qas": [
            {
              "id": "5c58923c86df2b9174000005_001",
              "question": "Is Tecovirimat effective for smallpox?"
            }
          ],
          "context": "tecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\noral tecovirimat for the treatment of smallpox.\n\ntecovirimat appears to be an effective smallpox therapeutic in nonhuman primates, suggesting that it is reasonably likely to provide therapeutic benefit in smallpox - infected humans.\ntecovirimat : first global approval.\n"
        },
        {
          "qas": [
            {
              "id": "5c010e09133db5eb78000024_001",
              "question": "Can simvastatin alleviate depressive symptoms?"
            }
          ],
          "context": ". early improvement and response rates were significantly greater in the simvastatin group than the placebo group ( p = 0. 02 and p = 0. 01, respectively ) but remission rate was not significantly different between the two groups ( p = 0. 36 ).\nsimvastatin - treated patients experienced significantly more reductions in hdrs scores compared to the placebo group by the end of the trial ( p = 0. 02 )\n\nhigh - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\n\nsimvastatin - treated patients experienced significantly more reductions in hdrs scores compared to the placebo group by the end of the trial ( p = 0. 02 )\nstudy does not support that acute simvastatin treatment improves cognitive outcome after aneurysmal subarachnoid hemorrhage. < br >\n"
        },
        {
          "qas": [
            {
              "id": "5c5f2b771a4c55d80b000020_001",
              "question": "Is P. gingivalis bacteria found in brain?"
            }
          ],
          "context": "the polymicrobial dysbiotic subgingival biofilm microbes associated with periodontal disease appear to contribute to developing pathologies in distal body sites, including the brain.\nstudies using animal model of periodontitis and human post - mortem brain tissues from subjects with ad strongly suggest that a gram - negative periodontal pathogen, porphyromonas gingivalis ( pg ) and / or its product gingipain is / are translocated to the\n"
        },
        {
          "qas": [
            {
              "id": "5c58ac2286df2b917400000f_001",
              "question": "Is ibudilast effective for multiple sclerosis?"
            }
          ],
          "context": "ibudilast for the treatment of multiple sclerosis.\n. ibudilast may have a role in the treatment of progressive ms phenotypes.\n\nconclusions : in a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache,\nibudilast for the treatment of multiple sclerosis.\n\nibudilast for the treatment of multiple sclerosis.\nconclusions : in a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache,\n"
        },
        {
          "qas": [
            {
              "id": "5c0114ec133db5eb78000028_001",
              "question": "Does gepotidacin activate bacterial topoisomerase?"
            }
          ],
          "context": "gsk2140944 is a novel bacterial topoisomerase inhibitor in development for the treatment of bacterial infections.\n. previously, we reported that a variety of cardenolides impart anti - transmissible gastroenteritis coronavirus ( tgev ) activity in swine testicular ( st ) cells, through targeting of the cell membrane sodium / potassium pump, na + / k + - atpase.\n"
        },
        {
          "qas": [
            {
              "id": "5c5607aa07647bbc4b00000e_001",
              "question": "Is durvalumab used for lung cancer treatment?"
            }
          ],
          "context": "single - agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non - small - cell lung cancer, particularly the \u226525 % pd - l1 + population.\nin the phase iii pacific trial consolidation with durvalumab, an anti - pdl - 1 antibody, was associated with survival benefit in patients diagnosed with la - nsclc who responded to concurrent chemoradiotherapy.\n\nactivity of durvalumab plus olaparib in metastatic castration - resistant prostate cancer in men with and without dna damage repair mutations.\nsingle - agent durvalumab showed clinical efficacy and a manageable safety profile in advanced non - small - cell lung cancer, particularly the \u226525 % pd - l1 + population.\n"
        },
        {
          "qas": [
            {
              "id": "5c5f0c5a1a4c55d80b00000f_001",
              "question": "Is  LRP1 interacting with Urokinase receptor?"
            }
          ],
          "context": "interaction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\nreceptors ( ors ) as well as key components of their signaling pathway\n\ninteraction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\nwe reviewed the literature for prospective studies evaluating pd - 1 / pd - l1 inhibitors in refractory urothelial carcinoma patients, which formed the basis for us food and drug administration approval of 5 different antagonistic antibodies targeting pd - 1\n\ndirect binding of domain 3 ( d3 ) of upar to lrp is required for clearance of upa - pai - 1 - occupied upar\ninteraction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\n\nto activate nlrp3 inflammasome, a multiprotein complex that processes pro - interleukin - 1\u03b2 into its mature form.\ninteraction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\n\nthe activation of mixed lineage kinase - like ( mlkl ) by receptor - interacting protein kinase - 3 ( ripk3 ) results in plasma membrane ( pm ) disruption and a form of regulated necrosis, called necroptosis.\ninteraction with a complex formed by upa and its inhibitor pai - 1 induces cell surface down regulation and recycling of the receptor via the clathrin - coated pathway, a process dependent on the association to lrp - 1.\n"
        },
        {
          "qas": [
            {
              "id": "5c0e838b133db5eb7800002e_001",
              "question": "Is obesity related to cognitive decline?"
            }
          ],
          "context": "obesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions.\nobesity is associated with decreased cognitive function, reduced gray matter volume, and impaired white matter integrity in cognition - related brain areas in patients with mdd.\n\nimpairments in cognitive function have been associated with obesity in both people and rodents.\nobesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions.\n\nobesity is a common medical illness that is increasingly recognised as conferring risk of decline in cognitive performance, independent of other comorbid medical conditions.\nevidence for the increased prevalence of diabetes and obesity is reviewed as it relates to cognitive decline.\n\nimpairments in cognitive function have been associated with obesity in both people and rodents.\nthere is parallel evidence that people who are overweight or obese tend to perform worse on a variety of cognitive tasks\n"
        },
        {
          "qas": [
            {
              "id": "5c589ddb86df2b917400000b_001",
              "question": "Is cabozantinib effective for hepatocellular carcinoma?"
            }
          ],
          "context": "cabozantinib in the treatment of hepatocellular carcinoma.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\n\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\n"
        },
        {
          "qas": [
            {
              "id": "5c56033607647bbc4b00000c_001",
              "question": "Is Tisagenlecleucel effective for B-Cell Lymphoma?"
            }
          ],
          "context": "tisagenlecleucel in children and young adults with b - cell lymphoblastic leukemia.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia.\n\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\ntisagenlecleucel for the treatment of b - cell acute lymphoblastic leukemia.\n\ntisagenlecleucel in children and young adults with b - cell lymphoblastic leukemia.\non august 30, 2017, the u. s. food and drug administration approved tisagenlecleucel for treatment of patients up to 25 years of age with b - cell precursor acute lymphoblastic leukemia ( all ) that is refractory or in second or later relapse.\n"
        },
        {
          "qas": [
            {
              "id": "5c76cea17c78d694710000a7_001",
              "question": "Is ADP-ribosylation a PTM?"
            }
          ],
          "context": "adp - ribosylation is a post - translational modification ( ptm ) implicated in several crucial cellular processes, ranging from regulation of dna repair and chromatin structure to cell metabolism and stress responses.\nadp - ribosylation is a ptm, in which adp - ribosyltransferases use nicotinamide adenine dinucleotide ( nad + ) to modify target proteins with adp - ribose\n"
        },
        {
          "qas": [
            {
              "id": "5c56fd7407647bbc4b000013_001",
              "question": "Does epidural anesthesia for pain management during labor affect the Apgar score of the the infant?"
            }
          ],
          "context": "conclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nbreastfeeding and mother's heartbeat sounds, which are non - pharmacological pain relief methods, are effective in neonatal pain management.\n\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nerythropoietin treatment of preterm infants did not result in neuroprotection at 2 years of age in two out of three published large randomized controlled trials ; however, long - term follow - up of these infants is needed to come to definite conclusions.\n\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\nwe observed the increase in sc concentrations in response to painful stimulus. the presence of a correlation between nips scores and sc increase suggests that sc can be used as an objective parameter to assess pain in neonates.\n\nwe retrospectively analyzed 93 consecutive single - preg \" \" cy patients who underwent cesarean section with combined spinal - epidural anesthesia\nconclusion subarachnoid or epidural sufentanil, in the doses used in this study, associated with local anesthetics, had the same effect on the duration of labor after analgesia and in the apgar score of newborns.\n"
        },
        {
          "qas": [
            {
              "id": "5c5f22951a4c55d80b00001d_001",
              "question": "Is phospholipid hydroperoxide glutathione peroxidase a selenoprotein?"
            }
          ],
          "context": "the major selenoprotein expressed by germ cells in the testis, the phospholipid hydroperoxide glutathione peroxidase ( phgpx / gpx4 )\nglutathione peroxidase ( gpx1 ) is the major selenoprotein in most tissues in animals.\n\nselenocysteine ( sec ), a rare genetically encoded amino acid with unusual chemical properties, is of great interest for protein engineering.\nselenocysteine ( sec ) is a naturally available se - containing amino acid that displays splendid anticancer activities against several human tumors.\n"
        },
        {
          "qas": [
            {
              "id": "5c73aced7c78d69471000087_001",
              "question": "Is inositol effective for trichotillomania?"
            }
          ],
          "context": "other body - focused repetitive behaviors, such as trichotillomania.\nfuture studies should examine whether inositol may be beneficial in controlling pulling behavior in a subgroup of individuals with trichotillomania.\n"
        },
        {
          "qas": [
            {
              "id": "5c640fa1e842deac67000011_001",
              "question": "Is TIAM1 favoring tumor progression in colorectal cancer (CRC)?"
            }
          ],
          "context": "using an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\n. importantly, high nuclear tiam1 in clinical specimens associates with increased crc patient survival. together, our findings suggest that in crc tiam1 suppresses tumor progression by regulating yap / taz activity.\n\nusing an orthotopic xenograft model in nude mice, we confirmed that tiam1 silencing could reduce tumor growth by subcutaneous injection and could suppress lung and liver metastases of colorectal cancer cells.\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n"
        },
        {
          "qas": [
            {
              "id": "5c663afe7c78d69471000013_001",
              "question": "Is pacritinib effective for treatment of myelofibrosis?"
            }
          ],
          "context": "pacritinib could be a treatment option for patients with myelofibrosis, including those with baseline cytopenias for whom options are particularly limited.\nexpert commentary : pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.\n"
        },
        {
          "qas": [
            {
              "id": "5c571f7607647bbc4b000017_001",
              "question": "Can exposure to heavy metals like lead(Pb) or cadmium(Cd) cause changes in DNA methylation patterns in Isoetes sinensis?"
            }
          ],
          "context": "induction and repair of dna damage as measured by the comet assay and the yield of somatic mutations in gamma - irradiated tobacco seedlings.\none possible but largely unexplored explanation is that exposure to sublethal doses of insecticides may alter epigenetic patterns that are heritable.\n\ndna methylation in an intron of the ibm1 histone demethylase gene stabilizes chromatin modification patterns.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\n\ninduction and repair of dna damage as measured by the comet assay and the yield of somatic mutations in gamma - irradiated tobacco seedlings.\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\n\ninduction and repair of dna damage as measured by the comet assay and the yield of somatic mutations in gamma - irradiated tobacco seedlings.\nhydrilla verticillata employs two different ways to affect dna methylation under excess copper stress. because of the accumulation of heavy metals, hydrilla verticillata ( l. f. ) royle, a rooted submerged perennial aquatic herb, is being developed as a\n"
        },
        {
          "qas": [
            {
              "id": "5c57031107647bbc4b000014_001",
              "question": "Has Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) been reported to be a plasminogen receptor in pathogenic bacteria?"
            }
          ],
          "context": ". several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),\nmoreover, several isoforms of the glyceraldehyde 3 - phosphate dehydrogenase ( gapdh ) and galectin ( gal ) were identified in both antigenic extracts as plasminogen - binding proteins.\n\nbinding of plasminogen ( plg ) to bacterial surfaces, as it has been shown that this interaction contributes to bacterial adhesion to host cells, invasion of host tissues, and evasion of the immune system\ngapdh exhibits a high affinity for plasmin and a significantly lower affinity for plasminogen.\n\n. several bacterial proteins are known to serve as receptors for plg including glyceraldehyde - 3 - phosphate dehydrogenase ( gapdh ),\nbinding of plasminogen ( plg ) to bacterial surfaces, as it has been shown that this interaction contributes to bacterial adhesion to host cells, invasion of host tissues, and evasion of the immune system\n"
        },
        {
          "qas": [
            {
              "id": "5c6549e1e842deac67000022_001",
              "question": "Can CPX-351 be used for the treatment of tuberculosis?"
            }
          ],
          "context": "cpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\nfrequent dosing. this review focuses on the potential benefits and considerations for the study and use of 2 long - acting injectable agents, cabotegravir ( gsk1265744la, cab la ) and rilpivirine ( tmc278la, rpv la ), for use as chemoprophylaxis for hiv\n\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\nclinical and immunological studies of rotavirus vaccines.\n\nmycobacterium abscessus lung disease is difficult to treat due to intrinsic drug resistance and the persistence of drug - tolerant bacteria.\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\n\ncpx - 351 ( united states : vyxeos\u00ae ; europe : vyxeos\u00ae liposomal ), a dual - drug liposomal encapsulation of daunorubicin and cytarabine in a synergistic 1 : 5 molar ratio, is approved by the us fda and the ema for the treatment of adults with newly diagnosed\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\n\ncpx - 351 is a novel liposomal formulation of cytarabine and daunorubicin which has recently been fda approved for treatment of acute myeloid leukemia ( aml ).\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5c654c14e842deac67000025_001",
              "question": "Does lucatumumab bind to CD140?"
            }
          ],
          "context": "in this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nanother cd20 directed mab, ofatumumab, is in phase 3.\n\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\nramucirumab in second - line treatment due to their benefits in terms of overall survival.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n\nrates of gastrointestinal side effects, headache, and depression.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n\navelumab for the treatment of urothelial cancer.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n"
        },
        {
          "qas": [
            {
              "id": "5c73ad0b7c78d69471000093_001",
              "question": "Does simvastatin improve outcomes of aneurysmal subarachnoid hemorrhage?"
            }
          ],
          "context": "high - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nconclusions simvastatin showed no benefits in decreasing the incidence of vasospasm, dci, or all - cause mortality after aneurysmal sah. we conclude that patients with sah should not be treated routinely with simvastatin during the acute stage.\n\nhigh - dose simvastatin is effective in preventing cerebral vasospasm after aneurysmal subarachnoid hemorrhage : a prospective cohort study in korean patients.\nconclusions high - dose simvastatin treatment should not be prescribed routinely for aneurysmal subarachnoid hemorrhage.\n"
        },
        {
          "qas": [
            {
              "id": "5c72aaed7c78d6947100006f_001",
              "question": "Is pazopanib an effective treatment of glioblastoma?"
            }
          ],
          "context": "variable response of cns hemangioblastomas to pazopanib in a single patient with von hippel - lindau disease : case report.\n. pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\n\nvariable response of cns hemangioblastomas to pazopanib in a single patient with von hippel - lindau disease : case report.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n\n. pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n"
        },
        {
          "qas": [
            {
              "id": "5c643485e842deac67000015_001",
              "question": "Are de novo mutations in regulatory elements responsible for neurodevelopmental disorders?"
            }
          ],
          "context": "de novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. we identified de novo mutations in three classes of putative regulatory elements in almost 8, 000 patients with developmental disorders\n\nde novo mutations in regulatory elements in neurodevelopmental disorders. we previously estimated that 42 % of patients with severe developmental disorders carry pathogenic de novo mutations in coding sequences.\n. here we show that de novo mutations in highly evolutionarily conserved fetal brain - active elements are significantly and specifically enriched in neurodevelopmental disorders\n\n. although these regulatory elements are often distant from their target genes, they affect gene expression by recruiting transcription factors to specific promoter regions.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n"
        },
        {
          "qas": [
            {
              "id": "5c7c0e2fd774d0424000000d_001",
              "question": "Are phagosomal proteins ubiquitinated?"
            }
          ],
          "context": "phagosomal proteins are ubiquitylated, and ubiquitylation was found to be required for formation of acidic multivesicular structures.\nmembranes of the bacterial phagosome are enriched with ubiquitinated proteins in a way that requires its dot / icm type iv secretion system, suggesting the involvement of effectors in the manipulation of the host ubiquitination machinery.\n"
        },
        {
          "qas": [
            {
              "id": "5c73ad327c78d69471000097_001",
              "question": "Does tremelimumab improve survival of mesothelioma patients?"
            }
          ],
          "context": "interpretation : tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malig \" \" t mesothelioma.\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\n\nbackground : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\ninterpretation : tremelimumab did not significantly prolong overall survival compared with placebo in patients with previously treated malig \" \" t mesothelioma.\n"
        },
        {
          "qas": [
            {
              "id": "5c6587d77c78d69471000005_001",
              "question": "Can enasidenib be used for the treatment of acute myeloid leukemia?"
            }
          ],
          "context": "in august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\n\nrates of gastrointestinal side effects, headache, and depression.\nin august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\n"
        },
        {
          "qas": [
            {
              "id": "5c783236d774d04240000001_001",
              "question": "Is collagen the most abundant human protein?"
            }
          ],
          "context": "as the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\ncollagen is a fibrillar protein that conforms the conjunctive and connective tissues in the human body, essentially skin, joints, and bones\n\ncollagen is the most abundant protein family in mammals.\nthe collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.\n\nas the most abundant protein in the body, collagen is essential to maintain the normal structure and strength of connective tissue, such as bones, skin, cartilage, and blood vessels.\ncollagen is the most abundant protein family in mammals.\n"
        },
        {
          "qas": [
            {
              "id": "5c76be617c78d694710000a5_001",
              "question": "Is the enzyme ERAP2 associated with the disease birdshot chorioretinopathy?"
            }
          ],
          "context": "a genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nretinopathy, retinoblastoma, retinal vascular dysfunction and hyperhomocysteinemia induced ocular diseases, emphasizing that circrnas could be promising biomarkers for the diagnosis and prognosis evaluation.\n\nretinopathy, age - related macular degeneration, retinopathy of prematurity, glaucoma, corneal neovascularization, cataract, pterygium, proliferative vitreoretinopathy, retinoblastoma, and ocular melanoma.\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\n\nbscr is also associated with endoplasmic reticulum aminopeptidase 2 ( erap2 ), an enzyme involved in processing hla class i ligands, thus implicating the a * 29 : 02 peptidome in this disease.\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\n\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\natropine occlusion in the treatment of strabismic amblyopia and its effect upon the non - amblyopic eye.\n\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nbscr is also associated with endoplasmic reticulum aminopeptidase 2 ( erap2 ), an enzyme involved in processing hla class i ligands, thus implicating the a * 29 : 02 peptidome in this disease.\n"
        },
        {
          "qas": [
            {
              "id": "5c73ad377c78d6947100009a_001",
              "question": "Does Panitumumab prolong survival of biliary tract cancer patients?"
            }
          ],
          "context": "shown to be effective for advanced biliary tract cancer.\ndespite many clinical trials being conducted with molecular targeted agents including erlotinib, cetuximab, panitumumab, bevacizumab, sorafenib, cediranib, trametinib and vandetanib, no agent has shown to be effective for advanced biliary tract\n\nshown to be effective for advanced biliary tract cancer.\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\n\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\nconclusions : panitumumab in combination with chemotherapy does not improve orr, pfs and os in patients with kras wild - type, advanced biliary cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5c6582207c78d69471000001_001",
              "question": "Is lucatumumab a polyclonal antibody?"
            }
          ],
          "context": "background dupilumab ( an anti - interleukin - 4 - receptor - \u03b1 monoclonal antibody ) blocks signalling of interleukin 4 and interleukin 13, type 2 / th2 cytokines implicated in numerous allergic diseases ranging from asthma to atopic dermatitis.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\nmonoclonal antibodies including nivolumab and pembrolizumab ; anti - pd - l1 antibodies including atezolizumab, avelumab, and durvalumab.\n\navelumab for the treatment of urothelial cancer.\nin this open - label, multicentre, phase 1 study a fully human anti - cd40 antagonist monoclonal antibody, lucatumumab, was evaluated in patients with relapsed / refractory multiple myeloma ( mm ).\n"
        },
        {
          "qas": [
            {
              "id": "5c662c507c78d6947100000d_001",
              "question": "Is lithium effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "background lithium has neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\n\nbackground a neuroprotective effect of lithium in amyotrophic lateral sclerosis ( als ) has been recently reported.\nhas neuroprotective effects in cell and animal models of amyotrophic lateral sclerosis ( als ), and a small pilot study in patients with als showed a significant effect of lithium on survival.\n\nneuroprotective agents are screened for use in patients with als.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n"
        },
        {
          "qas": [
            {
              "id": "5c73acea7c78d69471000085_001",
              "question": "Should dacomitinib be used for treatment of glioblastoma patients?"
            }
          ],
          "context": "expert opinion : despite the poor global results of dacomitinib in recurrent gb shown in a phase ii trial, some patients had a significant benefit.\nconclusions : dacomitinib has a limited single - agent activity in recurrent gb with egfr amplification.\n\nconclusions : dacomitinib has a limited single - agent activity in recurrent gb with egfr amplification.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n"
        },
        {
          "qas": [
            {
              "id": "5c6d7bb57c78d6947100003b_001",
              "question": "Are there ultraconserved regions in the budding yeast (Saccharomyces cerevisiae)?"
            }
          ],
          "context": "ultraconserved enhancers are required for normal development.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\n. to facilitate the investigation of unique ucss, the ucsc genome browser was utilized to visualize the chromosomal position and related annotations of ucss in s. cerevisiae genome.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\ngenomes contain many clusters of conserved noncoding elements\n\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\nalthough similar structures appear to be conserved in fission yeast, computational modeling and analysis of high - throughput chromosome conformation capture ( hi - c ) data have been used to argue that the small, highly constrained budding yeast\n"
        },
        {
          "qas": [
            {
              "id": "5c640c2ee842deac67000010_001",
              "question": "Is there any role for HUWE1 in MYC signalling?"
            }
          ],
          "context": ". taken together, these data identify huwe1 as a bona fide tumour suppressor gene in the intestinal epithelium and suggest a potential vulnerability of huwe1 - mutated tumours to dna - damaging agents and inhibitors of anti - apoptotic proteins.\nhuwe1 is a critical colonic tumour suppressor gene that prevents myc signalling, dna damage accumulation and tumour initiation.\n"
        },
        {
          "qas": [
            {
              "id": "5c674aed7c78d69471000019_001",
              "question": "Do raspberries improve postprandial glucose and acute and chronic inflammation in adults with type 2 Diabetes?"
            }
          ],
          "context": ". red raspberry ( rb ) contains high amounts of dietary fibers and polyphenolic compounds, which are known for their anti - oxidative and anti - inflammatory effects.\nhesperidin, a flavanoglycone abundantly present in citrus fruits, is reported to have antioxidant, anti - inflammatory, and neuroprotective properties.\n\nconclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\nfive weeks of treatment with the glp - 1 analogue liraglutide improves glycaemic control and lowers body weight in subjects with type 2 diabetes.\n\nour studies establish that resistance training in older adults with type 2 diabetes results in muscle fiber hypertrophy, despite a greater accumulation of inflammatory cytokine transcripts in muscle.\nmetformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti - inflammatory and anti - atherosclerotic properties.\n\napelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.\nmetformin and rosiglitazone both improve glycemic control in type 2 diabetes mellitus, however may possess different anti - inflammatory and anti - atherosclerotic properties.\n\nwise regression analysis demonstrated that baseline bmi and previous insulin dose were positively associated with body weight reduction and baseline hba1c was positively associated with reduction of hba1c at 2 years after liraglutide\napelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.\n"
        },
        {
          "qas": [
            {
              "id": "5c7836dad774d04240000002_001",
              "question": "Are Mesenchymal stem cells (MSC) multipotent cells?"
            }
          ],
          "context": "multipotent mesenchymal bone marrow - derived stem cells\nanimal studies have shown that mesenchymal stromal cell ( msc ) infusions improve acute kidney injury ( aki ) outcomes when administered early after ischemic / reperfusion injury or within 24 hours after cisplatin administration.\n\nmultipotent mesenchymal bone marrow - derived stem cells\nmultipotent hesc - derived mesenchymal cells ( mcs )\n"
        },
        {
          "qas": [
            {
              "id": "5c6b198f7c78d69471000025_001",
              "question": "Is there a deep-learning algorithm for protein solubility prediction?"
            }
          ],
          "context": ". key to their biological function are the molecular recognition features ( morfs ) located within long disordered regions. computationally identifying these morfs from disordered protein sequences is a challenging task\n. thus, it is imperative to develop novel, highly accurate in silico sequence - based protein solubility predictors. in this work we propose, deepsol, a novel deep learning - based protein solubility predictor\n\n. thus, it is imperative to develop novel, highly accurate in silico sequence - based protein solubility predictors. in this work we propose, deepsol, a novel deep learning - based protein solubility predictor\nopal : prediction of morf regions in intrinsically disordered protein sequences.\n\nprotein solubility plays a vital role in pharmaceutical research and production yield. for a given protein, the extent of its solubility can represent the quality of its function, and is ultimately defined by its sequence\n. thus, it is imperative to develop novel, highly accurate in silico sequence - based protein solubility predictors. in this work we propose, deepsol, a novel deep learning - based protein solubility predictor\n\n. thus, it is imperative to develop novel, highly accurate in silico sequence - based protein solubility predictors. in this work we propose, deepsol, a novel deep learning - based protein solubility predictor\nfor the accuracy of the structure prediction of the bound state.\n"
        },
        {
          "qas": [
            {
              "id": "5c5215e67e3cb0e231000004_001",
              "question": "Have machine learning methods been used to predict the severity of major depressive disorder(MDD)?"
            }
          ],
          "context": "here, we conduct a meta - review to identify predictors of response to antidepressant therapy in order to select robust input features for machine learning models of treatment response.\nobjective we aimed to integrate neural data and an advanced machine learning technique to predict individual major depressive disorder ( mdd ) patient severity.\n\nbackground growing evidence documents the potential of machine learning for developing brain based diagnostic methods for major depressive disorder ( mdd ).\nobjective we aimed to integrate neural data and an advanced machine learning technique to predict individual major depressive disorder ( mdd ) patient severity.\n"
        },
        {
          "qas": [
            {
              "id": "5c6583117c78d69471000002_001",
              "question": "Can midostaurin inhibit angiogenesis?"
            }
          ],
          "context": "the anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\nmidostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor.\n\nmidostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor.\npotential immunomodulatory, antiinflammatory, anti - angiogenic and sedative properties make thalidomide a good candidate for the treatment of several diseases such as multiple myeloma.\n\nmidostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor.\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\nits effectiveness in the clinic has been ascribed to wide - ranging properties, including anti - tnf - alpha, t - cell costimulatory and antiangiogenic activity.\nmidostaurin was a prototype kinase inhibitor, originally developed as a protein kinase c inhibitor and subsequently as an angiogenesis inhibitor, based on its inhibition of vascular endothelial growth factor receptor.\n"
        },
        {
          "qas": [
            {
              "id": "5c629fffe842deac67000009_001",
              "question": "Does Groucho related gene 5 (GRG5) have a role only in late development?"
            }
          ],
          "context": "groucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\n\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\n. by both loss and gain of function approaches we demonstrate that ablation of grg5 deregulates the embryonic stem cell ( esc ) pluripotent state whereas its overexpression leads to enhanced self - renewal and acquisition of cancer cell - like properties\n\ngroucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\nall mutations in the human gene for cuzn superoxide dismutase ( cuznsod ) reported to date are associated with the disease amyotrophic lateral sclerosis ( als ).\n\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\ngroucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n"
        },
        {
          "qas": [
            {
              "id": "5c6da11e7c78d69471000042_001",
              "question": "Are there tools for reviewing variant calls?"
            }
          ],
          "context": "viper : a web application for rapid expert review of variant calls.\n. we developed the variant inspector and expert rating tool ( viper ) to speed up this process by integrating the integrative genomics viewer into a web application\n\nviper : a web application for rapid expert review of variant calls.\nvariant review with the integrative genomics viewer.\n\nviper : a web application for rapid expert review of variant calls.\n. many tools have been developed to analyze genomic variation ranging from single nucleotide variants to whole chromosomal aberrations. as sequencing throughput increases, the number of variants called by such tools also grows\n"
        },
        {
          "qas": [
            {
              "id": "5c65495be842deac67000021_001",
              "question": "Has ivosidenib been FDA approved for use against acute myeloid leukemia?"
            }
          ],
          "context": "in august 2017, the united states federal drug administration ( fda ) approved enasidenib ( idhifa, celgene / agios ) for adults with relapsed and refractory acute myelogenous leukemia ( aml ) with an idh2 mutation.\nthe fda approved ivosidenib for patients with idh1 - mutant relapsed / refractory acute myeloid leukemia.\n"
        },
        {
          "qas": [
            {
              "id": "5c51f44c07ef653866000004_001",
              "question": "Are Copy Number Variants (CNVs) depleted in regions of low mappability?"
            }
          ],
          "context": ". in particular, we identify 347 genes with a novel exonic cnv in low - mappability regions, including 29 genes previously associated with disease.\nhuman copy number variants are enriched in regions of low mappability.\n"
        },
        {
          "qas": [
            {
              "id": "5c5b2f4b1a4c55d80b000001_001",
              "question": "Is Adar3 involved in learning and memory?"
            }
          ],
          "context": ". we also show that adar3 transiently translocates from the cytoplasm to the nucleus upon kcl - mediated activation in sh - sy5y cells. these results indicate that adar3 contributes to cognitive processes in mammals.\nadar3 is involved in learning and memory in mice.\n\nadar3 is involved in learning and memory in mice.\n. consistent with this, we show that mice lacking exon 3 of adar3 ( which encodes two double stranded rna binding domains ) have increased levels of anxiety and deficits in hippocampus - dependent short - and long - term memory formation\n"
        },
        {
          "qas": [
            {
              "id": "5c5f2cef1a4c55d80b000022_001",
              "question": "There is no drug available to prevent HIV infection, Pre-exposure prophylaxis (PrEP), yes or no?"
            }
          ],
          "context": "introduction use of pre - exposure prophylaxis ( prep ) among people who inject drugs ( pwid ) has been shown to be effective in preventing hiv transmission.\nrates of gastrointestinal side effects, headache, and depression.\n\nintroduction use of pre - exposure prophylaxis ( prep ) among people who inject drugs ( pwid ) has been shown to be effective in preventing hiv transmission.\nthe use of antiretrovirals as pre - exposure prophylaxis ( prep ) is highly efficacious in hiv prevention.\n\npre - exposure prophylaxis ( prep ) is an experimental approach to hiv prevention and consists of antiretroviral drugs to be taken before potential hiv exposure in order to reduce the risk of hiv infection and continued during periods of risk.\ndaily oral pre - exposure prophylaxis ( prep ) is the use of antiretroviral drugs by hiv - negative people to prevent hiv infection.\n\nthe use of antiretrovirals as pre - exposure prophylaxis ( prep ) is highly efficacious in hiv prevention.\nhiv pre - exposure prophylaxis ( prep ) is a new approach that involves the ongoing use of antiretroviral medications by hiv - negative individuals to reduce the risk of hiv infection.\n\nhiv pre - exposure prophylaxis ( prep ) is a new approach that involves the ongoing use of antiretroviral medications by hiv - negative individuals to reduce the risk of hiv infection.\ndaily oral pre - exposure prophylaxis ( prep ) is the use of antiretroviral drugs by hiv - negative people to prevent hiv infection.\n"
        },
        {
          "qas": [
            {
              "id": "5c52cde87e3cb0e23100000e_001",
              "question": "Does allele phasing improve the phylogenetic utility of ultraconserved elements?"
            }
          ],
          "context": "allele phasing greatly improves the phylogenetic utility of ultraconserved elements.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\nallele phasing greatly improves the phylogenetic utility of ultraconserved elements.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\n"
        },
        {
          "qas": [
            {
              "id": "5c5723a007647bbc4b000019_001",
              "question": "Have yeast prions become important models for the study of the basic mechanisms underlying human amyloid diseases?"
            }
          ],
          "context": "yeast prions, based on self - seeded highly ordered fibrous aggregates ( amyloids ), serve as a model for human amyloid diseases.\nyeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\n\nyeast prions increasingly are serving as models for the understanding and treatment of many mammalian amyloidoses.\nyeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\n\nyeast prions ( infectious proteins ) were discovered by their outre genetic properties and have become important models for an array of human prion and amyloid diseases.\nyeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\n\nyeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\nhere we summarize the results of studies of prions of the yeast saccharomyces cerevisiae and of the use of yeast model for investigation of some human amyloidoses, such as prion diseases, alzheimer's, parkinson's, and huntington's diseases.\n\nthe yeast system has provided considerable insight into the biology of amyloid and prions.\nyeast prions are important models for human amyloid diseases in general, particularly because new evidence is showing infectious aspects of several human amyloidoses not previously classified as prions.\n"
        },
        {
          "qas": [
            {
              "id": "5c6b7bee7c78d6947100002a_001",
              "question": "Is dupilumab effective for treatment of asthma?"
            }
          ],
          "context": "dupilumab : a novel treatment for asthma.\ndupilumab efficacy and safety in moderate - to - severe uncontrolled asthma.\n\ndupilumab efficacy and safety in moderate - to - severe uncontrolled asthma.\nconclusions in patients with glucocorticoid - dependent severe asthma, dupilumab treatment reduced oral glucocorticoid use while decreasing the rate of severe exacerbations and increasing the fev1.\n\ndupilumab : a novel treatment for asthma.\nexpert opinion : patients with severe asthma who are not sufficiently controlled with standard - of - care represent the target asthma population for dupilumab.\n\nexpert opinion : supported by a strategic mechanism of action, as well as by convincing preliminary clinical results, dupilumab currently appears to be a very promising biological drug for the treatment of severe uncontrolled asthma.\ndupilumab : a novel treatment for asthma.\n"
        },
        {
          "qas": [
            {
              "id": "5c6d441d7c78d69471000037_001",
              "question": "Does Eucommia ulmoides leaf extract ameliorates steatosis/fatty liver induced by high-fat diet?"
            }
          ],
          "context": "the hepatic fatty acid synthase and hmg - coa reductase activities were significantly lowered by a du - zhong leaf extract supplement in high fat - fed hamsters.\neucommia ulmoides oliver leaf extract ( ele ) has been shown to have anti - hypertensive and anti - obesity effects in rats that are fed a high - fat diet ( hfd ).\n\nboth forms of eucommia leaves minimised increases in body weight and visceral fat in a dose - dependent fashion.\neucommia ulmoides oliver leaf extract ( ele ) has been shown to have anti - hypertensive and anti - obesity effects in rats that are fed a high - fat diet ( hfd ).\n"
        },
        {
          "qas": [
            {
              "id": "5c6b82a17c78d6947100002f_001",
              "question": "Is verubecestat effective for Alzheimer\u2019s Disease?"
            }
          ],
          "context": "the lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nthese results support the continued global development of verubecestat as a potential disease - modifying agent for japanese and non - japanese subjects who are at - risk for developing ad.\n\nverubecestat is an inhibitor of \u03b2 - site amyloid precursor protein cleaving enzyme 1 ( bace1 ) being evaluated in clinical trials for the treatment of alzheimer's disease.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5c6f15577c78d69471000053_001",
              "question": "Is galcanezumab effective for treatment of migraine?"
            }
          ],
          "context": "galcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.\nbackground safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene - related peptide, for prevention of migraine ( nct02163993 ) are reported here.\n\ngalcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.\nin september 2018, the us fda approved galcanezumab as a once - monthly subcutaneous injection for the preventive treatment of migraine in adults.\n\nbackground safety findings from a phase 2b study of galcanezumab, a humanized monoclonal antibody against calcitonin gene - related peptide, for prevention of migraine ( nct02163993 ) are reported here.\nefficacy and safety of galcanezumab for the prevention of episodic migraine : results of the evolve - 2 phase 3 randomized controlled clinical trial.\n\ngalcanezumab appears efficacious, safe, and well tolerated for the preventive treatment of chronic migraine.\nefficacy and safety of galcanezumab for the prevention of episodic migraine : results of the evolve - 2 phase 3 randomized controlled clinical trial.\n"
        },
        {
          "qas": [
            {
              "id": "5c52028807ef653866000009_001",
              "question": "Can mitochondria be inherited by both parents in humans?"
            }
          ],
          "context": ". our results suggest that, although the central dogma of maternal inheritance of mtdna remains valid, there are some exceptional cases where paternal mtdna could be passed to the offspring.\nbiparental inheritance of mitochondrial dna in humans.\n\nand mtdna are exclusively maternally inherited in humans\nbiparental inheritance of mitochondrial dna in humans.\n"
        },
        {
          "qas": [
            {
              "id": "5c71648b7c78d69471000067_001",
              "question": "Can Diazepam be beneficial  in the treatment of  traumatic brain injury?"
            }
          ],
          "context": "cranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims ).\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\n\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\nhe present experiment examined the effects of diazepam, a positive modulator at the gaba ( a ) receptor, on survival and cognitive performance in traumatically brain - injured animals. i\n\nrates of gastrointestinal side effects, headache, and depression.\nhe present experiment examined the effects of diazepam, a positive modulator at the gaba ( a ) receptor, on survival and cognitive performance in traumatically brain - injured animals. i\n\nhesperidin attenuates depression - related symptoms in mice with mild traumatic brain injury\nhe present experiment examined the effects of diazepam, a positive modulator at the gaba ( a ) receptor, on survival and cognitive performance in traumatically brain - injured animals. i\n"
        },
        {
          "qas": [
            {
              "id": "5c57216e07647bbc4b000018_001",
              "question": "In clinical trials, the H3 R antagonist CEP-26401 has a positive effect on cognition, yes or no?"
            }
          ],
          "context": "cep - 26401 is a novel orally active, brain - penetrant, high - affinity histamine h3 receptor ( h3r ) antagonist, with potential therapeutic utility in cognition enhancement\ncep - 26401 ( irdabisant ), a potent and selective histamine h\u2083 receptor antagonist / inverse agonist with cognition - enhancing and wake - promoting activities.\n\nrates of gastrointestinal side effects, headache, and depression.\nresults : six participants were enrolled. all had adverse events, mostly behavioral. two completed the trial and the other four withdrew due to adverse events. all participants reported resolution of these events after discontinuation of the drug\n\nhowever, although a number of clinical studies examining the efficacy of h3 receptor antagonists for a variety of cognitive disorders are currently underway, no clinical proof of concept for an h3 receptor antagonist has been reported to date.\ncep - 26401 is a novel orally active, brain - penetrant, high - affinity histamine h3 receptor ( h3r ) antagonist, with potential therapeutic utility in cognition enhancement\n\nconclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\n. clinical improvements seen in the 24 - week blinded period were maintained during the ole.\n"
        },
        {
          "qas": [
            {
              "id": "5c6f6d997c78d69471000055_001",
              "question": "Is pimavanserin effective for Parkinson's disease psychosis?"
            }
          ],
          "context": "[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\n\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\n\n[ pimavanserin : a new treatment for the parkinson's disease psychosis ].\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\n"
        },
        {
          "qas": [
            {
              "id": "5c5b52731a4c55d80b000003_001",
              "question": "Is deletion at 6q24.2-26 associated with longer survival of patients with high-grade serous ovarian carcinoma (HGSOCs)?"
            }
          ],
          "context": ". the prognostic value of this deletion was validated in two independent series, one consisting of 36 hgsocs analyzed by fluorescent in situ hybridization ( p = 0. 04 ) and another comprised of 411 hgsocs from the cancer genome atlas study ( tcga ) ( hr =\nwe aimed to evaluate the prognostic and predictive value of the nucleotide excision repair - related gene gtf2h5, which is localized at the 6q24. 2 - 26 deletion previously reported by our group to predict longer survival of high - grade serous ovarian\n\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\n. the prognostic value of this deletion was validated in two independent series, one consisting of 36 hgsocs analyzed by fluorescent in situ hybridization ( p = 0. 04 ) and another comprised of 411 hgsocs from the cancer genome atlas study ( tcga ) ( hr =\n\nlonger survival of high - grade serous ovarian cancer patients.\nwe aimed to evaluate the prognostic and predictive value of the nucleotide excision repair - related gene gtf2h5, which is localized at the 6q24. 2 - 26 deletion previously reported by our group to predict longer survival of high - grade serous ovarian\n"
        },
        {
          "qas": [
            {
              "id": "5c65484ee842deac6700001f_001",
              "question": "Can mogamulizumab be used for the treatment of cutaneous T-cell lymphoma?"
            }
          ],
          "context": "although several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nrates of gastrointestinal side effects, headache, and depression.\n\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\n\nin the large international phase iii mavoric trial, patients with previously treated cutaneous t - cell lymphoma who received the anti - ccr4 monoclonal antibody mogamulizumab experienced significantly longer progression - free survival and higher response\npresenting clinical and preclinical evidence for rituximab, tocilizumab, pirfenidone, and nintedanib, as well as hematopoietic stem cell transplantation and lung transplantation.\n\nin the large international phase iii mavoric trial, patients with previously treated cutaneous t - cell lymphoma who received the anti - ccr4 monoclonal antibody mogamulizumab experienced significantly longer progression - free survival and higher response\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\n\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\nin the large international phase iii mavoric trial, patients with previously treated cutaneous t - cell lymphoma who received the anti - ccr4 monoclonal antibody mogamulizumab experienced significantly longer progression - free survival and higher response\n"
        },
        {
          "qas": [
            {
              "id": "5c72ba807c78d69471000076_001",
              "question": "Is avelumab effective for bladder cancer?"
            }
          ],
          "context": "atezolizumab, avelumab, durvalumab, nivolumab and pembrolizumab are promising pd - 1 / pd - l1 blockade drugs under investigation that will redefine the standard of care for bladder cancer.\navelumab for the treatment of urothelial cancer.\n\navelumab for the treatment of urothelial cancer.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc.\n\nexpert opinion : avelumab has shown clinical efficacy for metastatic and advanced uc in phase i studies after the failure of platinum - based therapy with a well - tolerated safety profile.\navelumab for the treatment of urothelial cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5c6b7a9e7c78d69471000029_001",
              "question": "Is cabozantinib effective for Hepatocellular Carcinoma?"
            }
          ],
          "context": "cabozantinib in the treatment of hepatocellular carcinoma.\n. 4 % ), and diarrhea ( 10 % vs. 2 % ). < br > < b > conclusions < / b > : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nconclusions : among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression - free survival than placebo.\n"
        },
        {
          "qas": [
            {
              "id": "5c5839e707647bbc4b00001f_001",
              "question": "Is there a link between BCL11B haploinsufficiency and syndromic neurodevelopmental delay?"
            }
          ],
          "context": "impairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13.\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\n\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\nconsistent with the findings described in bcl11b - deficient mice\n\nusing massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in bcl11b\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\n"
        },
        {
          "qas": [
            {
              "id": "5c6f6ae37c78d69471000054_001",
              "question": "Is Lasmiditan effective for migraine?"
            }
          ],
          "context": "classification of evidence this study provides class i evidence that for adult patients with migraine, lasmiditan increases the proportion of subjects who are headache pain free at 2 hours after treating a migraine attack.\nlasmiditan for the treatment of acute migraine : a review and potential role in clinical practice.\n\nlasmiditan for the treatment of acute migraine : a review and potential role in clinical practice.\ninterpretation oral lasmiditan seems to be safe and effective in the acute treatment of migraine.\n\nrates of gastrointestinal side effects, headache, and depression.\nlasmiditan for the treatment of acute migraine : a review and potential role in clinical practice.\n\nalthough ongoing phase iii clinical trials are needed to confirm its efficacy and safety, lasmiditan might offer an alternative to treat acute migraine with no associated cardiovascular risk.\nlasmiditan for the treatment of acute migraine : a review and potential role in clinical practice.\n"
        },
        {
          "qas": [
            {
              "id": "5c6d97497c78d69471000040_001",
              "question": "Are there graph kernel libraries available implemented in JAVA?"
            }
          ],
          "context": ". the core of all graph kernels is implemented in c + + for efficiency. using the kernel matrices computed by the package, we can easily perform tasks such as classification, regression and clustering on graph - structured samples.\n. graph kernels have been proposed as a powerful and efficient approach to this problem of graph comparison\n\n. here we provide graphkernels, the first r and python graph kernel libraries including baseline kernels such as label histogram based kernels, classic graph kernels such as random walk based kernels, and the state - of - the - art weisfeiler - lehman graph\n. graph kernels have been proposed as a powerful and efficient approach to this problem of graph comparison\n"
        },
        {
          "qas": [
            {
              "id": "5c6df86b7c78d69471000045_001",
              "question": "Is baricitinib effective for rheumatoid arthritis?"
            }
          ],
          "context": "conclusion : baricitinib 2 mg and 4 mg administered once daily, in combination with dmard, were efficacious interventions for active ra that had no significant risk of teae development.\nin february 2017, baricitinib was approved in the eu, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant\n\nin february 2017, baricitinib was approved in the eu, as monotherapy or in combination with methotrexate, for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant\nin patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.\n\nwe reviewed the application, efficacy, side effects, precautions, limitations and prospect of baricitinib in atopic dermatitis, psoriasis, vitiligo and alopecia areata ( aa ) in recent 5 years including clinical trials and case reports.\nconclusions : the efficacy and safety profile of baricitinib was maintained during long - term treatment of japanese patients with ra and background methotrexate therapy.\n\n< b > objective < / b > : baricitinib is an orally administered inhibitor of jak1 and jak2 that has been shown to be effective in treating rheumatoid arthritis ( ra ).\nin patients with rheumatoid arthritis who had had an inadequate response to methotrexate, baricitinib was associated with significant clinical improvements as compared with placebo and adalimumab.\n"
        },
        {
          "qas": [
            {
              "id": "5c73acf27c78d6947100008a_001",
              "question": "Is Semagacestat effective for treatment of Alzheimer's disease?"
            }
          ],
          "context": "recently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\n\nobjective : semagacestat, a \u03b3 - secretase inhibitor, demonstrated an unfavorable risk - benefit profile in a phase 3 study of patients with alzheimer's disease ( identity trials ), and clinical development was halted.\nconclusions : as compared with placebo, semagacestat did not improve cognitive status, and patients receiving the higher dose had significant worsening of functional ability.\n\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\n\n. semagacestat was associated with more adverse events, including skin cancers and infections.\n. other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin - related teaes, renal and hepatic changes, increased qt interval, and weight loss.\n"
        },
        {
          "qas": [
            {
              "id": "5c840daf617e120c34000007_001",
              "question": "Does Rhamnose have any effect on aging?"
            }
          ],
          "context": "some of these mechanisms will be reviewed as well as the capacity of fucose - and rhamnose - rich oligo - and polysaccharides ( frop and rrop ) to counteract several of the mechanisms involved in skin aging.\nthe monosaccharide analysis showed that rhamnose ( rha ) and glucose ( glu ) may play vital roles in maintaining the antioxidant and anti - aging activities.\n"
        },
        {
          "qas": [
            {
              "id": "5c7d6b3e45e140a523000001_001",
              "question": "Is there any approved treatment for NAFLD?"
            }
          ],
          "context": "nonalcoholic fatty liver disease ( nafld ) has an increasing prevalence worldwide. at present, no specific pharmacotherapy is approved for nafld.\nnonalcoholic fatty liver disease ( nafld ) is the most prevalent liver disease worldwide, and there is no approved pharmacotherapy.\n\nnonalcoholic fatty liver disease ( nafld ) has an increasing prevalence worldwide. at present, no specific pharmacotherapy is approved for nafld.\nnon - alcoholic fatty liver disease ( nafld ) is the leading chronic hepatic condition worldwide and new approaches to management and treatment are limited.\n\nnonalcoholic fatty liver disease ( nafld ) has an increasing prevalence worldwide. at present, no specific pharmacotherapy is approved for nafld.\nalthough much progress has been made in enhancing our understanding of nafld pathogenesis, development of pharmacologic treatments has been hindered by challenges in clinical trial enrollment and complexities in clinical trial design.\n"
        },
        {
          "qas": [
            {
              "id": "5c72bd047c78d69471000077_001",
              "question": "Can pazopanib be used for treatment von Hippel-Lindau disease?"
            }
          ],
          "context": "pazopanib therapy for cerebellar hemangioblastomas in von hippel - lindau disease : case report. von hippel - lindau ( vhl ) disease is a genetically acquired multisystem tumor syndrome of the viscera and central nervous system ( cns ).\n. pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\n\n. she was treated 24 months with pazopanib, a multityrosine kinase inhibitor ( tki ) targeting vegf and pdgf - \u03b2 pathways.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n\n. pazopanib could be considered as a treatment choice for patients with von hippel - lindau disease and growing lesions, or to reduce the size of unresectable lesions in these patients.\npazopanib was associated with encouraging preliminary activity in von hippel - lindau disease, with a side - effect profile consistent with that seen in previous trials.\n"
        },
        {
          "qas": [
            {
              "id": "5c89461675a4a5d219000013_001",
              "question": "Is Netrin-1 a secreted protein?"
            }
          ],
          "context": "netrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nnetrin - 1, a laminin - related secreted protein, displays proto - oncogenic activity in cancers.\n\nnetrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nthe axon guidance cues netrin - 1 is a secreted protein overexpressed in many different cancer tissues\n\nnetrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nnetrins are a family of secreted protein related to laminin and act as tropic cues directing axon growth and cell migration during neural development.\n\nnetrin - 1 is a secreted protein that directs long - range axon guidance during early stages of neural circuit formation and continues to be expressed in the mammalian forebrain during the postnatal period of peak synapse formation.\nnetrin - 1, a multifunctional secreted protein, is up - regulated in cancer and inflammation.\n"
        },
        {
          "qas": [
            {
              "id": "5c62a529e842deac6700000b_001",
              "question": "Is the yeast (Saccharomyces cerevisiae) genome organized into topologically associated domains (TADs)?"
            }
          ],
          "context": ". in contrast, herein we analyze hi - c data for budding yeast and identify 200 - kb scale tads, whose boundaries are enriched for transcriptional activity\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\nalthough similar structures appear to be conserved in fission yeast, computational modeling and analysis of high - throughput chromosome conformation capture ( hi - c ) data have been used to argue that the small, highly constrained budding yeast\n\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n. in a recent work ( tsochatzidou et al., nucleic acids res 45 : 5818 - 5828, 2017 ), we proposed the existence of a functional compartmentalization of the yeast genome according to which, genes occupying the chromosomal regions at the nuclear periphery\n"
        },
        {
          "qas": [
            {
              "id": "5c72a5ca7c78d6947100006d_001",
              "question": "As of Feb 2019, are major brain gangliosides a target for the treatment of Alzheimer's disease?"
            }
          ],
          "context": "administration and protection from covid - 19 and influenza for those in need.\n. t\n\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\nan understanding of the mechanism on the interaction of gm1 and a\u03b2s in ad may contribute to the development of new neuroregenerative therapies for this disorder.\n\nan understanding of the mechanism on the interaction of gm1 and a\u03b2s in ad may contribute to the development of new neuroregenerative therapies for this disorder.\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\n\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\n"
        },
        {
          "qas": [
            {
              "id": "5c72f8557c78d69471000080_001",
              "question": "Is Miller-Dieker syndrome associated with abnormalities of chromosome 1?"
            }
          ],
          "context": "miller - dieker syndrome with der ( 17 ) t ( 12 ; 17 ) ( q24. 33 ; p13. 3 ) pat presenting with a potential risk of mis - identification as a de novo submicroscopic deletion of 17p13. 3.\nmiller - dieker syndrome ( mds, chromosome 17p13. 3 microdeletion ).\n\nmiller - dieker syndrome ( mds, chromosome 17p13. 3 microdeletion ).\nand thus combines abnormalities of chromosome 15 associated with the prader - willi syndrome and of chromosome 17 associated with the miller - dieker syndrome.\n\nmiller - dieker syndrome with der ( 17 ) t ( 12 ; 17 ) ( q24. 33 ; p13. 3 ) pat presenting with a potential risk of mis - identification as a de novo submicroscopic deletion of 17p13. 3.\nand thus combines abnormalities of chromosome 15 associated with the prader - willi syndrome and of chromosome 17 associated with the miller - dieker syndrome.\n\nmiller - dieker syndrome with der ( 17 ) t ( 12 ; 17 ) ( q24. 33 ; p13. 3 ) pat presenting with a potential risk of mis - identification as a de novo submicroscopic deletion of 17p13. 3.\nthe miller - dieker syndrome ( mds ), a syndrome with lissencephaly, distinctive craniofacial features, growth impairment, and profound developmental failure, has been associated with a deletion of the distal part of chromosome band 17p13.\n\nincludes the critical region of the miller - dieker syndrome and 61 genes.\nmiller - dieker syndrome ( mds, chromosome 17p13. 3 microdeletion ).\n"
        },
        {
          "qas": [
            {
              "id": "5c93e6a1ecadf2e73f00001b_001",
              "question": "Does the interaction of MOV10 and RNASEH2 promote L1 retrotransposition?"
            }
          ],
          "context": "interplay between rnaseh2 and mov10 controls line - 1 retrotransposition.\nto explore the potential for using this methodology to express circular rna in vivo, circular forms of the hdv ribozyme and rnasep rna were produced in e. coli.\n\ninterplay between rnaseh2 and mov10 controls line - 1 retrotransposition.\ncircular retrotransposition products generated by a line retrotransposon\n"
        },
        {
          "qas": [
            {
              "id": "5c8cfca70101eac870000005_001",
              "question": "Has the protein SIRT2 been associated to cervical cancer?"
            }
          ],
          "context": "we demonstrate that treatment of cervical cancer cells with a rhogdi\u03b1 - derived k52 - trifluoroacetylated, substrate - derived peptidic sirtuin inhibitor severely impairs cell proliferation.\na progressive increase in the expression of both sirt2 and sirt7 was noted during cancer progression in the following order : normal < preneoplasia < cancer.\n\npecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\na progressive increase in the expression of both sirt2 and sirt7 was noted during cancer progression in the following order : normal < preneoplasia < cancer.\n\nthe special at - rich sequence binding protein 1 ( satb1 ) and its role in solid tumors.\na progressive increase in the expression of both sirt2 and sirt7 was noted during cancer progression in the following order : normal < preneoplasia < cancer.\n\nextensively established key effectors of such apoptotic bypass mechanisms, the antiapoptotic bcl - 2 ( apoptosis regulator bcl - 2 ) proteins, determine the response of cancer cells to chemotherapeutics\na progressive increase in the expression of both sirt2 and sirt7 was noted during cancer progression in the following order : normal < preneoplasia < cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5c6438a5e842deac67000016_001",
              "question": "Are recessive coding variants responsible for the majority of undiagnosed nonconsanguineous individuals?"
            }
          ],
          "context": "our results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\n. we also show how non - coding variants can help inform both the disease - causing mechanism underlying protein - coding variants and dosage tolerance of the gene.\n\nour results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\n. these non - coding region variants represent 23 % of likely diagnoses identified in mef2c in the ddd cohort, but these would all be missed in standard clinical genetics approaches\n\nour results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\nclinical genetic testing of protein - coding regions identifies a likely causative variant in only around half of developmental disorder ( dd ) cases\n"
        },
        {
          "qas": [
            {
              "id": "5c6445f0e842deac67000017_001",
              "question": "Is the NLM medical text indexer (MTI) still useful and relevant?"
            }
          ],
          "context": "to how frequently medline indexers refer to mti recommendations, how well mti performs against human indexing, and how often mti is used\n. the nlm medical text indexer ( mti ) is the main product of this project and has been providing automated indexing recommendations since 2002\n\n. the nlm medical text indexer ( mti ) is the main product of this project and has been providing automated indexing recommendations since 2002\n. after all of this time, the questions arise whether mti is still useful and relevant. methods : to answer the question about mti usefulness, we track a wide variety of statistics related to how frequently medline indexers refer to mti\n\n. this cross - library team's mission is to explore indexing methodologies for ensuring quality and currency of nlm document collections\n. the nlm medical text indexer ( mti ) is the main product of this project and has been providing automated indexing recommendations since 2002\n"
        },
        {
          "qas": [
            {
              "id": "5c8972d4d558e5f232000006_001",
              "question": "Has strimvelis been approved by the European Medicines Agency?"
            }
          ],
          "context": "despite the clear safety concerns, clinical trial data suggests that their intermittent use remains a viable and safe alternative, with 2 molecules remaining in clinical development ( ubrogepant and rimegepant ).\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\n\ndupilumab : a novel treatment for asthma.\nubrogepant for the treatment of migraine.\n\n. no adverse events were observed. routinely administered bel shows clinical efficacy on non - approved manifestations, but careful patient selection is warranted.\nsimvastatin - treated patients experienced significantly more reductions in hdrs scores compared to the placebo group by the end of the trial ( p = 0. 02 )\n\nthis article summarizes the milestones in the development of efgartigimod leading to this first approval for generalized myasthenia gravis.\ntecovirimat : first global approval.\n\nrates of gastrointestinal side effects, headache, and depression.\n. although levosimendan was generally well tolerated, increased heart rate and headache occurred more frequently with levosimendan than with placebo.\n"
        },
        {
          "qas": [
            {
              "id": "5c83f858617e120c34000003_001",
              "question": "Is treatment with Bacillus Calmette Guerin used for bladder cancer?"
            }
          ],
          "context": "intravesical bacillus calmette - guerin is used to treat patients with superficial bladder cancer.\npurpose bacillus calmette - guerin is the most effective therapy for nonmuscle invasive bladder cancer.\n\nbacillus calmette - guerin immunotherapy for bladder cancer. bacillus calmette - guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer.\neffects of local bacillus calmette - guerin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. the antitumoral effects of intravesical bacillus calmette - guerin against recurrent superficial urothelial bladder cancer\n\nbacillus calmette - guerin immunotherapy for bladder cancer. bacillus calmette - guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer.\nwe review how the bacillus calmette - guerin vaccine evolved to become standard therapy for superficial bladder cancer.\n\nbacillus calmette - guerin immunotherapy for bladder cancer. bacillus calmette - guerin immunotherapy has been found by a number of investigators to be effective in the treatment and prevention of superficial bladder cancer.\nintravesical bacillus calmette - guerin is used to treat patients with superficial bladder cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5c73acf17c78d69471000089_001",
              "question": "Is eculizumab used for treatment of myasthenia gravis?"
            }
          ],
          "context": "safety and efficacy of eculizumab in anti - acetylcholine receptor antibody - positive refractory generalised myasthenia gravis ( regain ) : a phase 3, randomised, double - blind, placebo - controlled, multicentre study.\na randomized, double - blind, placebo - controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis.\n\na randomized, double - blind, placebo - controlled phase ii study of eculizumab in patients with refractory generalized myasthenia gravis.\nrituximab seems to be particularly effective in musk myasthenia gravis, and eculizumab arises as an option in refractory achr myasthenia gravis.\n"
        },
        {
          "qas": [
            {
              "id": "5c928afeecadf2e73f000018_001",
              "question": "Can cardiospheres be produced from skin fibroblasts?"
            }
          ],
          "context": "here we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\nall three fibroblast populations were pdgfr\u03b1 + / cd34 + but were distinct in their expression of ngfr / spon2 / angptl7 ( f1 ), cxcl14 / smoc2 / rgs2 ( f2 ), and clec3b / col14a1 / mmp3 ( f3 ), with potential functions in the regulation of immune responses, response to\n\n. their function and distribution around important regulatory genes raises the question of how they relate to 3d conformation of these loci\nhere we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\n\nthe aim of this study was to analyze the formation of the most relevant inflammation mediators including proteins and lipids in human fibroblasts upon inflammatory stimulation and subsequent treatment with dexamethasone, a powerful antiphlogistic\nall three fibroblast populations were pdgfr\u03b1 + / cd34 + but were distinct in their expression of ngfr / spon2 / angptl7 ( f1 ), cxcl14 / smoc2 / rgs2 ( f2 ), and clec3b / col14a1 / mmp3 ( f3 ), with potential functions in the regulation of immune responses, response to\n\n. it is approved for idiopathic lung fibrosis and has demonstrated good results in inhibiting migration and proliferation of systemic sclerosis dermal fibroblasts, constituting a promising agent for systemic sclerosis - associated lung fibrosis.\nhere we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\n\nhere we provide the detailed protocol for generating induced cardiospheres ( ics ) for cardiac regeneration by somatic reprogramming of mouse fibroblasts using a panel of pluripotent transcription factors and cardiotrophic growth factors.\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\n"
        },
        {
          "qas": [
            {
              "id": "5c73ad347c78d69471000098_001",
              "question": "Does Axitinib prolong survival of Pancreatic Cancer patients?"
            }
          ],
          "context": "results : among japanese patients, median overall survival was not estimable ( 95 % confidence interval, 7. 4 months - not estimable ) with axitinib / gemcitabine ( n = 58 ) and 9. 9 months ( 95 % confidence interval, 7. 4 - 10. 5 ) with placebo / gemcitabine ( n = 56 )\ninterpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.\n\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\nexpert commentary : pacritinib has demonstrated promising results in patients with myelofibrosis and thrombocytopenia.\n\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n\n. 5. 4 months ( 1. 8 - 10. 5 ) with placebo / gemcitabine. similarly, no difference was detected in overall survival between axitinib / gemcitabine and placebo / gemcitabine in patients from north america or the european union.\ninterpretation : the addition of axitinib to gemcitabine does not improve overall survival in advanced pancreatic cancer.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nrationale for use, clinical trial data, and current recommendations for cabozantinib in renal cell cancer, thyroid cancer, prostate cancer, hepatocellular cancer, and lung cancer are detailed in this article.\n"
        },
        {
          "qas": [
            {
              "id": "5c5217fd7e3cb0e231000005_001",
              "question": "Is there any association between suicide and autism in adolescents, yes or no?"
            }
          ],
          "context": "risk of suicide attempts among adolescents and young adults with autism spectrum disorder : a nationwide longitudinal follow - up study.\ndetection of suicidality in adolescents with autism spectrum disorders\n"
        },
        {
          "qas": [
            {
              "id": "5c8c05c70101eac870000001_001",
              "question": "Is lactotransferrin a tumour suppressor?"
            }
          ],
          "context": "lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing akt through multiple mechanisms.\nlactotransferrin ( ltf ) has been confirmed to act as a tumor suppressor in multiple cancers\n\nthe tumor suppressor function of lactotransferrin ( ltf ) has been reported in a variety of tumors, including gc, nasopharyngeal carcinoma ( npc ) and prostate cancer.\nlactotransferrin ( ltf ) has been confirmed to act as a tumor suppressor in multiple cancers\n"
        },
        {
          "qas": [
            {
              "id": "5c6ad3be7c78d69471000021_001",
              "question": "Are there tools for visualizing and processing long-read sequencing data?"
            }
          ],
          "context": "predictions based on single - cell rna - seq ( scrna - seq ) can more accurately reconstruct bulk chromatin accessibility than using scatac - seq.\n. our simulations provide evidence that analyzing allele sequences leads to more accurate estimates of tree topology and divergence times than the more common approach of using contig sequences.\n\nhere we describe nanopack, a set of tools developed for visualization and processing of long - read sequencing data from oxford nanopore technologies and pacific biosciences. availability and implementation : the nanopack tools are written in python3 and\nvariant review with the integrative genomics viewer.\n"
        },
        {
          "qas": [
            {
              "id": "5c674eac7c78d6947100001b_001",
              "question": "Has Hesperidin any role as a Neuroprotective Agent?"
            }
          ],
          "context": "neuroprotective effects of hesperidin on cerebral vasospasm\nemerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\n\nemerging evidences indicate hesperidin, a citrus flavanone, attenuates neurodegenerative processes and related complications.\nhesperidin, a flavanoglycone abundantly present in citrus fruits, is reported to have antioxidant, anti - inflammatory, and neuroprotective properties.\n"
        },
        {
          "qas": [
            {
              "id": "5c8857e975a4a5d219000009_001",
              "question": "Are apoE mimetics being considered as a treatment against Alzheimer's disease?"
            }
          ],
          "context": "introduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\n"
        },
        {
          "qas": [
            {
              "id": "5c6d9a157c78d69471000041_001",
              "question": "Can you computationally predict Molecular Recognition Features (MoRFs) regions in Intrinsically Disordered Proteins (IDPs)?"
            }
          ],
          "context": ". predicting these morfs in disordered protein sequences is a challenging task. method : in this study, we present morfpred - plus, an improved predictor over our previous proposed predictor to identify morfs in disordered protein sequences\n. in addition, morfpred - plus is a downloadable predictor, which makes it useful as it can be used as input to other computational tools.\n\n. in addition, morfpred - plus is a downloadable predictor, which makes it useful as it can be used as input to other computational tools.\nmorfpred - plus : computational identification of morfs in protein sequences using physicochemical properties and hmm profiles.\n\n. these idps expose short binding regions called molecular recognition features ( morfs ) that permit interaction with structured protein regions\n. these intrinsically disordered regions ( idrs ) participate in binding events through regions called molecular recognition features ( morfs ). computational prediction of morfs helps identify the potentially functional regions in idrs\n\n. given the relative sparseness of morfs in protein sequences, the accuracy of the available morf predictors is often inadequate for practical usage, which leaves a significant need and room for improvement\nin this study, we introduce morfchibi, a new computational approach for fast and accurate prediction of morfs in protein sequences\n"
        },
        {
          "qas": [
            {
              "id": "5c97a08becadf2e73f000029_001",
              "question": "Velocardial facial syndrome, otherwise known as Di George syndrome  is caused by a deletion in chromosome 21, yes or no?"
            }
          ],
          "context": "3 clinical trials and will soon offer novel, effective, well - tolerated nonvasoconstrictor options to treat acute migraine.\nthe deletion of chromosome 22q11. 2 is involved in the majority of digeorge or velo - cardiofacial syndrome.\n\nthe deletion of chromosome 22q11. 2 is involved in the majority of digeorge or velo - cardiofacial syndrome.\nsubmicroscopic deletions of chromosome 22q11 have been reported in a multiple anomaly syndrome variously labelled as velocardiofacial syndrome, conotruncal anomaly face syndrome, and di george syndrome.\n\n22q11. 2ds has several presentations including di george's syndrome, velo - cardio - facial syndrome or shprintzen's syndrome and it is the most frequent microdeletion syndrome in the general population ( prevalence estimated at 1 / 4000 births, de novo :\nthe 22q11. 2 deletion syndrome ( di george syndrome ) is one of the most prevalent genetic disorders.\n"
        },
        {
          "qas": [
            {
              "id": "5c8ab614d558e5f23200000d_001",
              "question": "Is the protein Asporin related to disease?"
            }
          ],
          "context": "accumulating evidence demonstrates the involvement of asporin in oa pathogenesis.\nasporin has been reported as a tumor suppressor in breast cancer, while asporin - activated invasion has been described in gastric cancer.\n\nthese results suggested that asporin promoted the tumor growth and metastasis of crc, and it could be a potential therapeutic target for crc patients in future.\nasporin has been reported as a tumor suppressor in breast cancer, while asporin - activated invasion has been described in gastric cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5ca61176ecadf2e73f00004e_001",
              "question": "Can TAD disruption lead to disease?"
            }
          ],
          "context": "recent studies have shown that tad disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n\nwe demonstrate that disruption of tads can rewire long - range regulatory architecture and result in pathogenic phenotypes.\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\n\nwe demonstrate that disruption of tads can rewire long - range regulatory architecture and result in pathogenic phenotypes.\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n\nwe demonstrate that disruption of tads can rewire long - range regulatory architecture and result in pathogenic phenotypes.\nrecent studies have shown that tad disruption is often found in cancer cells and contributes to oncogenesis through two mechanisms.\n"
        },
        {
          "qas": [
            {
              "id": "5c8908a475a4a5d21900000c_001",
              "question": "Is L-4F an apoE mimetic peptide?"
            }
          ],
          "context": "l - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\nthe tumor suppressor function of lactotransferrin ( ltf ) has been reported in a variety of tumors, including gc, nasopharyngeal carcinoma ( npc ) and prostate cancer.\n\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nl - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\n\nl - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\nthe rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.\n\nand open - label extension studies are needed to determine the long - term safety and efficacy of this promising therapy.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n"
        },
        {
          "qas": [
            {
              "id": "5c890c3375a4a5d21900000e_001",
              "question": "Can oleuropein aglycone interfere with amyloid aggregation?"
            }
          ],
          "context": ". it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n\n. it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\ncytoprotective effects of hesperetin and hesperidin against amyloid \u03b2 - induced impairment of glucose transport through downregulation of neuronal autophagy.\n\n. it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\n\n. it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\nmechanism of amyloid formation is critical for a complete understanding of the yeast prion phenomenon and human amyloid - related diseases.\n\n. it has been reported that the aglycone form of oleuropein ( olea ) interferes in vitro and in vivo with amyloid aggregation of a number of proteins / peptides involved in amyloid, particularly neurodegenerative, diseases avoiding the growth of toxic\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5caa0806ecadf2e73f000057_001",
              "question": "Is Apelin usually decreased in diabetes?"
            }
          ],
          "context": ". moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.\napelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.\n\n. moreover, different studies in both animals and humans have shown that plasma apelin concentrations are usually increased during obesity and type 2 diabetes.\n. 5. 1 % / year, p < 0. 001 ). < br > < b > conclusions < / b > : plasma apelin is a novel biomarker for predicting type 2 diabetes in men. < br >\n\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\n\napelin has been shown to act on glucose and lipid metabolism but also to modulate insulin secretion\napelin levels are increased in morbidly obese subjects with type 2 diabetes mellitus.\n"
        },
        {
          "qas": [
            {
              "id": "5ca0fdb0ecadf2e73f000049_001",
              "question": "Is actin present in the nucleus?"
            }
          ],
          "context": "the revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin.\nthe discovery of nuclear actin opened new perspective on the field, suggesting that the nuclear activities of actin reflect the functions of primordial actin - like proteins.\n\nthe revitalization of research into nuclear actin occurred after it was found that cellular stresses induce the nuclear localization and alter the structure of actin.\nwhile it is long known that actin is part of the nuclear proteome, its properties and functions as regulated, functional and dynamically assembled actin filaments are only recently emerging.\n"
        },
        {
          "qas": [
            {
              "id": "5c8fea130101eac87000000d_001",
              "question": "Can miR-122 target RUNX2?"
            }
          ],
          "context": "mir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nit has been proposed that circrna regulate gene expression at the transcriptional or post - transcriptional level by interacting with mirnas and that circrnas may have a role in regulating mirna function in cancer initiation and progression.\n\nmir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nhowever, other genes such as the proto - oncogene c - myc are promising targets for anticancer therapy\n\nmir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nmultipotent mesenchymal bone marrow - derived stem cells\n\nmir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\nlb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\n\nmir - 122 functions as a tumor suppressor by inhibiting proliferation and inducing apoptosis, which is achieved by directly targeting runx2.\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\n"
        },
        {
          "qas": [
            {
              "id": "5c960d88ecadf2e73f00001f_001",
              "question": "Tocilizumab is an anti-TNF antibody, yes or no?"
            }
          ],
          "context": "was treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\n\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\ntocilizumab is a humanized anti - il - 6 receptor monoclonal antibody, which binds to circulating soluble il - 6 receptor and membrane - expressed il - 6 receptor, inhibiting il - 6 binding to both forms of il - 6 receptor.\n\nrates of gastrointestinal side effects, headache, and depression.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\n\ninhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast.\nsubsequent options include a tnf - alpha antagonist, followed by rituximab or possibly abatacept ; ( 2 ) tocilizumab, a monoclonal antibody, inhibits interleukin - 6 receptors.\n"
        },
        {
          "qas": [
            {
              "id": "5c9e6ab9ecadf2e73f000035_001",
              "question": "Is it possible to analyze exosomes with FACS?"
            }
          ],
          "context": "we used a novel strategy for generating metabolically - labeled fluorescent exosomes that can be counted by flow cytometry assay ( facs ) and characterized.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\n\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\n\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\nf exosome marker proteins ( e. g., cd63, alix )\n"
        },
        {
          "qas": [
            {
              "id": "5c915e51ecadf2e73f00000c_001",
              "question": "Can prevnar 13 be used in children?"
            }
          ],
          "context": "effectiveness of rotavirus pentavalent vaccine\nbased on published immunogenicity and safety data, as well as the recent recommendations by the acip for routine use in infants and indications for high - risk pediatric patients, pcv13 is a revised formulation of pneumococcal vaccine that should be\n\nbased on published immunogenicity and safety data, as well as the recent recommendations by the acip for routine use in infants and indications for high - risk pediatric patients, pcv13 is a revised formulation of pneumococcal vaccine that should be\nto traditional smallpox vaccines, such as the immunocompromised and those with eczema or dermatitis.\n\nbased on published immunogenicity and safety data, as well as the recent recommendations by the acip for routine use in infants and indications for high - risk pediatric patients, pcv13 is a revised formulation of pneumococcal vaccine that should be\nin this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of dtap ( 5 ) coadministered with ipv and hib vaccines or 1 lot of dtap ( 5 ) - ipv - hib combination vaccine.\n\neffectiveness of rotavirus pentavalent vaccine\nrisk of intussusception after monovalent rotavirus vaccination.\n"
        },
        {
          "qas": [
            {
              "id": "5c9160bcecadf2e73f00000d_001",
              "question": "Was stelara developed by Amgen?"
            }
          ],
          "context": "nice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\ntocilizumab ( actemra ; genentech, inc ) is the first biologic therapy targeting the cytokine interleukin 6 ( il - 6 ).\n\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nthe use of methotrexate in rheumatoid arthritis.\n\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\ninhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast.\n\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nbecoming the first biologic agent approved to treat this chronic skin condition.\n\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\n"
        },
        {
          "qas": [
            {
              "id": "5c9e766becadf2e73f000038_001",
              "question": "Can mitochondria pass through membrane nanotubes?"
            }
          ],
          "context": "membrane \" \" otubes ( mnts ) act as \" highways \" between cells to facilitate the transfer of multiple signals and play an important role in many diseases\nmembrane \" \" otubes play important functional roles in numerous cell activities such as cellular transport and communication.\n\ninterest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\n"
        },
        {
          "qas": [
            {
              "id": "5c9f1b0cecadf2e73f00003c_001",
              "question": "Are protamines ubiquitously expressed?"
            }
          ],
          "context": "protamines are nuclear proteins which are specifically expressed in haploid male germ cells.\nthe proto - oncogene protein c - myc\n\naltered glycoprotein expression has been demonstrated in tissue from patients with barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.\nin this study, we investigated the effect of small interfering rna ( sirna ) of connective tissue growth factor ( ctgf ) by pretro - super ( prs ) retrovirus vector on the expression of ctgf and related extracellular matrix molecules in human renal proximal\n\nprotamines are nuclear proteins which are specifically expressed in haploid male germ cells.\nvariants with gene expression from these cultured cells\n\nprotamines are nuclear proteins which are specifically expressed in haploid male germ cells.\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\n\nprotamines are nuclear proteins which are specifically expressed in haploid male germ cells.\nthe removal of n - terminal translation initiator met by methionine aminopeptidase ( metap ) is often crucial for the function and stability of proteins.\n"
        },
        {
          "qas": [
            {
              "id": "5c891d5075a4a5d219000011_001",
              "question": "Are Crocus sativus compounds being considered against Alzheimer's disease?"
            }
          ],
          "context": ". reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n"
        },
        {
          "qas": [
            {
              "id": "5ca0848aecadf2e73f000044_001",
              "question": "Are there any anti-amyloid antibody approved as drug for Alzheimer's disease treatment?"
            }
          ],
          "context": "the lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\n\nin 2009 the us food and drug administration accepted a complete - response submission for the use of actemra ( tocilizumab ), the first humanized il - 6 receptor - inhibiting monoclonal antibody, for the treatment of ra.\nusing tau antibodies for progressive supranuclear palsy.\n\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\n\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5c891e5575a4a5d219000012_001",
              "question": "Do Crocus sativus extracts loosen the blood-brain barrier?"
            }
          ],
          "context": ". reduced a\u03b2 load could be explained, at least in part, by crocus sativus extract effect to enhance a\u03b2 clearance pathways including bbb clearance, enzymatic degradation and apoe clearance pathway.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n\n. the aim of this study was to in vitro and in vivo investigate the mechanism ( s ) by which crocus sativus exerts its positive effect against ad.\ncrocus sativus extract tightens the blood - brain barrier, reduces amyloid \u03b2 load and related toxicity in 5xfad mice.\n"
        },
        {
          "qas": [
            {
              "id": "5ca0fa96ecadf2e73f000048_001",
              "question": "Are artificial blood cells available?"
            }
          ],
          "context": "engineered t cells have achieved success in the treatment of blood cancers, with four chimeric antigen receptor ( car ) - t cell therapies now approved for the treatment of b cell malig \" \" cies based on their unprecedented efficacy in clinical trials.\nthe critical point for the break through for artificial blood products did not come yet but could be ahead -\n"
        },
        {
          "qas": [
            {
              "id": "5c895cf0f9c2ba6b28000001_001",
              "question": "Have apolipoprotein mimetics been used in clinical trials?"
            }
          ],
          "context": "the apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\nl - 4f, an apolipoprotein a - i ( apoa - i ) mimetic peptide, is engineered to mimic the anti - inflammatory and anti - oxidative functionalities of apoa - i.\n"
        },
        {
          "qas": [
            {
              "id": "5ca10fefecadf2e73f00004a_001",
              "question": "Is the Philadelphia chromosome a fusion between parts of chromosomes 1 and 9?"
            }
          ],
          "context": "chronic myeloid leukemia is a stem cell disease with the presence of philadelphia chromosome generated through reciprocal translocation of chromosome 9 and 22.\nthe philadelphia chromosome, t ( 9 ; 22 ) ( q34 ; q11 ), is present in 95 % of cml patients, resulting in constitutive tyrosine kinase activity ; however, ~ 5 % of cml patients possess a philadelphia variant.\n"
        },
        {
          "qas": [
            {
              "id": "5c9f7bb6ecadf2e73f00003e_001",
              "question": "Can therapeutic levels of  Vedolizumab be found in the breast milk of nursing mothers following treatment for Inflammatory bowel disease?"
            }
          ],
          "context": "extracted breastmilk should be encouraged by the healthcare providers after a careful discussion of the risks of vertical transmission to the mother and her family\nthe duration between breastfeeding and heel lance may influence the perception of pain in newborns. keeping this period short, may reduce the perception of pain.\n\n. although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro - intestinal immune - suppression of the infant.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\n\nsacituzumab govitecan for metastatic triple - negative breast cancer : clinical overview and management of potential toxicities.\n. although more data are imperative, the concentrations of vedolizumab in breast milk are minute and are therefore unlikely to result in systemic or gastro - intestinal immune - suppression of the infant.\n"
        },
        {
          "qas": [
            {
              "id": "5c8fe71b0101eac87000000b_001",
              "question": "Does RUNX2 inhibit astrocyte differentiation?"
            }
          ],
          "context": "the method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\nwhich wnt signaling inhibits neuro - ectodermal lineage differentiation in mouse embryonic stem cells.\n\nthe transcription factor grainyhead - like 2 ( grhl2 ) plays a crucial role in various developmental processes\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\n\n. we then focus on one of these, silc1, and show that it regulates neuroregeneration in cultured cells and in vivo, through cis - acting activation of the transcription factor sox11.\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\n\nh - ferritin expression in astrocytes is necessary for proper oligodendrocyte development and myelination.\nthe method was able to recapitulate experimentally validated cell - fate determi \" \" ts, and validation of two predicted cell - fate determi \" \" ts confirmed that overexpression of esr1 and runx2 in mouse neural stem cells induces neuronal and astrocyte\n"
        },
        {
          "qas": [
            {
              "id": "5c9906dcecadf2e73f00002f_001",
              "question": "Are cardenolides inhibitors of Na+/K+ ATPase?"
            }
          ],
          "context": ": we found evidence for low cardenolides by hplc, but substantial toxicity when extracts were assayed on na + / k + - atpases.\ncardenolides have shown significant antitumor activity due to their ability to inhibit the na + k + atpase enzyme, and the expression of this enzyme is increased in tumor cells.\n"
        },
        {
          "qas": [
            {
              "id": "5c900779ecadf2e73f000001_001",
              "question": "Can antisense threapy be used for Huntington's disease?"
            }
          ],
          "context": "in this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\n\nin this issue of neuron, kordasiewicz et al. ( 2012 ) show the benefit of transient antisense oligonucleotide ( aso ) therapy to degrade huntingtin mrna and elicit sustained therapeutic benefit in hd mice.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5ca5127eecadf2e73f00004c_001",
              "question": "Is collagen matrix of human articular cartilage changing with disease?"
            }
          ],
          "context": "administration and protection from covid - 19 and influenza for those in need.\n. t\n\ntype ii collagen is a major component of articular cartilage and its breakdown is a key feature of osteoarthritis.\nthe collagen matrix of human articular cartilage is an essentially permanent structure that has no significant turnover in adults, even with the occurrence of disease.\n"
        },
        {
          "qas": [
            {
              "id": "5c9162b5ecadf2e73f00000e_001",
              "question": "Is ustekinumab a polyclonal antibody?"
            }
          ],
          "context": "inhibitors, tocilizumab, rituximab, alemtuzumab, ustekinumab, interferon - alpha - 2a, and apremilast.\nustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\n\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nustekinumab, a human monoclonal igg1 antibody targeting the p40 - subunit shared by interleukin ( il ) 12 and il - 23, represents a potential treatment for atopic dermatitis ( ad ).\n\nnice does not specifically recommend switching from one biologic to another, and only ustekinumab ( ust ; stelara\u00ae, janssen pharmaceuticals, inc., horsham, pa, usa ) is recommended after anti - tumour necrosis factor failure.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5cb37f76ecadf2e73f00005c_001",
              "question": "Is Pim-1 a protein phosphatase?"
            }
          ],
          "context": "the pim1 serine / threonine kinase is associated with multiple cellular functions including proliferation, survival, differentiation, apoptosis, tumorigenesis, immune regulation and inflammation in vertebrates.\npim - 1 proto - oncogene, serine / threonine kinase ( pim - 1 ) phosphorylates a series of substrates to exert its oncogenic function in numerous malig \" \" cies.\n"
        },
        {
          "qas": [
            {
              "id": "5cb38a56ecadf2e73f00005e_001",
              "question": "Is myc a tumour suppressor gene?"
            }
          ],
          "context": "huwe1 is a critical colonic tumour suppressor gene that prevents myc signalling, dna damage accumulation and tumour initiation.\nhe myc oncogene\n\nthe proto - oncogene protein c - myc\nhe myc oncogene\n\nhe myc oncogene\noncogenic myc, a master transcription factor that turns on anabolic metabolism to promote cell growth in many cancers.\n"
        },
        {
          "qas": [
            {
              "id": "5cb3a2dd99d1e53537000001_001",
              "question": "Is CD63 an exosomal marker?"
            }
          ],
          "context": "altered glycoprotein expression has been demonstrated in tissue from patients with barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.\nexpression of the immunoglobulin superfamily molecules muc18 / mcam and icam - 1 are associated with primary tumors and metastases.\n\nintercellular adhesion molecule 3 ( icam - 3, also known as cd50 ), a human leukocyte - restricted immunoglobulin super - family ( igsf ) member, has previously been implicated in apoptotic cell clearance,\nimmune system and plays a role as a signaling and costimulatory molecule on t lymphocytes.\n\nf exosome marker proteins ( e. g., cd63, alix )\nthe results demonstrated these exosomes all expressed cd9, cd63, cd81, alix\n\nflotillin 1 and tumor susceptibility gene 101 ( tsg101 ), two exosomal marker proteins,\nf exosome marker proteins ( e. g., cd63, alix )\n"
        },
        {
          "qas": [
            {
              "id": "5ca0c81eecadf2e73f000047_001",
              "question": "Is subdural empyema a complication of sinusitis?"
            }
          ],
          "context": "subdural empyema is an uncommon but serious complication of sinusitis.\nintracranial subdural empyema is most frequently a complication of sinusitis or, less frequently, otitis or neurosurgical procedures.\n\nsubdural empyema is an uncommon but serious complication of sinusitis.\nsubdural empyema is a rare complication of sinusitis although very severe.\n\nsubdural empyema is an uncommon but serious complication of sinusitis.\nthe symptoms of subdural empyema may be mild and may be the same as those associated with sinusitis, or the infection may result in alteration of the level of consciousness and focal neurologic deficits.\n"
        },
        {
          "qas": [
            {
              "id": "5c98ac7fecadf2e73f00002b_001",
              "question": "Anaplasma phagocytophilum is an obligate gram-negative, intracellular bacterium, yes  or no"
            }
          ],
          "context": "the genus anaplasma belonging to the anaplasmataceae family ( order rickettsiales ) comprises obligate intracellular gram - negative bacteria of veterinary and public health importance\nhuman granulocytic anaplasmosis ( hga ), an increasingly recognized febrile tick - borne illness, is caused by a gram - negative obligate intracellular bacterium anaplasma phagocytophilum\n\nhuman granulocytic anaplasmosis ( hga ), an increasingly recognized febrile tick - borne illness, is caused by a gram - negative obligate intracellular bacterium anaplasma phagocytophilum\n. six species and five types of strains genetically related are currently assigned to the genus anaplasma including anaplasma marginale, a. centrale, a. bovis, a. phagocytophilum, a. ovis and a. platys as classified species, and \" a. capra \", a\n"
        },
        {
          "qas": [
            {
              "id": "5cb380b8ecadf2e73f00005d_001",
              "question": "Is the crystal structure of Pim-1 available?"
            }
          ],
          "context": "the crystal structures of pim1 in apo form and bound with amppnp have been solved\nrecent crystallographic studies of pim - 1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates.\n\nusing the determined x - ray crystal structure of pim1 complexed to the compound 1 - r as a control, we discuss the importance of including the protein flexibility inherent in the ensemble docking protocol, for the accuracy of the structure prediction of\nthe crystal structures of pim1 in apo form and bound with amppnp have been solved\n\nhere, we describe the crystal structure of pim1 in complex with a newly developed pyrido [ 4, 3 - d ] pyrimidine - derivative inhibitor ( ski - o - 068 ).\nthe crystal structures of pim1 in apo form and bound with amppnp have been solved\n\nhere, we describe the crystal structure of pim1 in complex with a newly developed pyrido [ 4, 3 - d ] pyrimidine - derivative inhibitor ( ski - o - 068 ).\nrecent crystallographic studies of pim - 1 have identified unique structural features but have not provided insight into how the kinase recognizes its target substrates.\n"
        },
        {
          "qas": [
            {
              "id": "5c92159becadf2e73f000012_001",
              "question": "Do tumour-associated macrophages have a prognostic role in gliomas?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nthe janus kinase inhibitor tofacitinib impacts human dendritic cell differentiation and favours m1 macrophage development.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\ntherefore, a novel g4 - directed therapeutic strategy could specifically target cancer stem cells in gbm.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nthese observations indicate that 6otd targets gscs through g4 stabilization and promotion of dna damage responses. therefore, g4s are promising therapeutic targets for glioblastoma.\n\nmelanocytic markers melan - a and sox10\nthe most commonly used melanocytic markers include s100, melan - a, hmb45 and sox10\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\n. tp53 mutations are frequent in low - grade gliomas and secondary glioblastomas derived therefrom.\n"
        },
        {
          "qas": [
            {
              "id": "5c9f0dabecadf2e73f00003b_001",
              "question": "Is TNF-\u03b1 an activator of pancreatic stellate cells?"
            }
          ],
          "context": "pi3k - akt - nf - \u03bab signaling pathway, ii ) by exerting an efficient antioxidant effect, iii ) by inducing significant anti - inflammatory activity and iv ) by restoring brain - derived neurotrophic factor ( bdnf ) levels\ntnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\n\nm6a demethylase fto suppresses pancreatic cancer tumorigenesis by demethylating pja2 and inhibiting wnt signaling.\ntnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\n\nupregulated expression of resistin, vaspin, apelin and tnf - \u03b1 plays a significant role in induction of insulin resistance linked with obesity and type 2 diabetes.\ntnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\n\ntnf - \u03b1 is the prime factor responsible for the activation of pancreatic stellate cells\nactivated pscs expressed il - 33 in the nucleus, and the expression was increased by il - 1\u03b2, tnf - \u03b1, pdgf - bb, and ifn - \u03b3, but not tgf - \u03b21.\n"
        },
        {
          "qas": [
            {
              "id": "5c9e738decadf2e73f000037_001",
              "question": "Can mitochondria transfer from cell to cell?"
            }
          ],
          "context": "interest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\n. our previous work reported on the transfer of mitochondria via mnts between cardiomyocytes ( cms ) and cardiac myofibroblasts ( mfs )\n\nadministration and protection from covid - 19 and influenza for those in need.\n. t\n\ninterest in the recently discovered phenomenon of mitochondrial transfer between mammalian cells has gained momentum since it was first described in cell culture systems more than a decade ago.\nbiparental inheritance of mitochondrial dna in humans.\n"
        },
        {
          "qas": [
            {
              "id": "5e48e0e0f8b2df0d49000001_001",
              "question": "Are gut microbiota profiles altered by irradiation?"
            }
          ],
          "context": "specific members of the gut microbiota are reliable biomarkers of irradiation intensity and lethality in large animal models of human health.\nirradiation profoundly impacted gut microbiota profiles in both animals.\n"
        },
        {
          "qas": [
            {
              "id": "5c7a4c35d774d04240000007_001",
              "question": "Is TIM-3 a target for cancer immunotherapy in NSCLC?"
            }
          ],
          "context": ". furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\n. furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\n\nagents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\nthe abnormal expression of tim - 3 on mdsc might be involved in the pathogenesis of pe, and could be a marker to evaluate the immune function in pe.\n\n. these data might have direct implications for the ongoing phase iii clinical trial with nintedanib in ssc - associated interstitial lung disease.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n"
        },
        {
          "qas": [
            {
              "id": "5c7019557c78d6947100005f_001",
              "question": "Does an interferon (IFN) signature exist for SLE patients?"
            }
          ],
          "context": "based on our knowledge of pathophysiology, three therapeutic strategies are proposed : anti - inflammatory ( ocrelizumab, siponimod \u2026 ) ; remyelinating ( opicinumab ) ; and neuroprotective ( high - dose biotin, ibudilast, simvastatin \u2026 ).\n. the treatments that are under clinical trials for csu are anti - ige treatments such as ligelizumab, molecules targeting intracellular signaling pathways such as spleen tyrosine kinase inhibitors, surface inhibitory molecules such as siglec - 8,\n\ns end, there is limited post - hoc randomized evidence to suggest beneficial effect of belimumab, administered on top of standard - of - care, during mainte \" \" ce therapy in lupus nephritis. type i\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\n\njak inhibitor has the amelioration effect in lupus - prone mice : the involvement of ifn signature gene downregulation.\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\n\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\nthe ifn - i score ( positive or negative ), as a measure of ifn - i activation, was assessed using real - time quantitative pcr ( rt - pcr ) expression values of ifn - i signature genes ( ifi44, ifi44l, ifit1, ly6e, mxa, ifitm1 ) in cd14 + monocytes of csle patients\n"
        },
        {
          "qas": [
            {
              "id": "5e36d924b5b409ea5300000b_001",
              "question": "Is AND-1/Ctf4 essential for proliferation?"
            }
          ],
          "context": "in hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition.\n. thus, our findings uncover a fork protection function of and - 1 / ctf4 manifested via the wd40 domain that is essential for proliferation and averts genome instability.\n\n. functional studies using fibroblast cells from two affected individuals with the c. 1516c > t mutation showed a truncated wasf1 and a defect in actin remodeling\n. thus, our findings uncover a fork protection function of and - 1 / ctf4 manifested via the wd40 domain that is essential for proliferation and averts genome instability.\n\nand - 1 / ctf4 bridges the cmg helicase and dna polymerase alpha, facilitating replication\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\n\nin hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition.\ntcf3, is recruited to a palindromic motif enriched in the promoter of cell cycle repressor genes, such as p15ink4b, p16ink4a and p19arf, which mediate the wnt - dependent anti - proliferative effect in mescs. consistently, abl\n\nboth tcf3 depletion and wnt pathway activation cause increased expression of oct4, nanog, and other pluripotency factors and produce es cells that are refractory to differentiation.\nin hct - r cells, however, the overexpression of tcf3 inhibits wnt activity, and the cells are still able to proliferate due to the higher expression levels of cell cycle factors, particularly those driving the g ( 1 ) to s transition.\n"
        },
        {
          "qas": [
            {
              "id": "5e4adcbe6d0a277941000017_001",
              "question": "Does the BRAFV600E mutation have an effect on clinical response to radioiodine therapy?"
            }
          ],
          "context": "the results indicate that braf ( v600e ) mutation is correlated with a lower expression of nis in ptcs without ht, suggesting the radioiodine - refractory effects during ria therapy in these patients.\ndifferent types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and merkel cell cancer as well as hematological tumors such as classic hodgkin's lymphoma.\n\na new frontier to treat this therapeutically challenging subset of advanced egfr mutant patients.\nthe status of braf mutation may not affect the clinical response to rai therapy for patients with ptmc with intermediate - risk to high - risk features. more trials examining the role of braf mutation in guiding postoperative rai therapy are needed.\n\nthe results indicate that braf ( v600e ) mutation is correlated with a lower expression of nis in ptcs without ht, suggesting the radioiodine - refractory effects during ria therapy in these patients.\nthe status of braf mutation may not affect the clinical response to rai therapy for patients with ptmc with intermediate - risk to high - risk features. more trials examining the role of braf mutation in guiding postoperative rai therapy are needed.\n"
        },
        {
          "qas": [
            {
              "id": "5e30b56efbd6abf43b000037_001",
              "question": "Is the BAGEL algorithm used for arrayed CRISPR screens?"
            }
          ],
          "context": ". coupled with gold - standard reference sets of essential and nonessential genes, bagel offers significantly greater sensitivity than current methods, while computational optimizations reduce runtime by an order of magnitude. conclusions : using bagel,\nbagel : a computational framework for identifying essential genes from pooled library screens\n"
        },
        {
          "qas": [
            {
              "id": "5e2b253ffbd6abf43b000006_001",
              "question": "Is AZD5153 active in prostate cancer?"
            }
          ],
          "context": ". azd5153 induced apoptosis activation and cell cycle arrest in prostate cancer cells. azd5153 was non - cytotoxic to the prostate epithelial cells\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\n\n. azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay\nconclusion together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\n\n. azd5153 is a novel brd4 inhibitor. methods : prostate cancer cells were treated with azd5153. cell survival was tested by mtt assay and clonogenicity assay. cell proliferation was tested by [ h3 ] dna incorporation assay\n. its anti - tumor activity was further enhanced with co - treatment of the akt specific inhibitor mk - 2206. conclusion : together, our results indicate a promising therapeutic value of the novel brd4 inhibitor azd5153 against prostate cancer cells.\n"
        },
        {
          "qas": [
            {
              "id": "5e2b3784fbd6abf43b000009_001",
              "question": "Is GRG5 involved only in late embryonic mouse development?"
            }
          ],
          "context": "groucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\n\n. here, we describe a previously unknown role of grg5 in early developmental stages by analyzing its function in stem cell fate decisions\ngroucho related gene 5 ( grg5 ) is a multifunctional protein that has been implicated in late embryonic and postnatal mouse development\n"
        },
        {
          "qas": [
            {
              "id": "5e480909d14c9f295d000003_001",
              "question": "Are astronauts in higher risk for developing cancer?"
            }
          ],
          "context": "no significant associations between space radiation dose and mortality were found using logistic regression with an internal reference group, adjusting for medical radiation.\ndespite years of research, understanding of the space radiation environment and the risk it poses to long - duration astronauts remains limited. there is a disparity between research results and observed empirical effects seen in human astronaut crews\n\nrisks of lung, breast, and gastrointestinal ( gi ) cancers increase with higher radiation dose.\ndespite years of research, understanding of the space radiation environment and the risk it poses to long - duration astronauts remains limited. there is a disparity between research results and observed empirical effects seen in human astronaut crews\n\ndespite years of research, understanding of the space radiation environment and the risk it poses to long - duration astronauts remains limited. there is a disparity between research results and observed empirical effects seen in human astronaut crews\ndifferent types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and merkel cell cancer as well as hematological tumors such as classic hodgkin's lymphoma.\n\nhistorically, data from the chernobyl reactor accident 27 years ago demonstrated a strong correlation with thyroid cancer, but data on the radiation effects of chernobyl on breast cancer incidence have remained inconclusive.\ndespite years of research, understanding of the space radiation environment and the risk it poses to long - duration astronauts remains limited. there is a disparity between research results and observed empirical effects seen in human astronaut crews\n"
        },
        {
          "qas": [
            {
              "id": "5e2906948b3851296d00000a_001",
              "question": "Is Niraparib effective for ovarian cancer?"
            }
          ],
          "context": "niraparib for the treatment of ovarian cancer.\nniraparib in ovarian cancer : results to date and clinical potential.\n\nniraparib for the treatment of ovarian cancer.\nniraparib slows ovarian cancer progression.\n"
        },
        {
          "qas": [
            {
              "id": "5c72768a7c78d6947100006c_001",
              "question": "Are genes that escape X-chromosome inactivation related to mental impairment?"
            }
          ],
          "context": "examination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\ngenes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\n\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\ngenes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\n\ngenes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\n. there is an excess of escaping genes associated with mental retardation, consistent with this being a common phenotype of polyx phenotypes.\n\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation.\ngenes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\n\nthe normal x chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the hunter gene.\nfrom skewed x inactivation of the paternal nonmutant x chromosome.\n"
        },
        {
          "qas": [
            {
              "id": "5e29fe76aa19d74431000007_001",
              "question": "Has LB-100 been tested in clinical trials?"
            }
          ],
          "context": "based on positive results from a phase i / ii clinical trial\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\n. a global test statistic confirmed that lubeluzole - treated patients had a more favorable clinical outcome at 12 weeks ( p =. 041 ).\nbased on positive results from a phase i / ii clinical trial\n\nand open - label extension studies are needed to determine the long - term safety and efficacy of this promising therapy.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nbased on positive results from a phase i / ii clinical trial\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\nbased on positive results from a phase i / ii clinical trial\nand open - label extension studies are needed to determine the long - term safety and efficacy of this promising therapy.\n"
        },
        {
          "qas": [
            {
              "id": "5e290a268b3851296d00000d_001",
              "question": "Is palbociclib effective for glioblastoma?"
            }
          ],
          "context": "the authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\nniraparib in ovarian cancer : results to date and clinical potential.\n\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\nwe here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by bcma pyrrolobenzodiazepine ( pbd ) antibody drug conjugate ( adc ) medi2228 which can augment efficacy of these immunotherapies.\n\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nin phase ii clinical trials, including patients with advanced castration - resistant pc, olaparib seems to be efficacious and well tolerated.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\n"
        },
        {
          "qas": [
            {
              "id": "5e36d807b5b409ea5300000a_001",
              "question": "Does the Mcm2-Ctf4-Pol\u03b1 axis play a role in transfer of histones to leading strand DNA at the replication forks?"
            }
          ],
          "context": "the mcm2 - ctf4 - pol\u03b1 axis facilitates parental histone h3 - h4 transfer to lagging strands.\n. here, we show that the mcm2 - ctf4 - pol\u03b1 axis facilitates the transfer of parental ( h3 - h4 ) 2 tetramers to lagging - strand dna at replication forks\n\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\n. our results support a model whereby parental ( h3 - h4 ) 2 complexes displaced from nucleosomes by dna unwinding at replication forks are transferred by the cmg - ctf4 - pol\u03b1 complex to lagging - strand dna for nucleosome assembly at the original location.\n"
        },
        {
          "qas": [
            {
              "id": "5e2b0d71fbd6abf43b000001_001",
              "question": "Can discharge destinations be accurately predicted using the Risk Assessment and Prediction Tool (RAPT)?"
            }
          ],
          "context": "background : the risk assessment and prediction tool ( rapt ) is used to predict patient discharge disposition after total joint arthroplasty.\npurpose : the aim of this study was to evaluate the value of conventional factors, the risk assessment and predictor tool ( rapt ) and performance - based functional tests as predictors of delayed recovery after total hip arthroplasty ( tha ).\n\nconclusions : the rapt accurately predicted discharge disposition for high - and low - risk patients in our cohort.\nbackground : the risk assessment and prediction tool ( rapt ) is used to predict patient discharge disposition after total joint arthroplasty.\n"
        },
        {
          "qas": [
            {
              "id": "5e2db15cfbd6abf43b000014_001",
              "question": "Has amantadine ER been approved by the FDA?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nextended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\n\nads - 5102 ( amantadine ) extended - release ( er ) capsules ( gocovritm ) is a recent us fda - approved treatment for dyskinesia in pd patients.\nextended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\n"
        },
        {
          "qas": [
            {
              "id": "5e2a0eb1aa19d7443100000c_001",
              "question": "Can PRL3-zumab inhibit PRL3+ cancer cells in vitro and in vivo?"
            }
          ],
          "context": "here we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\nlow hoxa11 expression may promote the proliferation, migration, invasion of endometrial cancer cells, and increase their resistance to cisplatin through activating pten / akt pathway.\n\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\nhere we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\n\nhere we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\nconclusions : prasinezumab therapy had no meaningful effect on global or imaging measures of parkinson's disease progression as compared with placebo and was associated with infusion reactions.\n\nhere we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\n. there is still paucity of data regarding the use of canakinumab in the treatment of patients with rp.\n\n. signaling was tested by western blotting assay. the nude mice pc - 3 xenograft model was applied to test azd5153's activity in vivo. results : azd5153 inhibited proliferation and survival of established and primary prostate cancer cells\nhere we show that prl3 - zumab specifically inhibits prl3 + cancer cells in vivo, but not in vitro.\n"
        },
        {
          "qas": [
            {
              "id": "5ca61b14ecadf2e73f00004f_001",
              "question": "Does Estrogen lead to forkhead FoxA1 activation?"
            }
          ],
          "context": "location analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nfurthermore, knockdown of foxa1 expression blocks the association of er with chromatin and estrogen - induced gene expression demonstrating the necessity of foxa1 in mediating an estrogen response in breast cancer cells.\n\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nfoxa1 is a key determi \" \" t of estrogen receptor function and endocrine response.\n\nlocation analysis of estrogen receptor alpha target promoters reveals that foxa1 defines a domain of the estrogen response.\nthe phosphomimetic foxa1 promoted the activation of estrogen signaling, whereas the nonphosphorylatable foxa1 suppressed its activation.\n"
        },
        {
          "qas": [
            {
              "id": "5cc011e2a49efeb44c000001_001",
              "question": "Does association with the nuclear pore promote gene silencing?"
            }
          ],
          "context": "silencing nuclear pore protein tpr elicits a senescent - like phenotype in cancer cells.\neffect of numerous mechanisms and interactions working together to fine - tune gene expression\n\n. a likely explanation for the reduction of or transcription is the striking reorganization of nuclear architecture observed in the osn lineage, which disrupts multi - chromosomal compartments regulating or expression in humans and hamsters\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\n\nsilencing nuclear pore protein tpr elicits a senescent - like phenotype in cancer cells.\nnanog, oct4 and repressor proteins co - occupy nanog - target genes in mouse es cells, suggesting that nanog and oct4 together may communicate with distinct repression complexes to control gene transcription.\n\nhere, we show that the nucleoporin nup358 plays an important role in this process\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\n\nsilencing nuclear pore protein tpr elicits a senescent - like phenotype in cancer cells.\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\n"
        },
        {
          "qas": [
            {
              "id": "5e29f959aa19d74431000004_001",
              "question": "Can LB-100 sensitize ovarian carcinoma to cisplatin?"
            }
          ],
          "context": "niraparib in ovarian cancer : results to date and clinical potential.\nlb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\n\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\nlb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\n\nlactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing akt through multiple mechanisms.\nlb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\n\nsimilar to those dosed with lasmiditan 100 mg ( 28. 2 % ; or 2. 2, 95 % ci 1. 6 - 3. 0, p < 0. 001 )\nlb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\n\nrenal damage, following cisplatin administration, with subsequent accumulation of bleomycin was the likely cause of the high lung toxicity.\nlb100 sensitized ovarian carcinoma lines to cisplatin - mediated cell death.\n"
        },
        {
          "qas": [
            {
              "id": "5e2dac4efbd6abf43b00000f_001",
              "question": "Has istadefylline been considered as a treatment for Parkinson's disease?"
            }
          ],
          "context": "evidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\n\nconclusions : in a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache,\nrates of gastrointestinal side effects, headache, and depression.\n\nis the only fda - approved treatment for the hallucinations and delusions seen in patients with psychosis of parkinson's disease.\nisd might represent an alternative option for patients with advanced pd.\n\nis the only fda - approved treatment for the hallucinations and delusions seen in patients with psychosis of parkinson's disease.\nexpert opinion : despite early positive findings, larger phase - iii trials have failed to demonstrate any statistically significant impact on cognition for both idalopirdine and intepirdine, as adjunct to cholinesterase inhibitors.\n\nneurotrophic factors are among the most promising treatments aiming at slowing or stopping and even reversing parkinson's disease ( pd ). however, in most cases, they cannot readily cross the human blood - brain - barrier ( bbb )\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5e2dad57fbd6abf43b000010_001",
              "question": "Is amantadine ER the first approved treatment for akinesia?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nextended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\n\nevidence - based review of pharmacotherapy used for parkinson's disease psychosis. despite lack of rigor in study designs, published data to date suggest that clozapine and pimavanserin should be considered drugs of choice to treat pd psychosis.\nextended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\n\nads - 5102 ( amantadine ) extended - release ( er ) capsules ( gocovritm ) is a recent us fda - approved treatment for dyskinesia in pd patients.\nextended - release amantadine ( amantadine er ) is the first approved medication for the treatment of dyskinesia.\n"
        },
        {
          "qas": [
            {
              "id": "5e480ccfd14c9f295d000005_001",
              "question": "Is g-H2AX a marker for double strand breaks?"
            }
          ],
          "context": "expression of the dna double - strand break marker gamma - h2ax ( \u03b3h2ax )\nph2ax, a marker of the dna double - strand break ( dsb )\n\nthe specific phosphorylation of histone h2ax on serine residue 139, described as \u03b3 - h2ax, is an excellent indicator or marker of dna double - strand breaks ( dsbs ).\nexpression of the dna double - strand break marker gamma - h2ax ( \u03b3h2ax )\n\nof histone h2ax ( gamma - h2ax ) and alkaline comet assays.\nexpression of the dna double - strand break marker gamma - h2ax ( \u03b3h2ax )\n\ndouble - stranded breaks ( dsbs ) are the most injurious type of dna damage, being induced by ionizing radiation ( ir ) and cytotoxic agents used in cancer treatment\ndouble - stranded breaks ( dsbs ) are cytotoxic dna lesions caused by oxygen radicals, ionizing radiation, and radiomimetic chemicals\n"
        },
        {
          "qas": [
            {
              "id": "5c7f806d617e120c34000001_001",
              "question": "Are tumour specific antigens originating from known protein coding genes?"
            }
          ],
          "context": "agents targeting other immune inhibitory ( e. g., tim - 3 ) or immune stimulating ( e. g., cd137 ) receptors on t cells and other approaches such as adoptive cell transfer are tested for clinical efficacy in melanoma as well.\ntumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\n\nthese ctls recognize short peptides derived from tumour - associated antigens in conjunction with class i molecules expressed on tumour cells.\ntumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\n\ndata presented here expand the importance of fsps as shared and general tumour - specific antigens.\ntumour antigens are mostly of weak immunogenicity, because the vast majority are tumour - associated differentiation antigens already'seen'by the patient's immune system.\n"
        },
        {
          "qas": [
            {
              "id": "5e2a04feaa19d74431000009_001",
              "question": "Can LB-100 downregulate miR-33?"
            }
          ],
          "context": "lb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\n. we also showed that uc. 63 + regulated the expression of mmp2 via mir - 130b regulation. furthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\n\nlb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\n. mir - 130b was predicted to have binding sites within the uc. 63 + sequence. the expression of mir - 130b was significantly disturbed by the overexpression or knockdown of uc. 63 +\n\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nlb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\n\nlb100 profoundly upregulates mir - 181b - 1, which we show directly binds to the 3'untranslated region of bcl - 2 mrna leading to its translational inhibition\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n"
        },
        {
          "qas": [
            {
              "id": "5e30f638fbd6abf43b000045_001",
              "question": "Does teplizumab hold promise for diabetes prevention?"
            }
          ],
          "context": "teplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\n\nconclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm.\nteplizumab treatment may improve c - peptide responses in participants with type 1 diabetes after the new - onset period : a randomised controlled trial.\n\nrates of gastrointestinal side effects, headache, and depression.\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\n\nconclusions teplizumab is an anti - cd3 human monoclonal antibody with promising activity in treatment of patients with t1dm.\nareas covered in this review, we discuss the recent update on clinical data obtained from trials of teplizumab in type 1 diabetes, the drug's postulated mechanism of action and the identification of responders to therapy.\n"
        },
        {
          "qas": [
            {
              "id": "5e2dfab2fbd6abf43b00001d_001",
              "question": "Does ProSavin use an adenoviral vector?"
            }
          ],
          "context": "long - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\n"
        },
        {
          "qas": [
            {
              "id": "5e3238bcfbd6abf43b000056_001",
              "question": "Does radiation for tinea capitis increases brain tumor risk?"
            }
          ],
          "context": "there is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma.\nlong - term follow - up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.\n\na benign disease ( especially tinea capitis ), as well as after irradiation at higher doses of a few tens of grays for the treatment of cancer ( in particular cerebral irradiation in acute lymphoblastic leukaemia ).\nlong - term follow - up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.\n"
        },
        {
          "qas": [
            {
              "id": "5e2dbd0afbd6abf43b000017_001",
              "question": "Is pimavanserin a typical antipsychotic?"
            }
          ],
          "context": "pimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\nreceptor inverse agonist pimavanserin was recently approved by the us fda for the treatment of pdp and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.\n\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\nrationale : pimavanserin, a selective serotonin 2a receptor inverse agonist, is a promising candidate for treating parkinson's disease psychosis.\n\npimavanserin for the treatment of parkinson's disease psychosis. pimavanserin is an antipsychotic with a unique mechanism of action ( 5 - ht2a receptor inverse agonist ) and no measurable dopaminergic activity ; it has been demonstrated to be efficacious,\na retrospective study of pimavanserin use in a movement disorders clinic. pimavanserin, a 5 - ht2a inverse agonist, was commercially released in the united states in april 2016 for the treatment of parkinson disease psychosis.\n\npimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\npimavanserin 34 mg / d was effective in treating hallucinations and delusions associated with parkinson's disease.\n\npimavanserin is the first fda - approved atypical antipsychotic drug indicated for the treatment of hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\npimavanserin, a selective 5 - ht2a inverse agonist / antagonist, was approved in the u. s. for treating hallucinations and delusions associated with parkinson's disease psychosis ( pdp ).\n"
        },
        {
          "qas": [
            {
              "id": "5e5b93a2752ebcdc7a000003_001",
              "question": "Can Flotillin be used as exosomal marker?"
            }
          ],
          "context": "flotillin 1 and tumor susceptibility gene 101 ( tsg101 ), two exosomal marker proteins,\nexpressed exosomal marker tumor susceptibility gene ( tsg ) 101 and flotillin ( flot ) 1.\n\nf exosome marker proteins ( e. g., cd63, alix )\nthe most commonly used melanocytic markers include s100, melan - a, hmb45 and sox10\n"
        },
        {
          "qas": [
            {
              "id": "5e30f417fbd6abf43b000043_001",
              "question": "Is Apremilast effective for Beh\u00e7et\u2019s Syndrome?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\nin patients with oral ulcers associated with behcet's syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (\n\napremilast is now approved for the treatment of oral ulcer of behcet syndrome in the united states.\nin patients with oral ulcers associated with behcet's syndrome, apremilast resulted in a greater reduction in the number of oral ulcers than placebo but was associated with adverse events, including diarrhea, nausea, and headache. (\n\nconclusions apremilast was effective in treating oral ulcers, which are the cardinal manifestation of behcet's syndrome.\napremilast is now approved for the treatment of oral ulcer of behcet syndrome in the united states.\n"
        },
        {
          "qas": [
            {
              "id": "5e46ece93f5415952900000e_001",
              "question": "Is Rad4/XPC a DNA damage sensing protein?"
            }
          ],
          "context": "twist - open mechanism of dna damage recognition by the rad4 / xpc nucleotide excision repair complex.\nkinetic gating mechanism of dna damage recognition by rad4 / xpc.\n"
        },
        {
          "qas": [
            {
              "id": "5e5b60adb761aafe0900000b_001",
              "question": "Is the protein ABCG2 transmembrane?"
            }
          ],
          "context": "surface inhibitory molecules such as siglec - 8, anti - il - 1s such as canakinumab, bruton kinase ( btk ) inhibitors such as gdc - 0853 and anti - il - 5s such as benralizumab and mepolizumab. summary : the ongoing clinical trials on new targets of treatment hold\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\n\nthe transmembrane atp - binding cassette transporter g2\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\n\nthe transmembrane atp - binding cassette transporter g2\nthe atp - binding cassette ( abc ) transporter family is a large class of atp energy - dependent transmembrane proteins\n\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\n\nmycobacterium abscessus has emerged as a successful pathogen owing to its intrinsic drug resistance.\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\n"
        },
        {
          "qas": [
            {
              "id": "5e3247f1fbd6abf43b00005b_001",
              "question": "Can radiotherapy cause radiation induced osteosarcoma?"
            }
          ],
          "context": "radiation - induced osteosarcoma is a well - known but rare complication of radiotherapy for brain neoplasms with a poor prognosis\nosteosarcoma after radiotherapy for prostate cancer.\n\nradiation - induced osteosarcoma is a well - known but rare complication of radiotherapy for brain neoplasms with a poor prognosis\nradiation - induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma.\n\nradiation - induced osteosarcoma of the maxilla and mandible after radiotherapy for nasopharyngeal carcinoma.\nradiation - induced osteosarcoma is a well - known but rare complication of radiotherapy for brain neoplasms with a poor prognosis\n"
        },
        {
          "qas": [
            {
              "id": "5cf4dec0a49efeb44c00000c_001",
              "question": "Are lamina-associated domains (LADs) associated with transcriptional activation?"
            }
          ],
          "context": "we found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\nsuch lamina - associated domains ( lads ) are thought to help organize chromosomes inside the nucleus and have been associated with gene repression.\n\nthe nuclear lamina contributes to the regulation of gene expression and to chromatin organization.\nsuch lamina - associated domains ( lads ) are thought to help organize chromosomes inside the nucleus and have been associated with gene repression.\n"
        },
        {
          "qas": [
            {
              "id": "5e31cc22fbd6abf43b000050_001",
              "question": "Is Hemochromatosis type 4 is caused by a mutation in a recessive gene?"
            }
          ],
          "context": "type 4 hemochromatosis follows an autosomal domi \" \" t trait ; the corresponding mutation affects the basolateral iron carrier ferroportin 1.\nhemochromatosis type 4 is a rare form of primary iron overload transmitted as an autosomal domi \" \" t trait caused by mutations in the gene encoding the iron transport protein ferroportin 1 ( slc40a1 ).\n"
        },
        {
          "qas": [
            {
              "id": "5e371a1db5b409ea53000015_001",
              "question": "Can Patient-derived organoids (PDOs) recapitulate patient responses in the clinic?"
            }
          ],
          "context": "our data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs\n. our data suggest that pdos can recapitulate patient responses in the clinic and could be implemented in personalized medicine programs.\n\npatient - derived xenografts ( pdx ) and patient - derived organoids ( pdo ) serve as promising tools to identify new drugs with therapeutic potential in pdac.\n. we compared responses to anticancer agents ex vivo in organoids and pdo - based orthotopic mouse tumor xenograft models with the responses of the patients in clinical trials\n"
        },
        {
          "qas": [
            {
              "id": "5e49c5336d0a277941000011_001",
              "question": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?"
            }
          ],
          "context": "prolonging the survival of small cell lung cancer patients.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\n. immunohistochemical staining using 406 nsclc and 265 escc specimens confirmed that ly6k overexpression was associated with poor prognosis for patients with nsclc ( p = 0. 0003 ), as well as escc ( p = 0. 0278 ), and multivariate analysis confirmed its\ngene expression profile analyses of non - small cell lung carcinomas ( nsclc ) and esophageal squamous cell carcinomas ( escc ) revealed that lymphocyte antigen 6 complex locus k ( ly6k ) was specifically expressed in testis and transactivated in a majority\n"
        },
        {
          "qas": [
            {
              "id": "5d31daacb3a6380763000003_001",
              "question": "Are the members of the KRAB-ZNF  gene family promoting gene repression?"
            }
          ],
          "context": "the stem cell zinc finger 1 ( szf1 ) / znf589 protein belongs to the large family of kruppel - associated box domain - zinc finger ( krab - znf ) transcription factors, which are present only in higher vertebrates and epigenetically repress transcription by\nbecause kap1 is recruited to the dna via interaction with krab - znf proteins, we suggest that expression of krab - znf genes may be controlled via an auto - regulatory mechanism involving kap1.\n\nhere, using a reporter system, we show that trim28 / krab - znfs alter dna methylation patterns in addition to h3k9me3 to cause stable gene repression during reprogramming\nbecause kap1 is recruited to the dna via interaction with krab - znf proteins, we suggest that expression of krab - znf genes may be controlled via an auto - regulatory mechanism involving kap1.\n\n. using several expression datasets, we identified krab - znfs ( znf114, znf483, znf589 ) in the human genome that maintain pluripotency.\nbecause kap1 is recruited to the dna via interaction with krab - znf proteins, we suggest that expression of krab - znf genes may be controlled via an auto - regulatory mechanism involving kap1.\n\nbecause kap1 is recruited to the dna via interaction with krab - znf proteins, we suggest that expression of krab - znf genes may be controlled via an auto - regulatory mechanism involving kap1.\nfurther analyses of our data sets link gabpa to cognitive disorders, diabetes, krab zinc finger ( krab - znf ), and human - specific genes.\n"
        },
        {
          "qas": [
            {
              "id": "5e5b5c6fb761aafe0900000a_001",
              "question": "Is the protein ABCG2 (ATP-Binding Cassette, subfamily G, member 2, transporter) excreting uric acid?"
            }
          ],
          "context": "a genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\n\naltered glycoprotein expression has been demonstrated in tissue from patients with barrett's esophagus and esophageal cancer but the mechanisms regarding such changes are unknown.\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\n\nthe transmembrane atp - binding cassette transporter g2\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\n\natp - binding cassette ( abc ) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs.\ntp - binding cassette transporter, sub - family g, member 2 ( abcg2 / bcrp ) is a well - studied urate transporter expressed on apical membranes in several tissues, including the intestine, liver, and kidney.\n\natp - binding cassette ( abc ) transporters are transmembrane efflux transporters mediating the extrusion of an array of substrates ranging from amino acids and lipids to xenobiotics, and many therapeutic compounds, including anticancer drugs.\nthe discovery that abcg2 plays a central role on extra - renal uric acid excretion,\n"
        },
        {
          "qas": [
            {
              "id": "5e30f23cfbd6abf43b000042_001",
              "question": "Is modified vaccinia Ankara effective for smallpox?"
            }
          ],
          "context": "imvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\n\nmodified vaccinia ankara : potential as an alternative smallpox vaccine\nevaluation of modified vaccinia virus ankara as an alternative vaccine against smallpox in chronically hiv type 1 - infected individuals undergoing haart.\n\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\nmodified vaccinia ankara : potential as an alternative smallpox vaccine\n\nmodified vaccinia ankara : potential as an alternative smallpox vaccine\nimvamune : modified vaccinia ankara strain as an attenuated smallpox vaccine.\n"
        },
        {
          "qas": [
            {
              "id": "5e30f76afbd6abf43b000046_001",
              "question": "Does nintedanib hold promise for lung disease associated with systemic sclerosis?"
            }
          ],
          "context": "potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases.\ndesign of a randomised, placebo - controlled clinical trial of nintedanib in patients with systemic sclerosis - associated interstitial lung disease ( senscis\u2122 ).\n\ndesign of a randomised, placebo - controlled clinical trial of nintedanib in patients with systemic sclerosis - associated interstitial lung disease ( senscis\u2122 ).\nnintedanib, a tyrosine kinase inhibitor, has been shown to have antifibrotic and antiinflammatory effects in preclinical models of systemic sclerosis and ild.\n\n. these data might have direct implications for the ongoing phase iii clinical trial with nintedanib in ssc - associated interstitial lung disease.\ndesign of a randomised, placebo - controlled clinical trial of nintedanib in patients with systemic sclerosis - associated interstitial lung disease ( senscis\u2122 ).\n"
        },
        {
          "qas": [
            {
              "id": "5e49a1196d0a27794100000d_001",
              "question": "Is PF-05190457 an inverse agonist of the ghrelin receptor?"
            }
          ],
          "context": "pf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nreceptor inverse agonist pimavanserin was recently approved by the us fda for the treatment of pdp and may prove to be a more targeted therapy without the downsides of atypical antipsychotics.\n\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nantagonist fosphenytoin, magnesium, glycine site antagonist gv150526 and piracetam.\n\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\ndemonstrating antiatherothrombotic properties of dipeptidyl peptidase - 4 inhibitors on proven markers is of substantial clinical significance\n\npf - 05190457 is a well - tolerated first - in - class ghrelin receptor inverse agonist with acceptable pharmacokinetics for oral daily dosing.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5e30e9e3fbd6abf43b00003c_001",
              "question": "Is Ubrogepant effective for migraine?"
            }
          ],
          "context": "ubrogepant for the treatment of migraine.\nrates of gastrointestinal side effects, headache, and depression.\n\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\nubrogepant for the treatment of migraine.\n\nubrogepant for the treatment of migraine.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\n\nubrogepant for the treatment of migraine.\nubrogepant ( mk - 1602 ) is a novel, oral, calcitonin gene - related peptide receptor antagonist in clinical development with positive phase iii outcomes for acute treatment of migraine.\n"
        },
        {
          "qas": [
            {
              "id": "5e30f494fbd6abf43b000044_001",
              "question": "Is Selinexor effective for multiple myeloma?"
            }
          ],
          "context": "objective : to review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma ( mm ).\n. preclinical studies demonstrated synergistic antimyeloma activity between selinexor and proteasome inhibitors ( pi ) though suppression of nf\u03bab signaling and nuclear retention of tumor suppressor proteins.\n\nobjective : to review the pharmacology, pharmacokinetics, efficacy, and safety of selinexor for management of relapsed multiple myeloma ( mm ).\nsafety and efficacy of selinexor in relapsed or refractory multiple myeloma and waldenstrom macroglobulinemia.\n"
        },
        {
          "qas": [
            {
              "id": "5e447f2448dab47f26000013_001",
              "question": "Are there lncRNAs that control the extent of neuronal outgrowth?"
            }
          ],
          "context": ". we show that two of these lncrnas regulate the extent of neuronal outgrowth\nmicroexon alternative splicing of small gtpase regulators : implication in central nervous system diseases.\n\n. we show that two of these lncrnas regulate the extent of neuronal outgrowth\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\n\n. we show that two of these lncrnas regulate the extent of neuronal outgrowth\nhere, we profiled gene expression following sciatic nerve crush in mice and identified long noncoding rnas ( lncrnas ) that act in the regenerating neurons and which are typically not expressed in other contexts\n\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\n. lncrnas serve as precursors for many types of small rnas and, therefore, the pathways for small rna biogenesis can impinge upon the fate of lncrnas\n"
        },
        {
          "qas": [
            {
              "id": "5e4af1d86d0a277941000018_001",
              "question": "Does metformin has as an antitumor effect?"
            }
          ],
          "context": "the anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\nan association between metformin and tumorigenesis\n\nthe anti - tumor effect of metformin is widely known, however, there is only limited evidence regarding the anti - angiogenesis effect and chemosensitization of metformin and its underlying mechanisms in pdac\nthere is no evidence of antitumor effect of metformin. a possible decrease only for breast, liver and prostate cancer, is compatible with random fluctuations.\n\nthere is no evidence of antitumor effect of metformin. a possible decrease only for breast, liver and prostate cancer, is compatible with random fluctuations.\nan association between metformin and tumorigenesis\n"
        },
        {
          "qas": [
            {
              "id": "5e3234e0fbd6abf43b000054_001",
              "question": "Can radiation induced meningiomas be treated with radiosurgery?"
            }
          ],
          "context": "this article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nalthough meningiomas are known to be induced by low doses of cranial irradiation, such as those given to treat tinea capitis, little experience has been reported on the induction of meningiomas by high - dose cranial irradiation.\n\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\ngamma knife radiosurgery for meningiomas : four cases of radiation - induced edema.\n\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nalso, lc rates with radiosurgery are at least comparable to those of surgical series for radiation - induced meningiomas\n\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nstereotactic radiosurgery ( srs ) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation - induced tumors is unclear.\n"
        },
        {
          "qas": [
            {
              "id": "5e3709a4b5b409ea53000012_001",
              "question": "Is there a BRCA mutation analysis in the Greek population?"
            }
          ],
          "context": "comprehensive brca mutation analysis in the greek population. experience from a single clinical diagnostic center.\n. our results indicate that different types of mutational events in the brca1 and brca2 genes are responsible for the hereditary component of breast / ovarian cancer in the greek population\n"
        },
        {
          "qas": [
            {
              "id": "5e2dbf48fbd6abf43b00001a_001",
              "question": "Has ProSavin undergone phase IV clinical trials by 2018?"
            }
          ],
          "context": "long - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\n\nrates of gastrointestinal side effects, headache, and depression.\nprosavin, a lentiviral vector based gene therapy that delivers local and continuous dopamine, was previously shown to be well tolerated in a phase i / ii first - in - human study, with significant improvements in motor behavior from baseline at 1 year.\n\nlong - term safety and tolerability of prosavin, a lentiviral vector - based gene therapy for parkinson's disease : a dose escalation, open - label, phase 1 / 2 trial.\nbased on positive results from a phase i / ii clinical trial\n"
        },
        {
          "qas": [
            {
              "id": "5d35b9ecb3a6380763000004_001",
              "question": "Does deletion of cohesin change gene expression?"
            }
          ],
          "context": ". these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\nthe conditional deletion of cohesin from noncycling thymocytes preserved enhancer position, h3k27ac, h4k4me1, and enhancer transcription, but weakened interactions between enhancers.\n\nproviding mechanistic insights into and functional support for the role of trans interactions in gene expression.\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\n\nseveral landmark studies have shown that cohesin mutations perturb the balance between self - renewal and differentiation of hematopoietic stem and progenitor cells ( hspc )\n. these findings uncover an unexpected dependence of inducible gene expression on cohesin, link cohesin with myeloid differentiation, and may help explain the prevalence of cohesin mutations in human acute myeloid leukemia.\n\ninfluence of chromatin structure on the induction of dna double strand breaks by ionizing radiation.\nthese structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\n"
        },
        {
          "qas": [
            {
              "id": "5e2e1d6afbd6abf43b000026_001",
              "question": "Do MAIT cells have a role in multiple myeloma?"
            }
          ],
          "context": "here we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\nmxa, ifitm1 ) in cd14 + monocytes of csle patients and healthy controls ( hcs )\n\nhere we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\ncytolysis induction, and antigen - presenting cell functional modulation.\n\nprolonged activation of these immunomodulatory t cells in the treatment of mm.\nhere we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\n\nhere we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\nthe proteasome inhibitor bortezomib is used to treat multiple myeloma ( mm ).\n\nhere we have analysed the frequency and function of mait cells in multiple myeloma ( mm ) patients. we show that mait cell frequency in blood is reduced compared to healthy adult donors, but comparable to elderly healthy control donors\nthese ctls recognize short peptides derived from tumour - associated antigens in conjunction with class i molecules expressed on tumour cells.\n"
        },
        {
          "qas": [
            {
              "id": "5e3e843748dab47f26000007_001",
              "question": "Are stretch enhancers transcribed more than super-enhancers?"
            }
          ],
          "context": "enhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n\n. importantly, a vast majority of super - enhancers ( 85 % ) overlap with only a small subset of stretch enhancers ( 13 % ), which are enriched for cell type - specific biological functions, and control cell identity genes\nsuper - enhancers are transcriptionally more active and cell type - specific than stretch enhancers.\n\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\nsuper - enhancers are characterized by high levels of mediator binding and are major contributors to the expression of their associated genes.\n\n. in addition, active enhancers can be detected through signatures of bidirectional transcription initiation. described here is a protocol for performing super - low input carrier - cage ( slic - cage )\nin metazoans, enhancers of gene transcription must often exert their effects over tens of kilobases of dna\n\n. these results suggest that super - enhancers are transcriptionally more active and cell type - specific than stretch enhancers, and importantly, most of the stretch enhancers that are distinct from super - enhancers do not show an association with cell\nsuper - enhancers are transcriptionally more active and cell type - specific than stretch enhancers.\n"
        },
        {
          "qas": [
            {
              "id": "5e31c4adfbd6abf43b00004d_001",
              "question": "Is mesothelioma caused by asbestos exposure?"
            }
          ],
          "context": "background : tremelimumab, an anti - ctla4 monoclonal antibody, initially showed good activity when used alone in patients with mesothelioma, but did not improve the overall survival of patients who failed on first - line or second - line chemotherapy\nobjective malig \" \" t pleural mesothelioma in rural turkey frequently results from environmental exposure to tremolite asbestos or fibrous zeolite ( erionite ).\n\nmalig \" \" t mesothelioma is a rare and aggressive pleural or peritoneal tumour almost always caused by exposure to asbestos fibres.\nmesothelioma, a rare tumor, is highly correlated with asbestos exposure.\n\noccupational asbestos exposure occurs in many workplaces and is a well - known cause of mesothelioma and lung cancer.\nmesothelioma, a rare tumor, is highly correlated with asbestos exposure.\n\nmesothelioma, a rare tumor, is highly correlated with asbestos exposure.\nbackground malig \" \" t mesothelioma caused by asbestos exposure has a long latency period.\n"
        },
        {
          "qas": [
            {
              "id": "5e46fda33f54159529000012_001",
              "question": "Are there interactions between short and long noncoding RNAs?"
            }
          ],
          "context": ". here, i review the known types of interactions between small and long rnas, discuss their outcomes, and bring representative examples from studies in mammals.\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\n\n. among these noncoding rnas are short rnas, such as micrornas, snornas, and piwi - interacting rnas, and the functions of those are relatively well understood\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\n\n. other noncoding rnas are longer, and their modes of action and functions are also increasingly explored and deciphered. short rnas and long noncoding rnas ( lncrnas ) interact with each other with reciprocal consequences for their fates and functions\n. in addition, lncrna expression can be repressed by small rnas, and lncrnas can affect small rna activity and abundance through competition for binding or by triggering small rna degradation\n"
        },
        {
          "qas": [
            {
              "id": "5e5b90b3752ebcdc7a000002_001",
              "question": "Can brain derived exosomes carry APP molecules?"
            }
          ],
          "context": "here we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta\nthese exosomes contained app and were capable of efficiently transferring app to normal primary neurons.\n\nhere we have investigated the role of exosomes in the processing of app and show that these vesicles contain app - ctfs, as well as abeta\naccumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\n\nwe analyzed exosomes from mouse ( c57bl / 6 ) and breast, lung, and ovarian cancer patient samples and cultured cancer cells with different approaches, including \" \" oparticle tracking analysis, biolayer interferometry, facs, and electron microscopy.\nwe applied a technique to generate native fluorescent exosomes characterized by vesicles integrity, size, density, markers expression, and quantifiable by direct facs analysis\n\nthe apolipoprotein - e - mimetic cog112 protects amyloid precursor protein intracellular domain - overexpressing animals from alzheimer's disease - like pathological features.\naccumulating evidence has demonstrated that exosomes are associated with amyloid precursor ( app ) and tau proteins and play a controversial role in alzheimer's disease process.\n"
        },
        {
          "qas": [
            {
              "id": "5d38826ea1e1595105000016_001",
              "question": "Is SATB1 positioned close to AT-rich sequences?"
            }
          ],
          "context": "satb1 ( special at - rich binding protein 1 ) is a global chromatin organizer regulating the expression of a large number of genes\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nthe transcription factor satb1 that regulates the t - cell maturation\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\n\nspecial at - rich sequence - binding protein 1 ( satb1 ), a dna - binding protein expressed predomitly in thymocytes, recognizes an atc sequence context that consists of a cluster of sequence stretches with well - mixed a's, t's, and c's without g's on one\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\n\nspecial at - rich sequence - binding protein 1 ( satb1 ), a dna - binding protein expressed predomitly in thymocytes, recognizes an atc sequence context that consists of a cluster of sequence stretches with well - mixed a's, t's, and c's without g's on one\nchromatin organizers satb2 and satb1\n\nchromatin organizers satb2 and satb1\nsatb1 ( special at - rich sequence - binding protein - 1 ) provides a key link between dna loop organization, chromatin modification / remodeling, and association of transcription factors at matrix attachment regions ( mars ).\n"
        },
        {
          "qas": [
            {
              "id": "5d38462b7bc3fee31f000012_001",
              "question": "Does metformin alleviate atherosclerosis?"
            }
          ],
          "context": "pleiotropic benefits of metformin in attenuation of atherosclerosis.\nregulators in atherosclerotic cardiovascular disease, metabolic disease, and cancers ; 8 ) the potential mechanisms of several circrnas have been described in diseases, hinting at their potential applications as novel therapeutic targets.\n\npleiotropic benefits of metformin in attenuation of atherosclerosis.\nmetformin's effects on lipids and atherosclerotic vascular disease and / or provide insights into the drug's mechanisms of action on the heart and vasculature.\n\nmetformin's effects on lipids and atherosclerotic vascular disease and / or provide insights into the drug's mechanisms of action on the heart and vasculature.\nan association between metformin and tumorigenesis\n\nmetformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses\ncontrol ( placebo, sitagliptin, glimepiride, dulaglutide, insulin glargine, and nph ), liraglutide in combination with metformin resulted in significant reductions in hba1c, bodyweight, fpg, and ppg, and similar reductions in sbp, and dbp\n\npleiotropic benefits of metformin in attenuation of atherosclerosis.\nmetformin ameliorates the progression of atherosclerosis via suppressing macrophage infiltration and inflammatory responses\n"
        },
        {
          "qas": [
            {
              "id": "5e2e1017fbd6abf43b000020_001",
              "question": "Are CD8+ (cytotoxic) T cells and  CD4+ Helper T cells generated in the thyroid and express the T-cell receptor?"
            }
          ],
          "context": "in the mammalian thymus, cd4 helper t cells and cd8 cytotoxic t cells arise from a common precursor that expresses both cd4 and cd8.\nin the thymus, mature cd4 + cd8 - and cd4 - cd8 + t cells expressing alpha beta t - cell antigen receptors ( tcr ) develop from immature thymocytes through cd4 + cd8 + alpha beta tcr + intermediates.\n\ncd4 + cd8 + progenitor thymocytes undergo selection following interaction with mhc class i and class ii molecules bearing peptide self - antigens, giving rise to cd8 + cytotoxic and cd4 + helper or regulatory t cell lineages, respectively.\ncytotoxic t lymphocytes and the cd4 + 8 - tcr + t helper cells.\n\ndevelopment, differentiation, and function of thymocytes and cd4 ( + ) and cd8 ( + ) t cells are controlled by a multitude of secreted and intracellular factors\na fundamental question in developmental immunology is how bipotential thymocyte precursors generate both cd4 + helper and cd8 + cytotoxic t cell lineages.\n\nin the mammalian thymus, cd4 helper t cells and cd8 cytotoxic t cells arise from a common precursor that expresses both cd4 and cd8.\ncytotoxic t lymphocytes and the cd4 + 8 - tcr + t helper cells.\n\nin the thymus, mature cd4 + cd8 - and cd4 - cd8 + t cells expressing alpha beta t - cell antigen receptors ( tcr ) develop from immature thymocytes through cd4 + cd8 + alpha beta tcr + intermediates.\na fundamental question in developmental immunology is how bipotential thymocyte precursors generate both cd4 + helper and cd8 + cytotoxic t cell lineages.\n"
        },
        {
          "qas": [
            {
              "id": "5e31d181fbd6abf43b000053_001",
              "question": "Is Huntington's disease is caused by expansion of a CTG repeat in the HTT gene on Chromosome 4?"
            }
          ],
          "context": "huntington's disease ( hd ) is a neurodegenerative disorder caused by a cag trinucleotide repeat expansion in the huntingtin ( htt ) gene.\nbackground huntington's disease is caused by a cag repeat expansion in the huntingtin gene, htt.\n\nimportance huntington disease ( hd ), a prototypic monogenic disease, is caused by an expanded cag repeat in the htt gene exceeding 35 units.\nhuntington's disease ( hd ) is an autosomal progressive neurodegenerative disorder caused by the expansion of cag repeats in the htt gene.\n\nhuntington's disease ( hd ) is caused by a cag repeat expansion that encodes a polyglutamine ( polyq ) expansion in the hd disease protein, huntingtin ( htt ).\nbackground huntington's disease is caused by a cag repeat expansion in the huntingtin gene, htt.\n\nhuntington's disease ( hd ) is a neurodegenerative disorder characterized by involuntary choreic movements, cognitive impairment, and behavioral changes, caused by the expansion of an unstable cag repeat in htt.\nhuntington disease ( hd ) is a progressive autosomal domi \" \" t neurodegenerative disorder, characterized by abnormal movements, cognitive decline, and psychiatric symptoms, caused by a cag repeat expansion in the huntingtin ( htt ) gene on chromosome 4p.\n"
        },
        {
          "qas": [
            {
              "id": "5e323780fbd6abf43b000055_001",
              "question": "Is there an increased risk of meningiomas in atomic bomb survivors?"
            }
          ],
          "context": "emphasis is placed on meningiomas resulting from childhood treatment for primary brain tumor or tinea capitis, exposure to dental x - rays, and exposure to atomic explosions in hiroshima and nagasaki.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\n\npossible effects for further study include increased rates of thyroid, breast, and lung cancers and multiple myeloma ; reduction of radiation risks of leukemia to population levels ; and increased morbidity and mortality of cleanup workers from cardio -\n. the incidence among nagasaki atomic - bomb survivors over 40 years of age, especially in those proximally exposed, appears to be increasing, in inverse proportion to the exposure distance, since 1981, 36 years after the explosion of the atomic bomb.\n\nhigh incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.\n. the present findings strongly suggest that meningioma is one of the tumors induced by atomic bombing in hiroshima.\n\nthere is evidence to show that moderate doses of ionising radiations given in childhood for tinea capitis are associated with a late risk of developing a meningioma.\nradiation - induced world health organization grade ii meningiomas in young patients following prophylactic cranial irradiation for acute lymphoblastic leukemia in childhood. three case reports.\n\nthe incidences of meningioma among the survivors of hiroshima in 5 - year intervals since 1975 were 5. 3, 7. 4, 10. 1, and 14. 9, respectively.\n. the incidence among nagasaki atomic - bomb survivors over 40 years of age, especially in those proximally exposed, appears to be increasing, in inverse proportion to the exposure distance, since 1981, 36 years after the explosion of the atomic bomb.\n"
        },
        {
          "qas": [
            {
              "id": "5e41620648dab47f2600000e_001",
              "question": "Is poliosis circumscripta another term for a white or unpigmented patch of hair or skin?"
            }
          ],
          "context": "acanthosis nigricans maligna : symmetrical mainly intertriginous hyperpigmentation with partially verrucous hyperplasia and lichenification mostly in association with gastric adenocarcinoma\nalthough traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\n\nrepens, hypertrichosis lanuginosa acquisita, papuloerythroderma of ofuji, tripe palms, and multicentric reticulohistiocytosis )\nalthough traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\n\nsigns were inaugural ; b ) the association with crohn's disease ; c ) the presence of lesions to the genital mucosa ; d ) the unusual localization\nalthough traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\n\nepidemiological studies consistently cited increased tumor incidence in pediatric patients ( ages 0 - 18 ) exposed to head cts.\nalthough traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\n\nin terms of disease - modifying treatment options, several drugs such as dexpramipexole, pioglitazone, lithium, and many others have been tested in large multicenter trials, albeit with disappointing results.\nalthough traditionally known as \" white forelock, \" poliosis circumscripta, defined as a localized patch of white hair in a group of hair follicles, can involve any hairy area on the body including the scalp, eyebrows, and eyelashes\n"
        },
        {
          "qas": [
            {
              "id": "5e44bdba48dab47f2600001c_001",
              "question": "Is Selumetinib effective for low-grade glioma?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n\ninterpretation : selumetinib is active in recurrent, refractory, or progressive pilocytic astrocytoma harbouring common braf aberrations and nf1 - associated paediatric low - grade glioma.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n"
        },
        {
          "qas": [
            {
              "id": "5d35c227b3a6380763000007_001",
              "question": "Is SATB1 expressed in thymocytes?"
            }
          ],
          "context": "satb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\n\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\n\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nsatb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\n\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nsatb1 is a homeodomain protein and is predomi \" \" tly expressed in thymocytes.\n"
        },
        {
          "qas": [
            {
              "id": "5e44c18648dab47f2600001f_001",
              "question": "Does gavestinel improve outcomes of stroke patients?"
            }
          ],
          "context": "the wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\ngavestinel - - failed to show efficacy in clinical trials of stroke or traumatic brain injury.\n\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nconclusions : these observations from the combined gain international and gain americas trials suggest that gavestinel is not of substantial benefit or harm to patients with primary intracerebral hemorrhage.\n\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nmethods : we studied all patients of the glycine antagonist ( gavestinel ) in neuroprotection ( gain ) international trial with ischemic stroke alive at day 7, excluding patients with hemorrhagic events and deaths from nonstroke - related causes\n"
        },
        {
          "qas": [
            {
              "id": "5e4c06d96d0a27794100002e_001",
              "question": "Can Systemic Lupus Erythematosus cause seizures?"
            }
          ],
          "context": "epileptic seizures and eeg features in juvenile systemic lupus erythematosus.\nseizures are one of the most serious neuropsychiatric manifestations of systemic lupus erythematous ( sle ).\n\nepileptic seizures and eeg features in juvenile systemic lupus erythematosus.\nto determine the factors associated with seizures in systemic lupus erythematosus ( sle ).\n"
        },
        {
          "qas": [
            {
              "id": "5e4fd4d56d0a277941000034_001",
              "question": "Is Impetigo a viral infection that affects the skin?"
            }
          ],
          "context": "impetigo is a superficial bacterial infection that most commonly affects the face and extremities of children.\nimpetigo, a bacterial skin infection that involves the superficial layers of the skin, is one of the most common skin infections in children ages 2 to 5 but can occur in individuals across the lifespan.\n\nimpetigo is the most common bacterial skin infection of children.\nimpetigo contagiosa is a common, superficial, bacterial infection of the skin characterised by an inflamed and infected epidermis caused by staphylococcus aureus, streptococcus pyogenes or both.\n\nimpetigo is a superficial, but contagious, bacterial infection of the skin that predomi \" \" tly affects children and is common in primary care.\nimpetigo is a superficial bacterial infection that most commonly affects the face and extremities of children.\n\nimpetigo is a superficial bacterial infection that most commonly affects the face and extremities of children.\nimpetigo is a common, superficial, bacterial infection of the skin characterized by an inflamed and infected epidermis.\n\nof impetigo, a highly contagious bacterial skin infection\nimpetigo is a highly contagious bacterial skin infection and is one of the most common skin infections in children\n"
        },
        {
          "qas": [
            {
              "id": "5e44caaf48dab47f26000024_001",
              "question": "Should Lubeluzole be used for treatment of ischemic stroke?"
            }
          ],
          "context": ". of all subjects treated, 853 ( 95 % ) on lubeluzole and 826 ( 93 % ) on placebo reported an adverse event during their treatment period or within the next 2 days after discontinuation of treatment.\nhowever, clinical research on lubeluzole is now at a standstill, since lubeluzole seems to be associated with the acquired long qt syndrome and ventricular arrhythmias.\n\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\nconclusions : in patients with acute ischemic stroke, the dosage regimen of 7. 5 mg over 1 hour followed by 10 mg / d of intravenous lubeluzole is safe and statistically significantly reduced mortality.\n\nlubeluzole showed promising neuroprotective effects in animal stroke models, but failed to show benefits in acute ischemic stroke in humans.\ntreatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.\n\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\ntreatment with lubeluzole within 6 hours of the onset of ischemic stroke had a nonsignificant effect on mortality and resulted in improved clinical outcome compared with placebo, with no safety concerns.\n"
        },
        {
          "qas": [
            {
              "id": "5e36994092b3349b55000002_001",
              "question": "Is there a role for TET proteins in invariant natural killer T cells (iNKT) cell fate?"
            }
          ],
          "context": ". tet2 - tet3 double - knockout ( dko ) inkt cells displayed pronounced skewing toward the nkt17 lineage, with increased dna methylation and impaired expression of genes encoding the key lineage - specifying factors t - bet and thpok\n. our data indicate that tet proteins regulate inkt cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the t cell antigen receptor ( tcr ).\n\nwe found that simultaneous deletion of tet2 and tet3 in mouse cd4 + cd8 + double - positive thymocytes resulted in dysregulated development and proliferation of invariant natural killer t cells ( inkt cells )\n. our data indicate that tet proteins regulate inkt cell fate by ensuring their proper development and maturation and by suppressing aberrant proliferation mediated by the t cell antigen receptor ( tcr ).\n"
        },
        {
          "qas": [
            {
              "id": "5e3c80abb5b409ea53000024_001",
              "question": "Thymoquinone is ineffective against radiation induced enteritis, yes or no?"
            }
          ],
          "context": "our findings suggest that gut symbiont - based probiotics can be used as agents for reversing radiation - induced ecological fitness decrease.\ntq might be used for radiation enteritis treatment.\n\n. radiation - induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.\ntq might be used for radiation enteritis treatment.\n\npossible effects for further study include increased rates of thyroid, breast, and lung cancers and multiple myeloma ; reduction of radiation risks of leukemia to population levels ; and increased morbidity and mortality of cleanup workers from cardio -\nrates of gastrointestinal side effects, headache, and depression.\n\npurpose this study was undertaken to investigate the effects of radiation dose, chemotherapy, and smoking on the risk of lung cancer following treatment of hodgkin's disease.\nthalidomide ( thal ) has antiangiogenic and immunomodulatory activity.\n"
        },
        {
          "qas": [
            {
              "id": "5e5d27531af46fc130000007_001",
              "question": "Has the Spanich flu virus been reconstructed?"
            }
          ],
          "context": "reconstruction of the 1918 influenza virus has facilitated considerable advancements in our understanding of this extraordinary pandemic virus.\nreconstruction of the 1918 virus and studies elucidating the exceptional virulence and transmissibility of the virus are providing exciting new insights into this devastating pandemic strain.\n"
        },
        {
          "qas": [
            {
              "id": "5e3a6c49b5b409ea53000017_001",
              "question": "Is Verubecestat effective for Alzheimer's Disease?"
            }
          ],
          "context": "these results support the continued global development of verubecestat as a potential disease - modifying agent for japanese and non - japanese subjects who are at - risk for developing ad.\nverubecestat did not reduce cognitive or functional decline in patients with mild - to - moderate alzheimer's disease and was associated with treatment - related adverse events. (\n\nthe lack of efficacy of verubecestat in mild - to - moderate ad raises important questions about the timing of intervention with bace - 1 inhibitors, and anti - amyloid therapies in general, in ad treatment.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\n\nthese results support the continued global development of verubecestat as a potential disease - modifying agent for japanese and non - japanese subjects who are at - risk for developing ad.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\n\nverubecestat is an inhibitor of \u03b2 - site amyloid precursor protein cleaving enzyme 1 ( bace1 ) being evaluated in clinical trials for the treatment of alzheimer's disease.\nthis reaction was applied to the preparation of verubecestat, which is currently undergoing clinical evaluation for the treatment of alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5e44c76f48dab47f26000022_001",
              "question": "Is Aptiganel effective for treatment of stroke?"
            }
          ],
          "context": ". the mortality rate at 120 days in patients treated with high - dose aptiganel was higher than that in patients who received placebo ( 26. 3 % vs 19. 2 % ; p =. 06 ).\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\n\nconclusions aptiganel was not efficacious in patients with acute ischemic stroke at either of the tested doses, and m ay be harmful.\n. the larger proportion of patients with favorable outcomes and lower mortality rate in the placebo group suggest that glutamate blockade with aptiganel may have detrimental effects in an undifferentiated population of stroke patients.\n"
        },
        {
          "qas": [
            {
              "id": "5e47656935b8f0833c000004_001",
              "question": "Is indinavir effective for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nneuroprotective agents are screened for use in patients with als.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n\nrates of gastrointestinal side effects, headache, and depression.\nprofile of cabotegravir and its potential in the treatment and prevention of hiv - 1 infection : evidence to date.\n"
        },
        {
          "qas": [
            {
              "id": "5e324167fbd6abf43b00005a_001",
              "question": "Is there an increased risk for meningiomas in childhood leukemia survivors?"
            }
          ],
          "context": "high incidence of meningioma in cranial irradiated survivors of childhood acute lymphoblastic leukemia.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\n\ncranial radiotherapy improves survival of the most common childhood cancers, including brain tumors and leukemia. unfortunately, long - term survivors are faced with consequences of secondary neoplasia, including radiation - induced meningiomas ( rims ).\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\n\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\n"
        },
        {
          "qas": [
            {
              "id": "5e540ed36d0a277941000054_001",
              "question": "Does saracatinib promote oncogenesis?"
            }
          ],
          "context": ". these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n\n. saracatinib blocked the src / fak, her family, and oncogenic signaling pathways, and it induced g ( 1 ) arrest and apoptosis in snu216 and nci - n87 cells.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\n\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n"
        },
        {
          "qas": [
            {
              "id": "5e2e0fa2fbd6abf43b00001f_001",
              "question": "Is BCL11B involved in schizophrenia?"
            }
          ],
          "context": "interacting partners bcl11b and gatad2a are also schizophrenia risk genes indicating that other genes interacting with or are regulated by satb2 are making a contribution to schizophrenia and cognition.\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\n\nneural stem cells induces neuronal and astrocyte differentiation, respectively.\nconsistent with the findings described in bcl11b - deficient mice\n\ninteracting partners bcl11b and gatad2a are also schizophrenia risk genes indicating that other genes interacting with or are regulated by satb2 are making a contribution to schizophrenia and cognition.\nconsistent with the findings described in bcl11b - deficient mice\n\n. taken together, we show here that mutations leading either to bcl11b haploinsufficiency or to a truncated bcl11b protein clinically cause a non - syndromic neurodevelopmental delay\nconsistent with the findings described in bcl11b - deficient mice\n"
        },
        {
          "qas": [
            {
              "id": "5e338cf5fbd6abf43b00005d_001",
              "question": "Are Chernobyl survivors at increased risk for breast cancer?"
            }
          ],
          "context": "an increase in breast cancer incidence has been reported in areas of belarus and ukraine contaminated by the chernobyl accident and has become an issue of public concern.\nhistorically, data from the chernobyl reactor accident 27 years ago demonstrated a strong correlation with thyroid cancer, but data on the radiation effects of chernobyl on breast cancer incidence have remained inconclusive.\n\nhistorically, data from the chernobyl reactor accident 27 years ago demonstrated a strong correlation with thyroid cancer, but data on the radiation effects of chernobyl on breast cancer incidence have remained inconclusive.\nfurthermore, the upward trends of increases in a variety of other tumors including breast cancer, cancers of central nervous system and renal cancer have been reported in the persons exposed to chornobyl fallout.\n\nan increase in breast cancer incidence has been reported in areas of belarus and ukraine contaminated by the chernobyl accident and has become an issue of public concern.\nfor breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the chernobyl accident.\n\nepidemiological cohort studies found increased incidence ( 1990 - 2012 gg. ) of thyroid cancer in victims of chernobyl accident ( liquidators - in 4. 6 times, evacuated - in 4. 0 times, residents of contaminated areas - in 1. 3 times ) and increased incidence\nfurthermore, the upward trends of increases in a variety of other tumors including breast cancer, cancers of central nervous system and renal cancer have been reported in the persons exposed to chornobyl fallout.\n"
        },
        {
          "qas": [
            {
              "id": "5d36b4817bc3fee31f000007_001",
              "question": "Is SATB1 necessary for T-cell maturation?"
            }
          ],
          "context": "thymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nthe transcription factor satb1 that regulates the t - cell maturation\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\n\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nthe transcription factor satb1 that regulates the t - cell maturation\nsatb1 is a cell - type specific nuclear protein that recruits chromatin - remodeling factors and regulates numerous genes during thymocyte differentiation.\n\npecial at rich sequence binding protein 1 ( satb1 ) plays a crucial role in the biology of various types of human cancer.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n"
        },
        {
          "qas": [
            {
              "id": "5e46bf743f54159529000008_001",
              "question": "Have toll-like receptor 2 activators been found in food?"
            }
          ],
          "context": "tlr2 activators are found in many common foods, but the role of tlr2 in oral tolerance and allergic sensitization to foods is not well understood.\n. tlr2 activators are found in many common foods,\n"
        },
        {
          "qas": [
            {
              "id": "5e33904afbd6abf43b00005f_001",
              "question": "Does radiotherapy for Hodgkin disease increases risk for lung cancer?"
            }
          ],
          "context": "background : long - term hodgkin lymphoma ( hl ) survivors have an increased risk of late cardiac morbidity and secondary lung cancer after chemotherapy and mediastinal radiotherapy.\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\n\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\nit is recognized that survivors of hodgkin's disease are at a substantially increased risk of lung cancer.\n\npurpose this study was undertaken to investigate the effects of radiation dose, chemotherapy, and smoking on the risk of lung cancer following treatment of hodgkin's disease.\npurpose : hodgkin lymphoma ( hl ) survivors face an increased risk of treatment - related lung cancer.\n\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\npurpose this study was undertaken to investigate the effects of radiation dose, chemotherapy, and smoking on the risk of lung cancer following treatment of hodgkin's disease.\n"
        },
        {
          "qas": [
            {
              "id": "5e33916afbd6abf43b000061_001",
              "question": "Does radiotherapy for prostate cancer increase bladder cancer risk?"
            }
          ],
          "context": "radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\n\nradiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\nradiation therapy for prostate cancer is associated with an increased risk of bladder cancer.\n\nradiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer ( bc ).\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\n\nradiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer : a population based cohort study.\nresults : during the median follow - up period of 4. 3 and 3. 1 years, secondary bladder cancer occurred in 11 ( 3. 4 % ) and 5 ( 1. 1 % ) of patients with prostate cancer treated with external beam radiotherapy and radical prostatectomy, respectively.\n"
        },
        {
          "qas": [
            {
              "id": "5e51a2d76d0a27794100003a_001",
              "question": "Do genes with monoallelic expression contribute proportionally to genetic diversity in humans?"
            }
          ],
          "context": "genome - wide association studies of complex physiological traits and diseases consistently found that associated genetic factors, such as allelic polymorphisms or dna mutations, only explained a minority of the expected heritable fraction\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\n\nour results suggest that recessive coding variants account for a small fraction of currently undiagnosed nonconsanguineous individuals, and that the role of noncoding variants, incomplete penetrance, and polygenic mechanisms need further exploration.\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\n\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\ndna effects were analysed in leukocytes using the alkaline comet assay, gene mutations and chromosome aberrations were measured in erythrocytes using the flow cytometric pig - a gene mutation assay and the micronucleus test ( applying both microscopic\n\nwe report the results of studies on the characterization of the mutation associated with marked unbalanced expression of the mutant x chromosome in a karyotypically normal girl with hunter disease ( mucopolysaccharidosis type ii ). so\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\n\nan unexpectedly large number of human autosomal genes are subject to monoallelic expression ( mae ). our analysis of 4, 227 such genes uncovers surprisingly high genetic variation across human populations\ncombining methylation data with mrna sequencing revealed that dna methylation in promoters, introns and exons may have different roles in regulating gene expression.\n"
        },
        {
          "qas": [
            {
              "id": "5e5437ffb761aafe09000002_001",
              "question": "Has MLE4901 been tested in phase III clinical trials?"
            }
          ],
          "context": "based on positive results from a phase i / ii clinical trial\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nmetastatic colorectal cancer patients who had received one prior treatment and had measurable disease were enrolled in this phase 2 study.\npatients meeting diagnostic criteria for crs were prospectively enrolled in a cross - sectional study\n\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\nwithout causing overt myelosuppression, and therefore may provide an important treatment option for a range of patients with myelofibrosis.\n\nbased on positive results from a phase i / ii clinical trial\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\n\n. of all subjects treated, 853 ( 95 % ) on lubeluzole and 826 ( 93 % ) on placebo reported an adverse event during their treatment period or within the next 2 days after discontinuation of treatment.\nresults : six participants were enrolled. all had adverse events, mostly behavioral. two completed the trial and the other four withdrew due to adverse events. all participants reported resolution of these events after discontinuation of the drug\n"
        },
        {
          "qas": [
            {
              "id": "5e5508e2b761aafe09000006_001",
              "question": "Does ESN364 activate the hypothalamic-pituitary-gonadal axis?"
            }
          ],
          "context": "oral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\nthe short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor\n\nthis system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\n\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\ns1p - induced foxo1 and ereg gene expression suggests that the activation of s1p - s1pr axis may cooperate with gonadotropins in modulating follicle development.\n\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\n\noral administration of the nk3r antagonist, esn364, suppressed the hypothalamic - pituitary - gonadal axis in healthy volunteers by selective modulation of gonadotropin secretion, leading to a restrained decrease in ovarian hormone levels in women.\nrates of gastrointestinal side effects, headache, and depression.\n"
        },
        {
          "qas": [
            {
              "id": "5e763645c6a8763d2300000d_001",
              "question": "Has ORMD-0801 been tested in patients?"
            }
          ],
          "context": "based on positive results from a phase i / ii clinical trial\nthe study was a 4 - week phase ib multiple ascending dose, randomized, double - blind, placebo - controlled trial of azd0530 in ad patients with mini - mental state examination ( mmse ) scores ranging from 16 to 26.\n\nin efforts to provide patients with a more compliable treatment method, oramed pharmaceuticals tested the capacity of its oral insulin capsule ( ormd - 0801, 8 mg insulin ) in addressing this resistant clinical state.\nbased on positive results from a phase i / ii clinical trial\n\nno significant difference was detected in the proportion of patients with favorable six - month gose in either study group ( odds ratio ( or ) : 1. 49 ; 95 % confidence interval ( ci ) : 0. 43 - 5. 17 )\n. 20 ( 50 % ) of 40 participants reported adverse events in each group.\n\nin efforts to provide patients with a more compliable treatment method, oramed pharmaceuticals tested the capacity of its oral insulin capsule ( ormd - 0801, 8 mg insulin ) in addressing this resistant clinical state.\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\n\nin efforts to provide patients with a more compliable treatment method, oramed pharmaceuticals tested the capacity of its oral insulin capsule ( ormd - 0801, 8 mg insulin ) in addressing this resistant clinical state.\nfor the treatment of adults with newly diagnosed therapy - related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia - related changes.\n"
        },
        {
          "qas": [
            {
              "id": "5e763c3fc6a8763d23000010_001",
              "question": "Was vivotif licensed in Europe and the US at the same time?"
            }
          ],
          "context": "usa, there has been much controversy about the implementation of this prep regimen in other countries throughout the world, and in europe in particular.\nvivotif\u00ae is an oral live attenuated vaccine which contains a mutated strain of salmonella ( ty21a ) and reproduces the natural infection\n\nusa, there has been much controversy about the implementation of this prep regimen in other countries throughout the world, and in europe in particular.\n. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.\n\ntecovirimat : first global approval.\n. the vaccine was first licensed in europe in 1983 and in the us in 1989, and over the years it has proved efficacious and safe.\n\nusa, there has been much controversy about the implementation of this prep regimen in other countries throughout the world, and in europe in particular.\nin the usa, refractory gmg in the eu, or gmg with symptoms that are difficult to control with high - dose ivig therapy or plex in japan.\n\nin august 1998 the food and drug administration in the united states approved the licensure of a rotavirus vaccine.\ntecovirimat : first global approval.\n"
        },
        {
          "qas": [
            {
              "id": "5e43090d48dab47f26000011_001",
              "question": "Are stem cell transplants used to treat acute kidney injury?"
            }
          ],
          "context": "risk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on acute kidney injury network criteria.\nanimal studies have shown that mesenchymal stromal cell ( msc ) infusions improve acute kidney injury ( aki ) outcomes when administered early after ischemic / reperfusion injury or within 24 hours after cisplatin administration.\n\nearly diagnostic markers for detection of acute kidney injury in allogeneic hematopoietic stem cell transplant recipients.\nrisk assessment for acute kidney injury after allogeneic hematopoietic stem cell transplantation based on acute kidney injury network criteria.\n\nearly diagnostic markers for detection of acute kidney injury in allogeneic hematopoietic stem cell transplant recipients.\noptions for the anemia of chronic kidney disease.\n"
        },
        {
          "qas": [
            {
              "id": "5e51dab06d0a27794100003d_001",
              "question": "Is deletion at 6q24.2-26 associated with shorter survival for ovarian cancer patients?"
            }
          ],
          "context": ". altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\n\n. altogether our findings indicate that the 6q24. 2 - 26 deletion is an independent marker of favorable outcome in hgsocs with potential clinical value as it can be analyzed by fish on tumor sections and guide the selection of patients towards more\nwe found that loss at 6q24. 2 - 26 was significantly associated with the cluster of longer survival independently from other confounding factors ( hr = 0. 06, 95 % ci = 0. 01 - 0. 43, padj = 0. 005 )\n\nlonger survival of high - grade serous ovarian cancer patients.\nwe aimed to evaluate the prognostic and predictive value of the nucleotide excision repair - related gene gtf2h5, which is localized at the 6q24. 2 - 26 deletion previously reported by our group to predict longer survival of high - grade serous ovarian\n"
        },
        {
          "qas": [
            {
              "id": "5d35eb01b3a638076300000f_001",
              "question": "Are there negative enhancers?"
            }
          ],
          "context": "repressed or display condition - specific enhancer activity.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\n\nclones in which the transgene was down - regulated by dexamethasone survived and were designated att - 20 / net ( for negative enhancer trap ).\nmutations targeted to the carg - like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation\n\nclones in which the transgene was down - regulated by dexamethasone survived and were designated att - 20 / net ( for negative enhancer trap ).\n. our results suggest that the activity of the negative enhancer may determine the level of expression of the cox vb gene in different tissue\n\n. over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.\nmutations targeted to the carg - like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation\n\nthe site was similar to silencers, or negative enhancers, in that it acted to repress transcription from outside the transcribed region, but was distinct in that the function of a canonical silencer was independent of orientation.\nmutations targeted to the carg - like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation\n"
        },
        {
          "qas": [
            {
              "id": "5e540db06d0a277941000053_001",
              "question": "Has saracatinib been tested in clinical trials?"
            }
          ],
          "context": "saracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\na phase ii study of saracatinib ( azd0530 ), a src inhibitor, administered orally daily to patients with advanced thymic malig \" \" cies.\n"
        },
        {
          "qas": [
            {
              "id": "5e500d8c6d0a277941000035_001",
              "question": "Is \u03b1CGRP a member of the CGRP family?"
            }
          ],
          "context": "multiple sclerosis, neuropathic pain, medication overuse headache, stroke, opioid, alcohol and methamphetamine abuse.\ngiving additional cgrp - based therapeutic options for migraine patients.\n\n. these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\ntherefore, in this work, we investigated the amyloidogenic profile of \u03b1cgrp, a 37 - residue - long peptide hormone, utilizing both biophysical experimental techniques and molecular dynamics simulations\n\n. these efforts unravel a novel amyloidogenic member of the cgrp family and provide insights into the mechanism underlying the \u03b1cgrp polymerization.\nbackground galcanezumab is a humanized monoclonal antibody that selectively binds to the calcitonin gene - related peptide ( cgrp ) and has demonstrated efficacy in reducing migraine headache days ( mhd ) in patients with episodic and chronic migraine.\n"
        },
        {
          "qas": [
            {
              "id": "5e44c33a48dab47f26000020_001",
              "question": "Can Enlimomab improve stroke outcomes?"
            }
          ],
          "context": ". in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment.\nmany researchers have recognized the positive effects of fty720 and launched basic and clinical experiments to test the use of this agent against stroke\n\ntreatment with a murine anti - icam - 1 antibody ( enlimomab ) has been investigated in patients with acute ischemic stroke in the enlimomab acute stroke trial ( east )\nconclusions doses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 + / - 10 days.\n\nhowever, this treatment failed to show benefit in the enlimomab acute stroke trial.\nconclusions doses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 + / - 10 days.\n\n. the negative effect of enlimomab was apparent on days 5, 30, and 90 of treatment ( p = 0. 005 ). there were significantly more adverse events with enlimomab treatment than placebo, primarily infections and fever.\nconclusions doses of enlimomab between 140 and 480 mg administered over 5 days did not increase the risk of adverse events in patients with ischaemic or haemorrhagic stroke during an observation period of 30 + / - 10 days.\n"
        },
        {
          "qas": [
            {
              "id": "5d384ce87bc3fee31f000013_001",
              "question": "Does GRHL2 over-expression lead to EMT?"
            }
          ],
          "context": "grhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\ntranscription factor - - grainyhead - like 2 ( grhl2 ) maintains the epithelial phenotype\n\ngrhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\n. furthermore, overexpression of targetable immune checkpoints, such as ctla - 4 and tim - 3 were associated with emt in both nsclcs.\n\ngrhl2 plays an essential role in the determination of epithelial phenotype of breast cancers, emt and tumor progression.\ninterestingly, we could further demonstrate that expression of grhl2 is directly suppressed by the transcription factor zinc finger enhancer - binding protein 1 ( zeb1 ), which in turn is a direct target for repression by grhl2, suggesting that the emt\n"
        },
        {
          "qas": [
            {
              "id": "5e7f5cc5835f4e4777000015_001",
              "question": "Is the Fluzone intradermal and the Fluzone intradermal quadrivalent vaccine produced by different companies?"
            }
          ],
          "context": "covid - 19 vaccine causing guillain - barre syndrome, a rare potential side effect.\n. in advance of the 2015 - 2016 season, fluzone intradermal was replaced with fluzone intradermal quadrivalent vaccine, which contains 9 \u00b5g hemagglutinin per strain of the two a - strain viruses and both b - strain lineage viruses ( victoria and yamagata ).\n\n. in advance of the 2015 - 2016 season, fluzone intradermal was replaced with fluzone intradermal quadrivalent vaccine, which contains 9 \u00b5g hemagglutinin per strain of the two a - strain viruses and both b - strain lineage viruses ( victoria and yamagata ).\npasteur ), became available in the us during the 2011 - 2012 influenza season for adults 18 - 64 years of age\n\nan intradermal version of fluzone\u00ae split - virion inactivated trivalent influenza vaccine, containing 9 \u00b5g hemagglutinin per strain of a / h1n1, a / h3n2, and one b lineage virus ( fluzone intradermal, sanofi pasteur ), became available in the us during the\n. in advance of the 2015 - 2016 season, fluzone intradermal was replaced with fluzone intradermal quadrivalent vaccine, which contains 9 \u00b5g hemagglutinin per strain of the two a - strain viruses and both b - strain lineage viruses ( victoria and yamagata ).\n"
        },
        {
          "qas": [
            {
              "id": "5e821ac5835f4e4777000031_001",
              "question": "Is endotrophin derived from collagen?"
            }
          ],
          "context": "high levels of col6a3 and its cleaved product, endotrophin ( etp )\nendotrophin production from type iv collagen\n\nmatrix molecules in human renal proximal tubular cells ( hkcs ) induced by high glucose, to provide help for renal tubulointerstitial fibrosis therapy.\nendotrophin production from type iv collagen\n\nendotrophin is released from col vi\nendotrophin production from type iv collagen\n\nendotrophin is released from col vi\nhigh levels of col6a3 and its cleaved product, endotrophin ( etp )\n\nhigh levels of col6a3 and its cleaved product, endotrophin ( etp )\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n"
        },
        {
          "qas": [
            {
              "id": "5e7f6090835f4e477700001a_001",
              "question": "Can Daptacel be used instead of IPOL?"
            }
          ],
          "context": "tetanus, 5 - component acellular pertussis vaccine [ dtap ( 5 ) ; daptacel ], inactivated poliovirus vaccine [ ipv ; ipol ], and haemophilus influenzae type b [ hib ] vaccine [ acthib ] ), when administered to infants and toddlers concomitantly with other routinely\nten pneumococcal vaccine serotypes, protein d, antipolyribosyl - ribitol phosphate, antidiphtheria, antitetanus, and antipertactin.\n\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\ntetanus, 5 - component acellular pertussis vaccine [ dtap ( 5 ) ; daptacel ], inactivated poliovirus vaccine [ ipv ; ipol ], and haemophilus influenzae type b [ hib ] vaccine [ acthib ] ), when administered to infants and toddlers concomitantly with other routinely\n\nonce - daily oral daprodustat treatment was generally well tolerated and mean hemoglobin was achieved and maintained within the target range in japanese peritoneal dialysis participants.\nrates of gastrointestinal side effects, headache, and depression.\n\ntetanus, 5 - component acellular pertussis vaccine [ dtap ( 5 ) ; daptacel ], inactivated poliovirus vaccine [ ipv ; ipol ], and haemophilus influenzae type b [ hib ] vaccine [ acthib ] ), when administered to infants and toddlers concomitantly with other routinely\nin this randomized, multicenter study, 1939 healthy infants were immunized at 2, 4, and 6 months of age with 1 of 3 lots of dtap ( 5 ) coadministered with ipv and hib vaccines or 1 lot of dtap ( 5 ) - ipv - hib combination vaccine.\n"
        },
        {
          "qas": [
            {
              "id": "5e806ff7835f4e4777000027_001",
              "question": "Is ACE2 expressed on cell surfaces?"
            }
          ],
          "context": "the viral spike glycoprotein ( s ) utilizes angiotensin - converting enzyme 2 ( ace2 ) as a host protein receptor and mediates fusion of the viral and host membranes, making s essential to viral entry into host cells and host species tropism.\nangiotensin - converting enzyme 2 ( ace2 ), a relatively new member of the ras, has drawn extensive attention since 2003, because of the findings that ace2 is the receptor for sars corona virus and that mainte \" \" ce of normal ace2 levels in the lung is\n\nthe infection of target cells by the sars cov is mediated through the interaction of the viral spike ( s ) protein ( 1255 amino acids ) and its cellular receptor, angiotensin - converting enzyme 2 ( ace2 ).\nthe viral spike glycoprotein ( s ) utilizes angiotensin - converting enzyme 2 ( ace2 ) as a host protein receptor and mediates fusion of the viral and host membranes, making s essential to viral entry into host cells and host species tropism.\n\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\nangiotensin - converting enzyme 2 ( ace2 ), a relatively new member of the ras, has drawn extensive attention since 2003, because of the findings that ace2 is the receptor for sars corona virus and that mainte \" \" ce of normal ace2 levels in the lung is\n\ncell entry studies demonstrated that three newly identified sarsr - covs with different s protein sequences are all able to use human ace2 as the receptor\nangiotensin - converting enzyme 2 ( ace2 ), a relatively new member of the ras, has drawn extensive attention since 2003, because of the findings that ace2 is the receptor for sars corona virus and that mainte \" \" ce of normal ace2 levels in the lung is\n\nace2 is a type 1 integral membrane protein and contains a catalytically active ectodomain that can be shed from the cell surface into the extracellular space,\nrecent studies reported that shedding of the enzymatically active ectodomain of ace2 from the cell surface\n"
        },
        {
          "qas": [
            {
              "id": "5e7744c3835f4e4777000005_001",
              "question": "Can leuprorelin acetate be used as androgen deprivation therapy?"
            }
          ],
          "context": "facing serious cerebrovascular conditions, the predicted risk of secondary tumors, particularly in the youngest patients and those undergoing multiple procedures, is sobering.\nof patients with nsclc of squamous histology ; therefore, clinical development of this class of agents will need to proceed with caution.\n\neyelash trichomegaly is an uncommon drug - associated sequelae experienced during treatment with epidermal growth factor receptor ( egfr ) inhibitors\nrates of gastrointestinal side effects, headache, and depression.\n\nconclusions : oral daprodustat was noninferior to cera in achieving and maintaining target hemoglobin levels in japanese nd patients.\nmolecular diagnosis of 5\u03b1 - reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism.\n\ncastration - resistant prostate cancer in clinical practice.\nolaparib targets some advanced prostate cancers.\n\nour data clearly demonstrate that 5\u03b1 - reductase deficiency should be considered in xy adolescents with primary amenorrhea and no breast development associated with virilization at puberty and high plasma t\nmolecular diagnosis of 5\u03b1 - reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism.\n"
        },
        {
          "qas": [
            {
              "id": "5e6e35b07fc1ee872b000004_001",
              "question": "Are astrocytes part of the blood brain barrier?"
            }
          ],
          "context": "administration and protection from covid - 19 and influenza for those in need.\n. t\n\nthe blood - brain barrier ( bbb ) is a tight boundary formed between endothelial cells and astrocytes, which separates and protects brain from most pathogens as well as neural toxins in circulation.\nthe blood - brain barrier ( bbb ) consists of endothelial cells, astrocytes, and pericytes embedded in basal lamina ( bl ).\n"
        },
        {
          "qas": [
            {
              "id": "5e639a8b1af46fc130000011_001",
              "question": "Is Li\u2013Fraumeni syndrome a rare, autosomal recessive, hereditary disorder that predisposes carriers to cancer development?"
            }
          ],
          "context": "li - fraumeni syndrome is a rare autosomal domi \" \" t cancer predisposition syndrome.\nli - fraumeni syndrome ( lfs ), a multiorgan cancer predisposition caused by germline tp53 mutations, confers significant cancer risks for young people ( 15 - 39 years )\n\nli - fraumeni syndrome ( lfs ) is a rare hereditary cancer syndrome associated with an autosomal domi \" \" t mutation inheritance in the tp53 tumor suppressor gene and a wide spectrum of cancer diagnoses.\nli - fraumeni syndrome ( lfs ) is a rare cancer predisposition syndrome inherited in an autosomal domi \" \" t fashion that involves a germline mutation of tumor protein 53 ( tp53 ).\n\nli - fraumeni syndrome ( lfs ) is a rare hereditary autosomal domi \" \" t cancer disorder.\nli - fraumeni syndrome is a rare autosomal domi \" \" t cancer predisposition syndrome.\n\nli - fraumeni syndrome ( lfs ) is an autosomal domi \" \" t hereditary cancer disorder.\nli - fraumeni syndrome ( lfs ) is a rare cancer predisposition syndrome inherited in an autosomal domi \" \" t fashion that involves a germline mutation of tumor protein 53 ( tp53 ).\n\nli - fraumeni syndrome ( lfs ), a multiorgan cancer predisposition caused by germline tp53 mutations, confers significant cancer risks for young people ( 15 - 39 years )\nli - fraumeni syndrome is a rare autosomal domi \" \" t cancer predisposition syndrome.\n"
        },
        {
          "qas": [
            {
              "id": "5e776c72835f4e477700000e_001",
              "question": "Has the drug Afrezza been approved by the FDA?"
            }
          ],
          "context": "despite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\n. afrezza has been marketed since february, 2015 by sanofi after getting fda approval in june 2014.\n"
        },
        {
          "qas": [
            {
              "id": "5e8220e6835f4e4777000032_001",
              "question": "Is Protoporphyrinogen oxidase localized to the mitochondrium?"
            }
          ],
          "context": "based on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nthe selenoenzyme gpx4 is essential for early embryogenesis and cell viability for its unique function to prevent phospholipid oxidation.\n\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nhereditary polyneuropathy with optic atrophy due to pdxk variant leading to impaired vitamin b6 metabolism\n\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nin the present study, pfppo has been cloned, expressed and shown to be localized to the mitochondrion by immunofluorescence microscopy.\n\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nthe effects of two nrf2 activators, bardoxolone methyl and omaveloxolone, on retinal ganglion cell survival during ischemic optic neuropathy.\n\nbased on our results we propose a mechanism for protoporphyrinogen oxidase targeting to the mitochondrion.\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\n"
        },
        {
          "qas": [
            {
              "id": "5e36d498b5b409ea53000008_001",
              "question": "Do de novo truncating mutations in WASF1 cause cancer?"
            }
          ],
          "context": ". functional studies using fibroblast cells from two affected individuals with the c. 1516c > t mutation showed a truncated wasf1 and a defect in actin remodeling\n. this study provides evidence that de novo heterozygous mutations in wasf1 cause a rare form of intellectual disability.\n\namong them, the most studied is werner's syndrome, \" adult progeria \", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in dna repair.\n. this study provides evidence that de novo heterozygous mutations in wasf1 cause a rare form of intellectual disability.\n\nde novo truncating mutations in wasf1 cause intellectual disability with seizures.\n. this study provides evidence that de novo heterozygous mutations in wasf1 cause a rare form of intellectual disability.\n"
        },
        {
          "qas": [
            {
              "id": "5e64ed381af46fc130000015_001",
              "question": "Are ICAMS, Intracellular Adhesion Molecules, part of the immunoglobulin superfamily?"
            }
          ],
          "context": "intercellular adhesion molecule - 1 ( icam - 1 ), vascular cell adhesion molecule - 1 ( vcam - 1 ) and platelet - endothelial cell adhesion molecule - 1 ( pecam - 1 ) are members of the immunoglobulin super - family which are present on the surface of endothelial cells.\nintracellular adhesion molecule 1 ( icam - 1 ) is an adhesion - related molecule belonging to the immunoglobulin superfamily.\n\nthe intercellular adhesion molecules ( icams ) are members of the immunoglobulin superfamily and have been identified to play major roles in inflammation and immune responses.\nintercellular adhesion molecules ( icams ) belong to the immunoglobulin superfamily and participate in diverse cellular processes including host - pathogen interactions.\n\nintercellular adhesion molecules ( icams ) belong to the immunoglobulin superfamily and participate in diverse cellular processes including host - pathogen interactions.\nthe intercellular adhesion molecules ( icams ) are members of the immunoglobulin superfamily and have been identified to play major roles in inflammation and immune responses.\n"
        },
        {
          "qas": [
            {
              "id": "5e57fa23b761aafe09000008_001",
              "question": "Is traditional Chinese medicine associated with a decreased risk of heart failure in breast cancer patients receiving doxorubicin treatment?"
            }
          ],
          "context": "the risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\ndoxorubicin, bleomycin, vinblastine sulfate, and dacarbazine ( abvd ) is associated with severe toxicity in older patients, particularly from bleomycin - induced lung toxicity ( blt ). ther\n\nthis analysis was conducted to evaluate whether anemia is a risk factor for kidney function decrease in patients with heart failure.\nboth acupotomy and acupuncture have been widely used clinically to treat csr in china with satisfied efficacy.\n\nusing tcm significantly decreased the incidence of chf in patients with breast cancer who received conventional chemotherapy with or without radiotherapy.\noxidative stress and cancer ; the role of hesperidin, a citrus natural bioflavonoid, as a cancer chemoprotective agent.\n\nin addition, preclinical and early clinical evidence suggests that chemotherapy and radiation may work synergistically with anti - pd - 1 / pd - l1 therapy to promote antitumor immunity, which has led to the initiation of clinical trials testing these drugs\nusing tcm significantly decreased the incidence of chf in patients with breast cancer who received conventional chemotherapy with or without radiotherapy.\n\nthe risk of lung and breast cancer is significantly increased after therapy for hodgkin's disease ( hd ), but there are few data that describe the molecular profiles of these tumors.\nusing tcm significantly decreased the incidence of chf in patients with breast cancer who received conventional chemotherapy with or without radiotherapy.\n"
        },
        {
          "qas": [
            {
              "id": "5e6df5b51af46fc130000025_001",
              "question": "Is PTEN a tumour suppressor?"
            }
          ],
          "context": "pten is a potent tumour suppressor\ngenomic aberrations of the pten tumour suppressor gene are among the most common in prostate cancer.\n\npten is a potent tumour suppressor\ninhibition of the erk1 / 2 pathway relies largely on ampk activation\n"
        },
        {
          "qas": [
            {
              "id": "5d387098a1e1595105000006_001",
              "question": "Is the tyrosine kinase BTK implicated in autoimmunity?"
            }
          ],
          "context": "btk function in b cells in the context of host defense and autoimmunity.\nautoimmunity was fully dependent on btk kinase activity, because btk inhibitor treatment ( pci - 32765 ) could normalize b - cell activation and differentiation, and because autoantibodies were absent in btk transgenic mice overexpressing a kinase inactive\n\nautoimmunity, hypersensitivity to b cell receptor ( bcr ) cross - linking, and splenomegaly caused by myeloerythroid hyperplasia were alleviated by btk deficiency in lyn - / - mice.\ngiven the phenotype of affected patients, namely lack of b - lymphocytes and plasma cells with the ensuing inability to mount humoral immune responses, btk inhibitors were anticipated to have beneficial effects on antibody - mediated pathologies, such as\n\nbruton's tyrosine kinase ( btk ) is a proximal transducer of the bcr signal that allows for b - cell activation and differentiation\nbtk function in b cells in the context of host defense and autoimmunity.\n\n. recently, selective inhibition of btk by pci - 32765 has shown promise in limiting activity of multiple cells types in various models of cancer and autoimmunity.\nautoimmunity was fully dependent on btk kinase activity, because btk inhibitor treatment ( pci - 32765 ) could normalize b - cell activation and differentiation, and because autoantibodies were absent in btk transgenic mice overexpressing a kinase inactive\n"
        },
        {
          "qas": [
            {
              "id": "5d387721a1e159510500000c_001",
              "question": "Is induction of interferon by TLR7 higher in males?"
            }
          ],
          "context": "in response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\nin sle post - transplant, recurrent disease activity and induction of irf7 protein expression correlated with activation of the ifn signature.\n\ntoll - like receptor 9 ( tlr9 ) activation is attributed to delivery of bacterial dna\n. haplotype analysis confirmed the differential distribution of tlr7 variants between the groups. within the group of female patients with chronic hcv - infection, c. 32t was predictive of an unfavourable outcome of interferon - alpha therapy ( p < 0. 05 )\n\n. haplotype analysis confirmed the differential distribution of tlr7 variants between the groups. within the group of female patients with chronic hcv - infection, c. 32t was predictive of an unfavourable outcome of interferon - alpha therapy ( p < 0. 05 )\nwe found that cdcs from prediseased tcsle male mice express the ifn signature as female tcsle cdcs do. estrogens are necessary but not sufficient to express this ifn signature, but high doses of e2 can compensate for other steroidal components.\n"
        },
        {
          "qas": [
            {
              "id": "5e64f1921af46fc130000018_001",
              "question": "Is there a vaccine for rotavirus?"
            }
          ],
          "context": "urgency of introducing a vaccine to help control rotavirus disease\nrotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\n\nurgency of introducing a vaccine to help control rotavirus disease\nis there evidence that rotavirus vaccines are effective in preventing acute gastroenteritis complications such as dehydration and hospitalization\n\neffectiveness of rotavirus pentavalent vaccine\nimpact of rotavirus vaccines on rotavirus disease\n\nus rotavirus vaccine efficacy group.\nrotavirus vaccine was licensed on august 31, 1998, and subsequently recommended for routine use among infants.\n\nintussusception cases that may be associated with rotavirus vaccine.\nrisk of intussusception after monovalent rotavirus vaccination.\n"
        },
        {
          "qas": [
            {
              "id": "5e2d7ceefbd6abf43b00000b_001",
              "question": "Is BNN20 involved in Parkinson's disease?"
            }
          ],
          "context": ". thus bnn - 20 could be proposed for treatment of pd.\n. these results could be of clinical relevance, as they suggest bnn - 20 as an important neuroprotective agent acting through the trkb neurotrophin receptor pathway, mimicking the action of the endogenous neurotrophin bdnf\n"
        },
        {
          "qas": [
            {
              "id": "5e35d3c6158f994d3a000003_001",
              "question": "Is there a role for MRPL53 in cancer?"
            }
          ],
          "context": "here we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n. mrpl53 ( 2p13. 1 ) encodes a 39s protein subunit of mitochondrial ribosomes and interacts with myc, a transcription factor required for normal facial morphogenesis.\n\n. mrpl53 ( 2p13. 1 ) encodes a 39s protein subunit of mitochondrial ribosomes and interacts with myc, a transcription factor required for normal facial morphogenesis.\nmultiforme, mantle cell lymphoma, and metastatic melanoma.\n\n. mrpl53 ( 2p13. 1 ) encodes a 39s protein subunit of mitochondrial ribosomes and interacts with myc, a transcription factor required for normal facial morphogenesis.\nin this work, we investigated the role and regulatory mechanism of lncrna prostate cancer - associated transcript 6 ( pcat6 ) in breast cancer progression.\n\ntargeting plk1 to enhance efficacy of olaparib in castration - resistant prostate cancer\nintegrating therapeutic strategies to target tams to complement conventional therapies has yielded promising results in preclinical trials and warrants further investigation to determine its translational benefit in human cancer patients.\n\n. mrpl53 ( 2p13. 1 ) encodes a 39s protein subunit of mitochondrial ribosomes and interacts with myc, a transcription factor required for normal facial morphogenesis.\n. we therefore conclude that srrm4 acts as a proliferation brake, and tumors gain a selective advantage by cutting off this brake.\n"
        },
        {
          "qas": [
            {
              "id": "5e36a4b7b5b409ea53000003_001",
              "question": "Does Uc.63+ promote sensitivity to treatment in prostate cancer?"
            }
          ],
          "context": ". these results substantially support the important role that uc. 63 + plays in pc progression by interacting with mir - 130b and indicate that uc. 63 + could potentially be a promising serum marker for deciding the best treatment for patients with crpc.\nof advanced urothelial carcinoma in first - and second - line treatment setting.\n\n. these results substantially support the important role that uc. 63 + plays in pc progression by interacting with mir - 130b and indicate that uc. 63 + could potentially be a promising serum marker for deciding the best treatment for patients with crpc.\nprolonging the survival of small cell lung cancer patients.\n\n. these results substantially support the important role that uc. 63 + plays in pc progression by interacting with mir - 130b and indicate that uc. 63 + could potentially be a promising serum marker for deciding the best treatment for patients with crpc.\nfurthermore, overexpression of uc. 63 + increased the expression of ar and its downstream molecule psa and promoted resistance to docetaxel through ar regulation\n\ncastration - resistant prostate cancer in clinical practice.\n. in patients treated with docetaxel, the expression of serum uc. 63 + in the docetaxel - resistant patients was higher than that in the docetaxel - sensitive patients ( p = 0. 011 )\n\nradiotherapy for prostate cancer is associated with an increased incidence of secondary bladder cancer ( bc ).\n. these results substantially support the important role that uc. 63 + plays in pc progression by interacting with mir - 130b and indicate that uc. 63 + could potentially be a promising serum marker for deciding the best treatment for patients with crpc.\n"
        },
        {
          "qas": [
            {
              "id": "5e2b3d97fbd6abf43b00000a_001",
              "question": "Does BNN27 promote memory loss?"
            }
          ],
          "context": ". the present study was designed to investigate the effects of bnn27 on recognition memory in rats\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\n\n. these results could be of clinical relevance, as they suggest bnn - 20 as an important neuroprotective agent acting through the trkb neurotrophin receptor pathway, mimicking the action of the endogenous neurotrophin bdnf\n. these findings suggest that bnn27 may modulate different aspects of recognition memory, potentially interacting with the cholinergic system, relevant to cognition.\n"
        },
        {
          "qas": [
            {
              "id": "5e4946bf6d0a277941000005_001",
              "question": "Are genomic regulatory blocks (GRBs) any different than TADs?"
            }
          ],
          "context": "clusters of cnes define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks ( grbs )\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n\nrecent studies of tad boundaries disrupted in engineered mouse models show that boundary mutations can recapitulate human developmental disorders as a result of aberrant promoter - enhancer interactions in the affected tads.\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n\n. here, we show that clusters of cnes strongly coincide with topological organisation, predicting the boundaries of hundreds of topologically associating domains ( tads ) in human and drosophila\n. around the same time, it was also shown that the genome of saccharomyces cerevisiae is organized in topologically associated domains ( tads ), which are largely associated with the replication timing.\n\n. their function and distribution around important regulatory genes raises the question of how they relate to 3d conformation of these loci\nclusters of cnes define the span of regulatory inputs for many important developmental regulators and have been described previously as genomic regulatory blocks ( grbs )\n\n. the set of tads that are associated with high levels of noncoding conservation exhibit distinct properties compared to tads devoid of extreme noncoding conservation\nhowever, it is not clear to which extent tad regions are conserved in evolution and whether disruption of tads by evolutionary rearrangements can alter gene expression.\n"
        },
        {
          "qas": [
            {
              "id": "5e67bc121af46fc13000001c_001",
              "question": "Are Spinal Intradural Primary Malignant Peripheral Nerve Sheath Tumors(MPNST) rare in neurofibromatosis patients?"
            }
          ],
          "context": "this article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nspinal intradural primary malig \" \" t peripheral nerve sheath tumors ( mpnst ) are rare in patients without neurofibromatosis.\n\nspinal intradural primary malig \" \" t peripheral nerve sheath tumors ( mpnst ) are rare in patients without neurofibromatosis.\nprimary malig \" \" t peripheral nerve sheath tumors ( mpnsts ) are extremely rare in patients without a history of neurofibromatosis ; only 18 cases have been reported in the english - language literature to this point.\n"
        },
        {
          "qas": [
            {
              "id": "5e776541835f4e4777000009_001",
              "question": "Can MVA85A confer immunity against smallpox?"
            }
          ],
          "context": "modified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\nsmallpox antiviral currently in the us strategic national stockpile ), and has a resistance profile that reduces concerns in the scenario of a bioterror attack using genetically engineered smallpox.\n\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\nwe assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus ankara expressing antigen 85a ( mva85a ), in adults infected with hiv - 1.\n\na randomized, double - blind, placebo - controlled phase ii trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine ( mva - bn\u00ae ) in 56 - 80 - year - old subjects.\nwe assessed the safety, immunogenicity, and efficacy of a candidate tuberculosis vaccine, modified vaccinia virus ankara expressing antigen 85a ( mva85a ), in adults infected with hiv - 1.\n\na randomized, double - blind, placebo - controlled phase ii trial investigating the safety and immunogenicity of modified vaccinia ankara smallpox vaccine ( mva - bn\u00ae ) in 56 - 80 - year - old subjects.\nmodified vaccinia ankara virus ( mva ) is a smallpox vaccine candidate.\n"
        },
        {
          "qas": [
            {
              "id": "5e6e2c1e7fc1ee872b000002_001",
              "question": "Is MLL3 part of the ASCOM complex?"
            }
          ],
          "context": ". their function and distribution around important regulatory genes raises the question of how they relate to 3d conformation of these loci\nhe negative regulation of transcription mediated by these reiterated cis - acting elements and trans - acting factor ( s ) may play an essential role in the expression of the canp ml gene.\n\nmll3 as part of activating signal cointegrator - 2 - containing complex ( ascom )\ncomet assay as a tool to screen for mouse models with inherited radiation sensitivity.\n\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\nmll3 as part of activating signal cointegrator - 2 - containing complex ( ascom )\n\nepigenetic changes enforced by various environmental and lifestyle factors lead to heritable modifications.\nepigenetic change, which does not involve alteration to the nucleotide sequence, can also cause changes in gene activity by changing the structure of chromatin through dna methylation or histone modifications.\n"
        },
        {
          "qas": [
            {
              "id": "5e476da1d14c9f295d000002_001",
              "question": "Is marimastat effective for small-cell lung cancer?"
            }
          ],
          "context": "background lung cancer is a frequent cause of death in patients cured of hodgkin's disease, but the contributions of chemotherapy, radiotherapy, and smoking are not well described.\nprolonging the survival of small cell lung cancer patients.\n\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n\nrates of gastrointestinal side effects, headache, and depression.\nconclusion : treatment with marimastat after induction therapy for sclc did not result in improved survival and had a negative impact on quality of life.\n\nthere were no significant differences in survival in a non - small cell lung cancer prinomastat study, and in a small cell lung cancer marimastat trial.\nthe phase iii trial in small cell lung cancer was discontinued when the results of study 140 were released in february 2001 showing that marimastat was not significantly more effective than placebo in prolonging the survival of small cell lung cancer\n"
        },
        {
          "qas": [
            {
              "id": "5e4b64126d0a277941000028_001",
              "question": "Is Figitumumab effective for non-small cell lung cancer?"
            }
          ],
          "context": "one recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nphase iii trials of the anti - insulin - like growth factor type 1 receptor ( igf - ir ) antibody figitumumab ( f ) in unselected non - small - cell lung cancer ( nsclc ) patients were recently discontinued owing to futility.\n\nphase iii trials of the anti - insulin - like growth factor - 1 receptor ( igf1r ) antibody figitumumab in non - small cell lung cancer ( nsclc ) patients have been discontinued owing to lack of survival benefit.\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\n"
        },
        {
          "qas": [
            {
              "id": "5e3ab58db5b409ea5300001c_001",
              "question": "The LINCS L1000 data set contains gene expression data for drug treated human cells, yes or no?"
            }
          ],
          "context": "the library of integrated network - based cellular signatures ( lincs ) l1000 data set currently comprises of over a million gene expression profiles of chemically perturbed human cell lines.\nthe lincs l1000 data repository contains almost two million gene expression profiles for thousands of small molecules and drugs.\n\nthe ge data is from the library of integrated network - based cellular signatures ( lincs ) l1000 dataset that measured changes in ge before and after treatment of human cells with over 20 000 small - molecule compounds including most of the fda - approved\nthe library of integrated network - based cellular signatures ( lincs ) l1000 data set currently comprises of over a million gene expression profiles of chemically perturbed human cell lines.\n"
        },
        {
          "qas": [
            {
              "id": "5e46bdcd3f54159529000007_001",
              "question": "Is there a vaccine for peanut allergy?"
            }
          ],
          "context": "recent advances in immunotherapy and vaccine development for peanut allergy.\ncurrently, two forms of peanut immunotherapy, oral immunotherapy ( oit ) and epicutaneous immunotherapy ( epit ), are in phase iii clinical trials and have shown promise to induce desensitization in many subjects\n\nrecent advances in immunotherapy and vaccine development for peanut allergy.\nimmunotherapy, immunotherapy with modified food antigens, and immunotherapy with a recombi \" \" t peanut vaccine ).\n"
        },
        {
          "qas": [
            {
              "id": "5e476b99d14c9f295d000001_001",
              "question": "Is golimumab effective for sarcoidosis?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\n\nlow dose oral steroids or treatment with inhaled steroids.\nnewer agents with anti - fibrotic properties, such as pirfenidone or nintedanib, might hold promise also for the pulmonary fibrosis seen in sarcoidosis.\n\nalthough treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa.\n"
        },
        {
          "qas": [
            {
              "id": "5e80675d835f4e4777000026_001",
              "question": "Is SARS virus interacting with ACE2 encoded protein?"
            }
          ],
          "context": "cell entry studies demonstrated that three newly identified sarsr - covs with different s protein sequences are all able to use human ace2 as the receptor\nthe trimeric sars coronavirus ( sars - cov ) surface spike ( s ) glycoprotein consisting of three s1 - s2 heterodimers binds the cellular receptor angiotensin - converting enzyme 2 ( ace2 ) and mediates fusion of the viral and cellular membranes through a pre -\n\nthe infection of target cells by the sars cov is mediated through the interaction of the viral spike ( s ) protein ( 1255 amino acids ) and its cellular receptor, angiotensin - converting enzyme 2 ( ace2 ).\ncell entry studies demonstrated that three newly identified sarsr - covs with different s protein sequences are all able to use human ace2 as the receptor\n\nthere are theoretical concerns that angiotensin - converting enzyme inhibitors ( aceis ) and angiotensin receptor blockers ( arbs ) could increase the risk of severe covid - 19.\nthe infection of target cells by the sars cov is mediated through the interaction of the viral spike ( s ) protein ( 1255 amino acids ) and its cellular receptor, angiotensin - converting enzyme 2 ( ace2 ).\n"
        },
        {
          "qas": [
            {
              "id": "5e3ebaa348dab47f2600000a_001",
              "question": "Is the FIP virus thought to be a mutated strain for the Feline enteric Coronavirus?"
            }
          ],
          "context": "background feline infectious peritonitis ( fip ) is a lethal systemic disease, caused by the fip virus ( fipv ) ; a virulent mutant of feline enteric coronavirus ( fecv ).\nfeline infectious peritonitis ( fip ) is an almost invariably fatal feline coronavirus ( fcov ) - induced disease thought to arise from a combination of viral mutations and an overexuberant immune response.\n\nfeline infectious peritonitis ( fip ) is an almost invariably fatal feline coronavirus ( fcov ) - induced disease thought to arise from a combination of viral mutations and an overexuberant immune response.\nit is caused by fip virus ( fipv ), a virulent mutant strain of feline enteric coronavirus ( fecv ).\n\nfeline infectious peritonitis virus ( fipv ) was presumed to arise from mutations in the 3c of a ubiquitous and largely nonpathogenic feline enteric coronavirus ( fecv ).\nit is caused by fip virus ( fipv ), a virulent mutant strain of feline enteric coronavirus ( fecv ).\n\nbackground feline infectious peritonitis ( fip ) is a lethal systemic disease, caused by the fip virus ( fipv ) ; a virulent mutant of feline enteric coronavirus ( fecv ).\nit is caused by fip virus ( fipv ), a virulent mutant strain of feline enteric coronavirus ( fecv ).\n\nbackground feline infectious peritonitis ( fip ) is a lethal systemic disease, caused by the fip virus ( fipv ) ; a virulent mutant of feline enteric coronavirus ( fecv ).\nfeline infectious peritonitis ( fip ) results from mutations in the viral genome during a common feline enteric coronavirus ( fecv ) infection.\n"
        },
        {
          "qas": [
            {
              "id": "5d36bb777bc3fee31f00000a_001",
              "question": "Does SATB1 regulate the RAG1 and RAG2 genes?"
            }
          ],
          "context": "the transcription factor satb1 that regulates the t - cell maturation\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nin this study we show that special at - rich binding protein 1 ( satb1 ), a t lineage - enriched chromatin organizer and regulator, is induced in response to tcr signaling during early thymocyte development\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nimmune system and plays a role as a signaling and costimulatory molecule on t lymphocytes.\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n\nthe transcription factor satb1 that regulates the t - cell maturation\nsatb1 binds to the ase and rag promoters, facilitating inclusion of rag2 in the chromatin hub and the loading of rna polymerase ii to both the rag1 and rag2 promoters.\n\nchromatin organizers satb2 and satb1\nspecial at - rich sequence binding protein 1 ( satb1 ) regulates gene expression essential in immune t - cell maturation and switching of fetal globin species, by binding to matrix attachment regions ( mars ) of dna and inducing a local chromatin remodeling.\n"
        },
        {
          "qas": [
            {
              "id": "5d371ec97bc3fee31f00000c_001",
              "question": "Is CTCF bound at nucleosome free regions?"
            }
          ],
          "context": "nucleosome occupancy at nucleosome - free regions ( nfrs ), many of which are located at sites occupied by the multivalent factors ctcf and cohesin.\npioneer transcription factors recognise and bind their target sequences in inaccessible chromatin to establish new transcriptional networks throughout development and cellular reprogramming.\n\nrobust inter - nucleosomal interactions exist around transcription start site ( tss ), transcription termination sites ( tts ) or around ctcf binding sites\npolycomb repressive complex 2 is recruited through the interaction of ctcf\n\n. although these regulatory elements are often distant from their target genes, they affect gene expression by recruiting transcription factors to specific promoter regions.\npolycomb repressive complex 2 is recruited through the interaction of ctcf\n\nthis general architectural change correlates with enhanced binding of ctcf and cohesins and more pronounced insulation of contacts across chromatin boundaries in lineage - committed cells.\npolycomb repressive complex 2 is recruited through the interaction of ctcf\n\nnucleosome occupancy at nucleosome - free regions ( nfrs ), many of which are located at sites occupied by the multivalent factors ctcf and cohesin.\nnucleosome depletion at 5'- hs4 was dependent on interaction of the insulator protein ccctc - binding factor ( ctcf ) and was required for enhancer blocking.\n"
        },
        {
          "qas": [
            {
              "id": "5e3c6850b5b409ea5300001f_001",
              "question": "Is bortezomib a Proteasome inhibitor?"
            }
          ],
          "context": "the proteasome - inhibitor bortezomib\nproteasome inhibitor bortezomib\n"
        },
        {
          "qas": [
            {
              "id": "5d3856ca7bc3fee31f000016_001",
              "question": "Is PRDM9 essential for meiosis?"
            }
          ],
          "context": "prdm9 is essential for the progression through early meiotic prophase, including double strand break repair, homologous chromosome pairing, and sex body formation during spermatogenesis.\nprdm9 ( pr domain - containing protein 9 ) is a meiosis - specific protein that trimethylates h3k4 and controls the activation of recombination hot spots. it is an essential enzyme in the progression of early meiotic prophase.\n\nour findings do not identify the nature of the underlying dna sequences, but argue against the proposed role of prdm9 as an essential transcription factor in mouse meiosis\nwe found that although the post - set zinc finger and the krab domains are not essential for the methyltransferase activity of prdm9 in cell culture, the krab domain mutant mice show only residual prdm9 methyltransferase activity and undergo meiotic\n"
        },
        {
          "qas": [
            {
              "id": "5e4b5f9a6d0a277941000021_001",
              "question": "Should Pentoxifylline be used for treatment of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nconclusions : pentoxifylline is not beneficial in als and should be avoided in patients treated with riluzole.\n\nconclusions : pentoxifylline is not beneficial in als and should be avoided in patients treated with riluzole.\nmany researchers have recognized the positive effects of fty720 and launched basic and clinical experiments to test the use of this agent against stroke\n\nneuroprotective agents are screened for use in patients with als.\nconclusions : pentoxifylline is not beneficial in als and should be avoided in patients treated with riluzole.\n"
        },
        {
          "qas": [
            {
              "id": "5e52bc986d0a277941000049_001",
              "question": "Is the CADM2 gene associated with differences in information processing speed?"
            }
          ],
          "context": "our findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\n. our findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\n\nthe cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\n. our findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\n\nthe cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\nour findings suggest that genetic variation in the cadm2 gene is associated with individual differences in information processing speed.\n"
        },
        {
          "qas": [
            {
              "id": "5e494cf96d0a277941000008_001",
              "question": "Is Nivolumab (Opdivo) a PD-L1 inhibitor?"
            }
          ],
          "context": "an improvement in the understanding of the role of the immune system in tumor immunosurveillance has led to the development of the programmed death - 1 ( pd - 1 ) immune checkpoint inhibitor nivolumab ( opdivo ).\nnivolumab ( opdivo ( \u00ae ) ; nivolumab bms\u2122 ) was the first programmed death ( pd ) - 1 immune checkpoint inhibitor to be approved for use in advanced, squamous non - small cell lung cancer ( nsclc ) following prior chemotherapy.\n"
        },
        {
          "qas": [
            {
              "id": "5e4b5fd86d0a277941000022_001",
              "question": "Does clinical trial data support the use of minocycline for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "efficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n\na recent publication of the results of a clinical trial of minocycline in 412 als patient has aroused considerable controversy in the als scientific community.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n\na recent publication of the results of a clinical trial of minocycline in 412 als patient has aroused considerable controversy in the als scientific community.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n"
        },
        {
          "qas": [
            {
              "id": "5e776a10835f4e477700000c_001",
              "question": "Is the drug Exubera currently (March 2020) available?"
            }
          ],
          "context": "despite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\nin efforts to provide patients with a more compliable treatment method, oramed pharmaceuticals tested the capacity of its oral insulin capsule ( ormd - 0801, 8 mg insulin ) in addressing this resistant clinical state.\n\ndespite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\nby the japanese ministry of health and welfare in march 2020 and has recently become available for clinical practice\n\ndespite discontinuation of the first inhalable insulin, exubera\u00ae, due to suboptimal market acceptance, development of orally inhaled insulin delivery systems has been galvanized by the recent approval of afrezza\u00ae and several others awaiting approval.\nin contrary, mannkind corporation started developing its ultra - rapid - acting insulin afrezza in a bold bid, probably by managing the issues in which exubera was not successful\n\nrates of gastrointestinal side effects, headache, and depression.\n. of all subjects treated, 853 ( 95 % ) on lubeluzole and 826 ( 93 % ) on placebo reported an adverse event during their treatment period or within the next 2 days after discontinuation of treatment.\n"
        },
        {
          "qas": [
            {
              "id": "5e3c6e15b5b409ea53000023_001",
              "question": "Are breaks in double stranded DNA associated with ionizing radiation?"
            }
          ],
          "context": "ionizing radiation and radiomimetic drugs such as bleomycin, calichieamycin, neocarzinostatin chromophore, and other synthetic agents can produce both single and double strand breaks in dna.\nwhereas most endogenous and exogenous dna damaging agents typically generate lesions that are relatively isolated and can be repaired easily, ionizing radiation ( ir ) also induces clustered lesions causing dna double strand breaks ( dsbs )\n\ndna double - strand breaks are considered to be the most deleterious lesion induced by ionizing radiation.\nwhereas most endogenous and exogenous dna damaging agents typically generate lesions that are relatively isolated and can be repaired easily, ionizing radiation ( ir ) also induces clustered lesions causing dna double strand breaks ( dsbs )\n\ninfluence of chromatin structure on the induction of dna double strand breaks by ionizing radiation.\nexposure of cells to ionizing radiation induces dna double - strand breaks.\n"
        },
        {
          "qas": [
            {
              "id": "5e52c0c76d0a27794100004b_001",
              "question": "Is KAT2A involved in Acute myeloid leukemia (AML)?"
            }
          ],
          "context": "kat2a inhibition demonstrated anti - aml activity by inducing myeloid differentiation and apoptosis, and suppressed the growth of primary human amls of diverse genotypes while sparing normal hemopoietic stem - progenitor cells.\n. our results propose that kat2a inhibition should be investigated as a therapeutic strategy in aml and provide a large number of genetic vulnerabilities of this leukemia that can be pursued in downstream studies.\n"
        },
        {
          "qas": [
            {
              "id": "5e4b639c6d0a277941000027_001",
              "question": "Is NicVAX vaccine effective for smoking cessation?"
            }
          ],
          "context": "conclusion the nicotine vaccine, nicvax, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.\nauthors'conclusions : there is currently no evidence that nicotine vaccines enhance long - term smoking cessation.\n\ncovid - 19 vaccine causing guillain - barre syndrome, a rare potential side effect.\nrates of gastrointestinal side effects, headache, and depression.\n\nconclusion the nicotine vaccine, nicvax, does not appear to improve the chances of stopping smoking when given in addition to varenicline and behavioural support.\nrecently, the most advanced candidate vaccine, nicvax, failed to meet the primary endpoint in two large phase iii studies, although the correlation of higher abstinence rates in subjects with higher immunity to nicotine was observed.\n"
        },
        {
          "qas": [
            {
              "id": "5e48b1ddd14c9f295d000012_001",
              "question": "Does natalizumab improve disease course of secondary progressive multiple sclerosis?"
            }
          ],
          "context": "interpretation natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper - limb component.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\n"
        },
        {
          "qas": [
            {
              "id": "5e52c9266d0a27794100004e_001",
              "question": "AhR ligands are attractive drug targets for pharmaceutical development due to their induction of Cyp1a1, yes or no?"
            }
          ],
          "context": "thus representing a notable drug target to explore.\nhowever, recent discoveries of new ahr ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy\n\nhowever, recent discoveries of new ahr ligands with potential therapeutic applications have been reported, inviting reconsideration of this policy\ncombining in vivo and in vitro findings, we identified nine ahr agonists, six of which are marketed therapeutics and have been approved by the u. s. food and drug administration, including leflunomide, flutamide, and nimodipine.\n\ncytochrome p450 ( cyp ) epoxygenases metabolize arachidonic acid into epoxyeicosatrienoic acids ( eets ), which play important and diverse roles in the cardiovascular system. th\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\n\narachidonic acid is metabolized to epoxyeicosatrienoic acids ( eets ) by cytochrome ( cyp ) p450 epoxygenases, and to \u03c9 - terminal hydroxyeicosatetraenoic acids ( hetes ) by \u03c9 - hydroxylases.\nidentification of rabbit cytochromes p450 2c1 and 2c2 as arachidonic acid epoxygenases.\n"
        },
        {
          "qas": [
            {
              "id": "5d385f717bc3fee31f00001a_001",
              "question": "Does the chromatin remodeling complex, RSC target H2A.Z nucleosomes?"
            }
          ],
          "context": "in contrast, the upstream nucleosome which covers the tata box under repressed conditions is shifted approximately 50 bp further upstream by the atp - dependent chromatin remodeler rsc upon activation\naccordingly, the absence of swr - c or histone h2a. z results in compromised chromatin remodeling and impaired gene expression in the absence of rsc and h3k4 methylation.\n\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\nsuch as h3k9me, h3k27me, h2aub, or active marks such as h3k4me, h3k36me, h3ac ), and chromatin remodeling ( nucleosome composition, occupancy, and location ).\n\nemerging lines of evidence indicate that histone variants ( h2ax and h2a. z ), histone post - translational modifications ( acetylation, phosphorylation, methylation and ubiquitination ) and chromatin - remodeling complexes ( ino80, swr1, swi / snf, rsc and\naccordingly, the absence of swr - c or histone h2a. z results in compromised chromatin remodeling and impaired gene expression in the absence of rsc and h3k4 methylation.\n\nh2a. z probably helps rsc in keeping the gene nucleosome - fre\nin rsc - depleted cells, nfrs shrink such that the average positions of flanking nucleosomes move toward predicted sites.\n"
        },
        {
          "qas": [
            {
              "id": "5e7f69d2835f4e4777000021_001",
              "question": "Has ZP-PTH been tested in a phase II clinical trial?"
            }
          ],
          "context": "this system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\nbased on positive results from a phase i / ii clinical trial\n\nthis system was successfully tested in a phase 2 clinical trial for the treatment of post - menopausal women with osteoporosis.\n. the primary end point was e\n"
        },
        {
          "qas": [
            {
              "id": "5e48b9abd14c9f295d000015_001",
              "question": "Are multipotent adult progenitor cells effective for treatment of stroke?"
            }
          ],
          "context": "interpretation administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke.\n. although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke ( < 36\n"
        },
        {
          "qas": [
            {
              "id": "5e3d8edf48dab47f26000003_001",
              "question": "Autophagy is the process where a virus obtains nutrients from it's host, yes or no?"
            }
          ],
          "context": "autophagy is an evolutionarily conserved cellular process in which intracellular components are eliminated via lysosomal degradation to supply nutrients for organelle biogenesis and metabolic homeostasis.\nin this study, we demonstrate that autophagy is a critical mediator of the viral degradation pathway and that this pathway is not hiv - 1 specific.\n\nin this study, we demonstrate that autophagy is a critical mediator of the viral degradation pathway and that this pathway is not hiv - 1 specific.\npossible to construct a suppressive anti - viral regimen.\n\nduring viral infection, viral nucleic acids are detected by virus sensor proteins including toll - like receptor 3 or retinoic acid - inducible gene i - like receptors ( rlrs ) in mammalian cells.\n. our experiments uncover a novel molecular mechanism by which a virus with a very selective tropism can elicit persistent transcriptional changes in cells that evade it, contributing to the severity of covid - 19.\n\nin this study, we demonstrate that autophagy is a critical mediator of the viral degradation pathway and that this pathway is not hiv - 1 specific.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\n\nautophagy is a homeostatic process involved in the turnover or elimination of cytoplasmic components, damaged organelles, and protein aggregates via a lysosomal degradation mechanism.\nautophagy is important in cellular homeostasis for the cell survival mechanism.\n"
        },
        {
          "qas": [
            {
              "id": "5d387a51a1e159510500000e_001",
              "question": "Does CXorf21 escape X chromosome inactivation?"
            }
          ],
          "context": "genes that escape x - inactivation in humans have high intraspecific variability in expression, are associated with mental impairment but are not slow evolving.\nfrom skewed x inactivation of the paternal nonmutant x chromosome.\n\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\nthis revealed a 637 - kb tandem duplication that in addition to dax1 includes the four mageb genes, the hypothetical gene cxorf21, gk, and part of the map3k7ip3 gene\n\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation.\nthe normal x chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the hunter gene.\n\nexamination of x - linked degs, such as gtpbp6, taf9l, and cxorf21, that show verbal cognition - gene expression correlations may establish a causal link between these genes, neurodevelopment, and language function.\nmutations in the gene encoding cu / zn - superoxide dismutase ( sod - 1 ) have been identified in cases of familial amyotrophic lateral sclerosis linked to chromosome 21.\n"
        },
        {
          "qas": [
            {
              "id": "5e52ab626d0a277941000046_001",
              "question": "Does promoter shape vary across populations?"
            }
          ],
          "context": ". although highly conserved, the functional properties of promoters with different shapes and the genetic basis of their evolution remain unclear\n. our results identify promoter shape as a molecular trait that can evolve independently of promoter strength. broad promoters typically harbor shape - associated variants, with signatures of adaptive selection\n\n. our results identify promoter shape as a molecular trait that can evolve independently of promoter strength. broad promoters typically harbor shape - associated variants, with signatures of adaptive selection\nanimal promoters initiate transcription either at precise positions ( narrow promoters ) or dispersed regions ( broad promoters ), a distinction referred to as promoter shape\n\n. our results identify promoter shape as a molecular trait that can evolve independently of promoter strength. broad promoters typically harbor shape - associated variants, with signatures of adaptive selection\n. although highly conserved, the functional properties of promoters with different shapes and the genetic basis of their evolution remain unclear\n\nanimal promoters initiate transcription either at precise positions ( narrow promoters ) or dispersed regions ( broad promoters ), a distinction referred to as promoter shape\n. our results identify promoter shape as a molecular trait that can evolve independently of promoter strength. broad promoters typically harbor shape - associated variants, with signatures of adaptive selection\n"
        },
        {
          "qas": [
            {
              "id": "5e4b5ef36d0a27794100001f_001",
              "question": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?"
            }
          ],
          "context": "neuroprotective agents are screened for use in patients with als.\nan effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\n\nthe six months intent - to - treat analysis showed no statistically significant effect but a trend in favour of 2 mg xaliproden compared to placebo for reduction in the rate of deterioration of fvc, limbs functional score, and manual muscle testing score\nan effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\n\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nan effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nan effect of xaliproden on functional parameters, especially vc, was noted. although this effect did not reach statistical significance, xaliproden had a small effect on clinically noteworthy aspects of disease progression in als.\n"
        },
        {
          "qas": [
            {
              "id": "5e8101e3835f4e477700002e_001",
              "question": "Is cathepsin L active in endosomes?"
            }
          ],
          "context": "cathepsin l in the late endosome / lysosome\nendosomal cathepsin l\n"
        },
        {
          "qas": [
            {
              "id": "5e4b5f566d0a277941000020_001",
              "question": "Is celecoxib effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": "in conclusion, the celecoxib - creatine combination was selected as preferable to the minocycline - creatine combination for further evaluation.\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\n\nresults celecoxib did not slow the decline in muscle strength, vital capacity, motor unit number estimates, als functional rating scale - revised, or affect survival.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\ndespite several positive case reports and short studies, further controlled researches have failed to substantiate any positive effects of lithium exposure in amyotrophic lateral sclerosis.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nin a pilot clinical study that we recently published we found that lithium administration slows the progression of amyotrophic lateral sclerosis ( als ) in human patients.\nlithium delays progression of amyotrophic lateral sclerosis. als is a devastating neurodegenerative disorder with no effective treatment.\n"
        },
        {
          "qas": [
            {
              "id": "5e6e8600c6a8763d23000002_001",
              "question": "Is the protein MCL-1 anti-apoptotic?"
            }
          ],
          "context": "tumours to dna - damaging agents and to deletion of the anti - apoptotic protein mcl1\nhere we find mettl1 is frequently amplified and overexpressed in cancers and is associated with poor patient survival. mettl1 depletion causes decreased abundance of m7g - modified trnas and altered cell cycle and inhibits oncogenicity\n\n. these include the pikfyve kinase inhibitor apilimod, cysteine protease inhibitors mdl - 28170, z lvg chn2, vby - 825, and ono 5334, and the ccr1 antagonist mln - 3897\nsurface inhibitory molecules such as siglec - 8, anti - il - 1s such as canakinumab, bruton kinase ( btk ) inhibitors such as gdc - 0853 and anti - il - 5s such as benralizumab and mepolizumab. summary : the ongoing clinical trials on new targets of treatment hold\n\nanti - apoptotic bcl - 2 family members, such as bcl - 2, bcl - xl or mcl - 1\nanti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\n\nrepression of anti - apoptotic proteins ( mcl - 1, bcl - xl and xiap )\nincreased expression of anti - apoptotic proteins ( bcl - xl, mcl - 1 and xiap )\n\nrepression of anti - apoptotic proteins ( mcl - 1, bcl - xl and xiap )\nanti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\n"
        },
        {
          "qas": [
            {
              "id": "5e48bd2ed14c9f295d000017_001",
              "question": "Is ozanezumab effective for amyotrophic lateral sclerosis?"
            }
          ],
          "context": ". additionally, for secondary end points of clinical response, endoscopic improvement, corticosteroid - free remission, and mucosal healing, ozanimod performed significantly better than placebo.\nrates of gastrointestinal side effects, headache, and depression.\n\nit reduces apoptosis in mouse models of huntington's disease and familial amyotrophic lateral sclerosis ( als ) and is in clinical trial for sporadic als.\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n\nneuroprotective agents are screened for use in patients with als.\neculizumab ( soliris ) has been approved in several countries for refractory forms of generalized seropositive severe myasthenia gravis.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\nnatalizumab did not achieve a statistically significant primary composite disability outcome in a trial of 887 patients with secondary progressive ms, but it did demonstrate a benefit on a prespecified component of the 9 - hole peg test.\n"
        },
        {
          "qas": [
            {
              "id": "5e4b62946d0a277941000024_001",
              "question": "Is Dexmecamylamine effective for depression?"
            }
          ],
          "context": "no notable differences were observed between dexmecamylamine and placebo for any secondary end point.\nrates of gastrointestinal side effects, headache, and depression.\n\nno notable differences were observed between dexmecamylamine and placebo for any secondary end point.\ntc - 5214 ( dexmecamylamine ) is a nicotinic channel modulator that has previously been evaluated for treatment of major depression disorder ( mdd ) and is currently being evaluated by targacept as a treatment for overactive bladder.\n"
        },
        {
          "qas": [
            {
              "id": "5e7f64a5835f4e477700001e_001",
              "question": "Can CMB305 be used against sarcomas?"
            }
          ],
          "context": "the potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nradiation - induced sarcomas are recognized complications of radiation therapy and are associated with poor prognosis.\n\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\nthe potential of the cmb305 vaccine regimen to target ny - eso - 1 and improve outcomes for synovial sarcoma and myxoid / round cell liposarcoma patients.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n"
        },
        {
          "qas": [
            {
              "id": "60258ebe1cb411341a0000a8_001",
              "question": "Has tocilizumab been assessed against Covid-19?"
            }
          ],
          "context": "early treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\n\npatients with severe or critical covid - 19 while maintaining a good safety profile.\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\n\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\ntocilizumab, a monoclonal antibody against the il - 6 receptor, was initiated at a dose of 8 mg / kg every 4 weeks.\n\npreliminary clinical results have indicated that antagonism of the il - 6 receptor ( il - 6r ), including with the fda - approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical covid - 19 while\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\n"
        },
        {
          "qas": [
            {
              "id": "5fdb2e60a43ad3127800000c_001",
              "question": "Is the TFR1 gene dispensable for erythropoiesis?"
            }
          ],
          "context": "we found decreased expression of hepcidin and tfr2 and increased expression of tfr1 and ngal in the beta - thalassemia mouse models, compared with the control mice.\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\n\nthe signaling functions of both tfr1 and tfr2 in erythroid cells were unexpected and these recent findings open a new field of research regarding the last steps of erythroid differentiation and their regulation.\nin humans, hematopoietic erythroid precursor cells express high levels of tfr1 and specifically take up the fth homopolymer ( h - ferritin ).\n\nthe signaling functions of both tfr1 and tfr2 in erythroid cells were unexpected and these recent findings open a new field of research regarding the last steps of erythroid differentiation and their regulation.\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\n\nthese studies describe how point mutations of the transferrin receptor can cause a microcytic anemia that does not respond to iron therapy and would not be detected by routine iron studies, such as serum ferritin.\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\n"
        },
        {
          "qas": [
            {
              "id": "5e94aadf0d431b5f73000002_001",
              "question": "Is Bcl-2-like protein 1 an pro apoptotic protein?"
            }
          ],
          "context": "anti - apoptotic bcl - 2 family members, such as bcl - 2, bcl - xl or mcl - 1\nanti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\n\nincreased expression of anti - apoptotic proteins ( bcl - xl, mcl - 1 and xiap )\nanti - apoptotic bcl - 2 - like protein 1 ( bcl2l1, bcl - xl )\n"
        },
        {
          "qas": [
            {
              "id": "5e52c96b6d0a27794100004f_001",
              "question": "Glucoraphanin from broccoli can help reduce obesity , yes or no?"
            }
          ],
          "context": "conclusions : in adolescents with obesity, the use of liraglutide ( 3. 0 mg ) plus lifestyle therapy led to a significantly greater reduction in the bmi standard - deviation score than placebo plus lifestyle therapy.\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\n\nwhile research in this area is growing, our knowledge of obesity - related cognitive dysfunction and brain alterations has not yet been synthesized.\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\n\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\ndata from most recent meta - analyses showed that the overall placebo - subtracted weight reduction ( % ) with the use of anti - obesity drugs for at least 12 months ranges from 2. 9 % to 6. 8 % ; phentermine / topiramate ( - 6. 8 % ) liraglutide ( - 5. 4 % ),\n\ninflammation and insulin resistance by polarizing m2 macrophages and reducing metabolic endotoxemia\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\n\nrates of gastrointestinal side effects, headache, and depression.\nglucoraphanin : a broccoli sprout extract that ameliorates obesity - induced inflammation and insulin resistance.\n"
        },
        {
          "qas": [
            {
              "id": "5e6f774ec6a8763d23000009_001",
              "question": "Are bacteria in the genus Clostridium facultative anaerobes?"
            }
          ],
          "context": "clostridium is a large genus of obligate anaerobes belonging to the firmicutes phylum of bacteria, most of which have a gram - positive cell wall structure.\nantimicrobial production by strictly anaerobic clostridium spp.\n\nsuch bacteria are either obligate anaerobic bacteria like clostridium or bifidobacterium or facultative anaerobic like escherichia coli or salmonella.\nclostridia belong to those bacteria which are considered as obligate anaerobe, e. g. oxygen is harmful or lethal to these bacteria.\n\nantimicrobial production by strictly anaerobic clostridium spp.\nclostridia belong to those bacteria which are considered as obligate anaerobe, e. g. oxygen is harmful or lethal to these bacteria.\n\nantimicrobial production by strictly anaerobic clostridium spp.\nclostridium is a large genus of obligate anaerobes belonging to the firmicutes phylum of bacteria, most of which have a gram - positive cell wall structure.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb4253a43ad31278000022_001",
              "question": "Do nematodes contain architectural proteins like CTCF?"
            }
          ],
          "context": "so far poorly characterised mode present in more derived nematodes\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\n\nof ctcf from several nematodes is paralleled by a loss of two of its interactors, the polycomb repressive complex subunit suz12 and the multifunctional transcription factor tyy1. in contrast to earlier st\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\n\n. here, the authors provide evidence that these clusters coincide with distinct topologically associating domains in humans and drosophila, revealing a conserved regulatory genomic architecture.\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\n"
        },
        {
          "qas": [
            {
              "id": "6025912a1cb411341a0000aa_001",
              "question": "Is tocilizumab a tumor necrosis factor inhibitor?"
            }
          ],
          "context": "was treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\n\nrates of gastrointestinal side effects, headache, and depression.\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\n\ntocilizumab ( tcz ) is a compound that inhibits the il - 6 receptor.\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\n\ntocilizumab ( actemra ; genentech, inc ) is the first biologic therapy targeting the cytokine interleukin 6 ( il - 6 ).\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\n\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\n"
        },
        {
          "qas": [
            {
              "id": "5e43ee1f48dab47f26000012_001",
              "question": "Do circular exons increase gene expression?"
            }
          ],
          "context": "circular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\nin this review, we summarize current knowledge about gene expression regulators - long non - coding and circular rna molecules in eye diseases\n\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\nexonic circular rnas ( circrnas ) are rna molecules that are covalently closed by back - splicing via canonical splicing machinery.\n\nexonic circrna, circular intronic rna, and exon - intron circular rna.\nexonic circular rnas ( circrnas ) are rna molecules that are covalently closed by back - splicing via canonical splicing machinery.\n\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\nwell as circrnas generated from intronic lariats during colinear splicing, may exhibit physiologically relevant regulatory functions in eukaryotes.\n\ncircular rnas ( circrnas ) derived from back - spliced exons have been widely identified as being co - expressed with their linear counterparts.\nrecent evidence has demonstrated that circular rnas ( circrnas ) played crucial roles in fine - tuning the levels of gene expression by sequestering the corresponding microrna ( mirnas ).\n"
        },
        {
          "qas": [
            {
              "id": "5e4d6e446d0a27794100002f_001",
              "question": "Is MAGE-A3 immunotherapeutic effective for non-small-cell lung cancer?"
            }
          ],
          "context": "uvant treatment with the mage - a3 immunotherapeutic did not increase disease - free survival compared with placebo in patients with mage - a3 - positive surgically resected nsclc. ba\ninitiation of clinical trials testing these drugs in patients with stage iii nsclc\n\none recent phase iii trial of the igf - 1r inhibitor figitumumab in patients with non - small - cell lung cancer was discontinued after an interim analysis showed no survival improvement.\nuvant treatment with the mage - a3 immunotherapeutic did not increase disease - free survival compared with placebo in patients with mage - a3 - positive surgically resected nsclc. ba\n"
        },
        {
          "qas": [
            {
              "id": "5e94a8250d431b5f73000001_001",
              "question": "Does protein ALEX1 contain armadillo repeats?"
            }
          ],
          "context": "alex1 ( arm protein lost in epithelial cancers, on chromosome x ), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.\narm protein lost in epithelial cancers, on chromosome x 1 ( alex1 ) is a novel member of the armadillo family which has two armadillo repeats as opposed to more than six repeats in the classical armadillo family members.\n\narm protein lost in epithelial cancers, on chromosome x 1 ( alex1 ) is a novel member of the armadillo family which has two armadillo repeats as opposed to more than six repeats in the classical armadillo family members.\nalex1 ( arm protein lost in epithelial cancers, on chromosome x ), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.\n\n. the complex also may contain the pol ii ctd phosphatase cpl2, the plant homeodomain - containing protein aipp2, and another bah domain protein, aipp3\nalex1 ( arm protein lost in epithelial cancers, on chromosome x ), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.\n\nace2 is a type 1 integral membrane protein and contains a catalytically active ectodomain that can be shed from the cell surface into the extracellular space,\nalex1 ( arm protein lost in epithelial cancers, on chromosome x ), contains two armadillo repeats domains, is expressed different in normal and carcinomas tissues.\n"
        },
        {
          "qas": [
            {
              "id": "5e3390fafbd6abf43b000060_001",
              "question": "Does radiotherapy for cervical cancer increases risk of colon cancer?"
            }
          ],
          "context": ". radiation - induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.\nafter 8 years, the hazard ratio for developing colon cancer was 2. 00 ( 95 % ci 1. 43 - 2. 80 ) for women with radiation versus those without radiation treatment.\n\n. radiation - induced second cancers of the colon and rectum may occur 8 years after radiation treatment for cervical cancer.\ncervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites ( colon, rectum / anus, urinary bladder, ovary, and genital sites )\n\nradiotherapy for prostate cancer was associated with higher risks of developing second malig \" \" cies of the bladder, colon, and rectum compared with patients unexposed to radiotherapy, but the reported absolute rates were low.\ncervical cancer patients treated with radiotherapy, but not those who did not receive radiotherapy, were at increased risk for all second cancers and cancers at heavily irradiated sites ( colon, rectum / anus, urinary bladder, ovary, and genital sites )\n"
        },
        {
          "qas": [
            {
              "id": "5fe31321a43ad3127800004b_001",
              "question": "Is yeast fbp1 affected by glucose starvation stress?"
            }
          ],
          "context": "the fission yeast fbp1 gene, whose transcription is massively induced upon glucose starvation.\nfission yeast, glucose starvation triggers lncrna transcription across promoter regions of stress - responsive genes including fbp1 ( fructose - 1, 6 - bisphosphatase1 ). at\n\nthe fission yeast fbp1 gene, whose transcription is massively induced upon glucose starvation.\nchromatin is reconstituted in the fission yeast schizosaccharomyces pombefbp1 gene, which is robustly induced upon glucose starvation but tightly repressed under glucose - rich conditions.\n\nthe fission yeast fbp1 gene, whose transcription is massively induced upon glucose starvation.\nthe schizosaccharomyces pombe fbp1 gene, which encodes fructose - 1, 6 - bis - phosphatase, is transcriptionally repressed by glucose through the activation of the camp - dependent protein kinase a ( pka ) and transcriptionally activated by glucose starvation\n"
        },
        {
          "qas": [
            {
              "id": "5e4b64516d0a277941000029_001",
              "question": "Is Semagacestat effective for Alzheimer's Disease?"
            }
          ],
          "context": "recently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nhowever, a large phase 3 trial of semagacestat, a potential non - transition state analog ( non - tsa ) gsi, in patients with alzheimer's disease ( ad ) was terminated due to unexpected aggravation of cognitive deficits and side effects.\n\nobjective : semagacestat, a \u03b3 - secretase inhibitor, demonstrated an unfavorable risk - benefit profile in a phase 3 study of patients with alzheimer's disease ( identity trials ), and clinical development was halted.\n. other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin - related teaes, renal and hepatic changes, increased qt interval, and weight loss.\n\n. other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin - related teaes, renal and hepatic changes, increased qt interval, and weight loss.\n. patients treated with semagacestat lost more weight and had more skin cancers and infections, treatment discontinuations due to adverse events, and serious adverse events ( p < 0. 001 for all comparisons with placebo ).\n\nrecently disclosed phase iii findings on semagacestat indicated that alzheimer's disease ( ad ) patients on this drug showed significantly worsened cognitive function compared to those treated with placebo.\nintroduction : the negative efficacy study examining the \u03b3 - secretase inhibitor semagacestat in mild to moderate alzheimer's disease ( ad ) included a number of biomarkers of the disease as well as safety outcomes.\n"
        },
        {
          "qas": [
            {
              "id": "5e9eba150d431b5f73000005_001",
              "question": "Do nematodes contain a CTCF gene?"
            }
          ],
          "context": "so far poorly characterised mode present in more derived nematodes\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\n\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\n\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\nstrikingly, without atp, we observe the emergence of hundreds of ctcf - independent loops that link regulatory dna.\n\nof ctcf from several nematodes is paralleled by a loss of two of its interactors, the polycomb repressive complex subunit suz12 and the multifunctional transcription factor tyy1. in contrast to earlier st\nour findings show that ctcf and possibly chromatin insulation are present in basal nematodes. we suggest that the insulator protein ctcf has been secondarily lost in derived nematodes like c. elegans.\n"
        },
        {
          "qas": [
            {
              "id": "60259fe91cb411341a0000b3_001",
              "question": "Is tocilizumab a csDMARD?"
            }
          ],
          "context": "was treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\n\nthe humanized anti - human il - 6 receptor antibody, tocilizumab, have demonstrated outstanding clinical efficacy and tolerable safety profiles, resulting in worldwide approval for using these bdmards to treat moderate to severe active ra in patients\ntocilizumab is a monoclonal humanized anti - il - 6 - receptor antibody used for the treatment of rheumatoid arthritis.\n\ntocilizumab ( tcz ) is a monoclonal antibody which inhibits the interleukin - 6 receptor.\ntocilizumab ( tcz ) is a humanized monoclonal antibody against il - 6 receptor licensed in 2009 that has demonstrated clinical efficacy in various adult ra populations\n\nwas treated with tocilizumab, an anti - interleukin - 6 receptor monoclonal antibody\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\n"
        },
        {
          "qas": [
            {
              "id": "601c1a271cb411341a000011_001",
              "question": "Can SMAD6 variants cause craniosynostosis?"
            }
          ],
          "context": "rs1884302 genotype significantly modifies the phenotype. methods : we performed resequencing of smad6 in 795 unsolved patients with any type of craniosynostosis and genotyped rs1884302 in smad6 - positive individuals and relatives\n. we determined the occurrence of smad6 variants in all types of craniosynostosis, evaluated the impact of different missense variants on smad6 function, and tested independently whether rs1884302 genotype significantly modifies the\n\nand the embryological period in which the mutation itself occurs, a type of craniosynostosis arises that may involve one or more cranial sutures.\nthe risk of both nonsyndromic and syndromic presentations of craniosynostosis, especially metopic synostosis\n\nidentification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis.\nrecent genetic studies have identified several novel genes and pathways that cause nonsyndromic craniosynostosis, providing genetic evidence linking the causes of syndromic and nonsyndromic craniosynostoses, and allowing for genotype - based prediction\n\nidentification and analysis of the genetic causes in nine unrelated probands with syndromic craniosynostosis.\nthrough which skull growth abnormalities are seen\n\n. it is becoming clearer that in most patients with craniosynostosis, there is regional imbalance of skull growth, which co - exists with a variety of other equally important factors, such as genetic defects, raised intracranial pressure, venous\nthe risk of both nonsyndromic and syndromic presentations of craniosynostosis, especially metopic synostosis\n"
        },
        {
          "qas": [
            {
              "id": "5fdb4124a43ad31278000017_001",
              "question": "Is Tcf3 associated with the Wnt pathway?"
            }
          ],
          "context": "t - cell factor 3 ( tcf3 ) is a component of the wnt signaling and a domi \" \" t downstream effector in escs.\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\n\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\ntcf3 - mediated repression to tcf1 / lef1 - mediated enhancement of wnt signaling, constituting a positive feedback loop that facilitates neuronal differentiation.\n\nwe show that menin physically interacts with proteins involved in the canonical wnt signaling pathway, including beta - catenin, tcf3 ( tcfl1 ), and weakly with tcf4 ( tcfl2 ).\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\n\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\nthe transcription factor t - cell factor 3 ( tcf3 ), one component of the wnt pathway, is known as a cell - intrinsic inhibitor of many pluripotency genes in embryonic stem cells ( escs ) that influences the balance between pluripotency and differentiation.\n\nwe also find that tcf3 phosphorylation is triggered by canonical wnt ligands, lrp6, and domi \" \" t negative mutants for axin and gsk3, indicating that this process shares the same upstream regulators with \u03b2 - catenin stabilization.\ntcf3 is a transcriptional repressor that has been implicated in wnt signaling and plays key roles in embryonic axis specification and stem cell differentiation.\n"
        },
        {
          "qas": [
            {
              "id": "5e766256835f4e4777000003_001",
              "question": "Have the rotavirus vaccines changed the predominant rotavirus genotypes?"
            }
          ],
          "context": "change in rotavirus epidemiology in northeast florida after the introduction of rotavirus vaccine\nimpact of rotavirus vaccines on rotavirus disease\n\nus rotavirus vaccine efficacy group.\nthis study describes the distribution and diversity of rotavirus genotypes before and after rotavirus vaccine introduction into the australian nip.\n\nus rotavirus vaccine efficacy group.\neffectiveness of rotavirus pentavalent vaccine\n\nthis study describes the distribution and diversity of rotavirus genotypes before and after rotavirus vaccine introduction into the australian nip.\nchange in rotavirus epidemiology in northeast florida after the introduction of rotavirus vaccine\n\nimpact of rotavirus vaccine on rotavirus diarrhoea in countries of east and southern africa.\nimpact of rotavirus vaccines on rotavirus disease\n"
        },
        {
          "qas": [
            {
              "id": "5e323e93fbd6abf43b000059_001",
              "question": "Does head ct increase brain tumor risk?"
            }
          ],
          "context": ". converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\ncompared with the general population, incidence of brain tumors was higher in the cohort of children with ct scans, requiring cautious interpretation of the findings.\n\n. converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\n. subsequently, recommendations are offered for indications to perform ct before lp, grouped according to the safety and clinical utility of lp.\n\n. tumor incidence increased with number of pediatric head cts in a dose - dependent manner, with measurable excess incidence even after a single scan\n. converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\n\n. converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\nbackground : recent studies linking radiation exposure from pediatric computed tomography ( ct ) to increased risks of leukemia and brain tumors lacked data to control for cancer susceptibility syndromes ( css ).\n\n. converging evidence from epidemiological studies supported a small excess risk of brain tumor incidence after even a single ct exam in pediatric patients.\n1, 000 annual paediatric ct investigations of the skull will lead to about 3 excess neoplasms in the head region, i. e., the probability of an induced late effect must be suspected in the range of some thousandths.\n"
        },
        {
          "qas": [
            {
              "id": "5e764732c6a8763d23000017_001",
              "question": "Can AGY be used as antidiuretic replacement therapy?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\n. other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin - related teaes, renal and hepatic changes, increased qt interval, and weight loss.\n\nprevious results suggest that oxt and arginine vasopressin ( avp ) may play a role in the etiopathogenesis of asd\nthe mechanism of action of thalidomide is probably based on its immunomodulatory effect, namely the suppression of production of tumor necrosis factor alpha and the modulation of interleukins.\n\nprevious results suggest that oxt and arginine vasopressin ( avp ) may play a role in the etiopathogenesis of asd\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\n\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\ncombining in vivo and in vitro findings, we identified nine ahr agonists, six of which are marketed therapeutics and have been approved by the u. s. food and drug administration, including leflunomide, flutamide, and nimodipine.\n\noral egg yolk anti - gliadin antibody ( agy ) is a novel treatment to neutralize gluten and may improve the efficacy of the gfd.\npreclinical research suggests that arginine vasopressin ( avp ), a neuropeptide involved in promoting mammalian social behaviors, may be a possible treatment for asd.\n"
        },
        {
          "qas": [
            {
              "id": "5e323d79fbd6abf43b000058_001",
              "question": "Can secondary glioblastoma be caused by brain irradiation?"
            }
          ],
          "context": "secondary glioblastoma multiforme ( sgbm ) can occur after a long latency period following radiation treatment of various diseases including brain tumors, leukemia, and more benign disorders like tinea capitis.\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\n\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\nsecondary brain tumors rarely arise after cranial irradiation ; among them, meningiomas and glioblastomas are the most common and secondary oligodendroglial tumors the most rare.\n\noverall survival for recurrent high - grade glioma was 13. 6 months ( 95 % confidence interval, 10. 8 to 20. 0 ) and was statistically improved relative to an external control ( hazard ratio, 0. 45 ; p = 0. 003 ).\nduring a median of 2 years of follow - up review after the diagnosis of a secondary tumour, 3 patients died related to the secondary tumours ( 2 sarcomas, 1 glioblastoma ), one died of a recurrent primary glioma, while the remaining 7 have been alive for\n\nthe authors consider irradiation - induced glioblastomas secondary to primarily verified medulloblastomas in patients who had previously undergone craniospinal irradiation as a component of combined treatment after tumor resection.\nparadoxically, radiation is also a risk factor for gbm development, raising the possibility that radiotherapy of brain tumors could promote tumor recurrence or trigger secondary gliomas.\n"
        },
        {
          "qas": [
            {
              "id": "5e94902f2d3121100d000012_001",
              "question": "Is aggrephagy a variant of autophagy?"
            }
          ],
          "context": "the selective branch of autophagy that deals with identification, capture and degradation of protein aggregates is called aggrephagy.\nmechanistic insights into aggrephagy, a selective basal autophagy process to clear misfolded protein aggregates,\n"
        },
        {
          "qas": [
            {
              "id": "601d75281cb411341a000043_001",
              "question": "Is there any role of genotoxic pks + E. coli in cancer?"
            }
          ],
          "context": ". escherichia coli can carry the pathogenicity island pks, which encodes a set of enzymes that synthesize colibactin3. this compound is believed to alkylate dna on adenine residues4, 5 and induces double - strand breaks in cultured cells3\nmutational signature in colorectal cancer caused by genotoxic pks +\n\n. our study describes a distinct mutational signature in colorectal cancer and implies that the underlying mutational process results directly from past exposure to bacteria carrying the colibactin - producing pks pathogenicity island.\nmutational signature in colorectal cancer caused by genotoxic pks +\n"
        },
        {
          "qas": [
            {
              "id": "5e44c59848dab47f26000021_001",
              "question": "Should tirilazad be used for treatment of ischemic stroke?"
            }
          ],
          "context": ". although further trials of tirilazad are now unwarranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischemic stroke.\nconclusions : tirilazad mesylate increases death and disability by about one fifth when given to patients with acute ischemic stroke\n\n. although further trials of tirilazad are now unwarranted, analysis of individual patient data from the trials may help elucidate why tirilazad appears to worsen outcome in acute ischemic stroke.\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\n\nthe wonder drug, gavestinel, failed to produce any significant treatment benefits for patients treated within six hours after experiencing an acute ischemic stroke, according to the recent results of a major clinical trial of the neuroprotectant.\nthe two clinical trials of therapy aimed at limiting the inflammatory response in acute stroke that have been carried out to date, however, have not shown a benefit to such therapy.\n"
        },
        {
          "qas": [
            {
              "id": "5e64f11a1af46fc130000017_001",
              "question": "Is the Paramyxovirus geneome segmented, negative-sense RNA?"
            }
          ],
          "context": "an alternative method to determine the 5'extremities of non - segmented, negative sense rna viral genomes using positive replication intermediate 3'tailing : application to two members of the paramyxoviridae family.\nmembers of the paramyxoviridae such as measles, mumps, and parainfluenza viruses have pleomorphic, enveloped virions that contain negative - sense unsegmented rna genomes.\n\nthe paramyxovirus genome, a nonsegmented, negative - polarity, single - stranded rna of approximately 15 kb, contains six transcription units flanked at the 3'and 5'ends by a short ( approximately 50 - to 60 - nucleotide ) extracistronic sequence, dubbed\nthe paramyxovirus family has a genome consisting of a single strand of negative sense rna\n\nhuman metapneumovirus ( hmpv ), a single - stranded negative - sense rna virus belonging to the family paramyxoviridae, is associated with respiratory tract illness, primarily in young children and persons with underlying disease.\nmembers of the paramyxoviridae such as measles, mumps, and parainfluenza viruses have pleomorphic, enveloped virions that contain negative - sense unsegmented rna genomes.\n"
        },
        {
          "qas": [
            {
              "id": "602599251cb411341a0000b1_001",
              "question": "Does the use of bDMARDs during pregnancy impact neonatal development?"
            }
          ],
          "context": "exposure to bdmards during preg \" \" cy does not seem to interfere with post - natal development up to infancy.\nfor the first - line bdmard / tsdmard, either tumor necrosis factor inhibitors ( tnfi ), non - tnfi ( abatacept, tocilizumab, rituximab ), or tsdmards, may be considered.\n\nexposure to bdmards during preg \" \" cy does not seem to interfere with post - natal development up to infancy.\nconclusion : baricitinib demonstrated a consistent, beneficial treatment effect in bdmard - refractory patients across subgroups based on baseline characteristics and prior bdmard use.\n\nthe task force agreed on 5 overarching principles and 12 recommendations concerning use of conventional synthetic ( cs ) dmards ( methotrexate ( mtx ), leflunomide, sulfasalazine ) ; glucocorticoids ( gcs ) ; biological ( b ) dmards ( tumour necrosis factor\nexposure to bdmards during preg \" \" cy does not seem to interfere with post - natal development up to infancy.\n\nexposure to bdmards during preg \" \" cy does not seem to interfere with post - natal development up to infancy.\nthe safety and efficacy of the use of methotrexate in long - term therapy for rheumatoid arthritis.\n"
        },
        {
          "qas": [
            {
              "id": "601d46d61cb411341a000030_001",
              "question": "Do exon 38 or 39 KMT2D missense variants cause Kabuki syndrome type 1 (KS1)?"
            }
          ],
          "context": "spanning exons 38 and 39 and affecting highly conserved residues cause a novel multiple malformations syndrome distinct from ks1\nto investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\n\n. the frequency of clinical features, objective software - based facial analysis metrics, and genome - wide peripheral blood dna methylation patterns in these patients were significantly different from that of ks1\nto investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\n\n. notably, neither patient has epilepsy. homology modeling of these missense variants revealed that they are likely to disrupt the stabilization of a closed channel conformation of kcnt2 resulting in a constitutively open state\nto investigate if specific exon 38 or 39 kmt2d missense variants ( mvs ) cause a condition distinct from kabuki syndrome type 1 ( ks1 ). methods : multiple individuals, with mvs in exons 38 or 39 of kmt2d that encode a highly conserved region of 54 amino\n"
        },
        {
          "qas": [
            {
              "id": "601c4e5e1cb411341a000021_001",
              "question": "Is cabergoline used for treatment of the Nelson's syndrome ?"
            }
          ],
          "context": "this case demonstrates that long - term cabergoline treatment may be efficient in patients with nelson's syndrome.\nthis case demonstrated that cabergoline treatment is able to induce the remission of nelson's syndrome and may be a valid therapeutic alternative in this syndrome.\n"
        },
        {
          "qas": [
            {
              "id": "604903551cb411341a000162_001",
              "question": "Are mucins glycosylated proteins?"
            }
          ],
          "context": "mucin - type o - linked glycosylation\nmucin is a glycoprotein that is the primary component of the mucus overlaying the epithelial tissues.\n\nmucin is a glycoprotein that is the primary component of the mucus overlaying the epithelial tissues.\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\n\nmucin - type o - linked glycosylation\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\n"
        },
        {
          "qas": [
            {
              "id": "601d73ee1cb411341a00003f_001",
              "question": "Is carpal tunnel syndrome a type of nerve entrapment?"
            }
          ],
          "context": "carpal tunnel syndrome ( cts ) is a nerve entrapment disorder, involving the median nerve when it passes the carpal tunnel at the wrist.\ncarpal tunnel syndrome ( cts ) is a common form of peripheral nerve entrapment, which is observed due to compression of the median nerve at the level of the carpal tunnel in the wrist.\n\ncarpal tunnel syndrome is the most frequently encountered peripheral nerve entrapment.\n[ carpal tunnel syndrome and other nerve entrapment syndromes ].\n\nobjective : carpal tunnel syndrome ( cts ) is a common median nerve entrapment neuropathy characterized by pain, paresthesias, diminished peripheral nerve conduction velocity ( ncv ) and maladaptive functional brain neuroplastici\ncarpal tunnel syndrome ( cts ) is a common form of peripheral nerve entrapment, which is observed due to compression of the median nerve at the level of the carpal tunnel in the wrist.\n\ncarpal tunnel syndrome ( cts ) is a common entrapment neuropathy, often requiring carpal tunnel release ( ctr ) surgery.\n[ carpal tunnel syndrome and other nerve entrapment syndromes ].\n"
        },
        {
          "qas": [
            {
              "id": "602905e81cb411341a000108_001",
              "question": "Is there a link between rare variants in PPARG and type 1 diabetes?"
            }
          ],
          "context": "rare variants in pparg with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.\n. considered in aggregate ( with or without computational prediction of functional consequence ), these rare variants showed no association with t2d ( or = 1. 35 ; p = 0. 17 )\n\nclinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\ntreatment of type 1 diabetes with teplizumab : clinical and immunological follow - up after 7 years from diagnosis.\n\nrare variants in pparg with decreased activity in adipocyte differentiation are associated with increased risk of type 2 diabetes.\n. the combination of large - scale dna sequencing and functional testing in the laboratory reveals that approximately 1 in 1, 000 individuals carries a variant in pparg that reduces function in a human adipocyte differentiation assay and is associated\n"
        },
        {
          "qas": [
            {
              "id": "5fd78702a43ad31278000005_001",
              "question": "Does steroid 5A-Reductase deficiency lead to hermaphroditism?"
            }
          ],
          "context": "male pseudo hermaphroditism caused by steroid 5 alpha reductase deficiency is a rare autosomal recessive disorder.\nmale pseudohermaphroditism caused by steroid 5alpha - reductase deficiency is an autosomal recessive disorder.\n\nthe deficiency of steroid 5 alpha - reductase leads to the disturbances in sex differentiation that cause symptoms of male pseudohermaphroditism.\nsteroid 5 - alpha - reductase 2 deficiency is a rare disorder leading to male pseudohermaphroditism, a condition characterized by incomplete differentiation of male genitalia in 46, xy patients.\n\nmale pseudo hermaphroditism caused by steroid 5 alpha reductase deficiency is a rare autosomal recessive disorder.\n5\u03b1 steroid reductase deficiency ( 5\u03b1srd ) is an autosomal recessive enzymatic deficiency and mutations in the 5\u03b1 steroid reductase type 2 gene ( srd5a2 ) result in male pseudohermaphrodism caused by decreased dihydrotestosterone ( dht ) synthesis.\n\n5\u03b1 steroid reductase deficiency ( 5\u03b1srd ) is an autosomal recessive enzymatic deficiency and mutations in the 5\u03b1 steroid reductase type 2 gene ( srd5a2 ) result in male pseudohermaphrodism caused by decreased dihydrotestosterone ( dht ) synthesis.\nmolecular diagnosis of 5\u03b1 - reductase deficiency in 4 elite young female athletes through hormonal screening for hyperandrogenism.\n"
        },
        {
          "qas": [
            {
              "id": "6026db1f1cb411341a0000cf_001",
              "question": "Has ubrogepant entered clinical phase III trials?"
            }
          ],
          "context": "rates of gastrointestinal side effects, headache, and depression.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\n\nubrogepant ( mk - 1602 ) is a novel, oral, calcitonin gene - related peptide receptor antagonist in clinical development with positive phase iii outcomes for acute treatment of migraine.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\n\nubrogepant for the treatment of migraine.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\n\nthis trial supports ubrogepant's efficacy and provides further evidence that cgrp - ras are viable options for the acute treatment of migraine.\ntwo pivotal phase iii clinical trials ( achieve i and achieve ii ) demonstrated effectiveness and safety of ubrogepant in acute migraine attacks.\n\n3 clinical trials and will soon offer novel, effective, well - tolerated nonvasoconstrictor options to treat acute migraine.\ntwo gepants, ubrogepant and rimegepant, have completed positive pivotal trials for acute treatment of migraine, but have not yet been submitted to the fda for this indication.\n"
        },
        {
          "qas": [
            {
              "id": "6031002d1cb411341a000129_001",
              "question": "Are PDXK mutations linked to polyneuropathy?"
            }
          ],
          "context": "mutational signature in colorectal cancer caused by genotoxic pks +\n. response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. results : we identified biallelic mutations in pdxk in 5 individuals from 2 unrelated families with primary axonal\n\nwalk independently during the first year of plp normalization. interpretation : we show that mutations in pdxk cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced pdxk enzymatic activity and low plp\nhereditary polyneuropathy with optic atrophy due to pdxk variant leading to impaired vitamin b6 metabolism\n\nhereditary polyneuropathy with optic atrophy due to pdxk variant leading to impaired vitamin b6 metabolism\n. response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. results : we identified biallelic mutations in pdxk in 5 individuals from 2 unrelated families with primary axonal\n\nwalk independently during the first year of plp normalization. interpretation : we show that mutations in pdxk cause autosomal recessive axonal peripheral polyneuropathy leading to disease via reduced pdxk enzymatic activity and low plp\n. response to supplementation was measured with clinical validated rating scales, electrophysiology, and biochemical quantification. results : we identified biallelic mutations in pdxk in 5 individuals from 2 unrelated families with primary axonal\n"
        },
        {
          "qas": [
            {
              "id": "601d76131cb411341a000044_001",
              "question": "Is avelumab effective for urothelial carcinoma?"
            }
          ],
          "context": "avelumab for the treatment of urothelial cancer.\navelumab, an anti - programmed death - ligand 1 monoclonal antibody approved for the treatment of metastatic merkel cell carcinoma and platinum - treated urothelial carcinoma, was initially approved with a 10 mg / kg weight - based dose.\n\nbackground : avelumab has recently been approved by the food and drug administration for the therapy of merkel cell carcinoma and urothelial carcinoma.\navelumab for the treatment of urothelial cancer.\n\navelumab for the treatment of urothelial cancer.\nconclusion avelumab was well tolerated and associated with durable responses and prolonged survival in patients with refractory metastatic uc.\n\navelumab for the treatment of urothelial cancer.\nnivolumab, pembrolizumab, atezolizumab, durvalumab, and avelumab are among the exciting recent novel therapeutic advances gaining approvals by the fda for treatment of advanced - stage urothelial carcinoma.\n"
        },
        {
          "qas": [
            {
              "id": "601dc46c1cb411341a000050_001",
              "question": "Is MIS-C or Multisystem  Inflammatory syndrome in children a complication of Covid-19?"
            }
          ],
          "context": "multisystem inflammatory syndrome in children ( mis - c ) is a life - threatening post - infectious complication occurring unpredictably weeks after mild or asymptomatic sars - cov2 infection in otherwise healthy children.\ndata on multisystem inflammatory syndrome in children ( mis - c ) related to coronavirus disease - 19 ( covid - 19 ) is increasing in the current covid - 19 pandemic.\n\ndata on multisystem inflammatory syndrome in children ( mis - c ) related to coronavirus disease - 19 ( covid - 19 ) is increasing in the current covid - 19 pandemic.\nmuch remains unknown about the risk factors, pathogenesis, prognosis, and specific therapy for this emerging manifestation of covid - 19 known as multisystem inflammatory syndrome in children ( mis - c ).\n\nhere, we show that pediatric patients with multisystem inflammatory syndrome in children ( mis - c ) possess higher sars - cov - 2 spike igg titers compared to those with severe coronavirus disease 2019 ( covid - 19 ), likely reflecting a longer time since onset\nintroduction multisystem inflammatory syndrome in children ( mis - c ) is a unique clinical complication of sars - cov - 2 infection observed in pediatric patients.\n\nmultisystem inflammatory syndrome in children ( mis - c ) is a life - threatening post - infectious complication occurring unpredictably weeks after mild or asymptomatic sars - cov2 infection in otherwise healthy children.\nmultisystem inflammatory syndrome in children ( mis - c ) associated with coronavirus disease 2019 ( covid - 19 ) is a newly recognized condition in which children with recent sars - cov - 2 infection present with a constellation of symptoms including\n\ndata on multisystem inflammatory syndrome in children ( mis - c ) related to coronavirus disease - 19 ( covid - 19 ) is increasing in the current covid - 19 pandemic.\nmultisystem inflammatory syndrome in children ( mis - c ) associated with coronavirus disease 2019 ( covid - 19 ) is a newly recognized condition in which children with recent sars - cov - 2 infection present with a constellation of symptoms including\n"
        },
        {
          "qas": [
            {
              "id": "6020010a1cb411341a00007c_001",
              "question": "Is co-loss of BRCA2-RB1 associated with better prognosis for prostate cancer patients?"
            }
          ],
          "context": ". together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\ngenomic aberrations of the pten tumour suppressor gene are among the most common in prostate cancer.\n\n. co - loss of brca2 - rb1 in human prostate cancer cells induces an epithelial - to - mesenchymal transition, which is associated with invasiveness and a more aggressive disease phenotype\nin human prostate cancer cell lines ( lncap and lapc4 ), loss of brca2 leads to the castration - resistant phenotype\n\nmetastatic castration - resistant prostate cancer ( mcrpc ) with brca1, brca2 or atm mutations.\nof this aggressive form of prostate cancer offers potential for improved outcomes with early introduction of parp inhibitor - based therapy.\n\nin human prostate cancer cell lines ( lncap and lapc4 ), loss of brca2 leads to the castration - resistant phenotype\nresults : during the median follow - up period of 4. 3 and 3. 1 years, secondary bladder cancer occurred in 11 ( 3. 4 % ) and 5 ( 1. 1 % ) of patients with prostate cancer treated with external beam radiotherapy and radical prostatectomy, respectively.\n"
        },
        {
          "qas": [
            {
              "id": "6028ffae1cb411341a000106_001",
              "question": "Does erenumab target the calcitonin gene-related peptide?"
            }
          ],
          "context": "tocilizumab / actemra is an anti - il - 6r antibody, which can competitively block il - 6 binding to the il - 6r.\nreceptor ( erenumab ) effectively prevent migraine attacks.\n\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\nreceptor ( erenumab ) effectively prevent migraine attacks.\n\ncurrently, there is considerable excitement regarding monoclonal antibodies against calcitonin gene - related peptide ( eptinezumab, galcanezumab, fremanezumab ) and the calcitonin gene - related peptide receptor ( erenumab )\nfour monoclonal antibodies have been developed : one targeting the calcitonin gene - related peptide receptor ( erenumab ) and three targeting the calcitonin gene - related peptide ( eptinezumab, fremanezumab, and galcanezumab ).\n\nrates of gastrointestinal side effects, headache, and depression.\nreceptor ( erenumab ) effectively prevent migraine attacks.\n"
        },
        {
          "qas": [
            {
              "id": "601c44ab1cb411341a00001c_001",
              "question": "Can radiosurgery be used for the DNET tumors?"
            }
          ],
          "context": "this article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\n\nsalvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\nstereotactic radiosurgery ( srs ) has become an important primary or adjuvant management for patients with intracranial meningiomas, but the value of this approach for radiation - induced tumors is unclear.\n\nthis article reviews the unique characteristics and unusual response to the radiation induced meningiomas to radiosurgery.\nalso, lc rates with radiosurgery are at least comparable to those of surgical series for radiation - induced meningiomas\n\nsalvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\nlong - term follow - up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis.\n\nsalvage gamma knife radiosurgery in the management of dysembryoplastic neuroepithelial tumors : long - term outcome in a single - institution case series.\nalso, lc rates with radiosurgery are at least comparable to those of surgical series for radiation - induced meningiomas\n"
        },
        {
          "qas": [
            {
              "id": "6026754f1cb411341a0000c8_001",
              "question": "Should minocycline be used for mild Alzheimer disease?"
            }
          ],
          "context": "conclusions and relevance : minocycline did not delay the progress of cognitive or functional impairment in people with mild ad during a 2 - year period.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n\nefficacy of minocycline in patients with amyotrophic lateral sclerosis : a phase iii randomised trial.\ntwo double - blind, randomized, placebo - controlled feasibility trials of minocycline in als were conducted.\n\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\ncontinuous intraventricular infusion of gm1 has recently been shown to have a significant beneficial effect in alzheimer disease of early onset ( ad type i ). < br >\n"
        },
        {
          "qas": [
            {
              "id": "60290a131cb411341a000109_001",
              "question": "Is there an association of alterations in ADCY7 and ulcerative colitis?"
            }
          ],
          "context": "inactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\n. we discovered a 0. 6 % frequency missense variant in adcy7 that doubles the risk of ulcerative colitis\n\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. we discovered a 0. 6 % frequency missense variant in adcy7 that doubles the risk of ulcerative colitis\n\n. cyld expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.\n. we discovered a 0. 6 % frequency missense variant in adcy7 that doubles the risk of ulcerative colitis\n\n. these data indicate that adamts18 deficiency enhances tumorigenesis and intestinal inflammation through elevated wnt / \u03b2 - catenin and p38mapk / erk1 / 2 signaling and promotes colon cancer in this mouse model.\n. however, upon challenge with a combination of genotoxic ( aom ) and pro - inflammatory ( dss ) agents we found that the number of adenomas in the iec - cyld ( \u03b49 ) mice was dramatically increased compared to the control mice\n\nthe cadm2 gene is associated with processing speed performance - evidence among elderly with type 2 diabetes.\nit a candidate gene for involvement in this gene deletion syndrome.\n"
        },
        {
          "qas": [
            {
              "id": "604906ed1cb411341a000163_001",
              "question": "Are mucin overexpression associated with disease?"
            }
          ],
          "context": "mucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\nmany members of the mucin family are evolutionarily conserved and are often aberrantly expressed and glycosylated in various benign and malig \" \" t pathologies leading to tumor invasion, metastasis, and immune evasion.\n\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nmucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\n\nmuc1 is a membrane glycoprotein, which in adenocarninomas is overexpressed and exhibits truncated o - glycosylation.\nmucin 13 ( muc13 ) is reportedly overexpressed in human malig \" \" cies.\n"
        },
        {
          "qas": [
            {
              "id": "6025fdf41cb411341a0000c0_001",
              "question": "Should nerinetide be used for treatment of ischaemic stroke?"
            }
          ],
          "context": ". serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nthese observations provide several possible mechanisms for central nervous system - related clinical deterioration that occurred when enlimomab was given in acute ischemic stroke.\n\nin the overall study population, treatment with intravenous lubeluzole within 6 h of the onset of ischaemic stroke did not affect mortality or clinical outcome.\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\n\n. serious adverse events occurred equally between groups. interpretation : nerinetide did not improve the proportion of patients achieving good clinical outcomes after endovascular thrombectomy compared with patients receiving placebo. funding : canadian\nthe authors investigated whether the lack of effect of tirilazad on clinical outcome in patients with acute ischemic stroke is explained by failure of tirilazad to reduce infarct volume.\n"
        },
        {
          "qas": [
            {
              "id": "6026de661cb411341a0000d1_001",
              "question": "Are there small molecule CGRPs under development for the treatment of migraine?"
            }
          ],
          "context": "meanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\nrates of gastrointestinal side effects, headache, and depression.\n\ngiving additional cgrp - based therapeutic options for migraine patients.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\n\nrecently, orally administered next - generation small molecule cgrp - ras have been shown to have safety and efficacy in acute treatment ( ubrogepant and rimegepant ) and prevention ( atogepant ) of migraine, giving additional cgrp - based therapeutic options\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\n"
        },
        {
          "qas": [
            {
              "id": "6026ee821cb411341a0000d3_001",
              "question": "Is eptinezumab a small molecule?"
            }
          ],
          "context": "the cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\neptinezumab - jjmr ( referred to as eptinezumab hereafter ; vyepti\u2122 ) is a humanised monoclonal antibody that binds to calcitonin gene - related peptide ( cgrp ) and blocks its binding to the receptor.\n\nalthough several questions remain, such as duration of treatment, cost effectiveness and long - term efficacy and tolerability, current evidence indicates that eculizumab is a valuable emerging therapy for patients with refractory gmg.\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\n\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\nrates of gastrointestinal side effects, headache, and depression.\n\nsmall molecules ( e. g. ligustrazine and sp600125 ) and large molecule antibodies ( e. g. lebrikizumab, benralizumab, dupilumab ) are being considered as novel agents for the pharmacotherapy of asthma.\nthe cgrp ligand ( eptinezumab, fremanezumab, galcanezumab ) or the cgrp receptor ( erenumab ).\n"
        },
        {
          "qas": [
            {
              "id": "60324b771cb411341a000139_001",
              "question": "Is the apilimod inhibitor effective against SARS-CoV-2?"
            }
          ],
          "context": "early treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nis a monoclonal antibody that works directly against the spike protein of sars - cov - 2 to block its attachment and entry into a human cell.\n\nwe collected serological data of patients with covid - 19 who were treated with regn - cov 1200 mg ( casirivimab 600 mg / imdevimab 600 mg ).\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\n\nwe collected serological data of patients with covid - 19 who were treated with regn - cov 1200 mg ( casirivimab 600 mg / imdevimab 600 mg ).\nthere has been a lot of speculation that patients with coronavirus disease 2019 ( covid - 19 ) who are receiving angiotensin - converting enzyme ( ace ) inhibitors or angiotensin receptor blockers ( arbs ) may be at increased risk for adverse outcomes.\n\nearly treatment for covid - 19 with sars - cov - 2 neutralizing antibody sotrovimab\nms that monoclonal antibodies ( e. g., low dosage bamlanivimab, baricitinib, imatinib, and sotrovimab ) are a better choice for treating severe or non - severe covid - 19 patients. clini\n"
        },
        {
          "qas": [
            {
              "id": "602673e91cb411341a0000c7_001",
              "question": "Is Lanabecestat effective for Alzheimer's disease?"
            }
          ],
          "context": "conclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n\nconclusions and relevance : treatment with lanabecestat was well tolerated and did not slow cognitive or functional decline.\nintroduction : the apecs and amaranth trials showed that beta - secretase ( bace ) inhibitors verubecestat and lanabecestat failed to slow cognitive and functional decline in individuals with prodromal or early alzheimer's disease.\n"
        },
        {
          "qas": [
            {
              "id": "601c46f61cb411341a00001d_001",
              "question": "Was golimumab tested for diabetes?"
            }
          ],
          "context": "clinical studies are investigating whether tocilizumab ( anti - il - 6 receptor ) can help preserve beta cell function in patients recently diagnosed with t1d\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\n\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\nintroduced monoclonal antibodies ( infliximab, etanercept, adaluimumab, golimumab, rituximab ), tested for efficacy in other pathologies associated with the formation of granulomas, have a limited application in patients with sa.\n\nto receive subcutaneous golimumab or placebo for 52 weeks\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\n\nalthough treatment was well tolerated, neither ustekinumab nor golimumab demonstrated efficacy in pulmonary sarcoidosis.\ngolimumab and beta - cell function in youth with new - onset type 1 diabetes\n"
        },
        {
          "qas": [
            {
              "id": "604fc22894d57fd879000008_001",
              "question": "Is G3BP1 found in stress granules?"
            }
          ],
          "context": "ras gtpase - activating protein - binding protein ( g3bp1 ) is an rna - binding protein that is essential for assembling stress granules.\nthe selenoenzyme gpx4 is essential for early embryogenesis and cell viability for its unique function to prevent phospholipid oxidation.\n\nras gtpase - activating protein - binding protein ( g3bp1 ) is an rna - binding protein that is essential for assembling stress granules.\ncation stress and glucose starvation selectively caused chromatin structure alteration around cre - like sequences in cta3 ( + ) and fbp1 ( + ) promoters, respectively, in correlation with transcriptional activation.\n\nras gtpase - activating protein - binding protein ( g3bp1 ) is an rna - binding protein that is essential for assembling stress granules.\n. nup358 localizes to the nuclear pore complex and to the cytoplasmic annulate lamellae ( al ), and these structures dynamically associate with two mrnp granules : processing bodies ( p bodies ) and stress granules ( sgs ).\n"
        },
        {
          "qas": [
            {
              "id": "5fdb4290a43ad31278000024_001",
              "question": "Do polycomb group proteins (PcG) mediate the formation of chromatin loops?"
            }
          ],
          "context": "polycomb action at a distance can be organized by local chromatin topology\npcg proteins, dna methylation, and gene repression by chromatin looping.\n\nrepressive loops within polycomb domains are formed after the midblastula transition between polycomb response elements by the action of gaga factor and polycomb proteins.\npolycomb - mediated chromatin loops revealed by a subkilobase - resolution chromatin interaction map.\n\npcg proteins, dna methylation, and gene repression by chromatin looping.\npolycomb - mediated chromatin loops revealed by a subkilobase - resolution chromatin interaction map.\n\npcg proteins, dna methylation, and gene repression by chromatin looping.\nrepressive loops within polycomb domains are formed after the midblastula transition between polycomb response elements by the action of gaga factor and polycomb proteins.\n"
        },
        {
          "qas": [
            {
              "id": "5fe31319a43ad31278000046_001",
              "question": "Can ATAC-Seq be employed in single-cell mode?"
            }
          ],
          "context": "single - cell atac - seq ( scatac - seq ) maps from hundreds of single cells in aggregate closely resemble accessibility profiles from tens of millions of cells and provide insights into cell - to - cell variation.\nsingle - cell atac - seq ( scatac - seq ) technology has also been developed to study cell type - specific chromatin accessibility in tissue samples containing a heterogeneous cellular population.\n\nsingle - cell atac - seq ( scatac - seq ) maps from hundreds of single cells in aggregate closely resemble accessibility profiles from tens of millions of cells and provide insights into cell - to - cell variation.\nchroma can analyze single cell atac - seq data, correcting many biases generated by the sparse sampling inherent in single cell technologies.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb42fba43ad31278000027_001",
              "question": "Are there negative enhancers?"
            }
          ],
          "context": "enhancers have been identified at up to megabase distances from their regulated genes, and / or proximal to or within the introns of unregulated genes.\nmutations targeted to the carg - like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation\n\nrepressed or display condition - specific enhancer activity.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\n\nsuper - enhancers and preventing cross talk between distinct regulatory elements.\nenhancer regions contain multiple muscle - type - specific positive and negative cis - acting elements which together contribute toward full expression of the gene.\n\nclones in which the transgene was down - regulated by dexamethasone survived and were designated att - 20 / net ( for negative enhancer trap ).\nmutations targeted to the carg - like motif abolished the suppressive effect of the negative enhancer and the inducibility of the promoter during myogenic differentiation\n\n. our results suggest that the activity of the negative enhancer may determine the level of expression of the cox vb gene in different tissue\nthe proteins encoded by these genes, whose expression is often tissue - specific, act as epigenetic suppressors contributing to the addition of repressive chromatin marks and dna methylation.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb42b7a43ad31278000025_001",
              "question": "Are super enhancers structurally insulated in chromatin loops?"
            }
          ],
          "context": "in this review, it is argued that the relationship between the accessibility and activity of an enhancer is insufficiently described by simply considering open versus closed chromatin, or active versus inactive enhancers.\ndissecting super - enhancer hierarchy based on chromatin interactions\n\ndissecting super - enhancer hierarchy based on chromatin interactions\npcg proteins, dna methylation, and gene repression by chromatin looping.\n\ndissecting super - enhancer hierarchy based on chromatin interactions\nsuper - enhancers and preventing cross talk between distinct regulatory elements.\n\ndissecting super - enhancer hierarchy based on chromatin interactions\na number of studies have recently demonstrated that super - enhancers, which are large cluster of enhancers typically marked by a high level of acetylation of histone h3 lysine 27 and mediator bindings, are frequently associated with genes that control\n\ndissecting super - enhancer hierarchy based on chromatin interactions\nfunctional enhancers, in contrast with accessible chromatin regions that lack enhancer activity, were enriched for enhancer rnas ( ernas ) and preferentially interacted in vivo with b cell lineage - determining transcription factors.\n"
        },
        {
          "qas": [
            {
              "id": "6060e1a094d57fd879000049_001",
              "question": "Does IL18 signaling have a role in thymus?"
            }
          ],
          "context": "in the thymus, mature cd4 + cd8 - and cd4 - cd8 + t cells expressing alpha beta t - cell antigen receptors ( tcr ) develop from immature thymocytes through cd4 + cd8 + alpha beta tcr + intermediates.\ncollectively, this study provides a detailed characterization of the mature treg subsets in the mouse thymus and identifies a key role of il18 signaling in controlling the ccr6 - ccl20 - dependent migration of tregs into the thymus.\n\nthymic satb1 protein was reduced significantly in these mice, and the major cellular phenotype observed was a significant reduction in the percentage of cd8sp t cells in thymus, spleen, and lymph nodes.\ncollectively, this study provides a detailed characterization of the mature treg subsets in the mouse thymus and identifies a key role of il18 signaling in controlling the ccr6 - ccl20 - dependent migration of tregs into the thymus.\n\nimmune system and plays a role as a signaling and costimulatory molecule on t lymphocytes.\ncollectively, this study provides a detailed characterization of the mature treg subsets in the mouse thymus and identifies a key role of il18 signaling in controlling the ccr6 - ccl20 - dependent migration of tregs into the thymus.\n"
        },
        {
          "qas": [
            {
              "id": "601c18921cb411341a00000f_001",
              "question": "Does an antiphlogistic promotes inflammation?"
            }
          ],
          "context": "antiphlogistics were found to enhance the membrane viscosity both in control and under inflammation.\nthe antiphlogistic ibuprofen incorporated in liposomes caused a decrease of the inflammatory edema induced by carragee in the distal part of the rat's hind leg after both the intramuscular and percutaneous administration.\n\nantiphlogistics were found to enhance the membrane viscosity both in control and under inflammation.\nwith dexamethasone, a powerful antiphlogistic drug.\n\nwith dexamethasone, a powerful antiphlogistic drug.\nanalgesics or antipyretic medications are often used to alleviate vaccine side effects, but their effect on immunogenicity remains uncertain.\n"
        },
        {
          "qas": [
            {
              "id": "6020ad161cb411341a000082_001",
              "question": "Is liraglutide effective for weight reduction?"
            }
          ],
          "context": "conclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\nliraglutide ( lira ) treatment is associated with the dose - dependent reduction of weight. hig\n\nliraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials.\nconclusions : low - dose liraglutide still has high efficacy in weight reduction in taiwanese people, especially for those of younger age.\n\nliraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials.\nconclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\n\nconclusions and relevance : among overweight and obese participants with type 2 diabetes, use of subcutaneous liraglutide ( 3. 0 mg ) daily, compared with placebo, resulted in weight loss over 56 weeks.\nconclusion : in patients with t1d, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.\n\nliraglutide is associated with body weight loss, and reductions in systolic blood pressure have been observed throughout the clinical trials.\nconclusion : in patients with t1d, liraglutide might prove be an adjunct to insulin, improving glycemic control, inducing body weight loss and decreasing exogenous insulin requirements and severe hypoglycemia.\n"
        },
        {
          "qas": [
            {
              "id": "6020b0e21cb411341a000085_001",
              "question": "Is Eflornithine and Sulindac are effective for prevention of progression in Familial Adenomatous Polyposis?"
            }
          ],
          "context": "0. 71 ( 95 % confidence interval [ ci ], 0. 39 to 1. 32 ) for eflornithine - sulindac as compared with sulindac ( p = 0. 29 ) and 0. 66 ( 95 % ci, 0. 36 to 1. 24 ) for eflornithine - sulindac as compared with eflornithine.\neflornithine plus sulindac for prevention of progression in familial adenomatous polyposis\n\neflornithine plus sulindac for prevention of progression in familial adenomatous polyposis\nseveral new drugs have been approved to treat rare genetic disorders : setmelanotide for certain conditions causing obesity ; lumasiran for primary hyperoxaluria type 1, a kidney disorder ; and lonafarnib for two diseases that cause premature aging.\n"
        },
        {
          "qas": [
            {
              "id": "602498cb1cb411341a00009e_001",
              "question": "Is Olaparib effective for prostate cancer?"
            }
          ],
          "context": "experience with olaparib for prostate cancer at a comprehensive cancer center, and future directions of olaparib for the treatment of mcrpc.\npatient summary : a large clinical study concluded that treatment with the parp inhibitor olaparib benefits men with metastatic castration - resistant prostate cancer whose tumors harbor alterations in 15 different dna repair genes.\n\nexperience with olaparib for prostate cancer at a comprehensive cancer center, and future directions of olaparib for the treatment of mcrpc.\nolaparib targets some advanced prostate cancers.\n\nin a phase ii study, researchers found that the parp inhibitor olaparib led to stable disease or tumor regressions in patients with advanced breast, ovarian, pancreatic, and prostate cancers who had germline mutations in brca1 or brca2.\npatient summary : a large clinical study concluded that treatment with the parp inhibitor olaparib benefits men with metastatic castration - resistant prostate cancer whose tumors harbor alterations in 15 different dna repair genes.\n"
        },
        {
          "qas": [
            {
              "id": "6025fd261cb411341a0000bf_001",
              "question": "Is isradipine effective for Parkinson's disease?"
            }
          ],
          "context": "these findings suggest that greater exposure to isradipine might slow disease progression.\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\n\nhowever, in a recently completed phase 3 clinical trial, the dihydropyridine ( dhp ) ltcc inhibitor isradipine failed to slow disease progression in early pd patients, questioning the feasibility of dhps for pd therapy.\nresults : isradipine exposures did not correlate with the primary clinical outcome, changes in the antiparkinson therapy - adjusted unified parkinson's disease rating scale parts i - iii score over 36 months ( spearman rank correlation coefficient, rs :\n"
        },
        {
          "qas": [
            {
              "id": "6026c1071cb411341a0000cb_001",
              "question": "Is MK-1602 a CGRP antagonist?"
            }
          ],
          "context": "area covered : this review reports on compounds currently under development for the oral treatment of acute migraine attacks, focusing on calcitonin - gene - related - peptide receptor antagonists, specifically ubrogepant and rimegepant.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\n\nthe cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\n3 clinical trials and will soon offer novel, effective, well - tolerated nonvasoconstrictor options to treat acute migraine.\n\nrates of gastrointestinal side effects, headache, and depression.\n. other relevant safety findings associated with semagacestat treatment included cognitive and functional worsening, skin - related teaes, renal and hepatic changes, increased qt interval, and weight loss.\n\nthe cgrp receptor antagonist ubrogepant, also known as mk - 1602, has been recently evaluated in phase iii clinical trials for clinical efficacy and long - term safety as an abortive migraine treatment.\nmeanwhile, 1 small - molecule cgrp receptor antagonist ( ubrogepant, mk - 1602 ) is currently in phase 3 studies for the acute treatment of migraine.\n"
        },
        {
          "qas": [
            {
              "id": "6027dc011cb411341a0000eb_001",
              "question": "Does inactivation of CYLD help in colorectal cancer?"
            }
          ],
          "context": ". in the present study we evaluated the role of intestinal epithelial cyld in colitis - associated cancer using a conditional mouse cyld inactivation model. methods : in order to evaluate the role of cyld in intestinal epithelial carcinogenesis, mice\ninactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\n\ninactivation of cyld in intestinal epithelial cells exacerbates colitis - associated colorectal carcinogenesis - a short report\n. cyld expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.\n\n. the tumor - suppressing function of cyld is associated with its deubiquitinating activity, which maps to the carboxyl - terminal region of the protein\n. cyld expression and its associated pathways in intestinal tumors may be exploited for future prognostic and therapeutic purposes.\n"
        },
        {
          "qas": [
            {
              "id": "60290c2b1cb411341a00010a_001",
              "question": "Is there high nucleotide diversity in the Drosophila suzukii species?"
            }
          ],
          "context": "zelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\n. our results indicate high levels of nucleotide diversity in this species and suggest that the recent invasions of europe and the continental united states are independent demographic events.\n\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\n. here we used natural genetic variation across a panel of 81 drosophila lines to measure changes in transcriptional start site ( tss ) usage, identifying thousands of genetic variants affecting transcript levels ( strength ) or the distribution of tsss\n\n. here we used natural genetic variation across a panel of 81 drosophila lines to measure changes in transcriptional start site ( tss ) usage, identifying thousands of genetic variants affecting transcript levels ( strength ) or the distribution of tsss\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n"
        },
        {
          "qas": [
            {
              "id": "60327e541cb411341a00013e_001",
              "question": "Is Hunter's disease is associated with the X Chromosome?"
            }
          ],
          "context": "brother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation.\nwe describe a 3 year old girl with the typical clinical features of the x linked recessive condition, hunter's disease.\n\nbrother / sister siblings affected with hunter disease : evidence for skewed x chromosome inactivation.\nthe normal x chromosome was preferentially inactivated, supporting the view that the translocation had disrupted the hunter gene.\n\nintroduction : hunter syndrome, or mucopolysaccharidosis type ii, is an inherited disease linked to the x chromosome that is caused by a deficit of the enzyme iduronate - 2 - sulfatase and its main symptoms affect the bones, neurological system and the\nwe describe a 3 year old girl with the typical clinical features of the x linked recessive condition, hunter's disease.\n\nthe treatment of fshd is currently supportive only.\nwe describe a 3 year old girl with the typical clinical features of the x linked recessive condition, hunter's disease.\n"
        },
        {
          "qas": [
            {
              "id": "60328f351cb411341a000145_001",
              "question": "Can Freund's complete adjuvant induce arthritis?"
            }
          ],
          "context": "complete freund's adjuvant ( cfa ) induced ra\nrheumatoid arthritis ( ra ) was induced by freund's complete adjuvant ( fca ; 1 mg / 0. 1 ml paraffin oil ), injected subcutaneously on days 0, 30 and 40\n\nthis effect is probably due to a direct influence on the immune system\nthe ra model was established using freund's complete adjuvant,\n\nthe ra model was established using freund's complete adjuvant,\nthe rats were made arthritic using a subcutaneous injection with 0. 1 ml complete freund's adjuvant ( cfa ) into the footpad of the left hind paw.\n\nother disease modifying antirheumatic drugs and biologic agents, as they became available.\nthe rational use of methotrexate in rheumatoid arthritis and other rheumatic diseases.\n\ncomplete freund's adjuvant ( cfa ) induced ra\nthe ra model was established using freund's complete adjuvant,\n"
        },
        {
          "qas": [
            {
              "id": "603291f21cb411341a000146_001",
              "question": "Can saponins be used as adjuvant?"
            }
          ],
          "context": ". these results confirm that momordica saponins are a viable natural source to provide potent saponin adjuvants\nwe report the design, synthesis, immunological evaluation, and conformational analysis of new saponin variants as promising vaccine adjuvants\n\na saponin - based matrix - m\u2122 adjuvant\nwe report the design, synthesis, immunological evaluation, and conformational analysis of new saponin variants as promising vaccine adjuvants\n\na saponin - based matrix - m\u2122 adjuvant\n. these results confirm that momordica saponins are a viable natural source to provide potent saponin adjuvants\n"
        },
        {
          "qas": [
            {
              "id": "603bc16b1cb411341a000158_001",
              "question": "Is erabutoxin b usually found in plants?"
            }
          ],
          "context": "the variants are the curaremimetic toxin alpha from naja nigricollis and erabutoxin a or b from laticauda semifasciata\na systematic computer search of the three - dimensional structure of erabutoxin b ( an alpha - neurotoxin from the false sea snake laticauda semifasciata ) was performed to identify the locality that most closely matched the amino acid compositions of the\n\nthe three - dimensional structure of erabutoxin b, a short - chain neurotoxic peptide purified from the venom of the sea snake laticauda semifasciata,\nthe short neurotoxins to which erabutoxins belong act by blocking the nicotinic acetylcholine receptor\n\nthe three - dimensional structure of erabutoxin b, a short - chain neurotoxic peptide purified from the venom of the sea snake laticauda semifasciata,\nthe method was applied to a study of erabutoxin b molecule, a neurotoxic protein from a sea snake, to analyze the microenvironments of its single tryptophan and tyrosine residues.\n\nthe method was applied to a study of erabutoxin b molecule, a neurotoxic protein from a sea snake, to analyze the microenvironments of its single tryptophan and tyrosine residues.\nerabutoxin c, a minor neurotoxic component of the venom of a sea snake laticauda semifasciata, was isolated in pure form by repeated column chromatography on cm - cellulose columns.\n"
        },
        {
          "qas": [
            {
              "id": "603285861cb411341a000141_001",
              "question": "Are Toll-like receptors (TLRs) induced by microbes?"
            }
          ],
          "context": "toll - like receptor 9 ( tlr9 ) activation is attributed to delivery of bacterial dna\nthe c - type lectin receptor clec4e and toll - like receptor tlr4 expressed by host cells are among the first line of defense in encountering pathogens.\n"
        },
        {
          "qas": [
            {
              "id": "603e43d51cb411341a00015e_001",
              "question": "Is Ixodes a species of tick?"
            }
          ],
          "context": "ontinent. zoonotic babesia is vectored by ixodes ticks and is commonly transmitted in north america by ixodes scapularis, the tick species responsible for transmitting the pathogens that also cause lyme disease, powassan virus, and anaplasmosis in hu\nbiology of ixodes species ticks in relation to tick - borne zoonoses.\n\namong the various species of hard ticks, ixodes ricinus is the most frequently found tick throughout europe.\nthe ixodes ricinus species complex is a group of ticks distributed in almost all geographic regions of the world.\n\ntick, ixodes ricinus\nbiology of ixodes species ticks in relation to tick - borne zoonoses.\n\nixodid ticks\ntick, ixodes ricinus\n"
        },
        {
          "qas": [
            {
              "id": "60367f5e1cb411341a000157_001",
              "question": "Is HbA1c an ideal biomarker of well-controlled diabetes?"
            }
          ],
          "context": "hba1c is a biomarker with a central role in the diagnosis and follow - up of patients with diabetes, although not a perfect one\ndiscovery and validation of hsa _ circ _ 0001953 as a potential biomarker for proliferative diabetic retinopathy in human blood.\n\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nhba1c is a biomarker with a central role in the diagnosis and follow - up of patients with diabetes, although not a perfect one\n\nin men at risk for diabetes ( hba1c 5. 7 - 6. 4 %, fpg 100 - 125mg / dl, or ogtt - 2h - pg 140 - 199mg / dl ), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations ( 10. 6 % / year\nhba1c is a biomarker with a central role in the diagnosis and follow - up of patients with diabetes, although not a perfect one\n"
        },
        {
          "qas": [
            {
              "id": "6057003594d57fd879000020_001",
              "question": "Are the major royal jelly proteins similar to the yellow proteins?"
            }
          ],
          "context": "the expression of four of the major royal jelly proteins ( mrjp1, mrjp2, mrjp4, and mrjp5 ) and also several proteins associated with carbohydrate metabolism and energy synthesis, the antioxidant system, detoxification, biosynthesis, amino acid\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\n\nanalysis of drosophila yellow - b cdna reveals a new family of proteins related to the royal jelly proteins in the honeybee\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\n"
        },
        {
          "qas": [
            {
              "id": "6057014c94d57fd879000022_001",
              "question": "Is the Apis mellifera genome available?"
            }
          ],
          "context": "we show that the honeybee genome is structured with respect to plasticity ; genes that respond to an environmental trigger are colocated in the honeybee genome in a series of gene clusters, many of which have been assembled in the last 80 my during\nmining apis mellifera sequences made it possible to identify the honey bee subspecies both at the mitochondrial and nuclear genome levels.\n\nwe have mined histone methyltransferases and demethylases from the whole genome sequence of aedes aegypti ( diptera ), the pea aphid acyrthosiphon pisum, the triatomid bug rhodnius prolixus ( hemiptera ), the honeybee apis mellifera ( hymenoptera ),\nmining apis mellifera sequences made it possible to identify the honey bee subspecies both at the mitochondrial and nuclear genome levels.\n"
        },
        {
          "qas": [
            {
              "id": "60570af094d57fd879000025_001",
              "question": "Has the olive tree pollen proteome been studied?"
            }
          ],
          "context": "two - dimensional electrophoresis was used for the fractionation of royal jelly proteins\n. we have combined available genomics data with a comprehensive proteomics approach to get the annotated olive tree ( olea europaea l. ) pollen proteome and define its complex allergenome.\n\n. we have combined available genomics data with a comprehensive proteomics approach to get the annotated olive tree ( olea europaea l. ) pollen proteome and define its complex allergenome.\nolive pollen is a major allergenic source worldwide due to its extensive cultivation\n"
        },
        {
          "qas": [
            {
              "id": "6060c7c094d57fd879000046_001",
              "question": "Is cadherin a plasma membrane marker?"
            }
          ],
          "context": "recycling of ve - cadherin to the plasma membrane,\nve - cadherin protein levels were also increased in the plasma membrane fraction.\n\nthe plasma membrane - bound e - cadherin protein\ne - cadherin, a central component of the adherens junction ( aj ), is a single - pass transmembrane protein\n\nve - cadherin protein levels were also increased in the plasma membrane fraction.\ncomparative glycomic profiling of esophageal adenocarcinoma reveals a subset of glycans that can be selected as candidate biomarkers\n\n( vcam - 1 ), platelet - endothelial cell adhesion molecule - 1 ( pe - cam - 1 ), and mucosal addressin cell adhesion molecule - 1 ( madcam - 1 ).\nve - cadherin protein levels were also increased in the plasma membrane fraction.\n\nthe plasma membrane - bound e - cadherin protein\nve - cadherin protein levels were also increased in the plasma membrane fraction.\n"
        },
        {
          "qas": [
            {
              "id": "5fe31304a43ad3127800003a_001",
              "question": "Is methotrexate used for the treatment of Rheumatoid Arthritis (RA)?"
            }
          ],
          "context": "methotrexate is generally the first - line drug for the treatment of ra, psoriatic arthritis and other forms of inflammatory arthritis, and it enhances the effect of most biologic agents in ra.\nthe use of methotrexate in rheumatoid arthritis.\n\nthe use of methotrexate in rheumatoid arthritis.\nthe safety and efficacy of the use of methotrexate in long - term therapy for rheumatoid arthritis.\n\nmethotrexate has been used in treatment of rheumatoid arthritis ( ra ) since the 1980s and to this day is often the first line medication for ra treatment.\nthe use of methotrexate in rheumatoid arthritis.\n"
        },
        {
          "qas": [
            {
              "id": "605e3c8294d57fd879000037_001",
              "question": "Is atenolol metabolized by CYP2D6?"
            }
          ],
          "context": "among these beta - blockers atenolol is mainly eliminated by renal excretion, bisoprolol is in part excreted as parent compound via the renal route ( 50 % ), the other 50 % are hepatically metabolised, whereas metoprolol and carvedilol are metabolised by\nanother enzymatic pathway, the cytochrome p450 ( cyp ) system.\n\nmetformin's effects on lipids and atherosclerotic vascular disease and / or provide insights into the drug's mechanisms of action on the heart and vasculature.\nmetoprolol and carvedilol are metabolised by cyp2d6.\n\namong these beta - blockers atenolol is mainly eliminated by renal excretion, bisoprolol is in part excreted as parent compound via the renal route ( 50 % ), the other 50 % are hepatically metabolised, whereas metoprolol and carvedilol are metabolised by\nmetoprolol and carvedilol are metabolised by cyp2d6.\n"
        },
        {
          "qas": [
            {
              "id": "606b3b6794d57fd879000064_001",
              "question": "Is the glucocorticoid receptor a transcription factor?"
            }
          ],
          "context": "the glucocorticoid receptor ( gr ) is a ligand - activated transcription factor that translocates to the nucleus upon hormone stimulation and distributes between the nucleoplasm and membraneless compartments named nuclear foci.\nthe glucocorticoid receptor ( gr ) is a ligand - binding dependent transcription factor that ultimately regulates vital biological processes and inflammation response through specific gene expression control, thus representing a notable drug target to\n"
        },
        {
          "qas": [
            {
              "id": "601fff6a1cb411341a00007b_001",
              "question": "Are there sex differences in oncogenic mutational processes?"
            }
          ],
          "context": "sex differences in oncogenic mutational processes.\nextensive changes in dna methylation are common in cancer and may contribute to oncogenesis through transcriptional silencing of tumor - suppressor genes.\n\nsex differences in oncogenic mutational processes.\nfor breast cancer, the rates and age of onset appear to vary significantly in regions differentially affected by the chernobyl accident.\n\nsex differences in oncogenic mutational processes.\ngenomic aberrations of the pten tumour suppressor gene are among the most common in prostate cancer.\n\nsex differences in oncogenic mutational processes.\n. when these processes go awry through mutation or misexpression of certain regulatory elements, the subsequent deregulation of oncogenic gene expression can drive or enhance cancer pathogenesis.\n\nsex differences in oncogenic mutational processes.\nfrom skewed x inactivation of the paternal nonmutant x chromosome.\n"
        },
        {
          "qas": [
            {
              "id": "606a232a94d57fd87900004c_001",
              "question": "Is metoprolol metabolized by CYP2D6?"
            }
          ],
          "context": "metoprolol and carvedilol are metabolised by cyp2d6.\nor ssris without significant cyp2d6 inhibition ( citalopram / escitalopram / sertraline ), and the related prescribing of cyp2d6 - independent comparator drugs ( atenolol, rivastigmine, propoxyphene, anastrozole ).\n\namong these beta - blockers atenolol is mainly eliminated by renal excretion, bisoprolol is in part excreted as parent compound via the renal route ( 50 % ), the other 50 % are hepatically metabolised, whereas metoprolol and carvedilol are metabolised by\nmetoprolol and carvedilol are metabolised by cyp2d6.\n\nthe study analysed the prescribing and dispensing of cyp2d6 drugs ( metoprolol, donepezil, galantamine, codeine, tamoxifen ) together with cyp2d6 - blocking ssris ( paroxetine / fluoxetine ) or ssris without significant cyp2d6 inhibition\nmetoprolol and carvedilol are metabolised by cyp2d6.\n"
        },
        {
          "qas": [
            {
              "id": "60292e1b1cb411341a000111_001",
              "question": "Does Curare function by stimulating the acetylcholine receptor?"
            }
          ],
          "context": "in aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ach receptor, but rather to be a specific blocking agent for a class of receptor - activated na + and cl - responses.\nusual clinical concentrations of curare cause competitive inhibition of muscle nicotinic acetylcholine receptors while higher concentrations may induce open channel blockade.\n\nin aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ach receptor, but rather to be a specific blocking agent for a class of receptor - activated na + and cl - responses.\nthe mode of action of curare, a well - known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique.\n\nin aplysia nervous tissue, curare appears not to be a specific antagonist for the nicotinic ach receptor, but rather to be a specific blocking agent for a class of receptor - activated na + and cl - responses.\ncurare binding and the curare - induced subconductance state of the acetylcholine receptor channel.\n\nusual clinical concentrations of curare cause competitive inhibition of muscle nicotinic acetylcholine receptors while higher concentrations may induce open channel blockade.\nthe mode of action of curare, a well - known competitive antagonist of acetylcholine at the nicotinic receptor, was examined with the single channel recording technique.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb2ee4a43ad3127800000f_001",
              "question": "Are somatic mutations positioned towards the nuclear periphery?"
            }
          ],
          "context": "we found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\n. for instance, smoking and uv - related signatures, as well as substitutions at certain motifs, were more enriched in the nuclear periphery.\n\nsex differences in oncogenic mutational processes.\nwe found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\n\nwe found that lamina - associated regions, which are typically localized at the nuclear periphery, displayed higher somatic mutation frequencies than did the interlamina regions at the nuclear core.\nthe transgenerational changes in mutation rates were attributed to the presence of a persistent subset of endogenous dna lesions ( double - and single - strand breaks ), measured by the phosphorylated form of histone h2ax ( gamma - h2ax ) and alkaline comet\n\n. their function and distribution around important regulatory genes raises the question of how they relate to 3d conformation of these loci\na valuable approach to understand how individual and population genetic differences can predispose to disease is to assess the impact of genetic variants on cellular functions ( e. g., gene expression ) of cell and tissue types related to pathological\n"
        },
        {
          "qas": [
            {
              "id": "6020ab801cb411341a000081_001",
              "question": "Is belimumab effective for the lupus nephritis?"
            }
          ],
          "context": "a secondary analysis of the belimumab international study in lupus nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis.\nclinical efficacy of routinely administered belimumab on proteinuria and neuropsychiatric lupus.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb4311a43ad31278000028_001",
              "question": "Are enhancers directional in their targeting of gene promoters?"
            }
          ],
          "context": ". over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.\nenhancers function independently of their distance and orientation to the promoters of target genes.\n\ndissecting super - enhancer hierarchy based on chromatin interactions\nenhancers function independently of their distance and orientation to the promoters of target genes.\n\n. although these regulatory elements are often distant from their target genes, they affect gene expression by recruiting transcription factors to specific promoter regions.\nthese promoters initiate transcription in opposite directions and are separated only by a short enhancer region, which is likely to regulate both promoters simultaneously.\n\n. over the past decade it has become clear that to do this, enhancers come into close proximity with target promoters with the looping away of intervening sequences.\nenhancers are intergenic dna elements that regulate the transcription of target genes in response to signaling pathways by interacting with promoters over large genomic distances.\n"
        },
        {
          "qas": [
            {
              "id": "606b718994d57fd87900006b_001",
              "question": "Has dupilumab been FDA approved for atopic dermatitis?"
            }
          ],
          "context": "in addition, dupilumab is currently under phase iii development across the world for the treatment of asthma and nasal polyposis as well as for atopic dermatitis in paediatric patients.\ndupilumab : a novel treatment for asthma.\n\ndupilumab is the first biological treatment approved for moderate - to - severe atopic dermatitis ( ad ).\ndupilumab is the first us fda approved biologic for treatment of atopic dermatitis.\n\nthe efficacy and safety profile of dupilumab in the treatment of allergic diseases has been tested for more than 10 years in a variety of large clinical trials in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, and\ndupilumab is the first us fda approved biologic for treatment of atopic dermatitis.\n"
        },
        {
          "qas": [
            {
              "id": "6025dd0c1cb411341a0000b9_001",
              "question": "Should cerebrolysin be used for aneurysmal subarachnoid hemorrhage?"
            }
          ],
          "context": "and mortality in patients with acute aneurysmal subarachnoid hemorrhage.\nconclusion : cerebrolysin injection during the acute period of sah appeared to reduce the mortality rate, especially in poor - grade patients. this study suggests the potential of cerebrolysin for treating aneurysmal sah\n\nand mortality in patients with acute aneurysmal subarachnoid hemorrhage.\nstay, and mortality in patients with acute aneurysmal subarachnoid hemorrhage.\n"
        },
        {
          "qas": [
            {
              "id": "603213ea1cb411341a000131_001",
              "question": "Do bacteria release extracellular vesicles?"
            }
          ],
          "context": "bacterial extracellular vesicles ( evs ) are bilayered lipid membrane structures, bearing integral proteins and able to carry diverse cargo outside the cell to distant sites.\nbacteria derived - extracellular vesicles\n\nrelease of extracellular vesicles ( evs ) is a common feature among eukaryotes, archaea, and bacteria. however, the biogenesis and downstream biological effects of evs released from gram - positive bacteria remain poorly characterized.\nbacteria derived - extracellular vesicles\n\nknowledge of the structure, molecular cargo and function of bacterial extracellular vesicles ( bevs ) is primarily obtained from bacteria cultured in laboratory conditions.\nbacteria derived - extracellular vesicles\n"
        },
        {
          "qas": [
            {
              "id": "6025ddde1cb411341a0000ba_001",
              "question": "Is Tranexamic acid effective for intracerebral haemorrhage?"
            }
          ],
          "context": "interpretation : functional status 90 days after intracerebral haemorrhage did not differ significantly between patients who received tranexamic acid and those who received placebo, despite a reduction in early deaths and serious adverse events.\n. three observational studies ( n = 281 ) suggested less haematoma growth with rapid tranexamic acid infusion.\n"
        },
        {
          "qas": [
            {
              "id": "60490dc71cb411341a000167_001",
              "question": "Are interferons defensive proteins?"
            }
          ],
          "context": "in response to viral infections, various pattern recognition receptors ( prrs ) are activated for the production of type i interferon ( ifn i ).\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\n\nthe interferon - induced gtp - binding protein mx is responsible for a specific antiviral state against a broad spectrum of viral infections that are induced by type - i interferons ( ifn \u03b1 / \u03b2 ) in different vertebrates\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\n\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\nas immunomodulatory drugs, thalidomide and its analogues have been used to effectively treat various diseases\n\nactivating interferon ( ifn ) production and positively regulating antiviral response in mammals.\nthe innate immune system, in particular the type i interferon ( ifn ) response, is a powerful defence against virus infections.\n"
        },
        {
          "qas": [
            {
              "id": "60354a7b1cb411341a000154_001",
              "question": "Do honey contain diastases/amylases?"
            }
          ],
          "context": "the major alpha - amylase in honey was characterized.\nseparation of honey amylase\n\nthe major alpha - amylase in honey was characterized.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\n"
        },
        {
          "qas": [
            {
              "id": "601ecab41cb411341a000065_001",
              "question": "Is adenosine signaling prognostic for cancer outcome?"
            }
          ],
          "context": "adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response.\n. finally, adenosine signaling is associated with reduced efficacy of anti - pd1 therapy in published cohorts ( hr = 0. 29, p = 0. 00012 ). conclusions : these data support the adenosine pathway as a mediator of a successful antitumor immune response,\n\n. however, it is challenging to measure tumor adenosine levels at scale, thus novel, clinically tractable biomarkers are needed. experimental design : we generated a gene expression signature for the adenosine signaling using regulatory networks\nadenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response.\n\nadenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response.\nof a successful antitumor immune response, demonstrate the prognostic potential of the signature for immunotherapy, and inform patient selection strategies for adenosine pathway modulators currently in development.\n"
        },
        {
          "qas": [
            {
              "id": "5e67cd6b1af46fc13000001e_001",
              "question": "Does AZD3759 cross the blood brain barrier?"
            }
          ],
          "context": "good penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nthe results showed the bbb penetration of azd3759 was decreased within 24 hr after radiation, however, the free concentration of azd3759 in brain kept at a high level in the context of radiation.\n\ngood penetration of the blood - brain barrier by azd3759, and its promising clinical activity, support further assessment of this compound in studies. fund\nwe report the discovery and early clinical development of azd3759, a selective egfr inhibitor that can fully penetrate the blood - brain barrier ( bbb ),\n\nthe results showed the bbb penetration of azd3759 was decreased within 24 hr after radiation, however, the free concentration of azd3759 in brain kept at a high level in the context of radiation.\nanother promising class of egfr tki such as azd3759 has been designed to penetrate blood brain barrier to treat brain metastases and leptomeningeal disease and has showed promising responses in patients with brain metastases.\n"
        },
        {
          "qas": [
            {
              "id": "5fe0c141a43ad31278000035_001",
              "question": "Is the zelda transcription factor a chromatin remodeller?"
            }
          ],
          "context": "the zinc - finger tf zelda ( zld ) is essential for the maternal - to - zygotic transition ( mzt ) in drosophila melanogaster, where it directly binds over thousand cis - regulatory modules to regulate chromatin accessibility.\nzelda binds cis - regulatory elements ( tagteam heptamers ), making chromatin accessible for gene transcription.\n\nzelda binds cis - regulatory elements ( tagteam heptamers ), making chromatin accessible for gene transcription.\nthese different timing classes each associate with binding sites for two transcription factors, gaga - factor and zelda, previously implicated in controlling chromatin accessibility at zga.\n\nintriguingly, some zelda sites still maintain these chromatin patterns in drosophila embryos lacking maternal zelda protein.\nzelda overcomes the high intrinsic nucleosome barrier at enhancers during drosophila zygotic genome activation.\n"
        },
        {
          "qas": [
            {
              "id": "6025db0e1cb411341a0000b8_001",
              "question": "Is capmatinib effective for glioblastoma?"
            }
          ],
          "context": "saracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\nhowever, clinical trials of nonselective kinase inhibitors with c - met activity ( tivantinib, cabozantinib, foretinib, and golvatinib ) in patients with hcc have failed so far to demonstrate significant efficacy.\n\ncabozantinib in the treatment of hepatocellular carcinoma.\nsaracatinib as a metastasis inhibitor in metastatic castration - resistant prostate cancer : a university of chicago phase 2 consortium and dod / pcf prostate cancer clinical trials consortium study.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\n3 studies comparing standard chemotherapy to selumetinib in patients with newly diagnosed paediatric low - grade glioma both with and without nf1.\n\n. these data indicate that the inhibition of src kinase activity by saracatinib alone or in combination with other agents can be a strategy to target gastric cancer.\nantitumor activity of saracatinib ( azd0530 ), a c - src / abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nconclusion in this trial, despite adequate tissue pk, palbociclib monotherapy was not an effective treatment for recurrent glioblastoma.\n"
        },
        {
          "qas": [
            {
              "id": "6057151094d57fd879000027_001",
              "question": "Are there antimicrobial proteins in royal jelly?"
            }
          ],
          "context": "jellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nthe study showed significant antimicrobial activity from several proteins present in the honey of m. beecheii.\n\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nnutrients such as 24 - methylenecholesterol, major royal jelly proteins, and 10 - hydroxy - 2 - decenoic acid.\n\njelleines, isolated as novel antibacterial peptides from the royal jelly ( rj ) of bees, exhibit broad - spectrum protection against microbial infections.\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\n\njellein, a peptide derived from royal jelly of honeybee has been shown to have promising effect against several bacterial and fungal species.\nmajor royal jelly proteins ( named mrjp1 - 5 ) of honeybee ( apis mellifera ), yellow proteins of drosophila, together with putative proteins found in several bacteria, form a protein family termed the mrjp / yellow family.\n"
        },
        {
          "qas": [
            {
              "id": "6025e2641cb411341a0000bb_001",
              "question": "Can thiotepa be recommended for treatment of osteosarcoma?"
            }
          ],
          "context": ". despite a trend of prolonged survival and an acceptable toxicity, thiotepa cannot be recommended. key message : hdtp and autologous transplantation added to sct did not improve os and pfs in patients with resectable relapsed osteosarcomas\nconclusion. the use of hd thiotepa and asct is feasible in patients with relapsed osteosarcoma. a randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.\n\nosteosarcoma after radiotherapy for prostate cancer.\nconclusion. the use of hd thiotepa and asct is feasible in patients with relapsed osteosarcoma. a randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.\n\nadministration and protection from covid - 19 and influenza for those in need.\n. t\n\n. despite a trend of prolonged survival, thiotepa cannot be recommended.\nconclusion. the use of hd thiotepa and asct is feasible in patients with relapsed osteosarcoma. a randomized study for recurrent osteosarcoma between standard salvage chemotherapy and high dose thiotepa with stem cell rescue is ongoing.\n\nrates of gastrointestinal side effects, headache, and depression.\n. despite a trend of prolonged survival, thiotepa cannot be recommended.\n"
        },
        {
          "qas": [
            {
              "id": "601db7fb1cb411341a00004a_001",
              "question": "Does a comet assay measure radiation induced mutations?"
            }
          ],
          "context": "the comet assay is recognized as a rapid and sensitive method in quantifying radiation induced dna damage.\nthis paper attempts a correlation between the induction and repair of dna damage measured in the comet assay and the clinical observed reaction in order to evaluate the suitability of the comet assay for prediction of radiation sensitivity.\n\nthe comet assay is frequently used to measure dna damage in individual cells.\nthis paper attempts a correlation between the induction and repair of dna damage measured in the comet assay and the clinical observed reaction in order to evaluate the suitability of the comet assay for prediction of radiation sensitivity.\n\nevaluation of primary dna - damage is one way to identify potential genotoxic agents and for this purpose the comet assay has, for the last decades, been used to monitor dna single strand and double strand breaks in individual cells\nthe comet assay is frequently used to measure dna damage in individual cells.\n\nthe comet assay is recognized as a rapid and sensitive method in quantifying radiation induced dna damage.\nthe comet assay is frequently used to measure dna damage in individual cells.\n\nthe comet assay is a potential tool for use in neutron therapy, as well as a method for the rapid screening of samples from individuals accidentally exposed to radiation.\ncomet assay and the yield of induced leaf somatic mutations.\n"
        },
        {
          "qas": [
            {
              "id": "606c017294d57fd879000076_001",
              "question": "Has the companion diagnostic HercepTest received FDA approval?"
            }
          ],
          "context": "test ( ldt ) with the herceptest antibody and a leica bond automated stainer.\n. coupled with their proven good safety profile these findings could translate into a significant clinical benefit.\n\ndifferent types of cancers including both solid tumors such as melanoma, lung cancer, head and neck cancer, bladder cancer and merkel cell cancer as well as hematological tumors such as classic hodgkin's lymphoma.\nher2 fluorescence in situ hybridization ( fish ) and immunohistochemistry ( ihc ) tests were performed on 52 cases using a us food and drug administration ( fda ) - approved kit ( herceptest, fda kit ) and a laboratory - developed test ( ldt ) with the herceptest\n\none of these ( aem - 28 ) has recently been given orphan drug status and is undergoing clinical trials.\nher2 fluorescence in situ hybridization ( fish ) and immunohistochemistry ( ihc ) tests were performed on 52 cases using a us food and drug administration ( fda ) - approved kit ( herceptest, fda kit ) and a laboratory - developed test ( ldt ) with the herceptest\n\ntest ( ldt ) with the herceptest antibody and a leica bond automated stainer.\nher2 fluorescence in situ hybridization ( fish ) and immunohistochemistry ( ihc ) tests were performed on 52 cases using a us food and drug administration ( fda ) - approved kit ( herceptest, fda kit ) and a laboratory - developed test ( ldt ) with the herceptest\n"
        },
        {
          "qas": [
            {
              "id": "6033f5541cb411341a00014c_001",
              "question": "Is phosphoenolpyruvate carboxykinase 1 (PCK1) the rate-limiting enzyme in gluconeogenesis?"
            }
          ],
          "context": "the schizosaccharomyces pombe fbp1 gene, which encodes fructose - 1, 6 - bis - phosphatase, is transcriptionally repressed by glucose through the activation of the camp - dependent protein kinase a ( pka ) and transcriptionally activated by glucose starvation\npck1 is a rate - limiting gluconeogenic enzyme, where its deficiency or mutation contributes to serious clinical situations as neonatal hypoglycemia and liver failure.\n\nthe gluconeogenesis key enzymes pepck ( phosphoenolpyruvate carboxykinase )\ngluconeogenic enzymes such as phosphoenolpyruvate carboxykinase, glucose 6 - phosphatase, and fructose 1, 6 - bisphosphatase.\n\npck1 is a rate - limiting gluconeogenic enzyme, where its deficiency or mutation contributes to serious clinical situations as neonatal hypoglycemia and liver failure.\nthe gluconeogenesis key enzymes pepck ( phosphoenolpyruvate carboxykinase )\n"
        },
        {
          "qas": [
            {
              "id": "605265ee94d57fd87900000d_001",
              "question": "Has FTY720  been considered for the treatment of stroke?"
            }
          ],
          "context": ". although the mechanism of fty720 has not been fully elucidated, its efficacy against cerebral stroke is becoming clear, not only in animal models, but also in ischemic stroke patients through clinical trials\n. in this article, we review the data obtained from laboratory findings and preliminary clinical trials using fty720 for stroke treatment.\n"
        },
        {
          "qas": [
            {
              "id": "6081af3c4e6a4cf630000008_001",
              "question": "Is colistin an antibiotic?"
            }
          ],
          "context": "all antibiotics tested, apart from colistin,\nrates of gastrointestinal side effects, headache, and depression.\n\nall antibiotics tested, apart from colistin,\nmice received an antibiotic cocktail ( kanamycin, gentamicin, colistin, metronidazole, and vancomycin ) for 96 h.\n"
        },
        {
          "qas": [
            {
              "id": "602e84e61cb411341a000126_001",
              "question": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?"
            }
          ],
          "context": "tocilizumab ( roactemra or actemra ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin ( il ) - 6 receptor antagonist.\ntocilizumab / actemra is an anti - il - 6r antibody, which can competitively block il - 6 binding to the il - 6r.\n\ntocilizumab ( roactemra ( \u00ae ) ; actemra ( \u00ae ) ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin - 6 receptor antagonist.\nin 2009 the us food and drug administration accepted a complete - response submission for the use of actemra ( tocilizumab ), the first humanized il - 6 receptor - inhibiting monoclonal antibody, for the treatment of ra.\n\ntocilizumab ( roactemra or actemra ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin ( il ) - 6 receptor antagonist.\ntocilizumab ( roactemra ( \u00ae ) ; actemra ( \u00ae ) ) is a recombi \" \" t humanized monoclonal antibody that acts as an interleukin - 6 receptor antagonist.\n\nthis effect is probably due to a direct influence on the immune system\ntocilizumab binds to the interleukin - 6 receptor ( il - 6r ) and thereby blocks signaling of the pro - inflammatory cytokine il - 6.\n"
        },
        {
          "qas": [
            {
              "id": "5cebe41ea49efeb44c000006_001",
              "question": "Is the process of DNA loop-extrusion independent of ATP?"
            }
          ],
          "context": "the identification and quantification of further initiation steps - - atp binding and extrusion of an initial dna loop - - allowed us to deduce a complete kinetic reinitiation scheme.\nin support of this model, single - molecule imaging experiments indicate that saccharomyces cerevisiae condensin complexes can extrude dna loops in an atp - hydrolysis - dependent manner in vitro.\n\nthe identification and quantification of further initiation steps - - atp binding and extrusion of an initial dna loop - - allowed us to deduce a complete kinetic reinitiation scheme.\nour model explains what can be the driving force of chromatin loop extrusion and how it can be ensured that loops grow quickly and in a good direction\n\nhowever, the model requires a motor to generate the loops, and although cohesin is a strong candidate for the extruding factor, a suitable motor protein ( or a motor activity in cohesin itself ) has yet to be found\nour model explains what can be the driving force of chromatin loop extrusion and how it can be ensured that loops grow quickly and in a good direction\n\nthese structures depend on cohesin, a ring - shaped dna - entrapping adenosine triphosphatase ( atpase ) complex that has been proposed to form loops by extrusion.\nin support of this model, single - molecule imaging experiments indicate that saccharomyces cerevisiae condensin complexes can extrude dna loops in an atp - hydrolysis - dependent manner in vitro.\n"
        },
        {
          "qas": [
            {
              "id": "6060df1e94d57fd879000047_001",
              "question": "Is there an upper limit on the functional fraction of the human genome?"
            }
          ],
          "context": ". we illustrate that pines identifies functional noncoding variation more accurately than methods that do not use phenotype - weighted knowledge, while at the same time being flexible and easy to use via a dedicated web portal.\nthe systematic analysis of ultraconserved genomic regions in the budding yeast.\n\n. we estimate that, genome - wide, 1 - 3 % of patients without a diagnostic coding variant carry pathogenic de novo mutations in fetal brain - active regulatory elements and that only 0. 15 % of all possible mutations within highly conserved fetal\nmutational load considerations lead to the conclusion that the functional fraction within the human genome cannot exceed 25 %, and is probably considerably lower.\n\na genome - wide association study identifies a functional erap2 haplotype associated with birdshot chorioretinopathy.\nmutational load considerations lead to the conclusion that the functional fraction within the human genome cannot exceed 25 %, and is probably considerably lower.\n\nan order of magnitude. conclusions : using bagel, we identify ~ 2000 fitness genes in pooled library knockout screens in human cell lines at 5 % fdr, a major advance over competing platforms\nmutational load considerations lead to the conclusion that the functional fraction within the human genome cannot exceed 25 %, and is probably considerably lower.\n\ngenomes contain many clusters of conserved noncoding elements\nour objective was to characterize non - canonical circrnas, namely not originating from back splicing and circrna produced by non - coding genes.\n"
        },
        {
          "qas": [
            {
              "id": "601ec5661cb411341a000063_001",
              "question": "Is SLIC-CAGE used for quantification of translation?"
            }
          ],
          "context": ". the biggest limitation of cage is that even the most recently improved version ( nant - icage ) still requires large amounts of total cellular rna ( 5 \u00b5g ), preventing its application to scarce biological samples such as those from early embryonic\n. here, we present slic - cage, a super - low input carrier - cage approach to capture 5'ends of rna polymerase ii transcripts from as little as 5 - 10 ng of total rna\n\n. in addition, active enhancers can be detected through signatures of bidirectional transcription initiation. described here is a protocol for performing super - low input carrier - cage ( slic - cage )\n. here, we present slic - cage, a super - low input carrier - cage approach to capture 5'ends of rna polymerase ii transcripts from as little as 5 - 10 ng of total rna\n"
        },
        {
          "qas": [
            {
              "id": "6025fa371cb411341a0000be_001",
              "question": "Does hypofractionated radiotherapy offers any benefit for DIPG?"
            }
          ],
          "context": "xternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nmedian event - free survival ( efs ) and overall survival ( os ) for dipg were 7. 8 ( 95 % ci 5. 6 - 8. 2 ) and 10. 3 ( 7. 4 - 13. 4 ) months, and estimated one - year efs was 12 % ( 2 % - 31 % )\n\nxternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nlong - term survivors who received radiotherapy for all in childhood are at risk for late complications, including radiation - induced meningioma.\n\nxternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nconclusions : hypofractionated radiotherapy offers lesser burden on the patients, their families and the treating departments, with nearly comparable results to conventional fractionation, though not fulfilling the non - inferiority assumption.\n\nxternal radiotherapy with a radical hypofractionated regimen is feasible and well tolerated in children with newly diagnosed dipg. however, this regimen does not seem to change overall survival in this setting.\nphase i trial of dnx - 2401 for diffuse intrinsic pontine glioma newly diagnosed in pediatric patients.\n"
        },
        {
          "qas": [
            {
              "id": "601d72e61cb411341a000039_001",
              "question": "Is progeria caused by an autosomal recessive gene?"
            }
          ],
          "context": "pattern of inheritance of non - classical progeria is most probably autosomal recessive.\nevidence for autosomal recessive inheritance of progeria ( hutchinson gilford ).\n\namong them, the most studied is werner's syndrome, \" adult progeria \", caused by a recessive autosomal mutation with a frequency of 1 in 10 million, which affects a helicase involved in dna repair.\nevidence for autosomal recessive inheritance of progeria ( hutchinson gilford ).\n\nevidence for autosomal recessive inheritance of progeria ( hutchinson gilford ).\nprogeria is an autosomal domi \" \" t, premature aging syndrome.\n\nhutchinson - gilford progeria causing premature aging of children is a genetic disease and according to most authors has an autosomal domi \" \" t inheritance.\nevidence for autosomal recessive inheritance of progeria ( hutchinson gilford ).\n"
        },
        {
          "qas": [
            {
              "id": "601d73c71cb411341a00003e_001",
              "question": "Is acupotomy used to treat muscle stiffness?"
            }
          ],
          "context": "background : acupotomy has been widely used to treat nerve entrapment syndrome.\nboth acupotomy and acupuncture have been widely used clinically to treat csr in china with satisfied efficacy.\n\nacupotomy alleviates energy crisis at rat myofascial trigger points\nbackground : acupotomy has been widely used to treat nerve entrapment syndrome.\n\nto evaluate the clinical efficacy and safety of acupotomy in treatment of knee osteoarthritis\nboth acupotomy and acupuncture have been widely used clinically to treat csr in china with satisfied efficacy.\n"
        },
        {
          "qas": [
            {
              "id": "60234bd51cb411341a000093_001",
              "question": "Is ofatumumab effective for multiple sclerosis?"
            }
          ],
          "context": "conclusions : among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.\nconclusion : imaging showed that all subcutaneous ofatumumab doses demonstrated efficacy ( most robust : cumulative doses \u226530 mg / 12 wk ), with a safety profile consistent with existing ofatumumab data.\n\nconclusions : among patients with multiple sclerosis, ofatumumab was associated with lower annualized relapse rates than teriflunomide.\nofatumumab offers beneficial outcomes for rms by reducing relapse and disability progression risk.\n"
        },
        {
          "qas": [
            {
              "id": "60206bae1cb411341a00007d_001",
              "question": "Is there a role for Dickkopf-1 (DKK1) in prostate cancer?"
            }
          ],
          "context": "results support dkk1 as a contributor to the immunosuppressive tumor microenvironment of dnpc\nthe wnt inhibitor dickkopf - 1 ( dkk - 1 ) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis.\n\nckkopf - 1 ( dkk1 ) expression is increased in dnpc relative to prostate - specific antigen ( psa ) - expressing mcrpc in the stand up to cancer / prostate cancer foundation discovery cohort ( 11. 2 v 0. 28 reads per kilobase per million mapped reads ; q < 0. 05 ; n =\n. dkk1 expression can be regulated by activated wnt signaling in vitro and correlates with activating canonical wnt signaling mutations and low psa mrna in mcrpc biopsies ( p <. 05 )\n\nthe wnt inhibitor dickkopf - 1 ( dkk - 1 ) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis.\n. these data have provided the rationale for a clinical trial targeting dkk1 in mcrpc ( clinicaltrials. gov identifier : nct03837353 ).\n\nthe wnt inhibitor dickkopf - 1 ( dkk - 1 ) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis.\n. dkk1 expression can be regulated by activated wnt signaling in vitro and correlates with activating canonical wnt signaling mutations and low psa mrna in mcrpc biopsies ( p <. 05 )\n\n. epigenetic studies were carried out in a rapid autopsy cohort. results : dickkopf - 1 ( dkk1 ) expression is increased in dnpc relative to prostate - specific antigen ( psa ) - expressing mcrpc in the stand up to cancer / prostate cancer foundation discovery\nthe wnt inhibitor dickkopf - 1 ( dkk - 1 ) has been associated with the occurrence of bone metastases in osteotropic prostate cancer by inhibiting osteoblastogenesis.\n"
        },
        {
          "qas": [
            {
              "id": "602c28551cb411341a000123_001",
              "question": "Has AZD9668 been tested in clinical trials?"
            }
          ],
          "context": "efficacy, safety and tolerability of azd9668 ( 5, 20 and 60 mg bid ) were compared with placebo in a randomised, double - blind, placebo - controlled, 12 - week, phase iib trial ( nct00949975 : approved by an investigational review board ), in patients with\nresults : six participants were enrolled. all had adverse events, mostly behavioral. two completed the trial and the other four withdrew due to adverse events. all participants reported resolution of these events after discontinuation of the drug\n\nazd9668 is a reversible and selective inhibitor of ne, well tolerated at doses of 60 mg bid during phase i / iia development.\nefficacy, safety and tolerability of azd9668 ( 5, 20 and 60 mg bid ) were compared with placebo in a randomised, double - blind, placebo - controlled, 12 - week, phase iib trial ( nct00949975 : approved by an investigational review board ), in patients with\n\nefficacy, safety and tolerability of azd9668 ( 5, 20 and 60 mg bid ) were compared with placebo in a randomised, double - blind, placebo - controlled, 12 - week, phase iib trial ( nct00949975 : approved by an investigational review board ), in patients with\nthe study was a 4 - week phase ib multiple ascending dose, randomized, double - blind, placebo - controlled trial of azd0530 in ad patients with mini - mental state examination ( mmse ) scores ranging from 16 to 26.\n"
        },
        {
          "qas": [
            {
              "id": "5fdb415ba43ad31278000019_001",
              "question": "Is Nanog repressed in pluripotent stem cells?"
            }
          ],
          "context": "notably, the expression of nanog, a key pluripotency regulator and repressor of extraembryonic endoderm specification in es cells, was significantly reduced in zic3 knockdown cells.\nnanog maintains pluripotency of mouse embryonic stem cells by inhibiting nfkappab and cooperating with stat3.\n\ncurrent evidence suggests that es cells maintain their pluripotent state by expressing a battery of transcription factors including oct4 and nanog.\nmaintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\n\nnanog, oct4, and sox2 form the core of a transcription factor network that maintains embryonic stem cells in the pluripotent state in both humans and mice.\nmaintaining pluripotency and indefinite self - renewal of embryonic stem cells requires a tight control of the expression of several key stemness factors, particularly nanog and oct4 transcription factors.\n\nnanog safeguards pluripotency in mouse embryonic stem cells ( mescs ).\nnanog maintains pluripotency of mouse embryonic stem cells by inhibiting nfkappab and cooperating with stat3.\n\nearly embryonic development, when downregulation of nanog plays a crucial role.\nnanog, oct4 and repressor proteins co - occupy nanog - target genes in mouse es cells, suggesting that nanog and oct4 together may communicate with distinct repression complexes to control gene transcription.\n"
        },
        {
          "qas": [
            {
              "id": "6060e03394d57fd879000048_001",
              "question": "Are synonymous sites in primates and rodents functionally constrained?"
            }
          ],
          "context": "to resolve this contradiction between expectations and observations, we used processed pseudogenes as a model for strict neutral evolution, and estimated selective constraint on synonymous sites using the rate of substitution at pseudosynonymous and\n. after controlling for the effects of gc content, our results were similar to those from previous studies, i. e., synonymous sites in primates exhibited evidence for higher selective constraint that those in rodents\n\n. specifically, our results indicated that in primates up to 24 % of synonymous sites could be under purifying selection, while in rodents synonymous sites evolved neutrally.\n. after controlling for the effects of gc content, our results were similar to those from previous studies, i. e., synonymous sites in primates exhibited evidence for higher selective constraint that those in rodents\n"
        },
        {
          "qas": [
            {
              "id": "6027f7171cb411341a0000ec_001",
              "question": "Is there a role for TFII-I in megakaryopoiesis?"
            }
          ],
          "context": ". the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\nthese findings provide direct evidence that tfr1 is essential for hematopoiesis through binding diferric transferrin to supply iron to cells.\n\ntfii - i is a ubiquitously expressed transcription factor that positively or negatively regulates gene expression. tfii - i has been implicated in neuronal and immunologic diseases as well as in thymic epithelial cancer\n. the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\n\n. the data show that tfii - i acts as a repressor of \u03b2 - globin gene transcription and that it is implicated in the differentiation of erythro - megakaryocytic cells.\nnanog, oct4, and sox2 form the core of a transcription factor network that maintains embryonic stem cells in the pluripotent state in both humans and mice.\n"
        },
        {
          "qas": [
            {
              "id": "604915581cb411341a00016a_001",
              "question": "Is YKL-40 used as a biomarker for Alzheimer's disease?"
            }
          ],
          "context": "administration and protection from covid - 19 and influenza for those in need.\n. t\n\n. together these biomarkers recapitulate different stages of the disorder that, if validated can improve disease progression monitoring.\nrecently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\n\nykl - 40 appears to be a more reliable biomarker in neurological diseases than nse.\nrecently, cerebrospinal fluid ( csf ) ykl - 40 levels were reported to be a promising candidate biomarker of glial inflammation in alzheimer's disease ( ad ).\n"
        },
        {
          "qas": [
            {
              "id": "601c3f041cb411341a000018_001",
              "question": "Can propofol cause green urine?"
            }
          ],
          "context": "what is known and objective : propofol, a commonly used sedative, has on rare occasions, been reported to discolour urine green\nclinical significance of rare and benign side effects : propofol and green urine.\n\nclinical significance of rare and benign side effects : propofol and green urine.\nreasons for discontinuing propofol are signs of rhabdomyolysis ( 92. 9 % ), green urine, elevated liver enzymes ( 71. 4 % each ) and elevated triglycerides ( 57. 1 % ).\n\nthe green colour of urine due to propofol occurs when clearance of propofol exceeds hepatic elimination, and extrahepatic elimination of propofol occurs.\nclinical significance of rare and benign side effects : propofol and green urine.\n\nseveral substances in literature have been associated with green urine including propofol, biliverdin, metoclopramide, methylene blue, indigo blue, amitriptyline, methocarbamol, indomethacin, promethazine, cimetidine and food colourings.\ngreen urine is also caused by medications such as propofol and infections such as pseudomonas.\n\nthe green colour of urine due to propofol occurs when clearance of propofol exceeds hepatic elimination, and extrahepatic elimination of propofol occurs.\nwhat is known and objective : propofol, a commonly used sedative, has on rare occasions, been reported to discolour urine green\n"
        },
        {
          "qas": [
            {
              "id": "6032187e1cb411341a000132_001",
              "question": "Are Gram positive bacteria able to release extracellular vesicles?"
            }
          ],
          "context": "release of extracellular vesicles ( evs ) is a common feature among eukaryotes, archaea, and bacteria. however, the biogenesis and downstream biological effects of evs released from gram - positive bacteria remain poorly characterized.\nbacteria derived - extracellular vesicles\n"
        },
        {
          "qas": [
            {
              "id": "6025d88c1cb411341a0000b6_001",
              "question": "Is vocimagene amiretrorepvec effective for glioblastoma?"
            }
          ],
          "context": "findings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nniraparib in ovarian cancer : results to date and clinical potential.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nrates of gastrointestinal side effects, headache, and depression.\n\nconclusions gamma knife radiosurgery is both a safe and effective treatment for radiation - induced meningiomas.\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nto levamisole and p3 + re - glycolipid + bacillus calmette - guerin cell walls in the treatment of bladder cancer.\n\nfindings from a phase i study suggest that delivering high concentrations of the chemotherapy 5 - fu directly to brain tumors via the retroviral vector vocimagene amiretrorepvec, or toca 511, may benefit patients with recurrent high - grade glioma.\nmeningioma screening with mri in childhood leukemia survivors treated with cranial radiation.\n"
        },
        {
          "qas": [
            {
              "id": "601cb7a61cb411341a000026_001",
              "question": "Can Panitumumab cause trichomegaly?"
            }
          ],
          "context": "adding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.\nrates of gastrointestinal side effects, headache, and depression.\n\ndifferent antagonistic antibodies targeting pd - 1 or pd - l1 ( atezolizumab, durvalumab, avelumab, nivolumab, and pembrolizumab ).\nwe here delineated the molecular and cellular mechanisms underlying novel immunomodulatory effects triggered by bcma pyrrolobenzodiazepine ( pbd ) antibody drug conjugate ( adc ) medi2228 which can augment efficacy of these immunotherapies.\n\nadding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.\n. in a subgroup analysis, no differences in pfs according to the site of the primary tumor were observed ; patients with intrahepatic cholangiocarcinoma treated with panitumumab may have had a survival benefit in comparison with the control group\n\nadding panitumumab to standard protocols does not prolong survival but provokes additional adverse effects.\npten is a potent tumour suppressor\n"
        }
      ],
      "title": "BioASQ11b"
    }
  ],
  "version": "BioASQ11b"
}